

70427

Access DB#

192

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: RITAM MITRA Examiner #: 77995 Date: 7/8/02
 Art Unit: 1653 Phone Number 30 605-1211 Serial Number: 09/691344
 Mail Box and Bldg/Room Location: 9B01/CM1 Results Format Preferred (circle): PAPER DISK E-MAIL
Ln 9 B.03

If more than one search is submitted, please prioritize searches in order of need.

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: "Novel human proteins and polynucleotides encoding the same"
 Inventors (please provide full names): Gregory Donoho, C. Alexander Turner, Michael Nchles, Glenn Frie-

drich, Brian Zambrowicz, Arthur Sands
 Earliest Priority Filing Date: 10/19/1999

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

I would request an expedited literature (both Patent and Non-Patent) search on above application because this is a date case. Don't do Sequence
the search.

The search should encompass nucleotides that encode proteins, wherein proteins have structural similarity to animal CUB domain proteins, coagulation factors I and XIII, milk fat globule-EGF factor 8, transcriptional repressor AE-binding protein-1 and neuropilins 1 and 2.

Keywords: CUB domain, discordin domain, NHP, agonist, antagonist, receptor, protein, 1604-56, 15.46, receptor, transcription, activity, turnover

Mary Hale - Supervisor, Int. Branch
 STIC - Biotech/Chem. Library
 GM-1 Room E01
 703-308-4258

STAFF USE ONLY

Searcher: Mary Type of Search: NA Sequence (#) STN: 120.70
 Searcher Phone #: AA Sequence (#) Dialog
 Searcher Location: Structure (#) Questel/Orbit
 Date Searcher Picked Up: Bibliographic Dr. Link
 Date Completed: 7/9 Litigation Lexis/Nexis
 Searcher Prep & Review Time: Fulltext Sequence Systems
 Clerical Prep Time: Patent Family WWW/Internet
 Online Time: 18 Other Other (specify)

BEA ID NO: 4

Database: A-Geneseg-032802

At NO: AAU00670

QY 288 GSLSRPFLETSNCSRSLSFSPDOOTIRASSSNQVNSGDDVHNSGCAQLDDGSPSA 347
 DB 241 GLSLDRFLTSNGCSRSLSFSPDOOTIRASSSNQVNSGDDVHNSGCAQLDDGSPSA 300
 QY 348 SCDSSNNHKEPREMLGIDGKKKITGRTTSGTSGSNFVYKSPFMFNKNNKMTYK 407
 DB 301 SCDSSNNHKEPREMLGIDGKKKITGRTTSGTSGSNFVYKSPFMFNKNNKMTYK 360
 QY 408 IYNNKXVYQNSNPNONNRPVAVRYVYVPTMORIALKVELICCOITGSDS 467
 DB 361 IYNNKXVYQNSNPNONNRPVAVRYVYVPTMORIALKVELICCOITGSDS 420
 QY 468 IYNNKXVYQNSNPNONNRPVAVRYVYVPTMORIALKVELICCOITGSDS 527
 DB 421 IYNNKXVYQNSNPNONNRPVAVRYVYVPTMORIALKVELICCOITGSDS 480
 QY 528 RKKKKSGVYSAKAOIKTDKQIKYFARHOSASFTISYDNKEMTKDLITSDVAG 586
 DB 481 RKKKKSGVYSAKAOIKTDKQIKYFARHOSASFTISYDNKEMTKDLITSDVAG 539

RESULT 3
 AAU00670
 ID AAU00670 standard; Protein: 715 AA.
 AC AAU00670:
 DT 07-SEP-2001 (first entry)
 XX Human TANGO 229 polypeptide.
 DE Human TANGO 229 polypeptide.
 XX Human: TANGO 229; T cell; heart; liver; pancreas; placenta; brain; lung;
 skeletal muscle; kidney; spleen; lymph node; peripheral blood leukocytes;
 myoblasts; thymus tissue; abdominal blood coagulation; asthma; cancer;
 anaplasia; multiple sclerosis; coronary artery disease;
 malaria; atopic dermatitis; hypoglycemia; diabetes mellitus; goitre;
 hypoglycemia; diabetes mellitus; endometrial; pulmonary embolism;
 muscular dystrophy; immuno-competence; vertebrate; blood; serum.
 XX Homo sapiens.
 OS Homo sapiens.
 FH Location/Qualifiers
 FT Peptide
 FT 1..34
 FT /note="Signal peptide"
 FT Domain
 FT 35..455
 FT /note="Extracellular domain"
 FT Protein
 FT 35..715
 FT /note="Mature human TANGO 229"
 FT Domain
 FT 456..480
 FT /note="Transmembrane domain"
 FT Domain
 FT 481..715
 FT /note="Cytoplasmic domain"
 XX MO20012088-A1.
 XX 26-APR-2001.
 XX 23-JUN-2000: 2000MO-US17386.
 XX 19-OCT-1999: 99US-0420707.
 XX (MILL-) MILLENNIUM PHARM INC.
 XX Mackay CR, Myers PS, Kirst SJ, Fraser CC, Leiby KR:
 DR WPI: 2001-30847/32.
 DR N-PSDB: AAS00660.
 XX New isolated nucleic acid molecule for diagnosis, prevention, and
 XX therapy of human and other animal disorder, or as modulating agent for
 XX regulating cellular processes

XX Claim 8: Fig 1: 263pp; English.
 PS The sequence represents human TANGO 229 polypeptide. This protein and
 CC similar others exhibit the ability to direct growth, proliferation,
 CC survival, differentiation, activity, morphology, or movement/direction
 CC of 9. T cells and cells of the heart, liver, pancreas, placenta,
 CC skeletal muscle, kidney, spleen, lymph node, peripheral
 CC blood leukocytes, and other cells and tissues. They can be used as
 CC modulating agents for cellular processes. They can be used as
 CC and their associated nucleic acids
 CC diagnosis, or treat disorders associated with any prognostic, prevent,
 CC These disorders include abnormal blood coagulation, asthma, diabetes,
 CC hepatitis, multiple sclerosis, cancer, coronary artery disease, malaria,
 CC atopic dermatitis, amyotrophic lateral sclerosis, meningitis, attention
 CC deficit disorder, Crohn's disease, gastroenteritis, goitre,
 CC hypoglycemia, diabetes mellitus, endometritis, pulmonary embolism and
 CC muscular dystrophy. Antibodies to disorders such as these can be made by
 CC providing a polypeptide or nucleic acid sequence from the vertebrate
 CC vertebrate and harvesting blood or serum from the vertebrate.
 XX Sequence 715 AA:

Query Match 92.18; Score 2812; DB 22; Length 715;
 Best Local Similarity 100.0%; Pred. No. 2.8e-243;
 Matches 538; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 MYPGARGGALARMAGRGILALLAVSAPRLOAEHGGCGGCTATYDSSGTSNKNYK 107
 DB 1 MYPGARGGALARMAGRGILALLAVSAPRLOAEHGGCGGCTATYDSSGTSNKNYK 60
 QY 108 TYNNKXVYQNSNPNONNRPVAVRYVYVPTMORIALKVELICCOITGSDS 167
 DB 61 TYNNKXVYQNSNPNONNRPVAVRYVYVPTMORIALKVELICCOITGSDS 120
 QY 166 LLNNTSEVYFRESGSHSGGGLVYASGHPHITGLERASHVLTETYSKCPAGCRD 227
 DB 121 LLNNTSEVYFRESGSHSGGGLVYASGHPHITGLERASHVLTETYSKCPAGCRD 180
 QY 228 VAGDISNMYDGYRDTSLKKAALHAGIITABELGSGIYVLRGSGISRYEGLIANGVLRSD 287
 DB 181 VAGDISNMYDGYRDTSLKKAALHAGIITABELGSGIYVLRGSGISRYEGLIANGVLRSD 240
 QY 288 GSLSRPFLETSNCSRSLSFSPDOOTIRASSSNQVNSGDDVHNSGCAQLDDGSPSA 347
 DB 241 GSLSRPFLETSNCSRSLSFSPDOOTIRASSSNQVNSGDDVHNSGCAQLDDGSPSA 300
 QY 348 SCDSSNNHKEPREMLGIDGKKKITGRTTSGTSGSNFVYKSPFMFNKNNKMTYK 407
 DB 301 SCDSSNNHKEPREMLGIDGKKKITGRTTSGTSGSNFVYKSPFMFNKNNKMTYK 360
 QY 408 IYNNKXVYQNSNPNONNRPVAVRYVYVPTMORIALKVELICCOITGSDS 467
 DB 361 IYNNKXVYQNSNPNONNRPVAVRYVYVPTMORIALKVELICCOITGSDS 420
 QY 468 IYNNKXVYQNSNPNONNRPVAVRYVYVPTMORIALKVELICCOITGSDS 527
 DB 421 IYNNKXVYQNSNPNONNRPVAVRYVYVPTMORIALKVELICCOITGSDS 480
 QY 528 RKKKKSGVYSAKAOIKTDKQIKYFARHOSASFTISYDNKEMTKDLITSDVAG 586
 DB 481 RKKKKSGVYSAKAOIKTDKQIKYFARHOSASFTISYDNKEMTKDLITSDVAG 538

RESULT 4
 AAU00628
 ID AAU00628 standard; Protein: 487 AA.
 AC AAU00628:
 DT 29-AUG-2001 (first entry)
 XX

Db 6386 atgcccagagacgtgtgaatgctgtgcaagccaaagccaaacatacaga-----ag 6439
 1078 tggctggagatcgatttgggggaaagaataaacaagaaattagagccagagatc 1137
 Db 6440 cggctagaacttgatctaccacagacaaagaataaggaatatacaacaaggtgc 6499
 1138 acccgctggaacttcaactttatgttgaagatttggatgaactcaaaaacaat 1197
 Db 6500 aagctcgcgtcctcgtgaatgtatgtgaagagctatccatccactacagtgagagga 6559
 1198 tcaaatgtgaagacataaagaaatgtgaaataagaagaaggtgttcagagtaac 1257
 Db 6560 tctgaacttcggaccagctgcaatccctccatgtgtgacaagatttttgaagaaac 6519
 1258 ctgaacttcggaccagctgcaatccctccatgtgtgacaagatttttgaagaaac 6519
 Db 6620 actaataccaagaagacatgtgaagaaactttcaaccccccaatatttccagttatc 6679
 1318 cgggtgtccccccagacatgagcacaagaggaatagcttgaaggtgtgaggttgc 1377
 Db 6680 cgtgtatctcccaaaaacatggaatcaagatttgacttcgtcgtgaactcttggctgt 6739
 1378 caaat 1383
 6740 gatatt 6745

RESULT 11

AAAT03920 standard; cDNA; 6909 BP.

AAAT03920;

20-DEC-1995 (first entry)

Human Factor-V wild-type cDNA.

Factor-V; thrombosis; thrombophilia; diagnosis; anticoagulant; activated protein-C; APC; homozygosity; heterozygosity; ss.

Homo sapiens

MO9521938-A1.

17-AUG-1995.

14-FEB-1995; 95MO-EP00553.

14-FEB-1994; 94EP-0200377.

(UTRE-) RIJCKSNIJ LEIDEN.

Bertina RM, Reitsma PH.

WPI; 1995-293134/38.

Screening for genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein C - useful to determine homozygosity or heterozygosity for a mutation in Factor V, Val, VIII or VIII.

Claim 16; Page 60-65; 98PP; English.

The probes/primers given in AAAT03921-31 are used to isolate and/or amplify and/or detect mutations in human Factor-V DNA (AAAT03920), esp. in DNA encoding the APC binding and/or cleavage site.

Sequence 6909 BP; 2096 A; 1700 C; 1430 G; 1683 T; 0 other;

Query Match 5.3%; Score 92.8; DB 16; Length 6909; Best Local Similarity 51.0%; Pred. No. 2,3e-13;

Matches 248; Conservative 0; Mismatches 232; Indels 6; Gaps 1;
 898 aatggttgcagagatccttgattttgagacttgacagcaatagaagcttctccca 957
 Db 6280 atggaatgttccacacccctgggtatgaaatgaaagatagaacaagaacatcac 6339
 938 tggctggagatcgatttgggggaaagaataaacaagaaattagagccagagatc 1017
 Db 6340 gcttcttcagtttcaagaatcttgggggaaatatacgaaaccccttcgggtcgtc 6399
 1018 cagagccagccctcacttggtctggggcagcagcaggaacacaaacacagagag 1077
 Db 6400 aatgcccagagacgtgtgaatgtcgtggaagcagaagaaacaataatagc-----ag 6453
 1078 tggctggagatcgatttgggggaaagaataaacaagaaattagagccagagatc 1137
 Db 6454 tggctgaataatgtcttactcaagatcaagaagatacgcaatatacaacaaggtgc 6513
 1138 acccgctggaacttcaactttatgttgaagatttggatgaactcaaaaacaat 1197
 Db 6514 aagctcgcgtcctcgtgaatgtatgtgaagagctataccatccactacagtgagagga 6573
 1198 tcaaatgtgaagacataaagaaatgtgaaataagaagaaggtgttcagagtaac 1257
 Db 6574 gtagaattggaacacacagctgaaatccctccatgtgtgacaagatttttgaagaaac 6633
 1258 tctaacttcggaccagctgcaatccctccatgtgtgacaagatttttgaagaaac 6633
 Db 6634 actaataccaagaagacatgtgaagaaactttcaaccccccaatatttccagttatc 6693
 1318 cgggtgtccccccagacatgagcacaagaggaatagcttgaaggtgtgaggttgc 1377
 Db 6694 cgtgtatctcccaaaaacatggaatcaagatttgacttcgtcgtgaactcttggctgt 6739
 1378 caaat 1383
 6734 gatatt 6759

RESULT 12

AAAT0448 standard; cDNA; 6909 BP.

AAAT0448;

09-OCT-2000 (first entry)

Human Factor V cDNA sequence SEQ ID NO:28.

Factor V; FV; activated protein C; APC; anticoagulant; activated protein C resistant factor V; thrombosis; screening; thrombophilia; ds.

Homo sapiens.

US6066778-A.

23-MAY-2000.

06-NOV-1996; 96US-0746111.

06-NOV-1996; 96US-0746111.

(UNMT) UNIV MICHIGAN.

Glasburg D, Cui J.

WPI; 2000-410682/35.

New transgenic mice expressing activated protein C resistant factor V and factor V null transgenic mice useful for screening anticoagulants, gene therapy protocols and as models for testing in utero

SEA ID NO. 4
 Database: A-Gene-032802 Page 6
 Accession NO. AAB24216

Db 474 rsrnfagcagctcspadintvntvntdvalaavlylvmvltlllllllvcagwhr 533
 528 -RRKKKSGS---PY 537
 534 nrkkkctgtydlpy 547

RESULT 7

AAAY70539 standard; Protein: 669 AA.
 AAAY70539;

04-JUL-2000 (first entry)

Human Factor 8 Homologue.

Human Factor 8 Homologue; F8H; coagulation cofactor; haemostatic;
 cerebroprotective; therapeutic; coagulation related disorder;
 hemophilia; stroke; screening.

Homo sapiens.

MO200012533-A1.

09-MAR-2000.

20-AUG-1999; 99MO-US19QW7.

31-AUG-1998; 980US-0098521.

(ELIL) LILLY & CO ELI.

Rosstock PRJ, Su W, Li XM.

WPI: 2000-256580/22.

N-PSDB; AA251872.

Factor 8 homologue polypeptides and nucleic acids encoding them for

treating coagulation related disorders such as hemophilia and stroke

Claim 3; Page 64-66; 68pp; English

The present sequence is a human Factor 8 homologue (F8H),
 a coagulation cofactor which is selectively expressed in
 hemopoietic, heart and reproductive tissues. It has haemostatic and
 cerebroprotective activities. The F8H contains a Factor 5/8 signature
 and is useful as a therapeutic for treating coagulation related diseases
 such as hemophilia and stroke. The present sequence is a nucleic acid
 encoding the Factor 8 homologue polypeptide and is useful for detecting deficiencies
 in the level of F8H mRNA for screening F8H gene mutations and for
 monitoring regulation of gene expression. Fragments of the nucleic acid
 are also useful as diagnostic probes and primers, and can be used in
 screening methods such as those using DNA chips. The present sequence is
 also useful as a target to screen therapeutically useful modulators
 of the F8H.

Sequence 669 AA;

Query Match 25.8%; Score 786.5; DB 21; Length 669;

Best Local Similarity 35.9%; Pred. No. 1.9e-61; Models 81; Gaps 16;

Matches 190; Conservative 94; Mismatches 164; Models 81; Gaps 16;

Db 124 GRRLLTLDLIDLP-SQTCASDYLFTS---SSDQYPCPG-SKRYRELLINSEVY 177

2 gervtktgdtdgdcgcnfnyllyngtystetktycgsgyqmbhlekgneltl 61

178 RRESGSHISGCFILTVASSDPDLITCLERSHYLTKESKFCPCACDVAQDISGMV 237

62 lmsqllvsgrtfaasyvldkqdlfctcdlctasnfltepfstkyccpccllprafslgllp 121

238 DGYRDTSLCNAATHAGITADLGQISYVLQRKQISRYEGLIANGLVSRDQSLSDRELF 297

Db 122 hgyfaspdlomgahyagvsnltlsgqclstvytklbylsvsslanmvszvvshlslstlft 181

298 TSNCGSRSLSEF---PDGQIRASSNQSVNESCDDVYHNSFGQALDQGPANACSDSN 353

182 Kdsgcytclgmsagvialdpqitassvleatdchgagsskpkxkrltkpqpssadlde 241

354 NMRSEMLELIDGKKKTGIFRTGOSQSNFPEYFVSVMKNNKSKMTYKQIVNNE 413

242 ---Xpvtqldlnkcklltglitgslmwhnyvayrvlllyadqgkctvyrepqved 297

414 KVFQSNRFEEDVONNEIPIPVARVVRVYVPTWRIATKVELIGCO---ITO 463

298 Klfqnkayqdvnmllpplrlstlrlvmpcwgqklamkneilgqcltpkprpkltp 357

464 ---GNDSLNKRKTOSQSYKKEEDITPPI-----PSEET--STQIMTT 505

358 ppprrnsd---lnktlppklykqrpktlqdpqrssnefpaqlqetlaaplrinttv 413

506 ---VAIPVILVYVFPAGMGVFAAF-----RRKKKGS---PGSAAQKTDG 347

414 tnvtkdvaalavlyplvltlllllllvcawmtrikkkctgtydlpyw---dlagw 469

548 WKQIKRP-----ANSSAEFTSYDNKEMVOKQDLITSDMA 585

470 wkqmkgtlpakavdhceprvyssek-vnhlsprvltvlygdasaeya 516

RESULT 8

AAAB24216 standard; Protein: 889 AA.

06-FEB-2001 (first entry)

Soluble neuropilin protein sequence SEQ ID NO.4.

Mouse; soluble neuropilin.

Mus sp.

Synthetic.

JP2000236879-A.

05-SEP-2000.

17-FEB-1999; 99JP-0038920.

17-FEB-1999; 99JP-0038920.

(KAGN-) KAGANU GIJUTSU SHIKO JIGYODAN.

WPI: 2000-658505/64.

N-PSDB; AA600787.

Soluble neuropilin having a deleted cell membrane-penetrating region,
 used to diagnose human disease conditions

Claim 5; Page 13-17; 18pp; Japanese.

The present invention describes a recombinant soluble neuropilin (I)
 comprising an amino acid sequence in which the cell membrane penetrating
 region and/or the intracellular region of the neuropilin are deleted
 and the intracellular region of the neuropilin can be used for the elucidation of
 human disorders and disease conditions. The present sequence
 represents a specifically claimed soluble neuropilin protein
 sequence from the present invention.

Sequence 889 AA;

Query Match 11.6%; Score 353.5; DB 21; Length 889;

Best Local Similarity 23.1%; Pred. No. 2,36-22;
Matches 120; Conservative 73; Mismatches 189; Indels 137; Gaps 17;

Qy	49	VPAAGGALALAAAGGGLALLAVSAPFLQAELESD-CCGHLVYQDSQGTWTSKNTPG	107
Db	15	VPSTGDA-----qparvavslqdppegqgpnakdaagyltppypq	57
Qy	108	TYPNITVCEKTIYTPK-GRKLILRLG-DLDESQTCASDYLTF---TSSSDQYPCPS	161
Db	58	dytqpcqewlyvapepnqkylvlnfphelethckdydldldcsesadllqkncgn	117
Qy	162	MVPEKILLMSVYPERESGSHISGRGLITY---ASPD-----	198
Db	118	i-apllissagvlyktidqyargqsfslvelftktsgecknfksapngtlespgfr	176
Qy	199	--HEDLYTC---LERASHYLTATYKSRF-----CPAGCRVYAGDLS--GMY	236
Db	177	ekypmldctellakpmeillqflctldelhdpdqvgedckdydldwdqjphvpi	236
Qy	238	DEXMDISLCAAHAGIADAGGQISVQDRKGISRY-----DG	277
Db	237	gtygctkptkllsstjlsllcthmavakgafcaltyllhgepfnqcvplgmesg	296
Qy	278	ILANGVLSRDSLSKRELFTSNGCSRSLSFDEPDQIRASSMGVSNSDQVHNSQCA	337
Db	297	rlaneqtsasstlsdgr-----wtpqgs	319
Qy	338	RLDQGFSPMASGDSSNNHREMLETDLGEKKRTGIRTTG--STGSNFWYKSEFVNF	395
Db	320	rlhgdngvypnldn-----keyqydlrllctmltalagqalsretckkyvyskylev	375
Qy	396	KNNMSKMTKYGIVNNEKYVFGNSNFPDQPNFPIVARVYVYPMQIMQIALKYE	455
Db	376	stngedmwyryhghkh--klfgandateavlnklmplrltrfltrpqlmhlalrle	433
Qy	456	LIGCOITGQNDISVWRTS---GSTSVSTKDEDTITPR	491
Db	434	lfgvrltapcsnmglmsgladclqalsastreywsp	472
RESULT	9		
AA96308		AA96308 standard; Protein: 925 AA.	
AC	AA96308:		
XX	28-JUN-1999	(first entry)	
DE	Neuropilin-2.		
XX	Neuropilin; neuropilin-2; semaphorin; transmembrane protein; axon;		
XX	neuron; development; cell growth; immune response;		
XX	pathogenesis; treatment; disease; graft rejection;		
XX	viral diseases; oncological disease; cancer; screening; probes.		
OS	Rattus rattus.		
PN	MO904263-RA.		
XX	28-JAN-1999.		
PF	17-JUL-1998;	98MO-US14632.	
XX	17-JUL-1997;	9YUS-0052762.	
PR	17-JUL-1997;	9YUS-0052762.	
XX	(UYZO) UNIT JOHNS HOPKINS SCHOOL MEDICINE.		
XX	Ginty DD. Kolodkin AL:		
XX	WPI: 1999-132446/11.		
DR	N-PSDB: AAX08417.		
XX	New isolated semaphorin receptor, neuropilin-2 - used to develop		

products for the diagnosis and treatment of neurological, immunological, oncological and viral diseases
Claim 13; Page 77-79; 88pp; English.

The neuropilins are type I transmembrane proteins and act as semaphorin III (Sema III) receptors. The semaphorins have been shown to function in repulsive axon guidance. Sema III is a cell surface protein that in vitro causes neuronal growth cone collapse and chemorepulsion. Sema III is required in vivo for correct sensory afferent innervation and is required in vivo for development. Agents which inhibit or enhance the aspects of a semaphorin and a neuropilin can be potent modulators of nerve cell growth, immune responsiveness, and viral pathogenesis, and can be used in the treatment and diagnosis of neurological disease, neuro-regeneration, immune modulation including hypersensitivity and infection, and diagnosis and treatment of viral and oncological diseases. Agents which inhibit or enhance the aspects of a semaphorin and a neuropilin can be used in the treatment and diagnosis of neurological disease, neuro-regeneration, immune modulation including hypersensitivity and infection, and diagnosis and treatment of viral and oncological diseases. Agents which inhibit or enhance the aspects of a semaphorin and a neuropilin can be used in the treatment and diagnosis of neurological disease, neuro-regeneration, immune modulation including hypersensitivity and infection, and diagnosis and treatment of viral and oncological diseases.

Sequence 925 AA;

Query Match 11.5%; Score 351.5; DB 20; Length 925;
Best Local Similarity 21.4%; Pred. No. 3,76-22;
Matches 114; Conservative 76; Mismatches 161; Indels 97; Gaps 17;

Qy	88	CSGHVYQDSQGTWTSKNTPGYPMHNVCEKTIYTPK-GRKLILRLG-DLDESQTCASQY	145
Db	28	cggfrlmskagyltspypdpdqyqhncwvwyapepnkylvlnfphelethckdyd	87
Qy	146	LTF---TSSSDQYPCPSKTYKELLNTSVYPERESGSHISGRGLITY-----AS	196
Db	88	lctdgsesadllqkncgn-i-apllissagvlyktidqyargqsfslvelftktsge	146
Qy	197	SD-----HEDLYTC---LERASHYLTATYKSRF-----	220
Db	147	edcaskftspngtlespgfrpekylmldctellakpmeillqflctldelhdpdqvg	206
Qy	221	CPAGCRVYAGDLS--GMYVYKSEFVNF-----STGSNFWYKSEFVNF	275
Db	207	dckdydldwdqjphvpiqlgtygctkptkllsstjlsllcthmavakgafcalty	266
Qy	276	-----ESILANGVLSRD-GSLSKRELFTSNGCSRSLSFDEPDQIRASSMGVSNS	328
Db	267	vhgeppnfqcaplgmesgslane-----qlasest-----	300
Qy	329	CVHNSQCAHLADQGFSPMASGDSSNNHREMLETDLGEKKRTGIRTTG--STGSNFW	386
Db	301	dyrtqpsqllhgdngvypnldn-----keyqydlrllctmltalagqalsretck	356
Qy	387	YKSEFVNFENKNNMSKMTKYGIVNNEKYVFGNSNFPDQPNFPIVARVYVYPMQIM	446
Db	357	lyksyalevtstngedmwyryhghkh--kvtgandateavlnklmplrltrfltrp	414
Qy	447	HQRIATKVELIGCOITGQNDISVWRTS---GSTSVSTKDEDTITPR	491
Db	415	hlgsltrlelfgvrltapcsnmglmsgladclqalsastreywsp	462
RESULT	10		
AA964627		AA964627 standard; Protein: 439 AA.	
AC	AA964627:		
XX	22-MAR-2001	(first entry)	
DE	Human secreted protein BLAST search protein SPQ ID NO. 137.		

0126.

e 60-61; 75pp; English.

BP; 485 A; 471 C; 484 G; 431 T; 0 other;

conservative 0; Mismatches 128; Indels 0;

Db 774 gcgatttctttaaaccaccag 797

RESULT 6

ID	AAH34855 standard; CDNA; 2428 BP.
xy	

XX

XX
DE Human colon cancer antigen encoding cDNA SEQ ID NO:1937

Human; colon cancer; colon cancer antigen; diagnosis; detection;

05 ~~Homo sapiens.~~

PN WO200128920-A2
XX

33

PR 29-SEP-1999 9905-0157137.

XX
PA
(HIMA-) HUMAN GENOME SCT INC

PI Ruben SM, Barash SC

DR WFL; 2001-23333/24.
DR P-PSDB; AAG75450.

PT Nucleic acids encoding

PS Claim 1; Page 3444-3445; 9803pp; English

and treatment of colorectal carcinomas and cancers. AAH37196 to AAH37204

Gencore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: July 9, 2002, 01:13:23 ; Search time 59.09 Seconds

(without alignment)

815,000 Million cell updates/sec

Title: US-09-691-344A-4

Perfect score: 3052

Sequence: 1 MFGAGGRLRPVPAPRSSAE.....YDNKEKMTOKLDTLSDMAG 586

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283138 segs, 96089334 residues

Total number of hits satisfying chosen parameters: 283138

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database :

Listing first 45 summaries

1: PIR_71:*
2: PIR2:*
3: PIR3:*
4: PIR4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	331	10.8	2211	1_KF05	coagulation factor A5 antigen precursor
2	330	10.8	927	1_K06948	coagulation factor A5 antigen precursor
3	321	10.5	2224	1_KP05	coagulation factor A5 antigen precursor
4	318	10.4	2183	2_T42764	coagulation factor A5 antigen precursor
5	299	9.8	218	2_A47285	coagulation factor A5 antigen precursor
6	297.5	9.7	427	2_JC4915	coagulation factor A5 antigen precursor
7	285.5	9.4	216	2_A44258	coagulation factor A5 antigen precursor
8	275.5	9.1	2319	2_A47004	coagulation factor A5 antigen precursor
9	275.5	9.1	2319	2_A47004	coagulation factor A5 antigen precursor
10	275.5	9.1	2319	2_A47004	coagulation factor A5 antigen precursor
11	271.5	8.9	2133	2_T42763	coagulation factor A5 antigen precursor
12	268	8.8	401	2_S65138	coagulation factor A5 antigen precursor
13	268	8.8	427	2_S74211	coagulation factor A5 antigen precursor
14	259.5	8.5	409	2_T11743	coagulation factor A5 antigen precursor
15	217	7.1	845	2_JC5256	coagulation factor A5 antigen precursor
16	216.5	7.1	1749	2_S71739	coagulation factor A5 antigen precursor
17	216.5	7.1	1749	2_S71739	coagulation factor A5 antigen precursor
18	187	6.3	3133	2_S52093	coagulation factor A5 antigen precursor
19	186.5	6.1	3133	2_S52093	coagulation factor A5 antigen precursor
20	174	5.7	1524	2_T30337	coagulation factor A5 antigen precursor
21	172.5	5.7	319	2_S15169	coagulation factor A5 antigen precursor
22	168	5.5	3623	2_T09456	coagulation factor A5 antigen precursor
23	165.5	5.4	986	2_T09456	coagulation factor A5 antigen precursor
24	165	5.4	730	1_BH01	coagulation factor A5 antigen precursor
25	163.5	5.4	823	1_BH01	coagulation factor A5 antigen precursor
26	163.5	5.4	823	1_BH01	coagulation factor A5 antigen precursor
27	160.5	5.3	819	2_T18852	coagulation factor A5 antigen precursor
28	160.5	5.3	819	2_T18852	coagulation factor A5 antigen precursor
29	158	5.2	991	2_JC6554	coagulation factor A5 antigen precursor
					procollagen C-endo

ALIGNMENTS

RESULT 1

KF05

C:Species: Bos primigenius laurus (cattle)

C:Date: 04-Mar-1993 #sequence-revision 28-Apr-1995 #text-change 11-Jun-1999

A:Accession: A42580; A36497

B:Accession: A42580; A36497

J:BIOL. Chem. 267:2971-2978, 1992

A:Title: The complete cDNA sequence of bovine coagulation factor V.

A:Reference number: A42580; NUID:92147638

A:Accession: A42580

A:Molecule type: mRNA

A:Residues: 1-2211 <GUI>

A:Cross-references: GB:M01440; NID:9163037; PTD:AAA30512.1; PTD:9163038

A:Note: Sequence extracted from NCBI backbone (NCBI:80774, NCBI:80776)

J:BIOL. Chem. 265:21580-21589, 1990

A:Title: Identification and characterization of a phospholipid-binding site of bovine

A:Reference number: A36497; NUID:91072354

A:Accession: A36497

A:Molecule type: protein

A:Residues: 156-170, 'X', 1572-1581, 'X', 1583-1584, 1673-1676, 'X', 1678-1679, 'X', 1681, 'X'

A:Key: J.; Katalakis, M.; Silveira, J.R.; Kung, C.; Mann, K.G.

A:Location: 156-170, 1572-1581, 1583-1584, 1673-1676, 1678-1679, 1681-1682

A:Reference number: A55979; NUID:95034740

A:Contents: annotation

A:Note: 566-Cys and 617-Cys were shown to have free thiols

C:Comment: Factor V is activated by thrombin and partially by coagulation factor Xa.

C:Function: acts as a cofactor, with calcium and phospholipid, for the factor Xa p

A:Pathway: blood coagulation

A:Receptor: blood coagulation

F:1-28/Domain: signal sequence status predicted <SITS>

F:29-741/Product: coagulation factor V #status predicted <NMR>

F:33-345/Domain: A1 <DA1>

F:33-329/Domain: repeat homology <R01>

F:346-655/Domain: A2 <DA2>

F:346-655/Domain: repeat homology <R02>

F:346-655/Domain: repeat homology <R03>

F:1175-1437/Region: 9-residue repeats (O-X-T/R-I-S-P-P-I-S)

F:1565-1892/Product: coagulation factor V #status predicted <NMR>

F:1572-1892/Domain: ferroxidase repeat homology <R03>

F:1654-1752/Region: ferroxidase repeat homology <R03>

F:1893-2051/Domain: CI <DC1>

F:1893-2048/Domain: disordered I amino-terminal homology <DN1>

F:2052-2208/Domain: disordered I amino-terminal homology <DN2>

F:167-193,248-329,499-525/Dissulfide bonds: #status experimental

F-125-233/239,287,282,460,553,587,745,756,774,780,902,952,964,1044,1053,1062,1071,1078,1094
F-134-835/Cleavage site: Arg-Ser (proteom) *status predicted
F-137-377/410/Cleavage site: sulfatase (typ) *status predicted
F-137-377/410/Cleavage site: sulfatase (typ) *status predicted
F-153-534/Cleavage site: Arg-Gly (protein G) *status predicted
F-167-686,681,171-178,1894,2048,2053-2058/Disulfide bonds: *status predicted
F-741-742/Cleavage site: Arg-Ser (coagulation factor Xa, thrombin) *status predicted
F-1034-1035/Cleavage site: Arg-Ser (coagulation factor Xa, thrombin) *status predicted
F-1554-1565/Cleavage site: Arg-Ser (thrombin) *status predicted

Query Match	10.88;	Score 331;	DB 1;	Length 2211;
Best Local Similarity	32.58;	Pred. No. 6.1e-16;		
Matches 88;	Conservative 48;	Mismatches 89;	Indels 46;	Gaps 10;

QY 209 ASHLKTEY-SKECPA-----GCRDVGDISGNV--DGYRDTSLCKAAIHAGIAD 259
| |||| : : | : : : : :
Db 1968 AKHILKPYYTTEFCVAIYSLDRKNWRIFKNGNSTRNVMYFGNSDASTIKENOIDPPVYA-- 202

```
Db 2026 -----RIRISPGSYNKPALRLLEOGC-EVNGCSFPLGMESGKIENKOY 2077
```

```

Db 2071 ASSEKKSMMG-----NYWEEFLARLNAQGRVNAQAANNNN-----QWQIDLLKIKK 2111
Ou 371 TTGTTTTCGSMOSNENDEVRSTVDNKKNNNSKGEVVGKTVNNDEEYVBOGNSNEEDPVRVHR 420

```

Db	2120	ITALVTGCKSLSEWVKS	YTHSDGSTDNRK	YREKSSMDK	IEGNNNV	RGHVANF	2177
Oy	431	IPPIVARYVVPQTHORIALK	VELGCOI	461			

Db 2180 NPPIISRFTIRIIPKTNQSIARLELFGCDM 2210

000948
A5 antigen precursor - African clawed frog
C:Species: Xenopus laevis (African clawed frog)
C:Date: 10-Sep-1999 #sequence revision 10-Sep-1999 #text change 16-Jun-2000

R.Takagi, S.; Hirata, T.; Agata, K.; Mochiz, M.; Eguchi, G.; Fujisawa, H. *Neuron* 7, 295-307, 1991

A:Accession: J040466
A:Molecule type: mRNA
A:Residues: 1-927 <TAK>
A:Cross-references: GB:010467. GB:01077. NTD:022966. PTDN:BA01260 1. PT

A:Note: this protein has motifs homologous to complement components C1r and C1s;Comment: This protein is a neuronal cell surface molecule involved in the regulation of synaptic transmission;C:Superfamily: Xenopus A5 antigen; C1r/C1s repeat homology; discoidin I domain

F:1-21/Domain: signal sequence #status predicted <SIG>
F:22-927/Product: A5 antigen #status predicted <A5A>
F:27-138/Domain: Clf/Cls repeat homology <CIR1>
F:147-365/Domain: Clf/Cls repeat homology <CIR1>

F:861-883/Domain: transmembrane status predicted <TM>
F:430-584/Domain: discoidin I amino-terminal homology <DN1>
F:274-424/Domain: discoidin I amino-terminal homology <DN1>
F:646-812/Domain: MAM homology <MAM>
F:861-883/Domain: transmembrane status predicted <TM>

Query Match 10.8%; Score 330; DB 1; Length 927;

Matches 112; Conservative 74; Mismatches 171; Indels 106; Gaps

DB 5 LBSCCMLJCSLRSSWASRNDKCGDIKITSPSYLTSAGIPHSYBPSSQRCMLQIAPEHY 64

Qy	125	KLLILRIG-DLIESOTASLYLE	-----TSSSOYGPSCSMYKELLNLSVIVR	179
Dy	65	ORMLNHNHPLDECKRDYVEYDGNAGGLJAKCKRI	-----ASPLVSTGSPISITR	123
Qy	180	EGSGHSIGGALLTY	-----ASDP	205
Dy	124	VEDPTEFGAGSTIHYEVFKNGPECSRMFTSYGAS	-----HPDLTY	183
Qy	206	-----LERSHSLYKTYKSCFPG	-----GR-DVAGSIGMMVNGVRIOTSLILCAAHGIIAD	259
Dy	184	EYLVEFSELELSDNS	-----AGGGOTCRDMLG	223
Qy	260	LGGOISYLDRKGISREYGIILA	-----NCVLSHDG	305

06 306 LSPED----GQIRASSMOSVNESGDVHMSFGQARLDQCPMSACDSSNNHKPREWL 361

362 EIDIGKKKIGIRPTG--STQSNFNFYKSPVMEKNNNSKKTYKCIIVNNEKVFQCN 419

```

0y 420 SFRDPYQNNFIPRIVARVYVQTWQRIALKEVLLIGCOIT 462
    S F D P Y Q N N F I P R I V A R V Y V Q T W Q R I A L K E V L L I G C O I T
db 385 TMLTWTDVVBPDESKDVTREVRIRPVTWNGTSLRPLVGCXKIT 427
    T M L T W T D V V B P D E S K D V T R E V R I R P V T W N G T S L R P L V G C X K I T

```

RESULT 3

N/Alternate names: coagulation labile factor; proaccelerin
C/Species: Homo sapiens (man)
C/Date: 19-May-1989 #sequence_revision 02-Jun-1995 #text_change 08-Dec-2000

A:Reference number: A42344; MID:92232668
A>Title: Structure of the gene for human coagulation factor V.
Biochemistry 31, 3777-3785, 1992
RiCripe, L.D., Moore, K.D., Kane, W.H.

A: Molecule type: DNA
A: Residues: 1-2224 <CRI>
A: Cross-references: GB:J05368

A: Molecule type: DNA
A: Residues: 48-58; 79-89, 120-130, 191-201, 239-249, 313-323, 368-378, 428-437, 461-471, 533-570
A: Residues: 2111-2120, 2172-2181 <CR2>
R: Jernov, R.T.: Pittman, D.D.: Toolle, J.T.: Kriz, R.W.: Aldape, R.A.: Hewick, R.M.: K

A1:Title: Complete cDNA and derived amino acid sequence of human factor V.
A1:Reference number: A28028; NCID:87250886
A1:Accession: A28028

A: Residues: 1-857, 'R', 859-864, 'R', 866-924, 'E', 926-1763, 'I', 1765-2212, 'T', 2214-2224 < 2225
A: Cross-references: GB: M16967
A: Note: parts of this sequence, including the amino end of the mature protein, were

A:Title: Cloning of cDNAs coding for the heavy chain region and connecting region of A:Reference number: A27498; MUID:88107560
A:Accession: A27498
Biochemistry 26, 6508-6514, 1987

A;Residues: 1-1284, 'I', 1286-1600 <KAN>
A;Cross-references: GB:M17785
A;Note: parts of this sequence were determined by protein sequencing

Proc. Natl. Acad. Sci. U.S.A. 83, 6800-6804, 1986
A/Title: Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor X
A/Reference number: A25897; NCID:86313665

A; Molecule type: mRNA

C:Species: Rattus norvegicus (Norway rat)
 C:Date: 26-Sep-1996 #sequence:01-Nov-1996 #text-change:20-Jun-2000
 C:Accession: J04915
 R:Organ: K.; Nara, K.; Matanabe, Y.; Kohno, K.; Tai, T.; Sanli, Y.
 Biochem. Biophys. Res. Commun. 225, 932-938, 1996
 A:Title: Cloning and expression of cDNA for O-acetylation of Gm3 ganglioside.
 A:Accession: J04915
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-427 <OCU>
 A:Cross-references: DDBJ:D84068; NID:g1620006; PIDD:BAAL2210.1; PID:g1620007
 A:Experimental source: Csr cell
 A:Comment: This protein is required for the O-acetylation of disialoganglioside sialic A
 A:Genetics:
 C:Superfamily: milk fat globule protein: discoidin I amino-terminal homology; EGF homolo
 F:1-2/Domain: signal sequence status predicted <SIG>
 F:28-60/Domain: EGF homology <EG2>
 F:68-107/Domain: EGF homology <EG2>
 F:110-267/Domain: discoidin I amino-terminal homology <DN2>
 F:271-427/Domain: discoidin I amino-terminal homology <DN2>
 Query Match 9.7%; Score 297.5; DB 2; Length 427;
 Best Local Similarity 26.0%; Pred. No.1:8e-14;
 Matches 91; Conservative 44; Mismatches 96; Indels 119; Gaps 12;

215 TEYSKFCPA-----GCRVAGDISGNVGYRDSILKKAHAGIIA-DELGQOI 264
 DB 92 TETLCQPPVYSGIHCELSGSTRLEGGALAD-----SQISASSVGMFGIQRNGPEL 146
 QY 265 SYLQKRI-----SRVEGIILANCVSRD-----SL 290
 DB 147 AALRYGIYVAMTASSYDSPWIOYDFLEKRRVSGVMTQGA-SRAGRAEYLTFFKVAISL 205
 QY 291 SKRFLRLETS----- 299
 DB 206 DQRREFPIDESEGTGDEKFNQKNDONNELKTNMFPLEAQYIRLYPVSCRGCTLRFELL 265
 QY 300 -----NCGNSLSFE-----PDQIIRASSQSVNMSGQDVHNSPGQARLDQGP--SMAQC 349
 DB 266 GCEHGCSPRLGAKNNITPDSQIIRASSYKTNMLRA--PQWPHLGRIDNGSKTNIA--- 320
 QY 350 DSSNNHPRHELEIDEGKKKITGRTGTSQNFNFYVSKVNNFKNNKNTKQIY 409
 DB 321 -TQSSNAKEMLVQYDGTQKRYTGITGQADBGHGVKASVHSDGVQMTYVE--P 377
 QY 410 NNEEKVPGNSFRDPVNNFPIPIYARVVRVPPQTHRIALKEVLGIC 459
 DB 378 GGTSTVPGQNDNNKSKKNTFEKPRKARKVYRPLDSMHNITLRLDELGC 427

RESULT 7
 Factor VIII-associated gene B hypothetical protein - human
 C:Species: Homo sapiens (man)
 C:Date: 30-Sep-1993 #sequence:revision 30-Sep-1993 #text-change:18-Jun-1999
 R:Accession: A44258
 Biochem. Biophys. Res. Commun. 199, 585-589, 1999
 A:Title: Evidence for a third transcript from the human factor VIII gene.
 A:Reference number: A44258; MUID:93052386
 A:Accession: A44258
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-216 <LEV>
 A:Cross-references: GB:M90707; NID:g182316; PIDD:AA5846.1; PID:g182317
 F:Superfamily: coagulation factor VIII: discoidin I amino-terminal homology; ferroxidase
 F:1-2/Domain: discoidin I amino-terminal homology status typical <DN2>
 F:57-210/Domain: discoidin I amino-terminal homology <DN2>

Query Match 9.4%; Score 285.5; DB 2; Length 216;
 Best Local Similarity 37.6%; Pred. No.5:1e-14;
 Matches 62; Conservative 32; Mismatches 58; Indels 13; Gaps 4;

QY 300 NCGNSLSFE---PDQIIRASSQSVNMSGQDVHNSPGQARLDQGPSPASGSSNN 355
 DB 56 NCGNSLPLGMSKSLSDQALITASSYFNNHAT-----MSKRALHLDGSRNHRVYNN- 109
 QY 356 KRCHEMLIDEGKKKITGRTGTSQNFNFYVSKVNNFKNNKNTKQIYVNEKV 415
 DB 110 -KREMLVDVDFPKMTKMYGVTTQGVKSLTSMVKEFLISSDDHOMTLF--PQNGYKV 166
 QY 416 PQGNSFRDPVNNFPIPIYARVVRVPPQTHRIALKEVLGIC 460
 DB 167 PQGNDSPFVANSADPEPLTRITRIRHDSVHQAIALKEVLCGE 211

RESULT 8
 E2H
 coagulation factor VIII precursor [validated] - human
 N:Alternate names: antithrombophilic factor A; coagulation factor VIIIc; procoagulant co
 C:Species: Homo sapiens (man)
 C:Date: 28-Aug-1995 #sequence:revision 28-Aug-1995 #text-change:08-Dec-2000
 F:Accession: U154318; A00525; I58059; A23584; A26174; A42348; A43586; S63571; S66445;
 Hum. Mol. Genet. 1, 199-200, 1992
 A:Title: Sequence of the exon-containing regions of the human factor VIII gene.
 A:Reference number: I54318; MUID:93265012
 A:Accession: I54318
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-1521; 5'-1023-3251 <RSS>
 F:Accession: U154318; GB:M8648; NID:g182381; PIDD:AA52420.1; PID:g182383
 R:Wood, W.T.; Capon, D.L.; Simonsen, C.C.; Eaton, D.L.; Gitlschler, J.; Keyt, B.; Seeb
 Nature 312, 330-337, 1984
 A:Title: Expression of active human factor VIII from recombinant DNA clones.
 A:Reference number: A00525; MUID:85061546
 A:Accession: A00525
 A:Molecule type: mRNA
 A:Residues: 1-2351 <MOO>
 A:Cross-references: EMBL:X01165; EMBL:X01166; EMBL:X01119
 S:Don, Heide; Kozney, J.M.; Sultman, L.A.; Buckner, J.L.; Pittman, D.D
 Nature 312, 342-347, 1984
 A:Title: Molecular cloning of a cDNA encoding human antithrombophilic factor.
 A:Reference number: I58059; MUID:85061550
 A:Accession: I58059
 A:Status: nucleic acid sequence not shown; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-74; V,76-1259,7'E,1261-2351 <RC>
 A:Cross-references: EMBL:X01740; DDBJ:028202; SIB:AA5248.1; PID:g182803
 R:Butler, R.; Butler, R.L.; Capon, D.; Chu, C.; Dina, C.; Dina, C.; Hansen, J.;
 DNA 4, 333-349, 1985
 A:Title: Characterization of the polypeptide composition of human factor VIII:C and t
 A:Reference number: A23584; MUID:85081164
 A:Accession: A23584
 A:Molecule type: mRNA
 A:Residues: 1-2351 <RC>
 A:Cross-references: EMBL:X014113; NID:g182817; PIDD:AA5248.1; PID:g182818
 R:Butler, R.; Butler, R.L.; Capon, D.; Chu, C.; Dina, C.; Dina, C.; Hansen, J.;
 Biochemistry 25, 505-512, 1986
 A:Title: Proteolytic processing of human factor VIII. Correlation of specific cleavag
 ity.
 A:Reference number: A26174; MUID:86159740
 A:Accession: A26174
 A:Molecule type: Protein
 A:Residues: 20-26; 392-399, X,401-402;1668-1678;1709-1722, 'D',1723-1725;1741-1755 <EA
 R:Pittman, D.; Wang, J.H.; Seidman, R.J.
 Biochemistry 25, 505-512, 1986
 A:Title: Functional importance of tyrosine sulfite residues within
 A:Reference number: A42348; MUID:92207952
 A:Accession: A42348

[illegible]

[Faint, mostly illegible text body]

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OK protein - protein search, using sw model

Run on: July 9, 2002, 02:15:23 : Search time 35.54 Seconds

638,426 Million cell updates/sec

Title: US-09-691-344a-4

Sequence: 1 MGFAGQRLRPVAPPRSSAE.....YDNKEKMTOKLIDTSDMG 586

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 105224 seqs, 38719550 residues

Total number of hits satisfying chosen parameters: 105224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 08

Maximum Match 1008

Database : SwissProt_40.*

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	length	DB ID	Description
1	351.5	11.5	925	1	NRP2_RAT
2	349	11.4	931	1	NRP2_HUMAN
3	343.5	11.3	931	1	NRP2_MOUSE
4	336	11.1	934	1	NRP1_CHICK
5	331	10.8	922	1	NRP1_HUMAN
6	331	10.8	922	1	NRP1_RAT
7	331	10.8	921	1	FA5_BOVIN
8	330	10.8	928	1	NRP1_XENLA
9	329	10.8	923	1	NRP1_MOUSE
10	317	10.4	2224	1	FA5_HUMAN
11	314	10.3	2258	1	FA5_PIG
12	299	9.8	487	1	MEG3_HUMAN
13	297.5	9.7	487	1	MEG3_RAT
14	276.5	9.1	461	1	MEG3_MOUSE
15	276.5	9.1	2319	1	FA8_MOUSE
16	276.5	9.1	2319	1	FA8_MOUSE
17	271.5	8.9	2133	1	FA8_PIG
18	268	8.8	427	1	MEG3_BOVIN
19	259.5	8.5	409	1	MEG3_MOUSE
20	229.5	7.5	280	1	MEG3_PIG
21	221.5	7.3	224	1	XLR1_MOUSE
22	218.5	7.2	224	1	XLR1_HUMAN
23	195.5	6.4	1310	1	CTNA_HUMAN
24	194.5	6.4	1310	1	CTNA_MOUSE
25	194.5	6.3	1284	1	NRP2_HUMAN
26	192.5	6.3	1284	1	NRP2_MOUSE
27	187	6.1	3133	1	HMCT_BOVINE
28	186.5	6.1	686	1	MA52_HUMAN
29	172.5	6.0	1154	1	CTNA_HUMAN
30	163	5.7	564	1	DNS2_XENLA
31	163	5.7	564	1	DNS2_HUMAN
32	163	5.7	564	1	DNS2_MOUSE
33	162.5	5.3	704	1	CRAR_MOUSE

34	162.5	5.3	854	1	DDR2_MOUSE
35	161.5	5.3	449	1	PCOI_HUMAN
36	160	5.2	468	1	PCOI_MOUSE
37	159	5.2	550	1	COCH_HUMAN
38	158	5.2	991	1	BMP1_MOUSE
39	158	5.2	1022	1	TLD_BRAKE
40	157	5.2	532	1	COCH_MOUSE
41	157	5.1	855	1	DDR2_HUMAN
42	155.5	5.1	855	1	CASP_MESAU
43	149.5	4.9	695	1	LEFC_TGCR
44	146.5	4.8	1019	1	CTAL_MOUSE
45	142.5	4.7	1385	1	CTAL_MOUSE

ALIGNMENTS

Result ID	1	NRP2_RAT	STANDARD:	PRT:	925 AA.
DT	035276:				
DT	16-OCT-2001 (Rel. 40, Created)				
DT	16-OCT-2001 (Rel. 40, Last sequence update)				
DE	Neuropilin-2 precursor (Vascular endothelial cell growth factor 165 receptor 2).				
GN	NRP2				
CC	NRP2 is a semaphorin (Rel.).				
CC	Eukaryotes; Metazoa; Chordata; Vertebrata; Euteleostomi;				
CC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus.				
CC	NCBI_Taxid=10116;				
CC	[1]				
CC	SEQUENCE FROM N.A.				
CC	STRAIN=SEPARUS-DWLEY;				
CC	MDL=97435085; PubMed=928075;				
CC	MDL=97435085; Home E.C., Tal.Y.-T., Giger R.J.,				
CC	Glady D.D.				
CC	Neuropilin is a semaphorin III receptor. *				
CC	Cell 90:753-762(1997).				
CC	- FUNCTION: HIGH AFFINITY RECEPTOR FOR SEMAPHORINS 3C, 3F, VEGF-165				
CC	- SUBCELLULAR LOCATION: TYPE 1 membrane protein. POPULATIONS OF NRE				
CC	- TISSUE SPECIFICITY: FOUND IN CERTAIN NEURONAL POPULATIONS OF NRE				
CC	- CHS AND N RECEPTORS. UNCOMMONLY TISSUES INCLUDING MESCHRYMAL TISSUE				
CC	- SIMILARITY: BELONGS TO THE NEUROFILIN FAMILY.				
CC	- SIMILARITY: CONTAINS 2 CUB DOMAINS.				
CC	- SIMILARITY: CONTAINS 1 F5/8 TYPE C DOMAINS.				
CC	- SIMILARITY: CONTAINS 1 MAM DOMAIN.				
CC	- This SWISS-PROT entry is copyright. It is produced through a collaboration				
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation-				
CC	the European Bioinformatics Institute. There are no restrictions on ways				
CC	modified and this statement is not removed usage by "and for commercial				
CC	entities requires a license agreement (See http://www.isb-sb.ch/announce/				
CC	or send an email to license@isb-sb.ch).				
CC	EMBL: AF016297; AAC5338.1; -				
CC	Interpro: IPR000859; CUB.				
CC	Interpro: IPR000859; FAS8-C.				
CC	Interpro: IPR000859; MAM.				
CC	Interpro: IPR000859; MAM.				
CC	Pfam: PF00724; P1_PB_Type-C_2.				
CC	Pfam: PF00629; MAM_1.				
CC	SMART: SM0042; CUB; 2.				
CC	SMART: SM00231; FAS8C; 2.				
CC	PROSITE: PS01180; CUB; 2.				
CC	PROSITE: PS01285; FAS8C; 2.				
CC	PROSITE: PS00426; MAM2; 2.				
CC	Transmembrane, Glycoprotein, Neurone, Signal, Repeat, Receptor.				

CX	Mammalia/Eutheria; Primates; Catarrhini; Homidae; Homo.
RX	NBCL-Texid-9606;
RP	[1]
RA	SEQUENCE FROM N.A. (ISOFORMS A0 AND A17).
RR	MEDLINE=97470889; PubMed=9333348;
RT	Chen H., Chedotal A., He Z.-G., Goodman C.S., Tessier-Lavigne M.;
RT	"Neuropilin-2, a novel member of the neuropilin family, is a high
RT	affinity receptor for the semaphorins Sema E and Sema IV but not Sema
RL	Neurin 19:547-559(1997).
RV	[2]
RC	SEQUENCE FROM N.A. (ISOFORM A22).
RD	TISSUE-Breast;
RE	MEDLINE=98188099; PubMed=9529250;
RF	Soker S., Takashima S., Miao H.-O., Neufeld G., Klagsbrun M.;
RG	"Neuropilin-1 is expressed by endothelial and tumor cells as an
RI	isoform specific receptor for vascular endothelial growth factor."
RL	Cell 92:735-745(1996).
RV	[3]
RC	CHARACTERIZATION,
RD	MEDLINE=20309748; PubMed=10748121;
RE	Guzman-Poltorak Z., Cohen T., Herzog Y., Neufeld G.;
RF	"Neuropilin-2 and neuropilin-1 are receptors for the 15 ^o -amino acid
RG	form of vascular endothelial growth factor (VEGF) and of placenta
RH	growth factor-2, but only neuropilin-2 functions as a receptor for
RI	the 14 ^o -amino acid form of VEGF."
RL	J. Biol. Chem. 275:18040-18045(2000).
RV	[4]
RC	FUNCTION: HIGH AFFINITY RECEPTOR FOR SEMAPHORINS 3C, 3E, VEGF-165
RD	AND VEGF-121. ALSO FUNCTIONS AS THE PLAC ISOFORM OF VEGF
RE	STIMULY NEUROPOD FORMATION. POSSIBLY INVOLVED IN CELL WITH
RF	NEURAPILIN-1 IN ORDER TO BE A FUNCTIONAL SEMAPHORIN 3C RECEPTOR.
RG	- SUBCELLULAR LOCATION: Type I membrane protein.
RH	- ALTERNATIVE PRODUCTS: 3 ISOFORMS: A22 (SHOWN HERE), A0 AND A17,
RI	ARE PRODUCED BY ALTERNATIVE SPLICING.
RL	- SIMILARITY: BELONGS TO THE NEUROPILIN FAMILY.
RV	- SIMILARITY: CONTAINS 2 CUB DOMAINS.
RC	- SIMILARITY: CONTAINS 2 F3/9 TYPE C DOMAINS.
RD	- SIMILARITY: CONTAINS 1 MM DOMAIN.
RE	This SWISS-PROT entry is copyright © It is produced through a collaboration
RF	between the Swiss Institute of Bioinformatics and the National Institutes
RG	of Health Biotechnology Resource Project. There are no restrictions on its
RH	use by non-profit institutions as long as its content is in no way
RI	modified and this statement is not removed. Usage by and for commercial
RL	entities requires a license agreement (see http://www.isb-sib.ch/nucleotide/
RV	or send an email to license@isb-sib.ch).
CC	-----
CC	EMBL: AF022859; AAC51788.1; .
CC	EMBL: AF022860; AAC51789.1; .
CC	GENBANK: U000076; AAC12822.1; .
CC	MIK: 602070
CC	InterPro: IPR000859; CUB.
CC	InterPro: IPR000431; PAS8_C.
CC	InterPro: IPR000998; NAM.
CC	Pfam: PF00431; CUB; 2.
CC	Pfam: PF00754; F5_F8_Type_C; 2.
CC	Pfam: PF00629; NAM; 1.
CC	SMART: SM00042; CUB; 2.
CC	SMART: SM00231; PAS8C_2.
CC	SMART: SM00160; NAMCUB_2.
CC	PROSITE: PS01285; PAS6C_1.
CC	PROSITE: PS01285; PAS6C_2.
CC	PROSITE: PS00060; NAM_2; 1.
CC	Transmembrane: Glycoprotein; Neurone; Signal; Repeat; Receptor;
KW	Alternative splicing.
KV	FT SIGNAL 1 30
FT	CHAIN 21 931
FT	DOMAIN 21 664
FT	TRANSMEM 865 889
FT	DOMAIN 865 889
FT	TRANSMEM 928 942
FT	DOMAIN 928 142
FT	DOMAIN 149 267
FT	CUB 2
FT	CUB 2
FT	OR 22 (POTENTIAL).
FT	NEUROPILIN-2.
FT	EXTRACELLULAR (POTENTIAL).
FT	POTENTIAL.
FT	INTRACELLULAR (POTENTIAL).
FT	CYTOPLASMIC (POTENTIAL).

Query Match 11.48; Score 349; DB 1; Length 931;
Best Local Similarity 25.38; Pred. No. 1.1e-18;
Matches 109; Conservative 72; Mismatches 166; Indels 84; Gaps 16;

QY	88	CGHJLYUDCMTSEKXUYCQYUYNHCEKTIYVK-GRHILG-C-DLDEQCASD	145
QY	28	CGGSLMDACUITYSPGPODPYSHONCEMYVAEPERKUYLVNPHRELEKDXDE	87
QY	146	LLF---TSSSDYAPYCSQMYVKEKLLINTSVPYFRESGSHISGRGLTY-----	196
QY	86	LEHDDSSADLLKRCMGNT-APPKILSSGSLYAKTSDYARQAGSLRELEKTS	146
DY	197	SD-----HDDLYTC-----LRASHTLYTSKSF-----	220
DY	147	ECSCKEPSPNCTIESGPEPEYHMLDCTFLAKPMEHLLQFLFDLHDPQLDQED	206
QY	221	-CPAGCRVADGDS--GNWYDQYDNTSLICKAAIHAGIADLGGQISVLRGRGSRFX	277
DY	207	DOCKTMDLMDGIPVAGLIGYCKTRPSELSSTSGILSLFPHDMAVK-----	259
QY	278	ILANGLYSROSLSEKLEFLTSNCSRSLSFE-----PQOYIASSMOSVWESGDVHNS	333
DY	260	FSARYLVHOPLEPNFO-----CWPFLMGESGLINQISASSTY-----SDCHWT	305
QY	334	PQARLDQDGSMWAGGSSNNHKPRMSLEIDLDEKKRTIYITG--STOSNFYVNS	391
QY	306	POOSRHLDDMGKTEPNDLS--KEYLADVLFPLMTLTYTGALISHTONGVYVASV	361
DY	392	YVNRNNNSKKRTYIGIYNNEKYFGQSNFNRPOANNLPYIARYAVVPOTMHQRIA	451
DY	362	KLEVFNSEGMWYTRHCKNH--KTFQANNDAITVYLAKLHAHLDRVHISQTHMSQIA	419
QY	452	LKVELIGCQIT 462	
QY	420	LATLFGCRVT 430	

	RESULT#	3	
ID	NRP2_MOUSE		
AC	035375: 035373: STANDARD:	PRT.	931 AA.
D7	16-OCT-2001 (Rel. 40, Created)		035378;
D7	16-OCT-2001 (Rel. 40, last sequence update)		
D7	16-OCT-2001 (Rel. 40, last annotation update)		
DE	Neurokinin-2 precursor (Vascular endothelial cell growth factor 165 receptor 2).		
OS	Mus musculus (Mouse).		
OC	Mus musculus (Mouse).		
OC	Eukaryotes; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Rodentia; Scuriongnathi; Muridae; Murinae; Mus.		
NCBI_Textid	-10090;		
[1]			
RN	SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.		

[illegible]

RN	[1]	SEQUENCE FROM N.A.
CC		STRAIN-WHITE LEGHORN; TISSUE-Embryonic brain:
RC		MEDLINE=9532476; PubMed=7601310;
RA		Takagi S., Kasuya T., Shimizu H., Matsura T., Tsuboi M., Kawakami A.,
RT		"Expression of a cell adhesion molecule, neuropilin, in the
RT		developing chick nervous system."
CC		dev. Biol. 170:207-222(1995).
CC	-1-	FUNCTION: RECEPTOR INVOLVED IN THE DEVELOPMENT OF THE
CC		CEREBIN NEUROGLIAL SYSTEM, IN ANGIOGENESIS, IN THE FORMATION OF
CC		SYSTEM IT MEDIATES THE CHEMOKINE/LEUKOTAXIN ACTIVITY OF SEMAPHORINS (BY
CC		SIMILARITY). SEEMS TO HAVE CALCIUM-INDEPENDENT CELL ADHESION
CC		PROPERTIES. LOCATION: TYPE I membrane protein,
CC	-1-	TISSUE SPECIFICITY: DEVELOPING NERVOUS SYSTEM; OPTIC TECTUM
CC		DORSAL ROOT GANGLIA. ALSO EXPRESSED IN NONNEURONAL CELLS, E.G.
CC		BLOOD VESSELS IN THE EMBRYO.
CC	-1-	SIMILARITY: BELONGS TO THE NEUROPILIN FAMILY.
CC	-1-	SIMILARITY: CONTAINS 2 CUB DOMAINS.
CC	-1-	SIMILARITY: CONTAINS 2 F5/8 TYPE C DOMAINS.
CC		--
CC		THIS SWISS-PROT ENTRY IS COPYRIGHT © IT IS PRODUCED THROUGH A COLLABORATION
CC		OF THE SWISS FEDERAL INSTITUTE OF BIOINFOMATICS AND THE EMBL OUTPOST AT
CC		THE EUROPEAN BIOMATHMATICS INSTITUTE. THERE ARE NO RESTRICTIONS ON ITS
CC		USE BY NON-PROFIT INSTITUTIONS AS LONG AS ITS CONTENT IS IN NO WAY
CC		MODIFIED AND THIS STATEMENT IS NOT REMOVED. USAGE BY AND FOR COMMERCIAL
CC		ENTITIES REQUIRES A LICENSE AGREEMENT (see http://www.isb-sib.ch/announce/
CC		or send an email to license@isb-sib.ch).
CC		--
DR	EMBL:	D45416; XA08256.1; .
DR	InterPro:	IPIR000859; CUB_1.
DR	InterPro:	IPIR000951; FAM_LC.
DR	Pfam:	PF000431; CUB_2.
DR	Pfam:	PF000431; CUB_2.
DR	Pfam:	PF006254; F5_F8_Type_C_2.
DR	PRINTS:	PR00020; NAMDOMAIN.
DR	SMART:	SM00042; CUB_2.
DR	SMART:	SM00137; FAM_LC.
DR	PROSITE:	PS01180; CUB_2.
DR	PROSITE:	PS01286; FAMSC_2.
DR	PROSITE:	PS00740; MM_1_1.
DR	PROSITE:	PS00660; MM_2_1.
KW		Transmembrane; Glycoprotein; Neurone; Signal; Repeat; Receptor;
KW		Cell adhesion.
FT	SIGNAL:	1 .. 18
FT	CHAIN:	1 .. 914
FT	DOMAIN:	870 .. 847 POTENTIAL.
FT	TRANSMEM:	836 .. 870 EXTRACELLULAR (POTENTIAL).
FT	DOMAIN:	871 .. 914 CYTOPLASMIC (POTENTIAL).
FT	DOMAIN:	145 .. 263 CUB 1.
FT	DOMAIN:	273 .. 422 CUB 2.
FT	DOMAIN:	429 .. 581 F5/8 type C 1.
FT	DOMAIN:	636 .. 801 F5/8 type C 2.
FT	DISULFID:	25 .. 52 PROBABLE.
FT	DISULFID:	80 .. 102 PROBABLE.
FT	DISULFID:	145 .. 171 PROBABLE.
FT	DISULFID:	234 .. 226 PROBABLE.
FT	DISULFID:	429 .. 581 PROBABLE.
FT	DISULFID:	582 .. 581 BY SIMILARITY.
SO	SEQUENCE	914 AA; 102460 MW; DDZEEDEDFQCBG66C CRC64;

Query Match 11.1%; Score 336; DB 1; Length 914;
 Best Local Similarity 25.7%; Pred. no. 7,6e-18;
 Matches 115; Conservative 67; Mismatches 180; Indels 86; Gaps 17;

68 ALLVAVSAPRLQAEELGPGCGHLYVTQDSMTSKNYPGRYNNHTCEKTIITVPRG -KR 126
 11 ALFFELSLMAR-----SDKCGDTRIKLISPGTISGYSHFSCWELIOAPROR 64
 127 LILRLG-DIDIESQTCADYLITSSDQ---YGPYCGMTVPKELLMTSEVYREPS 181
 65 LKNNNHEDLDCKDCKDIDYEVLDQDAGRLMGKIGK1-APPVLASGGYLFITKPS 123
 182 GSHISGCGFLTY-----ASG-----DHDDITIC-----205
 124 DVTMGAGPSIFRYEVRKRCPSRNFTSSSGIKSPGPKRYNSLCTGYITFAPKMSI 183
 0Y 206 LERASHYIKTEYSKRCPCAGCNVDGDISGNVYDQRT---SLICKAHIAH11ADEL 260
 DB 148 LIFESFELSPSTPGCAGFCRIDLME---WQSPFDGHLGKVC-GQNPGRVHST 316
 0Y 261 GGGISIVYDYSALIKGFSGLANGYLKSGCSISGRKRFLEFISNCCSRLSTPE---DQIRA 316
 DB 239 GILSVYDYSALIKGFSANYSVSQSVSDQF---CMEDLAGSGEHSQITV 291
 0Y 317 SSSMSQVNESGDOYVHNSPGQARLDQCPASVASCSSNNMKPRMLDIDGEEKKATIGRT 376
 DB 292 SSQYSAL-----WSESRKLTMPKMGTKGDS---VFEMVDVGLALRFRVSGIGT 339
 0Y 377 TG-STQSNFYVYSFVYMRKNNKSNKWTYGVGVINEEYRQCSNRPDPQNNPTPT 434
 DB 340 OGAKIKETKKKKYLFATYVDSNGEDMTIK--EKNKRVYFGNSNPDVYVPRPFV 397
 0Y 435 VARYRVVQTHQRIALAKVELIGCOIT 462
 DB 398 LTFVRIKRPKSNWNGSVLRPEYGVKIT 425
 5
 NRPL_HUMAN STANDARD: PRT; 923 AA.
 ID NRPL_HUMAN 014786; 060461.
 AC 30-MAY-2000 (Ref. 39, Created)
 DT 16-OCT-2001 (Ref. 40, Last sequence update)
 DT 16-OCT-2001 (Ref. 40, Last annotation update)
 DE Neoptilin-1 precursor (vascular endothelial cell growth factor 165
 OS Homo sapiens (Human)
 GN NRPL OR NRP OR VEGF165R.
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 CX MCBT_XTAD19606;
 NX 11
 RP SEQUENCE FROM N.A. (MEMBRANE-BOUND ISOFORM).
 RF MEDLINE=97453084; PUBMED=9288753;
 RT "Neoptilin is a receptor for the axonal chemorepellent semaphorin
 RL Cell 90:739-751(1997).
 RP SEQUENCE FROM N.A. (MEMBRANE-BOUND ISOFORM), AND SEQUENCE OF 22-39.
 RF TISSUE-Breast;
 RX MEDLINE=98188099; PUBMED=9529250;
 RX SOKER S., Takashima S., Miao H.-Q., Neufeld G., Klagsbrun M.,
 RX "Neoptilin is expressed by endothelial and tumor cells as an
 RX isofunctional receptor for vascular endothelial growth factor.";
 RL Cell 92:735-745(1998).
 RP SEQUENCE FROM N.A. (SOLUBLE/SNR1 ISOFORM), AND SEQUENCE OF 22-31.
 RF TISSUE-Prostatic adenocarcinoma;
 RX MEDLINE=20183929; PUBMED=10688880;
 RX GAGNON M.L., Bieleberg D.R., Gechtman Z., Miao H.-O., Takashima S.,
 RX "Neoptilin is a natural soluble neoptilin-1 that binds vascular
 RX endothelial growth factor: In vivo expression and antitumor
 RX activity.";
 RL Proc. Natl. Acad. Sci. U.S.A. 97:2573-2578(2000).

14
 NR CHARACTERIZATION
 RX MEDLINE=20309748; PUBMED=10748121;
 RX GLUZMAN-POLTORAK Z., Cohen T., Herzog Y., Neufeld G.;
 RT "Neoptilin-2 and neoptilin-1 are receptors for the 165-amino acid
 RT form of vascular endothelial growth factor (VEGF) and of placenta
 RT growth factor-2, but only neoptilin-2 functions as a receptor for
 RT the 145-amino acid form of VEGF.";
 RL J. Biol. Chem. 275:18040-18045(2000).
 CC FUNCTION: THE MEMBRANE-BOUND ISOFORM IS A RECEPTOR INVOLVED IN THE
 CC FORMATION OF CERTAIN NEURONAL CIRCUITS AND IN ANGIOGENESIS IN THE
 CC OUTSIDE OF THE NERVOUS SYSTEM. IT MEDIATES THE CHEMOREPULSANT
 CC ACTIVITY OF SEMAPHORINS. IT BINDS TO SEMAPHORIN 3A, THE PLOF-2
 CC ISOFORM OF VEGF, THE VEGF-165 ISOFORM OF VEGF AND VEGF-B.
 CC COEXPRESSION WITH KDR RESULTS IN INCREASED VEGF-165 BINDING TO KDR
 CC AS WELL AS INCREASED CHEMOTAXIS. IT MAY REGULATE VEGF-INDUCED
 CC ANGIOGENESIS.
 CC TISSUE: THE SOLUBLE/SNR1 ISOFORM BINDS VEGF-165 AND APPEARS
 CC TO INITIATE THE BINDING OF OTHER KDR-LIGANDS UNDER
 CC SEMAPHORIN FAMILY. ITS EXPRESSION AS WELL VARIOUS MEMBERS OF THE
 CC VESSEL NUMBER AND INTEGRITY.
 CC SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN. THE SOLUBLE/SNR1
 CC ISOFORM IS SECRETED.
 CC ALTERNATIVE PRODUCTS: 2 ISOFORMS; MEMBRANE-BOUND (SHOWN HERE)
 CC AND SOLUBLE/SNR1. ARE PRODUCED BY ALTERNATIVE SPLICING.
 CC TISSUE: SEMAPHORIN-3A AND VEGF-165 ARE THE MAIN MEMBRANE-
 CC BOUND ISOFORM IS EXPRESSED BY THE BLOOD VESSELS OF DIFFERENT
 CC TISSUES. IN THE DEVELOPING EMBRYO IT IS FOUND PREDOMINANTLY IN THE
 CC NERVOUS SYSTEM. IN ADULT TISSUES, IT IS HIGHLY EXPRESSED IN HEART
 CC AND PLACENTA; MODERATELY IN LUNG, LIVER, SKELETAL MUSCLE, KIDNEY
 CC AND PANCREAS; AND LOW IN ADULT BRAIN. THE SOLUBLE/SNR1 ISOFORM IS
 CC FOUND IN LIVER HEPATOCYTES, KIDNEY DISTAL AND PROXIMAL TUBULES.
 CC SIMILARITY: CONTAINS 2 CDS OF THE NEOPTILIN FAMILY.
 CC SIMILARITY: CONTAINS 2 F58B TYPE C DOMAINS.
 CC SIMILARITY: CONTAINS 1 MM DOMAIN.
 CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed, usage by it for commercial/
 CC or send an email to license@ebi.ac.uk (see <http://www.ebi.ac.uk/submit/>)
 CC -----
 DR EMBL; AF018956; AAC51759.1; -
 DR EMBL; AF016050; AAC12921.1; -
 DR EMBL; AF145712; AAF4334.1; -
 DR MIM; 602069; -
 DR InterPro: IPR000859; CDB
 DR InterPro: IPR000421; FAS8_C
 DR InterPro: IPR000422; FAS8_G
 DR InterPro: IPR000998; MM
 DR Pfam: PF00754; F5_F8_Type_C; 2
 DR Pfam: PF00659; MM; 1
 DR PRINTS; PR00020; NAMD0MAIN
 DR SMART; SM00042; CUB; 2
 DR SMART; SM00231; EX58c; 2
 DR SMART; SM0137; MM; 1
 DR SMART; SM0138; MM; 2
 DR PROSITE; PS01285; FAS8c.1; 2
 DR PROSITE; PS01286; FAS8c.2; 2
 DR PROSITE; PS00740; MM.1; 1
 DR PROSITE; PS50060; MM.2; 1
 DR Transmembrane; Glycoprotein; Neurone; Signal; Repeat; Receptor;
 KW Alternative splicing;
 FT SIGNAL 1 21
 FT CHAIN 22 923
 FT DOMAIN 22 856 NEOPTILIN-1.
 EXTRACELLULAR (POTENTIAL).

```

FT TRANSMEM 857 879 POTENTIAL.
FT DOMAIN 880 923 CYTOSOLSMIC (POTENTIAL).
FT DOMAIN 127 141 CUB 1.
FT DOMAIN 147 265 CUB 2.
FT DOMAIN 275 424 F5/8 type C 1.
FT DOMAIN 431 583 F5/8 type C 2.
FT DOMAIN 645 811 MM.
FT DISULFID 82 104 PROBABLE.
FT DISULFID 147 173 PROBABLE.
FT DISULFID 206 228 PROBABLE.
FT DISULFID 275 424 BY SIMILARITY.
FT DISULFID 431 583 N-LINKED (GLCMAC. .) (POTENTIAL).
FT CARBOHD 150 150 N-LINKED (GLCMAC. .) (POTENTIAL).
FT CARBOHD 261 261 N-LINKED (GLCMAC. .) (POTENTIAL).
FT CARBOHD 320 320 N-LINKED (GLCMAC. .) (POTENTIAL).
FT CARBOHD 322 322 N-LINKED (GLCMAC. .) (POTENTIAL).
FT CARBOHD 842 842 EEP -> GIK (IN SOLUBLE/SNRP ISOFORM).
FT VASPLIC 645 923 MISSING (IN SOLUBLE/SNRP ISOFORM).
FT CONFLICT 26 26 K -> E (IN REF. 1).
FT CONFLICT 749 749 D -> H (IN REF. 2).
FT CONFLICT 855 855 E -> D (IN REF. 2).
SQ SEQUENCE 923 AA: ADEMDCAVA495D57 CRC64:

Query Match 11.0%: Score 335; DB 1; Length 923;
Best Local Similarity 24.9%: Pred. No. 1,3e-17;
Matches 124; Conservative 76; Mismatches 176; Indels 122; Gaps 23:

OY 64 RGL-----LALLAVASPLRLQAEELDGGGGLVLYQDSGTMRSKNVGTGYRPHVCEK 117
DB 3 RGLPLCALVLAALVLAQAAR-----NKKCGDTIKESPGELISPGYSHSTPSEKCEM 56
OY 118 TTPYKQ-KRLIRLGG-DLDSISQTSNVY-LFTSSDD--VGPQCSMTYPKELLAM 171
DB 57 LLOAPDYORIMNFPHPLDRCCKYVEVDFENHGFNRCKPCKI-APPVVS 115
OY 172 TSEYVTFESSHISGCGFLTYA-----SSDHPDLITC-. 205
DB 116 GPFPLTFEVSQYETHMAGPSIRIRFKRPGPCQNTTPSGVYASPOPEKTPMISLECY 175
OY 206 -----LERASHYIKTYSKCPAG--GROWAGDSSNMWQYDPTSLCKAHL 252
DB 176 IYFAPKSEIILFESEFLEDPDSNP--PGGFCRYORLEI-----WDGPD-----VCPH 223
OY 253 AG-11ADELGGQI-----SVLQRKGISREYELIANGVLSHDSLSLDRKFLP 297
DB 224 IGRGQKTPKIRRSSGILSWFYTDLSIMAKRETSAMTSVLOSSV-SDKR----- 274
OY 298 TSNCSISLSEPP-----DQIYASSSMQVNSGQWQPOARLDDGQISNAGSDSN 353
DB 275 -----CHEALGMESEGHSDQITASSQYST-----NMSARSRMLPENGMTPEEDSY 322
OY 354 NHRKREMLIDLEKKKKTIRITGG--STQSNFNFYVSVKNNKNNKKRYKATYNN 411
DB 323 -----REMDIVDLGLFTYAVGTQGLASKEKKRYVYKIDVSSGMDITIK--BGR 376
OY 412 EKKYQNGSNRPNQNNFTPIYAVYVYRPTMORIALAVELICQI-----QGNDS 467
DB 377 KVLQGGQNTNFDVYVAVFEXPLTRVWIKPAMTGMTISMPFVYCKITIDPSCMG 436
OY 468 LYMKRSTOSTSVSKKED 485
DB 437 MVSGLISDSTISSNOGD 454

```

```

DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Neutrophilin-1 precursor (Vascular endothelial cell growth factor 165
DE receptor).
GN NRPL.
OC Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eulipedia; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC NCBI:txid=10116;
RC SEQUENCE FROM N.A.
RP STRAIN=SPRAGUE-DAWLEY;
RA MEDLINE=97433085; PubMed=9288754;
RX Kolodka A.L., Levengood D.V., Rowe E.G., Tai Y.-T., Giger R.J.,
RA Glut D.D.;
RT "Neutrophilin is a semaphorin III receptor.";
RL Celi 90:153-162(1998).
CC -1- CARDIOVASCULAR SYSTEM. INVOLVED IN THE DEVELOPMENT OF THE
CC CEREBRAL NEURONAL CIRCUITS AND IN ORGANOREGULATION OF SEMAPHORIN. IT
CC SYSTEM. IT MEDIATES THE CHEMOREPULSANT ACTIVITY OF SEMAPHORIN. IT
CC BINDS TO SEMAPHORIN 3A, THE PLGF-2 ISOFORM OF PGF, THE VEGF-165
CC ISOFORM OF VEGF AND VEGF-B. COEXPRESSION WITH KDR RESULTS IN
CC INCREASED VEGF-165 BINDING TO KDR AS WELL AS INCREASED CHEMOTAXIS.
CC IT MAY REGULATE VEGF-INDUCED ANGIOGENESIS (BY SIMILARITY).
CC -1- SUBCELLULAR LOCATION: Type II membrane protein.
CC -1- SIMILARITY: BELONGS TO THE NEUTROPHILIN FAMILY.
CC -1- SIMILARITY: CONTAINS 2 F5/8 TYPE C DOMAINS.
CC -1- SIMILARITY: CONTAINS 1 MM DOMAIN.
CC -1- SIMILARITY: CONTAINS 1 MM DOMAIN.
CC THIS SWISS-PROT entry is copyrighted. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
CC at EMBL Grenoble. All rights reserved. No part of this entry may be
CC reproduced, stored in a retrieval system, or transmitted, in any form or by
CC any means, electronic, mechanical, photocopying, recording, or by any
CC information storage and retrieval system, without prior permission in
CC writing from the copyright owner. The copyright owner hereby grants
CC permission to use the material in this entry for non-profit educational
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DB EMBL: AF016296; AAC53337.1; .
DB InterPro: IPR000439; CUB 2.
DB InterPro: IPR000439; CUB 2.
DB InterPro: IPR001092; HHL dlm.
DB InterPro: IPR000998; MM.
DB Pfam: PF00431; CUB; 2.
DB Pfam: PF00754; F5_F8_Type_C; 2.
DB Pfam: PF00629; MM; 1.
DB PRINTS: PR00020; MAMDOMAIN.
DB SMART: SM00042; CUB 2.
DB SMART: SM00043; CUB 2.
DB SMART: SM00137; MM; 1.
DB PROSITE: PS01180; CUB; 2.
DB PROSITE: PS01285; FAS8C; 2.
DB PROSITE: PS01286; FAS8C; 2.
DB PROSITE: PS00740; MM; 1; 1.
DB PROSITE: PS50060; MM; 2; 1.
DB Transmembrane; Glycoprotein;
KW SIGNAL.
FT CUB 1.
FT CUB 2.
FT TRANSMEM 856 880 POTENTIAL.
FT TRANSMEM 881 922 CYTOSOLSMIC (POTENTIAL).
FT DOMAIN 27 141 CUB 1.
FT DOMAIN 147 265 CUB 2.
FT DOMAIN 275 424 F5/8 type C 1.
FT DOMAIN 431 583 F5/8 type C 2.
FT DOMAIN 645 811 MM.
FT DISULFID 82 104 PROBABLE.
FT DISULFID 147 173 PROBABLE.
FT DISULFID 206 228 PROBABLE.
FT DISULFID 275 424 BY SIMILARITY.
FT DISULFID 431 583

```

Query Match 10.8%; Score 331; DB 1; Length 922;
 Best local Similarity 24.1%; Pred. No. 2,6e-17;
 Matches 112; Conservative 81; Mismatches 166; Indels 106; Gaps 19;

FT CARBOHYD 150 150 N-LINKED (GLCNAC...) (POTENTIAL)
 FT CARBOHYD 261 261 N-LINKED (GLCNAC...) (POTENTIAL)
 FT CARBOHYD 300 300 N-LINKED (GLCNAC...) (POTENTIAL)
 FT CARBOHYD 522 522 N-LINKED (GLCNAC...) (POTENTIAL)
 FT CARBOHYD 841 841 N-LINKED (GLCNAC...) (POTENTIAL)
 SS SOURCE 922 AA; 103082 MW; CCGF82AD09B80FE2 CRC64;

64 RGL-----LALLAVSAPRLQAEELDDCCGHLYVYDQSTYKSNKPTGYPMHWCEK 117
 3 RGLULCALTALALALALAKGR-----SDKCGGTIKTEPMYLYTSHPHSHSEKCV 56
 118 RTVYPMG-KRLIRLNG-DLDESGTCADVLLFTSSDQ-----YPCSSMRYKELLIN 171
 57 LQAQPPYRIMINFNPHDELROCKDYVDVADGNEGCRJLAKCKCKI-ASPVVSS 115
 172 TSEYVRESGSHISGRGFLTYA-----SSSDPDLTYC- 205
 116 GPPIFKVYSDTHFGHNGSIRLEFRKRECSONTAPGVTSRPPREKYPNSLECTY 175
 206 -----LEBASYHLYEYSKPCAG-CEBDAQDTCGMGDTGRTSLCCAAH 219
 176 ITPAPMSEIILEEFSFLEDDSNP-PCGVCFGRLEI-----WDSPPE 252
 253 AGIADLGQISVYLQKISRYEGLA-----NCVLSDSLSIKRFLFETNG-----CS 303
 220 ----VPHLGTGCGKTPGRIRSSGISLWVFTLSALAEQFVAVLOSISIEDFCM 276
 304 RSLSEPP-----DQGIKASSWSQVSGDOVHFEQCAHLDQGFVSASGSSNNHKFRE 359
 277 EALGHSCEHSDQITASSOYGT-----NMSVERSLNMPKMGVTCESL-----RE 324
 360 WLEIDLEKKKIGTIGRTG-STOSNENFYVSSVNNKNNKMKYGGVYNNEKRFQ 417
 325 WIVQDLGLFVYVAVGQALISKERRKRYRTVETDYLSSNGEDMLTK-EGNKAIFFQ 382
 418 GSNSEPDVGNNEIPVAVRYNVPYPTMHQRIALVELGCOIT 462
 383 GNTNPTDVGVEFKPLITRFYRIKIPASMGISMGVYCKIT 427

RESULT 7
 F5-BOVINE BOVIN STANDARD; PRT; 2211 AA.
 AC 028107 028108; Rel. 35. Created
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 CS Coagulation factor V precursor (Activated protein C cofactor).
 GN F5.
 OS Bos taurus (Bovine).
 EC 3.4.21.30; 3.4.21.31; 3.4.21.32; 3.4.21.33; 3.4.21.34; 3.4.21.35; 3.4.21.36; 3.4.21.37; 3.4.21.38; 3.4.21.39; 3.4.21.40; 3.4.21.41; 3.4.21.42; 3.4.21.43; 3.4.21.44; 3.4.21.45; 3.4.21.46; 3.4.21.47; 3.4.21.48; 3.4.21.49; 3.4.21.50; 3.4.21.51; 3.4.21.52; 3.4.21.53; 3.4.21.54; 3.4.21.55; 3.4.21.56; 3.4.21.57; 3.4.21.58; 3.4.21.59; 3.4.21.60; 3.4.21.61; 3.4.21.62; 3.4.21.63; 3.4.21.64; 3.4.21.65; 3.4.21.66; 3.4.21.67; 3.4.21.68; 3.4.21.69; 3.4.21.70; 3.4.21.71; 3.4.21.72; 3.4.21.73; 3.4.21.74; 3.4.21.75; 3.4.21.76; 3.4.21.77; 3.4.21.78; 3.4.21.79; 3.4.21.80; 3.4.21.81; 3.4.21.82; 3.4.21.83; 3.4.21.84; 3.4.21.85; 3.4.21.86; 3.4.21.87; 3.4.21.88; 3.4.21.89; 3.4.21.90; 3.4.21.91; 3.4.21.92; 3.4.21.93; 3.4.21.94; 3.4.21.95; 3.4.21.96; 3.4.21.97; 3.4.21.98; 3.4.21.99; 3.4.22.1; 3.4.22.2; 3.4.22.3; 3.4.22.4; 3.4.22.5; 3.4.22.6; 3.4.22.7; 3.4.22.8; 3.4.22.9; 3.4.22.10; 3.4.22.11; 3.4.22.12; 3.4.22.13; 3.4.22.14; 3.4.22.15; 3.4.22.16; 3.4.22.17; 3.4.22.18; 3.4.22.19; 3.4.22.20; 3.4.22.21; 3.4.22.22; 3.4.22.23; 3.4.22.24; 3.4.22.25; 3.4.22.26; 3.4.22.27; 3.4.22.28; 3.4.22.29; 3.4.22.30; 3.4.22.31; 3.4.22.32; 3.4.22.33; 3.4.22.34; 3.4.22.35; 3.4.22.36; 3.4.22.37; 3.4.22.38; 3.4.22.39; 3.4.22.40; 3.4.22.41; 3.4.22.42; 3.4.22.43; 3.4.22.44; 3.4.22.45; 3.4.22.46; 3.4.22.47; 3.4.22.48; 3.4.22.49; 3.4.22.50; 3.4.22.51; 3.4.22.52; 3.4.22.53; 3.4.22.54; 3.4.22.55; 3.4.22.56; 3.4.22.57; 3.4.22.58; 3.4.22.59; 3.4.22.60; 3.4.22.61; 3.4.22.62; 3.4.22.63; 3.4.22.64; 3.4.22.65; 3.4.22.66; 3.4.22.67; 3.4.22.68; 3.4.22.69; 3.4.22.70; 3.4.22.71; 3.4.22.72; 3.4.22.73; 3.4.22.74; 3.4.22.75; 3.4.22.76; 3.4.22.77; 3.4.22.78; 3.4.22.79; 3.4.22.80; 3.4.22.81; 3.4.22.82; 3.4.22.83; 3.4.22.84; 3.4.22.85; 3.4.22.86; 3.4.22.87; 3.4.22.88; 3.4.22.89; 3.4.22.90; 3.4.22.91; 3.4.22.92; 3.4.22.93; 3.4.22.94; 3.4.22.95; 3.4.22.96; 3.4.22.97; 3.4.22.98; 3.4.22.99; 3.4.23.1; 3.4.23.2; 3.4.23.3; 3.4.23.4; 3.4.23.5; 3.4.23.6; 3.4.23.7; 3.4.23.8; 3.4.23.9; 3.4.23.10; 3.4.23.11; 3.4.23.12; 3.4.23.13; 3.4.23.14; 3.4.23.15; 3.4.23.16; 3.4.23.17; 3.4.23.18; 3.4.23.19; 3.4.23.20; 3.4.23.21; 3.4.23.22; 3.4.23.23; 3.4.23.24; 3.4.23.25; 3.4.23.26; 3.4.23.27; 3.4.23.28; 3.4.23.29; 3.4.23.30; 3.4.23.31; 3.4.23.32; 3.4.23.33; 3.4.23.34; 3.4.23.35; 3.4.23.36; 3.4.23.37; 3.4.23.38; 3.4.23.39; 3.4.23.40; 3.4.23.41; 3.4.23.42; 3.4.23.43; 3.4.23.44; 3.4.23.45; 3.4.23.46; 3.4.23.47; 3.4.23.48; 3.4.23.49; 3.4.23.50; 3.4.23.51; 3.4.23.52; 3.4.23.53; 3.4.23.54; 3.4.23.55; 3.4.23.56; 3.4.23.57; 3.4.23.58; 3.4.23.59; 3.4.23.60; 3.4.23.61; 3.4.23.62; 3.4.23.63; 3.4.23.64; 3.4.23.65; 3.4.23.66; 3.4.23.67; 3.4.23.68; 3.4.23.69; 3.4.23.70; 3.4.23.71; 3.4.23.72; 3.4.23.73; 3.4.23.74; 3.4.23.75; 3.4.23.76; 3.4.23.77; 3.4.23.78; 3.4.23.79; 3.4.23.80; 3.4.23.81; 3.4.23.82; 3.4.23.83; 3.4.23.84; 3.4.23.85; 3.4.23.86; 3.4.23.87; 3.4.23.88; 3.4.23.89; 3.4.23.90; 3.4.23.91; 3.4.23.92; 3.4.23.93; 3.4.23.94; 3.4.23.95; 3.4.23.96; 3.4.23.97; 3.4.23.98; 3.4.23.99; 3.4.24.1; 3.4.24.2; 3.4.24.3; 3.4.24.4; 3.4.24.5; 3.4.24.6; 3.4.24.7; 3.4.24.8; 3.4.24.9; 3.4.24.10; 3.4.24.11; 3.4.24.12; 3.4.24.13; 3.4.24.14; 3.4.24.15; 3.4.24.16; 3.4.24.17; 3.4.24.18; 3.4.24.19; 3.4.24.20; 3.4.24.21; 3.4.24.22; 3.4.24.23; 3.4.24.24; 3.4.24.25; 3.4.24.26; 3.4.24.27; 3.4.24.28; 3.4.24.29; 3.4.24.30; 3.4.24.31; 3.4.24.32; 3.4.24.33; 3.4.24.34; 3.4.24.35; 3.4.24.36; 3.4.24.37; 3.4.24.38; 3.4.24.39; 3.4.24.40; 3.4.24.41; 3.4.24.42; 3.4.24.43; 3.4.24.44; 3.4.24.45; 3.4.24.46; 3.4.24.47; 3.4.24.48; 3.4.24.49; 3.4.24.50; 3.4.24.51; 3.4.24.52; 3.4.24.53; 3.4.24.54; 3.4.24.55; 3.4.24.56; 3.4.24.57; 3.4.24.58; 3.4.24.59; 3.4.24.60; 3.4.24.61; 3.4.24.62; 3.4.24.63; 3.4.24.64; 3.4.24.65; 3.4.24.66; 3.4.24.67; 3.4.24.68; 3.4.24.69; 3.4.24.70; 3.4.24.71; 3.4.24.72; 3.4.24.73; 3.4.24.74; 3.4.24.75; 3.4.24.76; 3.4.24.77; 3.4.24.78; 3.4.24.79; 3.4.24.80; 3.4.24.81; 3.4.24.82; 3.4.24.83; 3.4.24.84; 3.4.24.85; 3.4.24.86; 3.4.24.87; 3.4.24.88; 3.4.24.89; 3.4.24.90; 3.4.24.91; 3.4.24.92; 3.4.24.93; 3.4.24.94; 3.4.24.95; 3.4.24.96; 3.4.24.97; 3.4.24.98; 3.4.24.99; 3.4.25.1; 3.4.25.2; 3.4.25.3; 3.4.25.4; 3.4.25.5; 3.4.25.6; 3.4.25.7; 3.4.25.8; 3.4.25.9; 3.4.25.10; 3.4.25.11; 3.4.25.12; 3.4.25.13; 3.4.25.14; 3.4.25.15; 3.4.25.16; 3.4.25.17; 3.4.25.18; 3.4.25.19; 3.4.25.20; 3.4.25.21; 3.4.25.22; 3.4.25.23; 3.4.25.24; 3.4.25.25; 3.4.25.26; 3.4.25.27; 3.4.25.28; 3.4.25.29; 3.4.25.30; 3.4.25.31; 3.4.25.32; 3.4.25.33; 3.4.25.34; 3.4.25.35; 3.4.25.36; 3.4.25.37; 3.4.25.38; 3.4.25.39; 3.4.25.40; 3.4.25.41; 3.4.25.42; 3.4.25.43; 3.4.25.44; 3.4.25.45; 3.4.25.46; 3.4.25.47; 3.4.25.48; 3.4.25.49; 3.4.25.50; 3.4.25.51; 3.4.25.52; 3.4.25.53; 3.4.25.54; 3.4.25.55; 3.4.25.56; 3.4.25.57; 3.4.25.58; 3.4.25.59; 3.4.25.60; 3.4.25.61; 3.4.25.62; 3.4.25.63; 3.4.25.64; 3.4.25.65; 3.4.25.66; 3.4.25.67; 3.4.25.68; 3.4.25.69; 3.4.25.70; 3.4.25.71; 3.4.25.72; 3.4.25.73; 3.4.25.74; 3.4.25.75; 3.4.25.76; 3.4.25.77; 3.4.25.78; 3.4.25.79; 3.4.25.80; 3.4.25.81; 3.4.25.82; 3.4.25.83; 3.4.25.84; 3.4.25.85; 3.4.25.86; 3.4.25.87; 3.4.25.88; 3.4.25.89; 3.4.25.90; 3.4.25.91; 3.4.25.92; 3.4.25.93; 3.4.25.94; 3.4.25.95; 3.4.25.96; 3.4.25.97; 3.4.25.98; 3.4.25.99; 3.4.26.1; 3.4.26.2; 3.4.26.3; 3.4.26.4; 3.4.26.5; 3.4.26.6; 3.4.26.7; 3.4.26.8; 3.4.26.9; 3.4.26.10; 3.4.26.11; 3.4.26.12; 3.4.26.13; 3.4.26.14; 3.4.26.15; 3.4.26.16; 3.4.26.17; 3.4.26.18; 3.4.26.19; 3.4.26.20; 3.4.26.21; 3.4.26.22; 3.4.26.23; 3.4.26.24; 3.4.26.25; 3.4.26.26; 3.4.26.27; 3.4.26.28; 3.4.26.29; 3.4.26.30; 3.4.26.31; 3.4.26.32; 3.4.26.33; 3.4.26.34; 3.4.26.35; 3.4.26.36; 3.4.26.37; 3.4.26.38; 3.4.26.39; 3.4.26.40; 3.4.26.41; 3.4.26.42; 3.4.26.43; 3.4.26.44; 3.4.26.45; 3.4.26.46; 3.4.26.47; 3.4.26.48; 3.4.26.49; 3.4.26.50; 3.4.26.51; 3.4.26.52; 3.4.26.53; 3.4.26.54; 3.4.26.55; 3.4.26.56; 3.4.26.57; 3.4.26.58; 3.4.26.59; 3.4.26.60; 3.4.26.61; 3.4.26.62; 3.4.26.63; 3.4.26.64; 3.4.26.65; 3.4.26.66; 3.4.26.67; 3.4.26.68; 3.4.26.69; 3.4.26.70; 3.4.26.71; 3.4.26.72; 3.4.26.73; 3.4.26.74; 3.4.26.75; 3.4.26.76; 3.4.26.77; 3.4.26.78; 3.4.26.79; 3.4.26.80; 3.4.26.81; 3.4.26.82; 3.4.26.83; 3.4.26.84; 3.4.26.85; 3.4.26.86; 3.4.26.87; 3.4.26.88; 3.4.26.89; 3.4.26.90; 3.4.26.91; 3.4.26.92; 3.4.26.93; 3.4.26.94; 3.4.26.95; 3.4.26.96; 3.4.26.97; 3.4.26.98; 3.4.26.99; 3.4.27.1; 3.4.27.2; 3.4.27.3; 3.4.27.4; 3.4.27.5; 3.4.27.6; 3.4.27.7; 3.4.27.8; 3.4.27.9; 3.4.27.10; 3.4.27.11; 3.4.27.12; 3.4.27.13; 3.4.27.14; 3.4.27.15; 3.4.27.16; 3.4.27.17; 3.4.27.18; 3.4.27.19; 3.4.27.20; 3.4.27.21; 3.4.27.22; 3.4.27.23; 3.4.27.24; 3.4.27.25; 3.4.27.26; 3.4.27.27; 3.4.27.28; 3.4.27.29; 3.4.27.30; 3.4.27.31; 3.4.27.32; 3.4.27.33; 3.4.27.34; 3.4.27.35; 3.4.27.36; 3.4.27.37; 3.4.27.38; 3.4.27.39; 3.4.27.40; 3.4.27.41; 3.4.27.42; 3.4.27.43; 3.4.27.44; 3.4.27.45; 3.4.27.46; 3.4.27.47; 3.4.27.48; 3.4.27.49; 3.4.27.50; 3.4.27.51; 3.4.27.52; 3.4.27.53; 3.4.27.54; 3.4.27.55; 3.4.27.56; 3.4.27.57; 3.4.27.58; 3.4.27.59; 3.4.27.60; 3.4.27.61; 3.4.27.62; 3.4.27.63; 3.4.27.64; 3.4.27.65; 3.4.27.66; 3.4.27.67; 3.4.27.68; 3.4.27.69; 3.4.27.70; 3.4.27.71; 3.4.27.72; 3.4.27.73; 3.4.27.74; 3.4.27.75; 3.4.27.76; 3.4.27.77; 3.4.27.78; 3.4.27.79; 3.4.27.80; 3.4.27.81; 3.4.27.82; 3.4.27.83; 3.4.27.84; 3.4.27.85; 3.4.27.86; 3.4.27.87; 3.4.27.88; 3.4.27.89; 3.4.27.90; 3.4.27.91; 3.4.27.92; 3.4.27.93; 3.4.27.94; 3.4.27.95; 3.4.27.96; 3.4.27.97; 3.4.27.98; 3.4.27.99; 3.4.28.1; 3.4.28.2; 3.4.28.3; 3.4.28.4; 3.4.28.5; 3.4.28.6; 3.4.28.7; 3.4.28.8; 3.4.28.9; 3.4.28.10; 3.4.28.11; 3.4.28.12; 3.4.28.13; 3.4.28.14; 3.4.28.15; 3.4.28.16; 3.4.28.17; 3.4.28.18; 3.4.28.19; 3.4.28.20; 3.4.28.21; 3.4.28.22; 3.4.28.23; 3.4.28.24; 3.4.28.25; 3.4.28.26; 3.4.28.27; 3.4.28.28; 3.4.28.29; 3.4.28.30; 3.4.28.31; 3.4.28.32; 3.4.28.33; 3.4.28.34; 3.4.28.35; 3.4.28.36; 3.4.28.37; 3.4.28.38; 3.4.28.39; 3.4.28.40; 3.4.28.41; 3.4.28.42; 3.4.28.43; 3.4.28.44; 3.4.28.45; 3.4.28.46; 3.4.28.47; 3.4.28.48; 3.4.28.49; 3.4.28.50; 3.4.28.51; 3.4.28.52; 3.4.28.53; 3.4.28.54; 3.4.28.55; 3.4.28.56; 3.4.28.57; 3.4.28.58; 3.4.28.59; 3.4.28.60; 3.4.28.61; 3.4.28.62; 3.4.28.63; 3.4.28.64; 3.4.28.65; 3.4.28.66; 3.4.28.67; 3.4.28.68; 3.4.28.69; 3.4.28.70; 3.4.28.71; 3.4.28.72; 3.4.28.73; 3.4.28.74; 3.4.28.75; 3.4.28.76; 3.4.28.77; 3.4.28.78; 3.4.28.79; 3.4.28.80; 3.4.28.81; 3.4.28.82; 3.4.28.83; 3.4.28.84; 3.4.28.85; 3.4.28.86; 3.4.28.87; 3.4.28.88; 3.4.28.89; 3.4.28.90; 3.4.28.91; 3.4.28.92; 3.4.28.93; 3.4.28.94; 3.4.28.95; 3.4.28.96; 3.4.28.97; 3.4.28.98; 3.4.28.99; 3.4.29.1; 3.4.29.2; 3.4.29.3; 3.4.29.4; 3.4.29.5; 3.4.29.6; 3.4.29.7; 3.4.29.8; 3.4.29.9; 3.4.29.10; 3.4.29.11; 3.4.29.12; 3.4.29.13; 3.4.29.14; 3.4.29.15; 3.4.29.16; 3.4.29.17; 3.4.29.18; 3.4.29.19; 3.4.29.20; 3.4.29.21; 3.4.29.22; 3.4.29.23; 3.4.29.24; 3.4.29.25; 3.4.29.26; 3.4.29.27; 3.4.29.28; 3.4.29.29; 3.4.29.30; 3.4.29.31; 3.4.29.32; 3.4.29.33; 3.4.29.34; 3.4.29.35; 3.4.29.36; 3.4.29.37; 3.4.29.38; 3.4.29.39; 3.4.29.40; 3.4.29.41; 3.4.29.42; 3.4.29.43; 3.4.29.44; 3.4.29.45; 3.4.29.46; 3.4.29.47; 3.4.29.48; 3.4.29.49; 3.4.29.50; 3.4.29.51; 3.4.29.52; 3.4.29.53; 3.4.29.54; 3.4.29.55; 3.4.29.56; 3.4.29.57; 3.4.29.58; 3.4.29.59; 3.4.29.60; 3.4.29.61; 3.4.29.62; 3.4.29.63; 3.4.29.64; 3.4.29.65; 3.4.29.66; 3.4.29.67; 3.4.29.68; 3.4.29.69; 3.4.29.70; 3.4.29.71; 3.4.29.72; 3.4.29.73; 3.4.29.74; 3.4.29.75; 3.4.29.76; 3.4.29.77; 3.4.29.78; 3.4.29.79; 3.4.29.80; 3.4.29.81; 3.4.29.82; 3.4.29.83; 3.4.29.84; 3.4.29.85; 3.4.29.86; 3.4.29.87; 3.4.29.88; 3.4.29.89; 3.4.29.90; 3.4.29.91; 3.4.29.92; 3.4.29.93; 3.4.29.94; 3.4.29.95; 3.4.29.96; 3.4.29.97; 3.4.29.98; 3.4.29.99; 3.4.30.1; 3.4.30.2; 3.4.30.3; 3.4.30.4; 3.4.30.5; 3.4.30.6; 3.4.30.7; 3.4.30.8; 3.4.30.9; 3.4.30.10; 3.4.30.11; 3.4.30.12; 3.4.30.13; 3.4.30.14; 3.4.30.15; 3.4.30.16; 3.4.30.17; 3.4.30.18; 3.4.30.19; 3.4.30.20; 3.4.30.21; 3.4.30.22; 3.4.30.23; 3.4.30.24; 3.4.30.25; 3.4.30.26; 3.4.30.27; 3.4.30.28; 3.4.30.29; 3.4.30.30; 3.4.30.31; 3.4.30.32; 3.4.30.33; 3.4.30.34; 3.4.30.35; 3.4.30.36; 3.4.30.37; 3.4.30.38; 3.4.30.39; 3.4.30.40; 3.4.30.41; 3.4.30.42; 3.4.30.43; 3.4.30.44; 3.4.30.45; 3.4.30.46; 3.4.30.47; 3.4.30.48; 3.4.30.49; 3.4.30.50; 3.4.30.51; 3.4.30.52; 3.4.30.53; 3.4.30.54; 3.4.30.55; 3.4.30.56; 3.4.30.57; 3.4.30.58; 3.4.30.59; 3.4.30.60; 3.4.30.61; 3.4.30.62; 3.4.30.63; 3.4.30.64; 3.4.30.65; 3.4.30.66; 3.4.30.67; 3.4.30.68; 3.4.30.69; 3.4.30.70; 3.4.30.71; 3.4.30.72; 3.4.30.73; 3.4.30.74; 3.4.30.75; 3.4.30.76; 3.4.30.77; 3.4.30.78; 3.4.30.79; 3.4.30.80; 3.4.30.81; 3.4.30.82; 3.4.30.83; 3.4.30.84; 3.4.30.85; 3.4.30.86; 3.4.30.87; 3.4.30.88; 3.4.30.89; 3.4.30.90; 3.4.30.91; 3.4.30.92; 3.4.30.93; 3.4.30.94; 3.4.30.95; 3.4.30.96; 3.4.30.97; 3.4.30.98; 3.4.30.99; 3.4.31.1; 3.4.31.2; 3.4.31.3; 3.4.31.4; 3.4.31.5; 3.4.31.6; 3.4.31.7; 3.4.31.8; 3.4.31.9; 3.4.31.10; 3.4.31.11; 3.4.31.12; 3.4.31.13; 3.4.31.14; 3.4.31.15; 3.4.31.16; 3.4.31.17; 3.4.31.18; 3.4.31.19; 3.4.31.20; 3.4.31.21; 3.4.31.22; 3.4.31.23; 3.4.31.24; 3.4.31.25; 3.4.31.26; 3.4.31.27; 3.4.31.28; 3.4.31.29; 3.4.31.30; 3.4.31.31; 3.4.31.32; 3.4.31.33; 3.4.31.34; 3.4.31.35; 3.4.31.36; 3.4.31.37; 3.4.31.38; 3.4.31.39; 3.4.31.40; 3.4.31.41; 3.4.31.42; 3.4.31.43; 3.4.31.44; 3.4.31.45; 3.4.31.46; 3.4.31.47; 3.4.31.48; 3.4.31.49; 3.4.31.50; 3.4.31.51; 3.4.31.52; 3.4.31.53; 3.4.31.54; 3.4.31.55; 3.4.31.56; 3.4.31.57; 3.4.31.58; 3.4.3

```

FT REPEAT 1395 1403 2-24.
FT REPEAT 1404 1412 2-25.
FT REPEAT 1413 1421 2-26.
FT REPEAT 1422 1430 2-27.
FT REPEAT 1431 1439 2-28.
FT REPEAT 1440 1448 2-29.
FT REPEAT 1445 1453 2-30.
FT REPEAT 1459 1890 P5/8 TYPE A 3.
FT DOMAIN 1569 1890 PLASTOCYANIN-LIKE 5.
FT DOMAIN 1748 1890 PLASTOCYANIN-LIKE 6.
FT DOMAIN 1894 2048 P5/8 TYPE C 1.
FT DOMAIN 2053 2208 CLEAVAGE (BY THROMBIN) (BY SIMILARITY).
FT SITE 1034 1035 CLEAVAGE (BY THROMBIN) (BY SIMILARITY).
FT SITE 1034 1035 CLEAVAGE (BY THROMBIN) (BY SIMILARITY).
FT SITE 1564 1565 PROBABLE.
FT DISULFID 167 193 PROBABLE.
FT DISULFID 499 525 PROBABLE.
FT DISULFID 1112 1738 PROBABLE.
FT DISULFID 1894 2048 PROBABLE.
FT DISULFID 2053 2208 PROBABLE.
FT MOD_RES 707 707 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 720 730 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1513 1513 SULFATION (POTENTIAL).
FT MOD_RES 1539 1539 SULFATION (POTENTIAL).
FT MOD_RES 1537 1537 SULFATION (POTENTIAL).
FT MOD_RES 1541 1541 SULFATION (POTENTIAL).
FT MOD_RES 225 225 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 225 225 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 257 297 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 382 382 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 460 460 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 553 553 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 587 587 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 745 745 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 756 756 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 760 780 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 902 902 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 922 922 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 944 964 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1044 1044 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1053 1053 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1052 1052 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1078 1078 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1094 1094 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1451 1451 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1451 1451 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1490 1490 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1550 1550 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1690 1690 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 1839 1839 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 2196 2196 N-LINKED (GLN-CNC) (POTENTIAL).
FT MOD_RES 587 592 N-TERMINAL (GLN-CNC) (POTENTIAL).
FT MOD_RES 2211 AA: 248981 MW: CBBF08738667C45 CRC64:
SEQUENCE

```

```

Query Match 10.8%; Score 331; DB 1; Length 2211;
Best Local Similarity: 32.5%; Pred. No. 9.2e-17;
Matches 88; Conservative 46; Mismatches 89; Indels 46; Gaps 10.

```

```

OY 209 ASHYATEY-SKRCPR-----GCDVADDDSCNMT--DGYDPSILCAAHIAIIND 259
DB 1968 AKHYATYTERFCVAYSLDRKNMIFKKNSTFRWYGCNSDASTKENDIPDVA-- 2025
OY 260 LGQOIVLAKGISTREGIILANGVLSHDSLSKRFLETCNSISLFE---PDQIR 315
DB 2026 -----RTRISPTGYSNAPALRIELQCC-EVNCSTPLNKGSKINEMKOTI 2070
OY 316 ASG---SMQSVNESQOVYHSGQALDQCC-PSMAQSGNSNHRPREMLFIDGEXK 370
DB 2071 ASBFAKMGW-----NWEPEPLARIKMGQGVYVAMQAKNNNN---OMQIDILKTR 2119

```

```

OY 371 ITGKTSTGTSNFWYKYSFVWYKFNKNSKKTGYKQIYKNNKXYPGONSNDPOYNN 430
DB 2120 ITATVYQCKSLSPKMYKSTIHYDQGDINKDPYRKSSWYKIFEDNNRFGHYKNF 2179
OY 431 IPPYARVRYVFPOTMQRALKEVILCOI 461
DB 2180 NPPIISRFIRIKPMQVOSTALRIELFCOM 2210

RESULT 8
ID NRPL_XENLA STANDARD: PRT; 928 AA.
P28824;
DT 01-DEC-1992 (Rel. 24, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 01-DEC-2001 (Rel. 40, Last protein update)
DE Neurotrophin-4 (p75NTRK), a member of the neurotrophin (A5 antigen),
DE Eukaryotic, Metazoa; Chordata; Craniota; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae;
OC Xenopodinae; Xenopus.
NCBI_TaxID=8355;
RX NCBI_TaxID=8355;
RN 1;
RS SEQUENCE FROM N.A.
RC MEDLINE=9137458; PubMed=1908252;
RA Takagi S., Hirata T., Agata K., Mochii M., Eguchi G., Fujisawa H.;
FT "type A5 antigen, a candidate for the neuronal recognition molecule,
has homologues to complement components and coagulation factors.";
RL Neuron 7:295-307(1991).
CC -1- FUNCTION: RECEPTOR INVOLVED IN THE DEVELOPMENT OF THE
CC CARDIOVASCULAR SYSTEM AND IN COORDINATING THE FORMATION OF
CC NERVOUS SYSTEM CIRCUITS AND IN ORGANOGENESIS OUTSIDE THE NERVOUS
CC SYSTEM. IT MEDIATES THE CHEMOREPULSANT ACTIVITY OF SEMAPHORINS (BY
CC SIMILARITY). PRESUMED TO BE INVOLVED IN THE NEURONAL RECOGNITION
CC BETWEEN THE OPTIC NERVE FIBERS AND THE VISUAL CENTERS.
CC -1- SUBCELLULAR LOCATION: TYPE I membrane protein.
CC -1- TISSUE SPECIFICITY: RETINAL GANGLION CELLS AND VISUAL CENTER
CC NERVONS.
CC -1- SIMILARITY: BELONGS TO THE NEUROTROPHIN FAMILY.
CC -1- SIMILARITY: CONTAINS 2 CUB DOMAINS.
CC -1- SIMILARITY: CONTAINS 2 F5/8 TYPE C DOMAINS.
CC -1- SIMILARITY: CONTAINS 1 NAM DOMAIN.
CC -1- SIMILARITY: CONTAINS 1 NAM DOMAIN.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL database.
CC the European Bioinformatics Institute, long as its content is in no way
CC use by non-profit institutions, long as its content is in no way
CC modified (e.g., by deletion, insertion, or other means) and for commercial
CC or send an email to license@sbdb.ch).
CC EMBL: D10467; BAA01260.1;
CC Interpro: IPR000859; CUB.
CC Interpro: IPR000421; FAS5.C.
CC Interpro: IPR000956; NAM.
CC Pfam: PF00451; CUB_2; Type-C_2.
CC Pfam: PF00581; FAS5.C.
CC PRINTS: PR00020; NAMDOMAIN.
CC SMART: SM00042; CUB; 2.
CC SMART: SM00231; FAS5C; 2.
CC SMART: SM00137; NAM; 1.
CC PROSITE: PS00740; NAM_1; 1.
CC PROSITE: PS01180; CUB; 2.
CC PROSITE: PS01285; FAS5C; 2.
CC PROSITE: PS01285; FAS5C; 2.
CC TRANSMEMBRANE: Glycoprotein; Neurone; Signal; Repeat; Receptor;
FT CHAIN 1 21 POTENTIAL.1.
FT SIGNAL 22 928 NEUROTROPHIN-1.

```


Query Match	10.88;	Score 330;	DB 1;	Length 928;
Best Local Similarity	24.28;	Pred. No. 3.2e-17;		
Matches 112;	Conservative 74;	Mismatches 171;	Indels 106;	Gaps 20;

[illegible]

	FT	REPEAT	1267	1265	2-9	
	FT	REPEAT	1286	1274	2-10	
	FT	REPEAT	1275	1283	2-11	
	FT	REPEAT	1284	1292	2-12	
	FT	REPEAT	1293	1301	2-13	
	FT	REPEAT	1302	1310	2-14	
	FT	REPEAT	1310	1318	2-15	
	FT	REPEAT	1320	1328	2-16	
	FT	REPEAT	1329	1337	2-17	
	FT	REPEAT	1338	1346	2-18	
	FT	REPEAT	1347	1355	2-19	
	FT	REPEAT	1356	1364	2-20	
	FT	REPEAT	1365	1373	2-21	
	FT	REPEAT	1374	1382	2-22	
	FT	REPEAT	1383	1391	2-23	
	FT	REPEAT	1392	1401	2-24	
	FT	REPEAT	1401	1409	2-25	
	FT	REPEAT	1410	1418	2-26	

	Query Match	10.4%	Score 317:	D8 1:	Length 2224;
	Best Local Similarity	42.0%	Pred.	N,1.le-15;	
	Matches 71;	Conservative	30;	No matches 52;	Indels 16; Gaps 5;
Oy	300 NCGRSLRSE-----DPOIIAAS-----SWSVNSQDOWHSGCARLADODPSMASGDS 352				
Dy	2064 NCGSTPLGMENKGIENNOJITASSFKSKSW-----GD--YMEPRALNAGRYMAQNA 2116				
Oy	353 NNHEPHEWLETDIGSEKKRIKGRTSTOSNFNFVFYSFVNMFNNKSNWTKCIYANE 412				
Dy	2117 NNKN--OVLDELIDKLIRKTALITOCCKSSLSMYVSYSIVHYEGGVAKMPEKRSKW 2174				
Oy	413 EKVYQNSPPFDQONFFPIPVARYVMOMIOLAIKYELICOI 461				
Dy	2175 DRFGGNNTKGVHNFNPINFRIFRVIPDKTWOSTITRLRELFGDI 2223				

	RESULT 11		
RN	PROTEIN		
RP	FAS_PIG	STANDARD;	PRT; 2258 AA.
AC	OGDGL1:		
DT	16-OCT-2001 (Rel. 40, Created)		
DT	16-OCT-2001 (Rel. 40, Last sequence update)		
DT	01-MAR-2002 (Rel. 41, Last annotation update)		
DE	Cogulation factor V precursor (Activated protein C cofactor).		
DE	Sus scrofa (Pig).		
OS	Eukaryotes; Metazoa; Chordata; Craniata; Vertebrata; Euarchosomti;		
OX	Mammalia; Eutheria; Cetartiodactyla; Suidae; Suidae; Sus.		
NCBI	Taxid=9823;		
RN	[1]		
RP	SEQUENCE FROM N.A., AND 3D-STRUCTURE MODELING OF F5/8 TYPE A AND C DOMAINS.		
RC	MEISSNER_111721497		
RC	MEISSNER_111721490; Pubmed=11229814;		
RA	Grlm D R.; Colter M.B.; Braunschweig M., Alexander L.J., Neane P.J., Kim H.K.W.;		
RA	*Protein factor V; cdna cloning, gene mapping, three-dimensional protein modeling of membrane binding sites and comparative anatomy of domains.*		
CC	Ceil. Mol. Life Sci. 58:148-159(2001).		
CC	-1 FUNCTION: Cogulation factor V is a cofactor that participates		
CC	in the activation of prothrombin to thrombin by the prothrombin,		
CC	serpinin. Factor Va is composed of heavy chain and a light		
CC	chain, noncovalently bound. The interaction between the two chains		
CC	is calcium dependent.		
CC	-1 DOMAIN: Domain B contains 41 X A tandem repeats. Domains C1		
CC	and C2 may be involved in membrane binding.		
CC	-1 FM: Thrombin activates cogulation factor V proteolytically to the active		
CC	cofactor, factor Va (formation of a heavy chain at the N-		
CC	terminus). The heavy chain contains 11 type A domains and 1		
CC	plasticocyanin-like repeats.		
CC	-1 SIMILARITY: CONTAINS 3 F5/8 TYPE A DOMAINS, EACH IS COMPOSED OF		
CC	2 PLASTOCYANIN-LIKE REPEATS.		

[illegible]

DB 2207 HYDIEGNNIKGHVNFNPDPISRIHILIPMMNMNOXIMALEHDCU 2257

RESULT 12

FROM HUMAN STANDARD: PRT: 387 AA.

AC 008431:

DT 01-OCT-1996 (Rel. 34, Created)

DT 01-NOV-1997 (Rel. 35, Last sequence update)

DT 16-OCT-2001 (Rel. 40, Last annotation update)

DE Lactadherin precursor (Milk fat globule-EGF factor 8) (MFG-E8) (HMFG)

DE Lactadherin precursor (Milk fat globule-EGF factor 8) (MFG-E8) (HMFG)

DE Breast epithelial antigen BA66 (MFGM) [Contains: Medin].

GN MFG8.

OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

OC NCBI_TaxID:9606;

RN [1]

RN SEQUENCE FROM N.A.

RC TISSUE=breast, and Breast carcinoma;

RX MEDLINE=6713908; PubMed=8639264;

RT O'Loon, J.R., Taylor, M.R., Godwin, S.G., Certini, R.L., Peterson, J.A.,

RT BA66 reveals an EGF-like domain in a protein sequence presented on an epidermal

RT growth factor-1-like domain.

RT DNA Cell Biol. 15:281-286(1996).

RN [2]

RN SEQUENCE OF 170-387 FROM N.A.

RC TISSUE=Mammary gland;

RX MEDLINE=9137151; PubMed=1909332;

RT Certini, R.L., Peterson, J.A., Ureña, R., Kuniyoshi, J., Bistrain, A.M.,

RT "A Mr 46,000 human milk fat globule protein that is highly expressed

RT in human breast tumors contains factor VIII-like domains".

RT Cancer Res. 51:4994-4998(1991).

RL [3]

RL PARTIAL SEQUENCE, AND CHARACTERIZATION.

RN PROTEIN=BA66;

RX MEDLINE=924; PubMed=9335776;

RT Gifford, M.G., Cavalletto, M., Giunta, C., Conti, A.,

RT Godovac-Zimmermann, J.,

RT Isolation and characterization of full and truncated forms of human

RT J. Protein Chem. 17:143-148(1998).

RN [4]

RN SEQUENCE OF 268-317, AND IDENTIFICATION OF MEDIN.

RX MEDLINE=9342076; PubMed=10411933;

RT Tienberg, L.O., Niesen, J., Stelten, K., Westmark, G.T., Mucchiano, G.,

RT "Medin: an integral fragment of the smooth muscle cell-produced

RT Lactadherin forms the most common human milk lipid."

RT Proc. Natl. Acad. Sci. U.S.A. 96:8669-8674(1999).

RL [5]

RL CHARACTERIZATION.

RX MEDLINE=97405885; PubMed=9260929;

RT Taylor, M.R., Conto, J.R., Scallan, C.D., Certini, R.L., Peterson, J.A.;

RT expressed in human milk fat globules, breast carcinomas, promotes Arg-Gly-Asp

RT (RGD)-dependent cell adhesion.

RL DNA Cell Biol. 16:861-869(1997).

CC -1- FUNCTION: MAY BE INVOLVED IN PHOSPHOLIPID BINDING. BINDS

CC SPECIFICALLY TO ROTAVIRUS AND INHIBITS ITS REPLICATION.

CC -1- FUNCTION: MEDIN IS THE MAIN CONSTITUENT OF AORTIC MEDIAL AMYLOID.

CC -1- SUBCELLULAR LOCATION: PERIPHERAL MEMBRANE PROTEIN.

CC -1- MEMBRANE SPECIFICITY: MAMMARY EPITHELIAL CELL SURFACES AND AORTIC

CC MEDIAL AMYLOID.

CC -1- PTM: MEDIN HAS SEVERAL N-TERMINUS WITH MINOR SPECIES STARTING AT

CC AMINO ACID 264 AND 273.

CC -1- SIMILARITY: CONTAINS 1 EGF-LIKE DOMAIN.

CC -1- SIMILARITY: CONTAINS 2 FS/8 TYPE C DOMAINS.

CC This Swiss-Prot entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation.

CC The European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and the source is acknowledged. For commercial

CC or send an email to license@ebi.slb.ch.

CC -----

DR EMBL: 058516; AAC50549.1; -

DR INTERPRO: IPR000561; EGF-like.

DR MIM: 602281; -

DR EMBL: 058515; AAB19771.1; -

DR Pfam: PF000754; FS_P8_Type_C; 2.

DR SMART: SM00231; PFS8C; 2.

DR PROSITE: PS00022; EGF_1; 1.

DR PROSITE: PS01186; EGF_2; 1.

DR PROSITE: PS01285; PFS8C_1; 2.

DR PROSITE: PS01286; PFS8C_2; 2.

KW SIGNAL

FT CHAIN 24 387

FT CHAIN 202 387

FT CHAIN 268 317

FT DOMAIN 24 67

FT DOMAIN 70 225

FT SITES 27 38

FT DISULFID 32 55

FT DISULFID 57 66

FT DISULFID 70 225

FT DISULFID 212 216

FT DISULFID 230 367

FT DISULFID 328 328

FT CARBOHYD 329 329

FT CARBOHYD 350 350

FT CARBOHYD 387 AA; 43123 MW; 286571DEC83782D CMC4;

SEQUENCE

Query Match 9.88; Score 299; DB 1; Length 387;

Best Local Similarity 37.3%; Pred. No. 2,1e-15;

Matches 63; Conservative 33; Mismatches 55; Indels 18; Gaps 5;

QY 300 NCSCRSLEPF---PGQIRASSMSQWNSQDHY---NSGQNRLODQ--PSSASC 350

DB 228 NCANLNLKNSIPDQITASSYKTMG---LILFSNIPYARLDQCNFPMVAAS 282

QY 351 SSNNKPREMLDLDEKKKITGTTGYSQSNENYKSFYNNKNNKSNKTYGIV 410

DB 283 YGMD---QMLVDLSSSEVETGILTGANFCSYQFVASYVYNSDSAMTEYDPE 338

QY 411 MEKYQNSNRPDNNIPYATYARYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVY 459

DB 339 GSKSIFRQNDHSHKKNLPEFTILATYRIIPVAMHNRKALKEHLC 387

RESULT 13

FROM RAT STANDARD: PRT: 427 AA.

AC 01-NOV-1997 (Rel. 35, Created)

DT 01-NOV-1997 (Rel. 35, Last sequence update)

DT 30-MAY-2000 (Rel. 39, Last annotation update)

DE Lactadherin precursor (Milk fat globule-EGF factor 8) (MFG-E8) (O-

DE acetyl) GD3 ganglioside synthase (ACS) (MFGM).

GN MFG8 OR AGS.

OC Rattus norvegicus (Rat).

OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.

OC NCBI_TaxID:10116;

OY			291 SDRFLTS-----	265
			: :	
Dy			206 DGRREFPJOESGEQFEMGNODNSLTKMREPTLEADYRIKYVRSCHRTAFELL	255
OY			207 -----NCSMSLFSE-----PGCIIRASSSGWSGEOGVHSRCAALDDQQGP--SWASG	349
Dy			300 -----NCSMSLFSE-----PGCIIRASSSGWSGEOGVHSRCAALDDQQGP--SWASG	349
OY			266 GCLLCSSCPGLDKNNTITDPDSIIVTASSSTKMLRLA-FCWPLHLRDDNGIKNAH---	320
Dy			300 GCLLCSSCPGLDKNNTITDPDSIIVTASSSTKMLRLA-FCWPLHLRDDNGIKNAH---	320
OY			350 DSNNHKRPPELMDEIDJGSKKKTTIGTRFTOSTOSNFVEYSFVNKRNNKSRRKTYKGIV	409
Dy			351 :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :	
OY			321 -TNSSAKMKVLGYDGCKRKVTGLTGDAKDGHIOYAVSAKMSDDGWQVTVS-E	377
Dy			410 NNEEKYGKSNFFKDVONVFPIYARVVARYVRPPWHOMIALVALISLEC	459
OY			378 QGSATFGSLNDLNSSKKFKIFEXPMARFYVAFLPSMHNRITELTELISC	427
Dy			378 QGSATFGSLNDLNSSKKFKIFEXPMARFYVAFLPSMHNRITELTELISC	427
RESULT	14			
FAB_HUMAN		STANDARD:	PRT: 2351 AA.	
ID	FAB_HUMAN			
AC	P00451:			
NC	2-JUL-1986 (Rel. 01, Created)			
DT	21-JUL-1986 (Rel. 01, Last sequence update)			
DI	01-MAR-2002 (Rel. 41, Last annotation update)			
DE	Couagulation factor VIII precursor (Procoagulant component)			
DN	(Antihemophilic factor) (AHF).			
OE	p8 or FcC.			
OS	Homo sapiens (human)			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OA	Mammalia; Artiodactyla; Primates; Catarrhini; Homnidae; Homo-			
NB	NCEL_TaxID=9606;			
RX	[1]			
RZ	SEQUENCE FROM N.A.			
RA	MEDLINE=6081134; PubMed=9355400;			
RB	"rueuet M.A., Blichner R., Butke R.L., Caput D., Chu C., Diana P.,			
RC	Hartog K.", Kou C.H., Maslitz J., Muller T., Neill U.P., Notidian R.,			
RD	Brecht M.S., Fogliaziomenia P., Dahl H.-H.M., Favalaro V., Hansen J.,			
RE	Noirard O., Ezdan M. ;			
RF	"Characterization of the polypeptide composition of human factor			
RG	VIII.C and the nucleotide sequence and expression of the human kidney			
RH	cDNA." ;			
RI	DNA 4.1:331-349(1985).			
RJ	[2]			
RK	SEQUENCE FROM N.A.			
RL	MEDLINE=85061548; PubMed=6438526;			
RM	Wood W.I., Capron D.R., Simonsen C.C.; Eaton D.L., Gitlschier J.,			
RN	Keyt B., Seeburg P.H., Smith D.B., Hollingshead P., Wilson R.L.,			
RO	Deilwatt E., Tuddenham E.G.D., Vehar G.A., Lavan R.W. ;			
RP	"Expression of active human factor VIII from recombinant DNA clones."			
RQ	Nature 312:330-337(1984).			
RJ	[3]			
RK	SEQUENCE FROM N.A.			
RL	MEDLINE=85061550; PubMed=6438528;			
RM	Toole J.J., Knopf J.T., Mooney J.M., Sulzman I.A., Buckner J.L.,			
RN	Pittman D.O., Kaufman R.B., Brown E.B., Shoemaker C., Orr E.C.,			
RO	Amplett G.W., Foster W.B., Cox M.L., Krutson G.J., Fass D.N.,			
RP	Hewick R.M. ;			
RQ	"Molecular cloning of a cDNA encoding human antihemophilic factor."			
RJ	Nature 312:342-347(1984).			
RK	SEQUENCE FROM N.A.			
RL	MEDLINE=93265012; PubMed=1303178;			
RM	Gitlschier J., Wood W.I. ;			
RN	"Sequence of the exon-containing regions of the human factor VIII			
RO	gene". Hum. Mol. Genet. 1:199-200(1992).			
RJ	[5]			
RK	SEQUENCE OF 2064-2070 FROM N.A.			
RL	GenBank accession number: AF015153.1. Contact: Bennett P.J.;			
RM	Dr. Walter M.S., NIH contract grant #1R01-HL-35469-01A1, Bethesda,			
RN	MD, United States, 20892. Submitted (Jun 1997) to the EMBL/Genbank/DBJ databases.			
RO	[6]			
RP	SUFLATION OF TYR-1699.			

- RA MEDLINE-91093266; PubMed-1898735;
 RA Layte A., van Schijndel H.B., Nichols C., Rutten W.B., Verbeek M.P.,
 RA Mertens K., van Mourik J.A.;
 RT "Isolation of Tyr1680 of human blood coagulation factor VIII is
 RT essential for the interaction of factor VIII with von Willebrand
 RT factor.";
 RN J. Biol. Chem. 266:740-746(1991).
 RP SOLUTATION.
 RP MEDLINE-92207952; PubMed-1554716;
 RA Pittman D.D., Wang J.H., Kaufman R.J.;
 RT "Identification and functional importance of tyrosine sulfate
 RT residues within recombinant factor VIII.";
 RN J. Biochemistry 31:315-3125(1992).
 RP STRUCTURE BY NMR OF 2322-2333.
 RA MEDLINE-93200924; PubMed-7839714;
 RA Gilbert G.E., Balala J.D.;
 RT "Membrane-binding peptide from the C2 domain of factor VIII forms an
 RT amphipathic structure as determined by NMR spectroscopy.";
 RN J. Biochemistry 34:3022-3031(1995).
 RP REVIEW ON MOLECULAR BASIS OF HEMOPHILIA A.
 RA MEDLINE-91221499; PubMed-1902642;
 RA Gitschler J., Wood W.I., Shumak A.;
 RT "The molecular basis of hemophilia A.";
 RN Ann. N.Y. Acad. Sci. 614:89-96(1991).
 RP REVIEW ON MOLECULAR BASIS OF HEMOPHILIA A.
 RA MEDLINE-89088506; PubMed-2491949;
 RA White G.C. II, Shoemaker C.B.;
 RT Factor VIII gene and hemophilia A.";
 RN Hum. Mutat. 5:1-22(1995).
 RP REVIEW ON MOLECULAR BASIS OF HEMOPHILIA A.
 RA MEDLINE-9345332; PubMed-7728145;
 RA Antonarakis S.E., Kazanian H.H., Tuddenham E.G.D.;
 RT "Molecular etiology of factor VIII deficiency in hemophilia A.";
 RN Hum. Mutat. 5:1-22(1995).
 RP VARIANT GLN-2326
 RA MEDLINE-86235438; PubMed-3012775;
 RA Gitschler J., Wood W.I., Shumak A.;
 RT "Identification of a missense mutation in the factor VIII gene of a
 RT mild hemophiliac.";
 RN Science 232:1415-1416(1986).
 RP VARIANT PRO-2135.
 RA MEDLINE-8609539; PubMed-3122181;
 RA Kousourian R., Phillips J.A. III, Gitschler J.;
 RT "A novel missense mutation in the factor VIII gene identified by
 RT analysis of amplified hemophilia DNA sequences.";
 RN Nucleic Acids Res. 15:9797-9805(1987).
 RP VARIANT GLN-2228.
 RA MEDLINE-88191889; PubMed-2833855;
 RA Kousourian R., Antonarakis S.E., Bell W., Griffin A.M.,
 RT "Nonense and missense mutations in hemophilia A: estimate of the
 RT relative mutation rate at CG dinucleotides.";
 RN Am. J. Hum. Genet. 42:718-725(1988).
 RP VARIANT GLY-291.
 RA MEDLINE-8820354; PubMed-2835904;
 RA Kousourian R., Wong C., Aronson S., Platakoulis H., Kazanian H.H. Jr.,
 RT "Moderate missense mutation in the factor VIII gene
 RT in exon 7 of the factor VIII gene.";
 RN Am. J. Hum. Genet. 42:867-871(1988).
 RP VARIANT CYS-1708.
 RA MEDLINE-89274393; PubMed-2499363;
 RA O'Brien D.P., Tuddenham E.G.;
 RT "Purification and characterization of factor VIII 1,689-Cys: a
 RT nonfunctional cofactor occurring in a patient with severe hemophilia
 RT Blood 73:2117-2122(1989).
 RN [17]
 RP VARIANT CYS-391.
 RA MEDLINE-90001543; PubMed-2506948;
 RA Shima M., Ware J., Yoshioka A., Fukui H., Pulcher C.A.;
 RT "An arginine to cysteine amino acid substitution at a critical
 RT thrombin cleavage site in a dysfunctional factor VIII molecule.";
 RN Blood 74:1612-1617(1989).
 RP VARIANT LEU-189.
 RA MEDLINE-90057680; PubMed-2510835;
 RA Chan V., Chan T.K., Tong T.M., Todd D.;
 RT "A novel missense mutation in exon 4 of the factor VIII:C gene
 RT resulting in moderately severe hemophilia A.";
 RN Blood 74:2688-2691(1989).
 RP VARIANT LEU-2326.
 RA MEDLINE-89197223; PubMed-2459245;
 RA Inaba H., Fujimaki M., Kazanian H.H. Jr., Antonarakis S.E.;
 RT "Mild hemophilia A resulting from Arg-to-Leu substitution in exon 26
 RT of the factor VIII gene.";
 RN Hum. Genet. 81:335-338(1989).
 RP VARIANT HIS-391.
 RA MEDLINE-89264602; PubMed-2498882;
 RA Antonarakis S.E., Kazanian H.H. Jr.,
 RT "Direct characterization of factor VIII in plasma: detection of a
 RT mutation altering a thrombin cleavage site
 RT (arginine-372->histidine).";
 RN Proc. Natl. Acad. Sci. U.S.A. 86:4277-4281(1989).
 RP VARIANT CYS-1708.
 RA MEDLINE-90107523; PubMed-2104766;
 RA Antonarakis S.E., Kazanian H.H. Jr.,
 RT "Characterization of a thrombin cleavage site mutation (Arg 1689 to
 RT Cys) in the factor VIII gene of two unrelated patients with
 RT cross-reacting material-positive hemophilia A.";
 RN Blood 75:384-389(1990).
 RP VARIANT GLN-2228 AND LEU-2326.
 RA MEDLINE-90125103; PubMed-2105106;
 RA Gitschler J., Wood W.I., Shumak A.;
 RT "Characterization of a thrombin cleavage site mutation (Arg 1689 to
 RT Cys) in the factor VIII gene of two unrelated patients with
 RT cross-reacting material-positive hemophilia A.";
 RN Blood 75:384-389(1990).
 RP VARIANT CYS-391.
 RA MEDLINE-90329422; PubMed-19730301;
 RA Gitschler J., Wood W.I., Shumak A.;
 RT "Direct characterization of factor VIII in plasma: detection of a
 RT mutation altering a thrombin cleavage site.";
 RN Br. J. Haematol. 75:73-77(1990).
 RP VARIANTS PHE-1699 AND CYS-1708.
 RA MEDLINE-90152691; PubMed-2105906;
 RA Higuchi M., Wong C., Kochan L., Olek K., Aronson S., Kasper C.K.,
 RT "Characterization of factor VIII gene by direct
 RT sequencing of amplified genomic DNA.";
 RN J. Hematol. 6:65-71(1990).
 RP VARIANT CYS-1728 AND ASP-1941.
 RA MEDLINE-90169988; PubMed-2106480;
 RA Kousourian R., Higuchi M., Kasper C.K., Antonarakis S.E.,
 RT "Use of denaturing gradient gel electrophoresis to detect point
 RT mutations in the factor VIII gene.";

QY 402 MFTYKGIYNNKEKVEFOGNSFRDPYONNETIPTVARYRVYPOTWHORIALVELJGC 459
DB 408 MFTVE--EGSSKVEFOGMLDNNSHKKNIFERPFNARYRVLPVSWHNRITLRLLEJGC 463

Search completed: July 9, 2002, 02:26:11
Job time: 648 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: July 9, 2002, 02:14:03 ; Search time 130.73 Seconds

(without alignments) 75.453 Million cell updates/sec

Title: US-09-691-344A-4

Sequence: 3052

1 MGFAGORLPPAPVAPNSAE.....YDNREKMTOKIDITSDMAC 586

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 562222 seqs, 17294929 residues

562222

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

1: SPTRMBL_19:*
2: SP_archaea:*
3: SP_bacteria:*
4: SP_fungi:*
5: SP_invertebrate:*
6: SP_mammal:*
7: SP_mhc:*
8: SP_organelle:*
9: SP_phase:*
10: SP_plant:*
11: SP_protist:*
12: SP_reptile:*
13: SP_vertebrate:*
14: SP_unclassified:*
15: SP_virus:*
16: SP_bacteriophage:*
17: SP_archaeophage:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1310.5	32.9	403	11	0904J3
2	1154.5	30.9	769	11	0912K2
3	942	30.7	769	11	0912K2
4	937	30.7	769	11	0912K2
5	929	30.4	775	4	0910B9
6	572.5	18.8	364	4	0910B9
7	349	11.4	555	4	09H2E2
8	349	11.4	555	4	09H2E2
9	349	11.4	501	4	09H2E3
10	349	11.4	506	4	09H2E3
11	349	11.0	609	4	09H2E3
12	335	11.0	644	4	09H2E3
13	335	11.0	704	4	09H2E3
14	325.5	10.7	921	11	090X38
15	321	10.5	2224	4	043737

17	318	10.4	2183	11	088783	088783 mus musculus
18	306.5	10.0	2343	6	018806	018806 canis familiaris
19	295.5	9.8	2773	4	082730	082730 canis familiaris
20	295.5	9.5	426	11	090W73	090W73 mus musculus
21	290	9.5	426	11	090W73	090W73 mus musculus
22	285.5	9.4	216	4	014286	014286 mus musculus
23	279.5	9.2	463	11	090X19	090X19 mus musculus
24	277	9.1	2119	13	090X47	090X47 brachydontio
25	268	8.8	480	4	043874	043874 mus musculus
26	264	8.7	480	4	035474	035474 mus musculus
27	252	7.8	1563	6	077718	077718 equus caballus
28	232.5	7.3	221.5	11	0981M6	0981M6 mus musculus
29	221.5	7.3	221.5	11	0981M6	0981M6 mus musculus
30	217	7.1	158	4	014113	014113 mus musculus
31	216.5	7.1	119	11	061281	061281 mus musculus
32	209.5	6.9	728	6	097567	097567 bos taurus
33	199.5	6.5	858	5	076470	076470 lytechinus
34	197	6.5	721	4	036M80	036M80 mus musculus
35	184.5	6.4	3835	4	0987L9	0987L9 mus musculus
36	184.5	6.1	3843	5	030V90	030V90 drosophila
37	187.5	6.1	745	4	096M75	096M75 mus musculus
38	186.5	6.1	745	4	096M75	096M75 mus musculus
39	185.5	6.1	963	4	096M75	096M75 mus musculus
40	182.5	6.0	764	11	09D2L5	09D2L5 mus musculus
41	182.5	6.0	764	11	095M80	095M80 mus musculus
42	182	6.0	604	4	096M74	096M74 mus musculus
43	174	5.7	1224	13	091674	091674 xenopus laevis
44	173	5.7	1224	13	091674	091674 xenopus laevis
45	173	5.7	414	11	09CXB6	09CXB6 mus musculus

ALIGNMENTS

RESULT	1	PRELIMINARY:	PRT:	503 AA.
0904J3				
AC	0904J3			
DT	01-JUN-2001 (TRENDAUT)	17, Created		
DT	01-JUN-2001 (TRENDAUT)	17, Last sequence update		
DT	01-DEC-2001 (TRENDAUT)	19, Last annotation update		
DE	463143K1IKIRK PROTEIN.			
DE	463143K1IKIRK			
CC	musculus (mouse)			
CC	Eukaryota: Metazoa: Chordata: Craniata: Vertebrata: Euteleostomi:			
CC	Mammalia: Eutheria: Rodentia: Sciurognathi: Muridae: Murinae: Mus.			
CC	NCBI_Taxid=10090.			
NC	11			
RP	SEQUENCE FROM N.A.			
NC	STRAIN=C57BL/6J; TISSUE=TESTIS;			
NC	MEHLIN=21085560; PUBMED=11217851;			
RA	Kawai J., Shinagawa A., Shibata K., Yoshino H., Itoh M., Ishii Y.,			
RA	Alizawa K., Nakamura Y., Kikuchi Y., Kono H., Adachi J., Fukuda S.,			
RA	Saito T., Okazaki Y., Gotohori T., Nakamura H., Kono S., Yamamoto K.,			
RA	Kadota K., Matsuda H.A., Ashburner M., Batilov S., Casavant P.,			
RA	Fleischmann W., Gaasterland T., Glaser C., King B., Kochaya H.,			
RA	Kuehl P., Lewis S., Matsuo Y., Nishida I., Pesole G., Quackenbush J.,			
RA	Schirrali I.M., Staubli P., Suzuki R., Tomita M., Wagner L., Wastio T.,			
RA	Blake J., Boileau D., Bojuno M., Aono H., Baldarelli R., Barsch G.,			
RA	Gusterson B.J., Balle C., Fletcher C., Fujita M., Gariboldi M.F.,			
RA	Lyons P., Marchionni D., Mashin U., Hume D.A., Kamilya M., Lee N.H.,			
RA	Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto			
RA	Suzuki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-P.,			
RA	Wyszynski-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohsaki S.,			
RA	Yashizaki Y.,			
RA	Functional annotation of a full-length mouse cDNA collection. *			
CC	NCBI_Taxid=10090(10090); CDB DOMAIN.			
CC	ENBL AK016465; EMBL0205.1;			

DE ENDOTHELIAL AND SMOOTH MUSCLE CELL-DERIVED NEUROPILIN-LIKE
 GN ES DN.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 DE Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 GN EMBL; AF387549; AAL30180.1;
 RT J. Biol. Chem. 276:34105-34114(2001).
 RA EMBL; AF387549; AAL30180.1;
 RC STRAIN=SPRAGUE-DAWLEY;
 RX PubMed=11447234;
 RA Kobuke K., Furukawa Y., Sugai M., Tanigaki K., Ohashi N.,
 Matsumori A., Sasayama S., Honjo T., Tashiro K.,
 CS DN. A Novel Neuropilin-Like Membrane Protein Cloned from Vascular
 RT Up-regulated after Vascular Injury.
 DR EMBL; AF387549; AAL30180.1;
 SO SEQUENCE 769 AA; 83915 MW; 5B7936C8FA063A93 CRC64;

Query Match 30.9%; Score 942; DB 11; Length 769;
 Identical Similarity 37.5%; Pred. No. 1,46-66;
 Matches 220; Conservative 96; Mismatches 204; Indels 98; Gaps 19;

44 PSGVWPGAGCGALAAA-----GCG-----LALLLVASRLDAEFLDCCG 89
 16 PGRAAPAAAGRAALPAGACCPPLPGENSSSPRLTLTLTL-----GAGGDCG 70
 0Y HLVYDSGTMTSNKPGTYPNITVCERTITVPKGRLLRLGLDITE-SQTCASDY-L 147
 70 HVLVDSGTMTSNKPGTYPNITVCERTITVPKGRLLRLGLDITE-SQTCASDY-L 130
 71 HVLVDSGTMTSNKPGTYPNITVCERTITVPKGRLLRLGLDITE-SQTCASDY-L 130
 148 FTS--SSDQGYPCG-SMVPPELLNLTSEVYRPGSGSHISGEGILYVYASSHPDT 203
 131 FNGICVSTETKTCGIGLQMNOSIESKSEEVYLPNGSHHAGRGFLASVYIDKDL 190
 0Y 204 TGLBASVLTKEYKPCPCACADVADISGNWVDYRQTSLLCKAALHAGILADLQCG 263
 191 TGLDVTNLEPERSKYCPACCLPFAELSGTIEHGYDSSPLCMAGIHAGVSDVLDGQ 250
 264 ISYLORGISRYEGLIANVLSMDSISDKRPLTSCNCSLSF-----PDQIRASS 319
 251 ISVYISGPPYESSLANVTSVGYLSLFTKTSCTGVLMEGVADQITASSAL 310
 0Y 320 MVSVESGDVMSFGQARLDQGPSMAAGSDSNMKRPMLEFLDLEKKKTYGRTTGS 379
 311 LENTHMGDSNMPKARLRKPGPPAA-FATDEH--OMQDIDLMKKKRTGLVYVGS 366
 380 TLENHNYSAIRVLSDDQKMYRFGQCAQKTRQAKDITKDVKNLLEPILANET 435
 367 TLENHNYSAIRVLSDDQKMYRFGQCAQKTRQAKDITKDVKNLLEPILANET 428
 440 RVVPTQHORIALVELIGCOIT-----QGNDSNLVWKTSSVSTKKED 485
 427 RVVPTQHORIALVELIGCOIT-----QGNDSNLVWKTSSVSTKKED 484
 0Y 486 EITTRP-----IPESET-SGINTT-----VALPLVLVYVAFAGGIFPAF 527
 485 TQALDPSRNDLPVQVETITPDKNITVTPSYTKDVALANVLVPLVALTLTLLDYL 544
 0Y 528 -----RKKKKSGPYGSAEAKQTCCKROKYR-----K 571
 545 CAMHNRKRRKAAECT-YDLPHMDRAGMKGVQLLPKASVDEHEETPVRSNVSNSHLS 603
 0Y 572 EKTQKLDLITSDMA 585
 604 EYTVYLDASDNEA 617

AC 0912V3-2001 (Trembl) 19 Created
 DT 01-DEC-2001 (Trembl) 19 Sequence update
 DT 01-DEC-2001 (Trembl) 19 Last
 DE ENDOTHELIAL AND SMOOTH MUSCLE CELL-DERIVED NEUROPILIN-LIKE
 GN ES DN.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 DE Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 GN EMBL; AF387548; AAL30179.1;
 RT J. Biol. Chem. 276:34105-34114(2001).
 RA EMBL; AF387548; AAL30179.1;
 RC STRAIN=ICR;
 RX PubMed=11447234;
 RA Kobuke K., Furukawa Y., Sugai M., Tanigaki K., Ohashi N.,
 Matsumori A., Sasayama S., Honjo T., Tashiro K.,
 CS DN. A Novel Neuropilin-Like Membrane Protein Cloned from Vascular
 RT Up-regulated after Vascular Injury.
 DR EMBL; AF387548; AAL30179.1;
 SO SEQUENCE 769 AA; 83774 MW; 73C1F616FA39E017 CRC64;

Query Match 30.7%; Score 937; DB 11; Length 769;
 Identical Similarity 37.2%; Pred. No. 3,66-66;
 Matches 229; Conservative 100; Mismatches 200; Indels 86; Gaps 17;

44 PSGVWPGAGCGALAAA-----GCG-----LALLLVASRLDAEFLDCCG 91
 16 PGRAAPAAAGRAALPAGACCPPLPGENSSSPRLTLTLTL-----LDAGGDCGCGH 72
 0Y 92 VTYDSGTMTSNKPGTYPNITVCERTITVPKGRLLRLGLDITE-SQTCASDY-L 149
 73 VLYDSGTMTSNKPGTYPNITVCERTITVPKGRLLRLGLDITE-SQTCASDY-L 132
 150 S--SSDQGYPCG-SMVPPELLNLTSEVYRPGSGSHISGEGILYVYASSHPDT 205
 133 GICVSTETKTCGIGLQMNOSIESKSEEVYLPNGSHHAGRGFLASVYIDKDL 192
 0Y 206 LERASHVLTKEYKPCPCACADVADISGNWVDYRQTSLLCKAALHAGILADLQCG 265
 193 LDTNLEPERSKYCPACCLPFAELSGTIEHGYDSSPLCMAGIHAGVSDVLDGQ 252
 266 VLRKGISRYEGLIANVLSMDSISDKRPLTSCNCSLSF-----PDQIRASS 321
 253 IYVSKGPPYESSLANVTSVGYLSLFTKTSCTGVLMEGVADQITASSAL 312
 0Y 322 SVNESGDVMSFGQARLDQGPSMAAGSDSNMKRPMLEFLDLEKKKTYGRTTGS 381
 313 WTGHMGDSNMPKARLRKPGPPAA-FATDEH--OMQDIDLMKKKRTGLVYVGS 368
 382 TLENHNYSAIRVLSDDQKMYRFGQCAQKTRQAKDITKDVKNLLEPILANET 441
 369 TLENHNYSAIRVLSDDQKMYRFGQCAQKTRQAKDITKDVKNLLEPILANET 428
 444 VPTQHORIALVELIGCOIT-----QGNDSNLVWKTSSVSTKKED 474
 423 NVVQVQKRIAMVELIGCOIT-----QGNDSNLVWKTSSVSTKKED 474
 0Y 475 -----QSTYSKRADEETTRPIPESETSGINTTVALVPLVLVYVAFAGGIFPAF 527
 486 QVLDPSRNDLPVQVETITPDKNITVTPSYTKDVALANVLVPLVALTLTLLDYL 545
 0Y 528 -----RKKKKSGPYGSAEAKQTCCKROKYR-----AHQSGFETSSVDNE 570
 546 AMHNRKRRKAAECT-YDLPHMDRAGMKGVQLLPKASVDEHEETPVRSNVSNSHLS 602
 0Y 571 EKTQKLDLITSDMA 585
 603 RYTVYLDASDNEA 617


```

01-MAR-2001 (Tremblrel. 16, Last sequence update)
01-DEC-2001 (Tremblrel. 19, Last annotation update)
DE NEUROFILIN-2 SOURCE: ISOFORM 9.
GN NRP2
OS Homo sapiens (Human).
OC Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Eukaryota; Eumetazoa; Primates; Catarrhini; Hominoidea; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20564205; PubMed=1112349;
RA Rosengren M., Gagnon M.L., Klaessgen M.;
RT 'Genomic Organization and Distribution of Human Neurofilin-1 and Neurofilin-2 Genes:
RT Identification and Distribution of Splice Variants and Soluble
RL Genomics 70:211-222(2000).
CC -1- SIMILARITY: CONTAINS 2 CUB DOMAINS.
DR EMBL; AF280546; AAC1405.1.
DR HSSP; P12259; ICDZ.
DR InterPro; IPR000421; FAS8.C.
DR InterPro; IPR000421; FAS8.C.
DR Pfam; PF00431; CUB; 2.
DR SMART; SM00221; FAS8C_1.
DR SMART; SM00137; MAM_1.
DR PROSITE; PS01180; CUB; 2.
DR PROSITE; PS01285; FAS8C_1; FAS8C_1.
SQ SEQUENCE 555 AA; 6430 MW; B67B7C92A80546F CRC64;

Query Match 11.4%; Score 349; DB 4; Length 555;
Best Local Similarity 25.3%; Pred. No. 2,3e-19;
Matches 109; Conservative 72; Mismatches 166; Indels 84; Gaps 16;

01 88 CGHLVYVDSCTMTSKNYRGTYVNEVCERTITVPK-GKRLILRLG-DLDSQTCASDY 145
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
28 CGRLNSDAGYITSGYDYPDSQNCENIYVAPBNQKIVLNFNPELEIKHCKYDF 87

01 146 LLF-----TSSDYQVPGCSWYVPELLNTSEVYVRESGSHISGRFLTY-----AS 196
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
88 IETRDGSESADLAKHGNL-APPTIISGSMKIYKFTSYANQAGSFILAREITFRTGS 146

01 197 SD-----HPLTTC-----LEASHTYKTERSKF----- 220
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
147 EDSKNTFSPNCTIESPGPEKYPHNLDTCTFLIAPKMKELIQLFLDEHDFLQVGG 206

01 221 -CPAGCNDVAGDIS--GNVVDGYRDTSLCKAAIHAGIIADLGQISVLRKGISRYEG 277
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
207 DCKYIMDLIWDGIDPHVGLQIKYCGKTPSELRSSTGLISLTFHDMAYAK-----DG 259

01 278 ILANVLSRDSGLSKRELFTSNGCSNLSFE-----PGQCIIRASSWQSNQVSGDQVHS 333
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
260 FSARYYLVHDEPLENFO-----CNVPLGMSGRIRANQDISASTY-----SGGKWT 305

01 334 PQGARLDGQPSMASSGSSNNKPREMELIDGKKRTIGIRTS--STGNSFNFYVNSF 391
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
306 PQOSRLHDGNGKTPNLDSN---KEYLDVDFLRLTLALATQASISRETONKGYVNSF 361

01 392 VVNFKNNSKRYTKGTYNNEEKYVQGNSTFDPQVNNFIPPLVARYVYVPOTHMORIA 451
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
362 KLEVSTNGEDMWWYRGRKNH--KYQANNDATIEVYLNRLADPLFVRIPOTHMISGIA 419

01 452 LKVELIGCOIT 462
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
420 LRLLEFGCHVT 430

RESULT 8
O9H2E4 PRELIMINARY: PRT: 901 AA.
AC O9H2E4;
DT 01-MAR-2001 (Tremblrel. 16, Created)
DT 01-MAR-2001 (Tremblrel. 16, Last sequence update)

```

```

01-DEC-2001 (Tremblrel. 19, Last annotation update)
DE NEUROFILIN-2(10).
GN NRP2
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eumetazoa; Primates; Catarrhini; Hominoidea; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20564205; PubMed=1112349;
RA Rosengren M., Gagnon M.L., Klaessgen M.;
RT 'Genomic Organization and Distribution of Human Neurofilin-1 and Neurofilin-2 Genes:
RT Identification and Distribution of Splice Variants and Soluble
RL Isoforms 70:211-222(2000).
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN (BY SIMILARITY).
CC -1- SIMILARITY: CONTAINS 2 CUB DOMAINS.
CC -1- SIMILARITY: BELONGS TO THE NEUROFILIN FAMILY.
DR EMBL; AF280546; AAC1405.1.
DR HSSP; P12259; ICDZ.
DR InterPro; IPR000421; FAS8.C.
DR InterPro; IPR000421; FAS8.C.
DR Pfam; PF00431; CUB; 2.
DR Pfam; PF00431; CUB; 2.
DR SMART; SM00221; FAS8C_1.
DR SMART; SM00137; MAM_1.
DR PROSITE; PS01180; CUB; 2.
DR PROSITE; PS01285; FAS8C_1; FAS8C_1.
KW Glycoprotein; Neurexin; Receptor; Transmembrane.
SQ SEQUENCE 501 AA; 10130 MW; 1F3107A9CC665EA2 CRC64;

Query Match 11.4%; Score 349; DB 4; Length 901;
Best Local Similarity 25.3%; Pred. No. 4,8e-19;
Matches 109; Conservative 72; Mismatches 166; Indels 84; Gaps 16;

01 88 CGHLVYVDSCTMTSKNYRGTYVNEVCERTITVPK-GKRLILRLG-DLDSQTCASDY 145
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
28 CGRLNSDAGYITSGYDYPDSQNCENIYVAPBNQKIVLNFNPELEIKHCKYDF 87

01 146 LLF-----TSSDYQVPGCSWYVPELLNTSEVYVRESGSHISGRFLTY-----AS 196
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
88 IETRDGSESADLAKHGNL-APPTIISGSMKIYKFTSYANQAGSFILAREITFRTGS 146

01 197 SD-----HPLTTC-----LEASHTYKTERSKF----- 220
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
147 EDSKNTFSPNCTIESPGPEKYPHNLDTCTFLIAPKMKELIQLFLDEHDFLQVGG 206

01 221 -CPAGCNDVAGDIS--GNVVDGYRDTSLCKAAIHAGIIADLGQISVLRKGISRYEG 277
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
207 DCKYIMDLIWDGIDPHVGLQIKYCGKTPSELRSSTGLISLTFHDMAYAK-----DG 259

01 278 ILANVLSRDSGLSKRELFTSNGCSNLSFE-----PGQCIIRASSWQSNQVSGDQVHS 333
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
260 FSARYYLVHDEPLENFO-----CNVPLGMSGRIRANQDISASTY-----SGGKWT 305

01 334 PQGARLDGQPSMASSGSSNNKPREMELIDGKKRTIGIRTS--STGNSFNFYVNSF 391
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
306 PQOSRLHDGNGKTPNLDSN---KEYLDVDFLRLTLALATQASISRETONKGYVNSF 361

01 392 VVNFKNNSKRYTKGTYNNEEKYVQGNSTFDPQVNNFIPPLVARYVYVPOTHMORIA 451
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
362 KLEVSTNGEDMWWYRGRKNH--KYQANNDATIEVYLNRLADPLFVRIPOTHMISGIA 419

01 452 LKVELIGCOIT 462
|| : : : : : || : : : : : || : : : : : || : : : : : || : : : : : ||
420 LRLLEFGCHVT 430

```

```

RESULT 9
ID 09H205 PRELIMINARY; PRT: 901 AA.
AC 09H205;
DT 01-MAR-2001 (Tremblrel, 16, Created)
DT 01-MAR-2001 (Tremblrel, 16, Last sequence update)
DT 01-DEC-2001 (Tremblrel, 19, Last annotation update)
DE NEUROFILIN-2B(10).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
NCBI_Taxid=9606;
FN [1]_Textid=9606;
RP SEQUENCE FROM N.A. PubMed-11112349.
RX MEDLINE-2054205; PubMed-11112349.
RT Genomic Organization of Human Neuropilin-1 and Neuropilin-2 Genes:
RT Identification and Distribution of Splice Variants and Soluble
RT Isoforms.
RL Genomics 70:211-222(2000).
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN (BY SIMILARITY).
CC -1- SIMILARITY: CONTAINS 2 CUB DOMAINS.
CC -1- SIMILARITY: BELONGS TO THE NEUROFILIN FAMILY.
CC -1- SIMILARITY: BELONGS TO THE NEUROFILIN FAMILY.
DE EMBL: AF281074; AAC14959.1.
DR HSPB: P12259; ICDT.
DR InterPro: IPR000859; CUB.
DR InterPro: IPR000421; FASB_C.
DR InterPro: IPR000998; NAM.
DR Pfam: PF00431; CUB; 2.
DR Pfam: PF00629; NAM; 1.
DR PRINTS: PR00020; NAMDOMAIN.
DR SMART: SM00431; CUB; 2.
DR SMART: SM00231; FASB_C_2.
DR SMART: SM00137; NAM; 1.
DR PROSITE: PS01180; CUB; 2.
DR PROSITE: PS01285; FASB_C_1; UNKNOWN_1.
DR PROSITE: PS50060; NAM_2; 1.
DR GlycoProtein: Neutome; Receptor; Transmembrane.
KW SEQUENCE 901 AA; 101381 MW; A1310304AD086AB CRC64;
SQ

Query Match 11.4%; Score 349; DB 4; Length 901;
Best Local Similarity 25.3%; Pred. No. 4; Be-19;
Matches 109; Conservative 72; Mismatches 166; Indels 84; Gaps 16;

```

```

DB 362 KLEVSTGEMMYRICKNH-KVFOANNDATEYVUKLKHAFLETRFRIQTHSGIA 419
OY 452 LKVELICQIT 462
DB 420 LRIELFCRCVT 430

RESULT 10
ID 09H2E3 PRELIMINARY; PRT: 906 AA.
AC 09H2E3;
DT 01-MAR-2001 (Tremblrel, 16, Created)
DT 01-MAR-2001 (Tremblrel, 16, Last sequence update)
DT 01-DEC-2001 (Tremblrel, 19, Last annotation update)
DE NEUROFILIN-2B(5).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
NCBI_Taxid=9606;
FN [1]_Textid=9606;
RP SEQUENCE FROM N.A. PubMed-11112349.
RX MEDLINE-2054205; PubMed-11112349.
RT Genomic Organization of Human Neuropilin-1 and Neuropilin-2 Genes:
RT Identification and Distribution of Splice Variants and Soluble
RT Isoforms.
RL Genomics 70:211-222(2000).
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN (BY SIMILARITY).
CC -1- SIMILARITY: CONTAINS 2 CUB DOMAINS.
CC -1- SIMILARITY: BELONGS TO THE NEUROFILIN FAMILY.
CC -1- SIMILARITY: BELONGS TO THE NEUROFILIN FAMILY.
DE EMBL: AF280545; AAC14404.1.
DR HSPB: P12259; ICDT.
DR InterPro: IPR000859; CUB.
DR InterPro: IPR000421; FASB_C.
DR InterPro: IPR000998; NAM.
DR Pfam: PF00431; CUB; 2.
DR Pfam: PF00629; NAM; 1.
DR PRINTS: PR00020; NAMDOMAIN.
DR SMART: SM00431; CUB; 2.
DR SMART: SM00231; FASB_C_2.
DR SMART: SM00137; NAM; 1.
DR PROSITE: PS01180; CUB; 2.
DR PROSITE: PS01285; FASB_C_1; UNKNOWN_1.
DR PROSITE: PS50060; NAM_2; 1.
DR GlycoProtein: Neutome; Receptor; Transmembrane.
KW SEQUENCE 906 AA; 101935 MW; 0FB01F24D0B950BD CRC64;
SQ

Query Match 11.4%; Score 349; DB 4; Length 906;
Best Local Similarity 25.3%; Pred. No. 4; Be-19;
Matches 109; Conservative 72; Mismatches 166; Indels 84; Gaps 16;

```



```

Db 260 PSARYLVHQBPLENQ-----CNPVLQMSRIANQJNSASTY-----SGKMT 305
OY 334 PQGARLDQGPQSMASGDSSNNHKPREMELTIDGSKKKTIGRTG--STOSNFYFVYSP 391
Db 306 PQOSRKHDDNCGMTPLNDN---KEYIYDRLFLMLTALATOGALSTRETONGYVASY 361
OY 392 VMMFKNNNSKMTYKTCIGVINEEKVYFQGSNFRDYOANNEPTPVARYVAVPOTMHOPIA 451
Db 362 KLEVSTNCEDMWVYRGRKNH--KVYQANDATAEVYLNKLAPLREVRIRPOTMHSOIA 419
OY 452 LKVELIGCOIT 462
Db 420 LRLELFGCRVT 430

RESULT 11
ID 09H2D4 PRELIMINARY: PRT: 906 AA.
AC 09H2D4
DT 01-MAR-2001 (TREMBLrel, 16, Created)
DT 01-MAR-2001 (TREMBLrel, 16, Last sequence update)
DE 01-DEC-2001 (TREMBLrel, 19, Last annotation update)
DE NEUROFILIN-2B(5).
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
NCBI_TaxID=9606;
NM NCB1
RX SEQUENCE FROM N.A.
RX MEDLINE-2054205; PubMed-11112349;
RX Kosigisno M., Gagnon M.L., Klagsbrun M.;
RX "Organization of Human Neuropilin-1 and Neuropilin-2 Genes;
RX Identification and Distribution of Splice Variants and Soluble
RX Isoforms";
RL Genomics 70:211-222(2000).
CC -1- SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN (BY SIMILARITY).
CC -1- SIMILARITY: CONTAINS 2 CUB DOMAINS.
CC -1- SIMILARITY: BELONGS TO THE NEUROFILIN FAMILY.
CC -1- SIMILARITY: BELONGS TO THE NEUROFILIN FAMILY.
DR EMBL: AB020104; NCBI: 150001.1;
DR HSP: P12259; ICD: NC41900.1;
DR InterPro: IPR000855; CUB;
DR InterPro: IPR000421; PS58_C;
DR InterPro: IPR000938; MAM;
DR Pfam: PF00431; CUB; 2.
DR SMART: SMO020; MAM; 1.
DR SMART: SMO021; PS58_C; 2.
DR SMART: SMO0137; MAM; 1.
DR PROSITE: PS01180; CUB; 2.
DR PROSITE: PS01285; PS58_C; 1.
DR PROSITE: PS01060; MAM_2; 1.
DR GlycoProtein; Neutome; Receptor; Transmembrane.
SM SEQUENCE 906 AA: 101956 MW: 8181326545780B9 CCK64;

```

```

Query Match 11.4%; Score 349; DB 4; Length 906;
Best Local Similarity 25.3%; Pred. No. 4, 9e-19;
Matches 109; Conservative 72; Mismatches 166; Indels 84; Gaps 16;

OY 88 CCHLVYQDSQWTGSKNPPGYTPNHYVEKTIYVR--GRKLILALG-DLDESQTCASDY 145
Db 28 CGGRNKNKMTYKTCIGVINEEKVYFQGSNFRDYOANNEPTPVARYVAVPOTMHOPIA 145
OY 146 LTF-----TSSDQYQGSMTYKTCIGVINEEKVYFQGSNFRDYOANNEPTPVARYVAVPOTMHOPIA 145
Db 88 IIRKQGSNADLGRKNGNI-APPTIISGSMLTIFSDYQAGQAFSLRTEPFTGS 146
OY 197 SD-----HEDLITC-----LRRASNYLKYERK----- 220
Db 147 EDCSKNFTSPNGTIESGPEPEKTYHMDCTFTILAKRKEMLIIOLFLDLEHDPLOYGDS 206

```

```

OY 221 -CPAGCRVAGDIS--GNWYDQRTDLSLKAKTHAGIADLEGQISYLOKRGISREY 277
Db 207 DQYKMDLMDGIPVHVPGLIKTCGTCPTSEKSSYGLSLSTREHDAVAK-----DG 259
OY 278 ILANVLSRQGISDKREPLFTSKGSRSLTF-----PQGITASSSQVNESQDVHMS 333
Db 260 PSARYLVHQBPLENQ-----CNPVLQMSRIANQJNSASTY-----SGKMT 305
OY 334 PQGARLDQGPQSMASGDSSNNHKPREMELTIDGSKKKTIGRTG--STOSNFYFVYSP 391
Db 306 PQOSRKHDDNCGMTPLNDN---KEYIYDRLFLMLTALATOGALSTRETONGYVASY 361
OY 392 VMMFKNNNSKMTYKTCIGVINEEKVYFQGSNFRDYOANNEPTPVARYVAVPOTMHOPIA 451
Db 362 KLEVSTNCEDMWVYRGRKNH--KVYQANDATAEVYLNKLAPLREVRIRPOTMHSOIA 419
OY 452 LKVELIGCOIT 462
Db 420 LRLELFGCRVT 430

RESULT 12
ID 096190 PRELIMINARY: PRT: 609 AA.
AC 096190
DT 01-DEC-2001 (TREMBLrel, 19, Created)
DT 01-DEC-2001 (TREMBLrel, 19, Last sequence update)
DT 01-DEC-2001 (TREMBLrel, 19, Last annotation update)
DE STYR1, A MEMBER OF THE NEUROFILIN 1.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
NCBI_TaxID=9606;
NM NCB1
RX SEQUENCE FROM N.A.
RX STYR1, A MEMBER OF THE NEUROFILIN 1.
RX STYR1, A MEMBER OF THE NEUROFILIN 1.
RX Submitted (MAY-2001) to the EMBL/Genbank/DBJ databases.
DR EMBL: BC007737; AA007737.1;
SM SEQUENCE 609 AA: 68347 MW: 799AFAFD2D568C127 CCK64;

```

```

Query Match 11.0%; Score 335; DB 4; Length 609;
Best Local Similarity 24.9%; Pred. No. 3, 5e-18;
Matches 144; Conservative 76; Mismatches 176; Indels 122; Gaps 23;

OY 64 RGL-----LALLAYAPRLQARLQAGCGGCHLYYQDGSMTKSNKYGVYHNITCEK 117
Db 3 RGLPILAVMLAVLAPAFVR-----NKGCDITKISGYLTSPPSHYSPKCEKM 56
OY 118 TTVKRG-KRLILALG-DLDESQTCASDY-LFTSSSD--CGPYCSMTYKPELIL 171
Db 57 LIADPQYQNTININPHEDELDKQCTIYEVYDGENGHEFGKFCGKI-APPVAVS 115
OY 172 TSEVYFSSGSHSGRGLTYA-----SSDHPDLIC-- 205
Db 116 GPELIFKVFYSDYETHGAGFIRIETFRGRCPSQNTYTPGVIRSGPEKYNLSCTCY 175
OY 206-----LEBASHTYKTESKCPAG--CRVAGDISQNNWGYRDTLSLKAKH 252
Db 176 IYAPAKMSLTLLESFSLDEPSAN--PGGWFCKDRLEL-----WGSPD--VGR 223
OY 253 AG-TIADLEGQI-----SYLDRGISIRBGLIAYLANSQSLSKRFLF 297
Db 224 IGYGCGKTPKRISSSQILSMWYVDSALAKRGSANVSVLQSV-SEDRK----- 274
OY 298 TSNQCSLSFEP--DQGITASSSQVNESQDVHMSPOGARLDQGPQSMASGDSSNN 353
Db 275-----GMRALWESGKTHSDQITASSQIST--NMSAERSLANTPENGWTPGSDSY 322
OY 354 NIKPRELEIDLEKKKKTIGRTG--STOSNFYFVYSPVMMFKNNNSKMTYKTCIGVINE 411

```

Db 323 -----REMIQVDLGLFPTAVTQGAISKETKKKKYKYYKIDVSNCEBDMITK--EEN 376
 Oy 412 EEKVGQSNRNPDOVNNFPPIVARYVAVPOTMORLALKVELLGCQT---QGNDS 467
 Db 377 KPVLEFGQNTNPDYVAVFPRKLTTRVRIKPAITWEGISNREPVYCKITDYPCSGMLG 436
 Oy 468 LVMKRTSOSTSTYKED 485
 Db 437 MVSGLTSDOSTTSSNOGD 454

RESULT 13

096IHS PRELIMINARY: PRT: 644 AA.
 ID 096IHS
 AC 096IHS:2001 (TREMblrel: 19 Created)
 DT 01-MAR-2001 (TREMblrel: 19 Last sequence update)
 DT 01-DEC-2001 (TREMblrel: 19 Last annotation update)
 DE NEUROPLIN 1
 OS Homo sapiens (human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 NX NCBI_TaxID:9606;
 RN SOURCE FROM N.A.
 RC TISSUE:KIDNEY, AND RENAL CELL ADENOCARCINOMA.
 RA Stausberg R.;
 RL Submitted (MAY-2001) to the EMBL/Genbank/DBJ databases.
 DR EMBL: BC007533; AAH07533.1;
 SQ SEQUENCE 644 AA: 71907 MW: 920486F5C3D2A21 CRC64;

Query Match 11.0%; Score 335; DB 4; Length 644;
 Best Local Similarity 24.9%; Pred. No. 3, 8e-19;
 Matches 124; Conservative 76; Mismatches 176; Indels 122; Gaps 23;

Oy 64 RCL-----LALLVSNAPRLQAELELDGCGGLVYQDSGTMNSKNPCTYNNHYCKR 117
 Db 3 RCLPLCALVAVLAPAGAR-----NDKGGDTIKIESGYLISPGYSHSPSEKCEM 56
 Oy 118 TTTPVKG-KRLILRG-DLDSQTCASDYL-LFTSSSQ---YGYCGSNVPEKELIN 171
 Db 57 LIDAPDYORIMNFPHDLDDKCKDYVEFGEENEGHFGKFCGI-APPVVS 115
 Oy 172 TSEVTVFPESSHISGKGLTYA-----SSDPDLITC-- 205
 Db 116 GPELTHFVSDEYETNAGFSINELFRKQPCSONYTTSPGVKISGPEPKYNSMLCTY 175
 Oy 206 -----LEBASHTKTYEKCPCAG--CRVAGDISGNVGYRDTSLCKALH 252
 Db 176 IYFAFKMSIILFESFDLPDSNP--PGMCRDRLEI---WGSPD-----VGRH 223
 Oy 253 AG-IILADELQOI-----SYLQKGISREYGLANGVLSNGSLSKRFLE 297
 Db 224 IGRVCGQKTPRISSSGLISWFTYDSIAKKGSNMVSJLQSV-GEPRK----- 274
 Oy 298 TSNCSKSI-SLEP---DOQIRASSMSQVNESGQVHMSPGQARLQDQGPSMASGDSN 353
 Db 275 -----CMALGMSGEIHSQDIYASQYST-----NMSASRSLNTPENKWTYGDY 322
 Oy 354 NHRPRELEIDLEKKKKTIGRTTG--STQSNNEFYKSVFNMKNNSKAKTYGGLVNN 411
 Db 323 -----REMIQVDLGLFPTAVTQGAISKETKKKKYKYYKIDVSNCEBDMITK--EEN 376
 Oy 412 EEKVGQSNRNPDOVNNFPPIVARYVAVPOTMORLALKVELLGCQT---QGNDS 467
 Db 377 KPVLEFGQNTNPDYVAVFPRKLTTRVRIKPAITWEGISNREPVYCKITDYPCSGMLG 436
 Oy 468 LVMKRTSOSTSTYKED 485
 Db 437 MVSGLTSDOSTTSSNOGD 454

RESULT 14

094ZEL

ID 094ZEL

AC 094ZEL

DT 01-MAR-2001 (TREMblrel: 16 Created)

DT 01-MAR-2001 (TREMblrel: 16 Last sequence update)

DE NEUROPLIN 1

OS Homo sapiens (human).

OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

CC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

NX NCBI_TaxID:9606;

RN SOURCE FROM N.A.

RC TISSUE:KIDNEY, AND RENAL CELL ADENOCARCINOMA.

RA Stausberg R.;

RL MEDLINE:20564205; PubMed:11112349;

DR InterPro: IPR000859; PUBM: 19900421; P58_C.

DR Pfam: PF00431; CUB; 2.

DR SMART: SM0042; CUB; 2.

DR SMART: SM0031; P58C; 2.

DR PROSITE: PS01180; CUB; 2.

DR PROSITE: PS01289; P58C; 1.

SQ SEQUENCE 704 AA: 79502 MW: 1625DD561459307 CRC64;

Query Match 11.0%; Score 335; DB 4; Length 704;

Best Local Similarity 24.9%; Pred. No. 4, 4e-18;

Matches 124; Conservative 76; Mismatches 176; Indels 122; Gaps 23;

Oy 64 RCL-----LALLVSNAPRLQAELELDGCGGLVYQDSGTMNSKNPCTYNNHYCKR 117
 Db 3 RCLPLCALVAVLAPAGAR-----NDKGGDTIKIESGYLISPGYSHSPSEKCEM 56
 Oy 118 TTTPVKG-KRLILRG-DLDSQTCASDYL-LFTSSSQ---YGYCGSNVPEKELIN 171
 Db 57 LIDAPDYORIMNFPHDLDDKCKDYVEFGEENEGHFGKFCGI-APPVVS 115
 Oy 172 TSEVTVFPESSHISGKGLTYA-----SSDPDLITC-- 205
 Db 116 GPELTHFVSDEYETNAGFSINELFRKQPCSONYTTSPGVKISGPEPKYNSMLCTY 175
 Oy 206 -----LEBASHTKTYEKCPCAG--CRVAGDISGNVGYRDTSLCKALH 252
 Db 176 IYFAFKMSIILFESFDLPDSNP--PGMCRDRLEI---WGSPD-----VGRH 223
 Oy 253 AG-IILADELQOI-----SYLQKGISREYGLANGVLSNGSLSKRFLE 297
 Db 224 IGRVCGQKTPRISSSGLISWFTYDSIAKKGSNMVSJLQSV-GEPRK----- 274
 Oy 298 TSNCSKSI-SLEP---DOQIRASSMSQVNESGQVHMSPGQARLQDQGPSMASGDSN 353
 Db 275 -----CMALGMSGEIHSQDIYASQYST-----NMSASRSLNTPENKWTYGDY 322
 Oy 354 NHRPRELEIDLEKKKKTIGRTTG--STQSNNEFYKSVFNMKNNSKAKTYGGLVNN 411
 Db 323 -----REMIQVDLGLFPTAVTQGAISKETKKKKYKYYKIDVSNCEBDMITK--EEN 376
 Oy 412 EEKVGQSNRNPDOVNNFPPIVARYVAVPOTMORLALKVELLGCQT---QGNDS 467
 Db 377 KPVLEFGQNTNPDYVAVFPRKLTTRVRIKPAITWEGISNREPVYCKITDYPCSGMLG 436
 Oy 468 LVMKRTSOSTSTYKED 485

Db 437 MVSGLISDSOITSSNCGD 454

RESULT 15

990X38 PRELIMINARY; PRT: 921 AA.

AC 090X38

DT 01-MAY-2000 (TREMURIEL, 13, Created)

DT 01-MAY-2000 (TREMURIEL, 13, Last sequence update)

DE 01-DEC-2001 (TREMURIEL, 19, Last annotation update)

DE NEUROPOILIN.

OS Rattus norvegicus (Rat).

OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.

RA NCBI_TaxID=10116;

RP SEQUENCE FROM N.A.

RX MEDLINE=97433084; PubMed=9288753;

RA He Z., Tessier-Lavigne M.;

RT "Neuropilin is a receptor for the axonal chemorepellent Semaphorin III.";

RT Cell 90:739-751(1997).

RL -1- SUBCELLULAR LOCATION: TYPE 1 MEMBRANE PROTEIN (BY SIMILARITY).

CC -1- SIMILARITY: CONTRAINS 2 CUB DOMAINS.

CC -1- SIMILARITY: BELONGS TO THE NEUROPOILIN FAMILY.

CC -1- SIMILARITY: CONTRAINS 158 HYDROPHOBIC REGIONS.

CC -1- SIMILARITY: CONTRAINS 1 MAM DOMAIN.

DR EMBL: AF018957; AAC5345.1; -.

DR HSSP: P12259; 1CXT.

DR InterPro: IPR000859; CUB.

DR InterPro: IPR000421; FA58_C.

DR InterPro: IPR001092; HLH_dlm.

DR InterPro: IPR000988; MAM.

DR Pfam: PF00441; CUB_2.

DR Pfam: PF00421; CUB_2.

DR Pfam: PF00429; MAM_1 type C; 2.

DR PRINTS: PR00020; MAMDOMAIN.

DR SMART: SM00042; MAM_2.

DR SMART: SM00137; MAM; 1.

DR SMART: SM00137; MAM; 2.

DR PROSITE: PS01180; CUB; 1.

DR PROSITE: PS01180; CUB; 2.

DR PROSITE: PS01285; FA58C_1; 2.

DR PROSITE: PS01285; FA58C_2; 2.

DR PROSITE: PS01400; MAM_1.

DR PROSITE: PS01400; MAM_2; 1.

DR PROSITE: PS01400; MAM_2; 2.

KM Glycoprotein; Neurone; Receptor; Transmembrane

SEQUENCE 921 AA: 103052 MW: 588296AA4078971 CRC64;

Query Match 10.7%; Score 325.5; DB 11; Length 921;

Best Local Similarity 24.0%; Pred. No. 3.8e-17;

Matches 110; Conservative 81; Mismatches 173; Indels 95; Gaps 18;

Db 64 RGLLALLVSNPLRLQNEELDDCCGLLYTQDSGHTSKNRTGYNNHTVCERTYTPK 123

Db 3 RGLPULCATIALMALAGFR-SDKCGGTIKIEMGYLISPGYFHSHPSEKCEMLQNP 61

Db 124 G-KRLILRLG-DLDIRSQTCAADYILETSSSDQ---YGPYCSWVYPKPELLNTSEVTV 177

Db 62 PYORIMINPNHDLIEDRCKYDYEVYIDGENEGHMGKFCGKI-APSPVSSGPFLEI 120

Db 178 RFGSSHISGNGELLTA-----SDHIDLITC----- 205

Db 121 KVSQYVYTGAGSINVEIKFAGPECSQNTAIPGYIKSPGPEKYNLSLCTIYIIFAPK 180

Db 206 -----LEKSHYLTKEYSKCPAG--CRDVGDISGNVGYGRDTSILCKAALHAGITAD 258

Db 181 MSEIILFEFSFDLEDSNP--PGGMFCRYDLEI-----WDGPE-----VGP 221

Db 259 ELGASQISVLAKRGISNYEGILA-----NGVLSRDSLSDRKPLFTSNG-----CSRSLFE 309

Db 222 HIGRYCGQKTPGRIRNSSGILSNVPTTDSALAKGFSANYSVALSSISLSDTKRCKMLQME 281

Oy 310 P-----DQITRASSWQSYNCSGDDVHMSPGQARLQDGPSSVASGSDSSNNKPREMLRDL 365

Db 282 SGEIHSDDITRASSOYGT-----NMVSERSHLYNENGMTPGEDSY---REWIOVCL 329

Oy 366 GKKKKTIGIRTGS--STQSNFNYVYSFVNNFNNNSKRTYKGYVNEEKYVQNSNFR 423

Db 330 GLARPTAVAGTQALSKETKKKTYVKTVDISSGCDWTLR--EKNNALIFQSNVNP 387

Oy 424 DPYQNNFIPPIYARVYVYVQTHQORILAKYELICQIT 482

Db 388 DVFQVFPPLIRVRIRIKPMSTGISMREYVYCKIT 426

Search completed: July 9, 2002, 02:25:21

Job time: 678 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 8, 2002, 23:32:43 ; Search time 3285.5 Seconds

Without all updates/sec
11216.445 Million cell updates/sec

Title: US-09-691-344A-3

Perfect score: 1 atggagtcctgagcgagga.....caatgatactgcaggttaa 1761

Sequence: IDENTITY:NTC

Scoring table: gapop 10.0, gapext 1.0

Searched: 1797656 seqs, 10463268293 residues

Total number of hits satisfying chosen parameters: 3595312

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenBank1.*
1: gb-ba.*
2: gb-ba.*
3: gb-ba.*
4: gb-ba.*
5: gb-ba.*
6: gb-ba.*
7: gb-ba.*
8: gb-ba.*
9: gb-ba.*
10: gb-ba.*
11: gb-ba.*
12: gb-ba.*
13: gb-ba.*
14: gb-ba.*
15: gb-ba.*
16: gb-ba.*
17: gb-ba.*
18: gb-ba.*
19: gb-ba.*
20: gb-ba.*
21: gb-ba.*
22: gb-ba.*
23: gb-ba.*
24: gb-ba.*
25: gb-ba.*
26: gb-ba.*
27: gb-ba.*
28: gb-ba.*
29: gb-ba.*
30: gb-ba.*
31: gb-ba.*
32: gb-ba.*
33: gb-ba.*

Pred. No. is the number of results predicted by chance to have a score as high as or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description

AX118818 1761 100.0 1761 6 AX118818
2 1620 92.0 1620 6 AX118822
3 1522 86.4 1522 6 AX118822
4 1464 83.1 1464 6 AX118816
5 359.6 20.7 249429 2 AC099419
6 257 14.6 131060 9 HS039208
7 229.8 13.0 2642 10 AE387548
8 224.2 12.7 2939 9 AE387547
9 221.8 12.5 3039 9 AE387549
10 218 12.4 302546 2 AC092646
11 218 12.4 302546 2 AC092646
12 159 9.0 171300 2 AC092646
13 132.4 7.6 142616 2 AC092646
14 132.4 7.5 1388 9 HSN420528
15 131.4 7.5 2072 9 HSN420528
16 95 5.4 6895 4 BOVFCAC2A
17 95 5.4 6895 4 BOVFCAC2A
18 95 5.4 6895 4 BOVFCAC2A
19 95 5.4 6895 4 BOVFCAC2A
20 95 5.4 6895 4 BOVFCAC2A
21 95 5.4 6895 4 BOVFCAC2A
22 95 5.4 6895 4 BOVFCAC2A
23 95 5.4 6895 4 BOVFCAC2A
24 95 5.4 6895 4 BOVFCAC2A
25 95 5.4 6895 4 BOVFCAC2A
26 95 5.4 6895 4 BOVFCAC2A
27 95 5.4 6895 4 BOVFCAC2A
28 95 5.4 6895 4 BOVFCAC2A
29 95 5.4 6895 4 BOVFCAC2A
30 95 5.4 6895 4 BOVFCAC2A
31 95 5.4 6895 4 BOVFCAC2A
32 95 5.4 6895 4 BOVFCAC2A
33 95 5.4 6895 4 BOVFCAC2A
34 95 5.4 6895 4 BOVFCAC2A
35 95 5.4 6895 4 BOVFCAC2A
36 95 5.4 6895 4 BOVFCAC2A
37 95 5.4 6895 4 BOVFCAC2A
38 95 5.4 6895 4 BOVFCAC2A
39 95 5.4 6895 4 BOVFCAC2A
40 95 5.4 6895 4 BOVFCAC2A
41 95 5.4 6895 4 BOVFCAC2A
42 95 5.4 6895 4 BOVFCAC2A
43 95 5.4 6895 4 BOVFCAC2A
44 95 5.4 6895 4 BOVFCAC2A
45 95 5.4 6895 4 BOVFCAC2A

ALIGNMENTS

RESULT 1
AX118818 1761 bp DNA linear . PART 11-MAY-2001
DEFINITION
AX118818
VERSION
AX118818.1 GI:14035775
SOURCE
human.
ORGANISM
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
Doolittle, R.F., Turner, C.A., Wells, M., Friedrich, G., Zambrowicz, B. and
Sands, A.T. Human cub-domain-containing protein and gene encoding the same
Patent: WO 0129219-A 3 26-APR-2001;
JOURNAL
Lexicon Genetics Incorporated (US)
FEATURES
Source
1..1761
/organism="Homo sapiens"
/db_xref="taxon:9606"
BASE COUNT 471 a 402 c 483 g 405 t
ORIGIN

[illegible][illegible]

Dh	121	ACGTCGCTTGGACATCTTCCTCCACACCTCTCAGTAAATGCTCCAAACTGT	180
Oy	478	ggagatctgagctctcccaagaacattctgttgaacacagatgaatgaacgtccgctt	537
Dh	181	GAAATGTATGCTCTCCCAAGACACTCTTGTGAAACAAATGAATGAACGTCCGCTTT	240
Oy	538	ggagatctgagctctcccaagaacattctgttgaacacagatgaatgaacgtccgctt	597
Dh	241	GAAATGTATGCTCCCAATTTCTGGCCGGGGTTTTCTGTACACTGACGACAGACAT	300
Oy	598	cggagctttaaataagtttggagagcgctgacacattcttggagacagataaataa	657
Dh	301	CCAGTTTAAATAAACGTGTGGAAAGAGCTACCCATTATTTTGAACAGAAACAGAA	360
Oy	658	ctgcgcgcagctgctgttgaagagctgacgaagagacattcttggatatagttaga	717
Dh	361	TTTCTCCACCTGGGTGTGAAAGACCTACAGAGAAATTTGTGGAAATGTGATGGA	420
Oy	718	tatagaataaacctctcttcttggaaagctgtgcctccctggagaaataatgtctaga	777
Dh	421	TATGAATATACCTTTTATGTGTCAAACTGCCATCATGACAGATATATCTGATGA	480
Oy	778	ctatgtgcgcagatcagctgtgtctcaagccaaaggatacgtgtatctgaagaattcg	837
Dh	481	CTAGTGTCCACATACAGTGTCTTACAGAAAGAGATACATGTGATTAAGAGATTGCG	540
Oy	838	ggcaatgagctctctctctgagagatgtgtccctccaaagacatgtctgtctatcc	897
Dh	541	GCCATATGTTGTTTCCAGAGATATGTTCCCTGTCTCAGACAAAGCATTTCTGTACTCC	600
Oy	898	aatgatttgagagatacctcttgattcttgaaccctgaagcgaaatacaagctctctca	957
Dh	601	AATGTGTGACACAAATCTCTTAATTTGAACTCCTACCGGAATATACAGCTTCTCTCA	660
Oy	958	tggcagctcgtcgaatgaatctggagacgaagctctccctgtctctctgcgaagccgact	1017
Dh	661	TGGACATCGCTCATAGAAATGSAACAAACATTTACTGTCTCTCGCCACCCCACTT	720
Oy	1018	caggagccaaagcccaatactgggtcttcggcgacgaataaacaacaaacacgaag	1077
Dh	721	CAGACCAAGGCCCATCTGAGGTCTCGGCGACGATGACAAACAAACACAGAG	780
Oy	1078	tggctgagatctcgattctgggggagaaagaaatacaagaaataaagacacgaagact	1137
Dh	781	TGGCTGATCTTATGGAGATATGGAGAAATTAAGCAAGATTAAGACACAGATCT	840
Oy	1138	aacagatcgaaactaatcttatgtatgaagtttgtgtatgtaactgaactgaact	1197
Dh	841	ACACGTCGCACTTCATTTTATTTTAAAGATTGTGTGAATCACTTCAAAAATAAT	900
Oy	1198	tctaatgggaagacctaataaagaaattgtgaaataagaataaagtgcttcaaggtaac	1257
Dh	901	TCTAATGGAGAACCTTAATAAGAAATGTGAATTAAGAAATAAAGATGTTTACAGCTAAC	960
Oy	1258	cttaactctcggagacgagtgaaacaacttataccctcccaactcgtgtgcagaatactg	1317
Dh	961	TCCTAATCTTGCGGCCGACGTCGMAAAATTTTCACTCTCCATGTGGCCAGATATG	1020
Oy	1318	cggagtgatcccccgaacatgacacgaagagataaactctgaagatggagagcttatgttgc	1377
Dh	1021	CGGGTGTCTCCCGACAGCTACGCACACAGATATACCTTGAAGTGTGAGCTATTTGGTTC	1080
Oy	1378	cagatctacaaggttaatgattctctctgtgtgtgaggaagacaagtcacaagccagtgct	1437
Dh	1081	CAGATATCAACAGGATAAAGATCAATATGATGTGTGAGAGCAAGCAAGCAACACATG	1147
Oy	1438	tcaactcaagaataaattggagacatctgaagagcgatccctctggagaaataatccca	1497
Dh	1141	TCAACTCAACAAAGAGATGAGCAATCAACAGAGCCATCCCTCGGAAGAAATCCCA	1200
Oy	1498	ggagataaatactcaagagtgagctatccactgtgacactctgtgtgacctgtgtgtct	1557
Dh	1201	GGATTAACATTTCAAGCGTGAGATTTCCATTTGGTCTCTCTGTTGCTCTGGTGGTTCCT	1260

[illegible]

Db	4310	GTGCACAGGATCATAGT- GACCTATTGTGGAGATTGGCGCTTTCACAGACACTGGC	4312
Oy	509	TGAACAAGTGAAGTAACGTCGGCTTGGAGTGGATCCCACTTCTGACGGAGGTT	568
Dy	4311	TGACATTCACAGAGGACGTTGGCTTCAGCAAGTGGATGGATATTCCTGGCGGGGCT	4252
Oy	569	TTTGTCTACCTACGAGCGACCGACCTCAATAAATGTTTGAAGAGCTA	628
Dy	4251	TTCTGTACCTCTTCTGCAATGATCATCCAGATTAAATACCTGTTTGAAGAGCA	4192
Oy	629	ggccattctTgaagaagaatcagcaactctgcgcgcgctggttgaagaagcagag	668
Dy	4191	GTCAATATTCACAGAAAATATACAGCCGATTCGTCCACGCTGGTGTAGACATATGCA	4132
Oy	669	ggagcattcttgggaattctgtaaatgagattatgaagaccccttatcttggcaaacctg	748
Dy	4131	GGGCAATTCCTGGAAATACAAAGATGGCTCTGATGATACCTCTTTTTCACAACTG	4072
Oy	749	ccatcaatgcaggaataattgctgctgaacacagtcagtcgcagatc-----gctgct	800
Dy	4071	CAATCCACAGGAGATCTCAAAAGAAACATGATGCTCTGCACACACCTCTTCACACT	4012
Oy	801	tcaagcaagagacacagtcgattcttgaagatcttgcacaaatggtctcttcttgaagga	860
Dy	4011	TGATGTCAAAAGGATTAATCACTGATCAAGATCTCGGACATGATGTCTCTCCACACA	3952
Oy	861	tggtctccctgcagcaagagattcttgcgttaccatcccaagag	902
Dy	3951	TGGTCTCTGTGACGA- AAGGCAATTTCTGTTATCATCCCAAG	3911

RESULT	/6
LOCUS	HSDJ92C8/c
DEFINITION	HSDJ92C8
ACCESSION	F071
KEYWORDS	Al132671.20 GI:9805189
SOURCE	HTG.
ORGANISM	human.
REFERENCE	Homo sapiens Bukuzyota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Plimates; Catarrhini; Hominoidea; Homo. 1 (bases 1 to 13106)

TITLE Direct Submission
JOURNAL Submitted (21-M06-2000) Sanger Centre, Hinxton, Cambridgeshire,
CH10 1SA, UK. E-mail enquiries: hinxquery@sanger.ac.uk Clone
requests: clonequest@sanger.ac.uk
COMMENT On Aug 22, 2000 this sequence version replaced dt:12282316.

Where differences are found these are annotated as variations together with a note of the overlapping clone name. Note that the variation annotation may not be found in the sequence submission corresponding to the overlapping clone, as we submit sequences with only a small overlap as described above.

Only a few sequences have been finished according to sequence map criteria as follows. In some cases, attempts were made to resolve all sequencing problems, such as compression and deletions, but not necessarily within known annotated human repeat sequences (e.g. Alu). Where the feature key is ambiguous, there is an annotation using the 'unstable' feature key.

The following abbreviations are used to associate primary accession numbers given in the feature table with their source databases: Bm1, Bm2L, Swi, SWISSPROT; Tr, TREMBL; Wp1, WORMPEP; information on the WORMPEP database can be found at http://www.sanger.ac.uk/Projects/C_elegans/WormPep This sequence chromosome is from a part of bacterial clones contigs of human chromosome 6. The Sanger Centre has a Human Genome Mapping Group. Further information can be found at <http://www.sanger.ac.uk/HGP/Chr6>

RPL-938C is from the library R6C-1 constructed at the Roswell Park Cancer Institute by the group of Pleacer *de Jong*. For further

details see <http://haepac.med.buffalo.edu/VECTOR/cpypac2>
IMPORTANT: this sequence is not the entire insert of clone Rpl-9208. It may be shorter because we sequence overlapping sections only once, except for a 100 base overlap. The true left end of clone Rpl-1799 is at 13095 in this sequence. The true right end of clone Rpl-94616 is at 100 in this sequence.

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/clone="RP1-92C8"
/clone_lib="RPC1-1"
1..88140db repeat: matches 11. .293 of consensus*
425..513
/ote="L2 repeat: matches 2562. .2648 of consensus"
514. .856
/ote="MER1a repeat: matches 1. .337 of consensus"
857. .1162
/ote="L2 repeat: matches 2246. .2562 of consensus"
1977. .2048
/ote="L2 repeat: matches 2629. .2704 of consensus"
3004. .3273
/ote="L2 repeat: matches 18. .287 of consensus"
4127. .5300 repeat: matches 18. .287 of consensus*
/ote="CDS island"
/evidence="not_experimental"
4614. .4755
/ote="71 copies 2 mer cc 59% conserved"
4631. .4707
/ote="3 copies 29 mer 81% conserved"
6477. .6564
/ote="2 copies 44 mer 95% conserved"
7144. .7280 repeat: matches 22. .163 of consensus"
7828. .7868 repeat: matches 1. .61 of consensus"
/ote="MERa repeat: matches 1. .61 of consensus"
8038. .8120
/ote="L2 repeat: matches 2465. .2551 of consensus"
8223. .8531
/ote="Alu5g repeat: matches 1. .305 of consensus"
8639. .9030
/ote="MER1a repeat: matches 1. .417 of consensus"
9455. .9559
/ote="MER37-internal repeat: matches 1232. .1347 of consensus"
9543. .9743
/ote="MER37-internal repeat: matches 2005. .2220 of consensus"
9732. .9907
/ote="MER37-internal repeat: matches 2456. .2629 of consensus"
9900. .10770
/ote="MER37-internal repeat: matches 2777. .3637 of consensus"
10770. .11327
/ote="MER1a-internal repeat: matches 3972. .4550 of consensus"
11328. .11618
/ote="Alu5g repeat: matches 1. .292 of consensus"
11619. .12914
/ote="MER1a-internal repeat: matches 4590. .4554 of consensus"
12915. .13144
/ote="L1P5 repeat: matches 5914. .6143 of consensus"
13144. .14195
/ote="MER1a-internal repeat: matches 4553. .5213 of consensus"
13824. .14458
/ote="MER1a repeat: matches 1. .633 of consensus"
15991. .16301

```

[illegible]

Oy	770	cggtaaacctaggtagccagatcagtgagcttcgaacgcaaaaggaacagtcgtcttgaag	829
Db	1096	CAAAACAGGTGGGCGAACAATCAGTGTGAATTATTAAGAACACCCTCATTTATCCAG	1155
Oy	830	gagttctgcacaaagtgtgtctcttcgaagaagtgattcgctcgtcaggaacaattctcga	889
Db	1156	gttttttggtctaacacagctcacatctgtgtgtgtggagacacttatctaacanagctttttgcat	1215
Oy	890	ttaaccaccaaggtctgcagagatgcccttgaatttgacctgaaggag	c 937
Db	1216	ttttagacaaagtgatattgatgaaacacgtggataagcttgtctgtatccgactccctc	1275
Oy	938	aatatcagagcttctctccaatgagatgtgcataagagatggagagacacagttcaactggt	997
Db	1276	AATAATCACATCATCTGTCTGTGTGAGTGAGTCACACACAGGCCAAGAGAACACTTGGA	1355
Oy	998	ctctctgcgcaagcccgcagctcttcagagacaaagccccatacgaaggcttcgagcagaagtga	1057
Db	1336	AATCCCCAAAAAGCAAAGCTGTAAAAMAAACCTGCACCCCCTGGGCTCTTTTGCCACTGATC	1395
Oy	1058	aatccacacacacacacacagaggtgtcggagatcgatttggagtgagaaaagaaataaacag	1117
Db	1396	ATATACC-----ATGTGTTTCAATTAATTAATTTGAAAGAAAAGAAAATTAACAG	1443
Oy	1118	gaattcagaccacagatcatcacaaagctgaactcaactttaagttaaagagttctgga	1177
Db	1444	GCAATTTATTAACCTCTGTGATCCACATGTGTGGAGACAAATTAATCTATGTGTCTCCCTACAGAA	1503
Oy	1178	tgaaactcaataacataatctctaagtgtgaagagcctttaaagaaatgtgaaataaagaag	1237
Db	1504	TCTGTGTGATGATGATGTGGCAAAATGAGACTGTGTGACAGNAGACCTGTGTGTGAGCCAG	1563
Oy	1238	aaaaagtggttcacaggtaactctcaactcttcggagaccagagacaaacaattcaactc	1297
Db	1564	ATAAAGATATTTCCAAGAACAAMAATAATTAACACAGATGTGGTAAATATCTTTGCCAC	1633
Oy	1298	ccatctgtagccagatatactgaggtgtgtctccccaacatactgcacacagagatcttga	1357
Db	1624	CATTAATTCACGCTTTTATTAATGATATCTTACATCCACATGACAGCAAGAAATTTGCCATGA	1683
Oy	1358	aggtcagagctcatctgttgcacagatta	1384
Db	1684	AATGTGACGTCTCGCATGACCTTTA	1710
RESULT	9		
LOCUS	AF387547	2939 bp	mRNA linear PRI 11-NOV-2001
DEFINITION	Homo sapiens endothelial and smooth muscle cell-derived neurofilin-like protein (ESDN) mRNA, complete cds.		
ACCESSION	AF387547		
VERSION	AF387547.1	GI:16902434	
KEYWORDS	human.		
ORGANISM	Homo sapiens		
REFERENCE	Bokilayev, A., Choudhary, C., Grunstein, R., Vertebnaya, E., Euleleostomi, I. (bases 1 to 2939)		
AUTHORS	Kobuke,K., Furukawa,Y., Sugai,M., Tanigaki,K., Ohashi,N., Matsumori,A., Sasayama,S., Honjo,T. and Tashiro K.		
TITLE	ESDN, A Novel Neurofilin-Like Membrane Protein Cloned from Vascular Cells with the Longest Secretory Signal Sequence among Eukaryotes, Is Up-regulated after Vascular Injury		
JOURNAL	J Biol Chem	276 (36), 34105-34114	(2001)
REFERENCE	1 (bases 1 to 2939)		
AUTHORS	Kobuke,K., Furukawa,Y., Sugai,M., Tanigaki,K., Ohashi,N., Sasayama,S., Matsumori,A., Honjo,T. and Tashiro K.		
TITLE	Direct Submission		
JOURNAL	Submitted (30-MAY-2001) Department of Medical Chemistry, Kyoto University Graduate School of Medicine, Yoshida Konoe-cho, Sakyo-Ku, Kyoto 606-8501, Japan		

IMPORTANT: This sequence is the entire insert of clone 94G16. During sequence assembly data is compared from overlapping clones. Where differences are found these are annotated as variations together with a note of the overlapping clone name. Note that the variations annotated may not be found in the sequence submission corresponding to the overlapping clone as we submit sequences with only a small overlap.

This sequence was generated from part of bacterial clone contigs of human chromosome 6, constructed by the Sanger Centre chromosome 6 mapping group. Further information can be found at <http://www.sanger.ac.uk/HGP/Chr6/>

This sequence has been finished according to sequence map criteria as follows. An attempt is made to resolve all sequencing problems, annotated human repeat regions, but not necessarily within known sequence is ambiguous, there is an annotation using the 'unsure' feature key.

The true left end of clone 94G16 is at 1 in this sequence. The true right end of clone 94G16 is at 100808.

94G16 is from the library RPCI1 constructed at the Roswell Park

Cancer Institute by the group of Pieter de Jong.

For further details see <http://dbpac.med.buffalo.edu/>.

FEATURES

source

1. 100808
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/map="6q21"
/clone="RP1_94G16"
2. 109
/note="RPCI1-RPCI1"
/note="AluSg repeat: matches 193. 300 of consensus;
incomplete repeat"
586. 684
repeat_region
/note="MIR2 repeat: matches 32. 134 of consensus"
828. 1128
repeat_region
/note="AluDb repeat: matches 1. 300 of consensus"
2069. 2366
repeat_region
/note="MIR3 repeat: matches 426. 1 of consensus"
2560. 2589
repeat_region
/note="AluY repeat: matches 1. 297 of consensus"
4018. 4220
repeat_region
/note="2 copies of 2 mer 100 & conserved"
4380. 4673
repeat_region
/note="MER42B repeat: matches 1204. 1005 of consensus"
5272. 5272
repeat_region
/note="MER42C repeat: matches 983. 690 of consensus"
6052. 6137
repeat_region
/note="MIR3A repeat: matches 131. 183 of consensus"
7850. 8066
repeat_region
/note="MIR repeat: matches 57. 144 of consensus"
9495. 9676
repeat_region
/note="MIR repeat: matches 262. 47 of consensus"
13051. 13336
repeat_region
/note="AluSx repeat: matches 119. 300 of consensus;
incomplete repeat"
13579. 13930
repeat_region
/note="AluSb repeat: matches 1. 302 of consensus"
12013. 12188
repeat_region
/note="L1MD1 repeat: matches 971. 793 of consensus"
12310. 12500
repeat_region
/note="AluSg repeat: matches 108. 299 of consensus;
incomplete repeat"
13051. 13336
repeat_region
/note="Alu repeat: matches 1. 289 of consensus"
13800. 13800
repeat_region
/note="AluSg repeat: matches 302. 3 of consensus"
16740. 16877
repeat_region
/note="MIR2 repeat: matches 144. 1 of consensus"

17538. 17581
repeat_region
/note="2 copies of 27 mer 100 & conserved"
1854. 18722
repeat_region
/note="FLAM.C repeat: matches 1. 131 of consensus"
1854. 18722
repeat_region
/note="MIR repeat: matches 261. 84 of consensus"
20152. 20294
repeat_region
/note="MER42C repeat: matches 1097. 949 of consensus"
21524. 21613
repeat_region
/note="MIR repeat: matches 60. 144 of consensus"
21613. 21613
repeat_region
/note="AluDb repeat: matches 1. 301 of consensus"
21916. 22025
repeat_region
/note="MIR repeat: matches 141. 262 of consensus"
21983. 21992
misc_feature
/note="Tn10 flanking repeat: Tn10 sequence was inserted at position 21992. 21993; in some sequenced clones which were not included: in the final assembly."
22792. 22848
repeat_region
/note="2 copies of 2 mer 93 & conserved"
23337. 23527
repeat_region
/note="MIR repeat: matches 243. 45 of consensus"
26788. 27074
repeat_region
/note="MIR repeat: matches 1. 299 of consensus"
27487. 27787
repeat_region
/note="AluYo repeat: matches 297. 1 of consensus"
28460. 28524
repeat_region
/note="MIR2 repeat: matches 146. 86 of consensus"
28475. 28524
repeat_region
/note="MIR repeat: matches 257. 195 of consensus"
28538. 28843
repeat_region
/note="AluY repeat: matches 1. 299 of consensus"
29096. 29432
repeat_region
/note="MIR repeat: matches 354. 1 of consensus"
29433. 30977
repeat_region
/note="THE1B-INTERNA repeat: matches 1580. 2 of
30980. 31322
repeat_region
/note="MIR repeat: matches 354. 1 of consensus"
32594. 32810
repeat_region
/note="MER30 repeat: matches 1. 229 of consensus"
34663. 34860
repeat_region
/note="MER20 repeat: matches 218. 2 of consensus"
34906. 35188
repeat_region
/note="AluSg repeat: matches 302. 2 of consensus"
36467. 36599
repeat_region
/note="AluSg repeat: matches 299. 1 of consensus"
37045. 37345
repeat_region
/note="MER33 repeat: matches 9. 332 of consensus"
39246. 39818
repeat_region
/note="MIR repeat: matches 568. 1 of consensus"
41305. 41604
repeat_region
/note="Alu repeat: matches 301. 1 of consensus"
42255. 42299
repeat_region
/note="MER2 repeat: matches 46. 2 of consensus"
42703. 43037
repeat_region
/note="MER18 repeat: matches 337. 1 of consensus"
44291. 44516
repeat_region
/note="MIR repeat: matches 541. 300 of consensus"
47198. 47261
repeat_region
/note="2 copies of 32 mer 92 & conserved"
49349. 49557
repeat_region
/note="MIR repeat: matches 7. 203 of consensus"
49728. 497016
repeat_region
/note="Alu repeat: matches 10. 298 of consensus"
50103. 50104
unsure
50110. 50111
unsure
50117
repeat_region
50140. 50235
repeat_region
/note="FLAM.A repeat: matches 133. 40 of consensus"
51950. 52234
repeat_region
/note="AluYo repeat: matches 1. 297 of consensus"
52235. 52357

```

TITLE      The sequence of Homo sapiens clone
JOURNAL    Unpublished
REFERENCE   2 (bases 1 to 142616)
AUTHOR     M. Hagiya, T. H. Ransohoff
TITLE      Direct Submission
JOURNAL    Submitted (22-MAR-2000) Genome Sequencing Center, Washington
           University School of Medicine, 4444 Forest Park Parkway, St. Louis,
MO 63108, USA
COMMENT    MO Oct 25, 2000 this sequence version replaced g1:9558143.

----- Genome Center -----
Center: Washington University Genome Sequencing Center
Center code: WGCSC
Web site:http://genome.wustl.edu/gsc/Index.shtml
Project Information
Center Project name: H.MH0117013
Summary Statistics
Sequencing vector: M13; 100%
Sequencing method: plasmid; 100%
Consensus quality: 139293 bases at least Q40
Chemistry: Dye-terminator Big Dye; 0% of reads
Assembly program: Phrap; version 0.950319
Consensus quality: 140128 bases at least Q40
Consensus quality: 140609 bases at least Q20
Insert size: 141000; agarose-FP
Insert coverage: 5.56 in Q20 bases; agarose-FP
Quality coverage: 5.84 in Q20 bases; sum-of-contigs

*****
NOTE: This is a "working draft" sequence. It currently
consists of 7 contigs. The true order of the pieces
is not known and their order in this sequence record is
arbitrary. Gaps between the ends of the contigs are
marked by asterisks. The sizes of the gaps are unknown.
This record will be updated with the finished sequence
as soon as it is available and the accession number will
be preserved.

1. 1680: contig of 1680 bp in length
*
* 1681 1780: gap of unknown length
*
* 1781 11282: contig of 9302 bp in length
*
* 11283 20724: gap of unknown length
*
* 20725 20731 20830: gap of unknown length
*
* 20831 39951: contig of 19121 bp in length
*
* 39952 40051: gap of unknown length
*
* 40052 67132: contig of 27261 bp in length
*
* 67133 97063: gap of unknown length
*
* 97064 97183: contig of 28651 bp in length
*
* 97184 142616: contig of 45315 bp in length.

FEATURES
Location/Qualifiers
1..142616
/oranism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/clone="RP11-117013"
/misc_feature
1781..11282
/note="assembly_name:Contig4"
misc_feature
11383..20730
/note="assembly_name:Contig5"
misc_feature
20831..39951
/note="assembly_name:Contig6"
misc_feature
40052..67132
/note="assembly_name:Contig7"
misc_feature
67133..97063
/note="assembly_name:Contig8"
misc_feature
97064..142616
/note="assembly_name:Contig9"
vector_side:left

```


Db 301 TCATGAGTGGATCCATGTTCTTGAGACGGGATTTTGGCCCTCACTCTGTATAGATA 360
Oy 596 atc-cagatttaataacatglltgagagagctagaca-ttatitgaagacagatacaag 653
Db 361 AACAAAGATCTAATTACTGTGTTGACACAGTCACATTTTGTGGAACTGAGTTGAG 420
Oy 654 caaatccg--ccagctggctgtgagagctagcagagacatcttcggagataatgtag 712
Db 421 TAACTACGCCCCACACTGGTGTCTGCTCTCTTTGTGTGAATCTGGAACTATCTCTC 480
Oy 713 atgataataagataacccctllatgtgtcaagctgcacacacagagataatgtag 772
Db 481 ATGGATATAGAAATCTCTGGCATGTGTGCATGTGTGTGATTCACAGAGATGTGCAA 540
Oy 773 atgpaatcagtgagccagcaacagtgctgtccacgcgaagagacacacacacacacac 832
Db 541 AACGTTGGGGGCCCAATCAGTGTGTGTAATTAAGTAATTCCTTAATTAAGTAAGTT 600
Oy 833 tctcgcacaatgtagtctcttcgagagagatgctcgtcagagagagatctc---gt 889
Db 601 CTTTGCTTACAACTCACAATCTGTGTGGACACTTGAATCTACAAAGTCTTTTACAT 660
Oy 890 ttaccctcaatgtgtcagcagagatccttgagcttgagacctgacggagcaalcagagct 949
Db 661 TTAAGACAACTGATGCTTAAGAACACTGGNAATGAGCTGTGTGTGTATCTGCGATCT 720
Oy 950 ctccctcatgacgctgcgtcaatgagatgagagacagatcaatcgtctcctcgccaag 1009
Db 721 CAATTACACGATCACTGTCTGTGATGTGACTGACACACAGGCGAAGACAGATTGGA 780
Oy 1010 ccgagcttcagagcagaagcccatctgagcttcgggcgacagtagcaacacacacac 1069
Db 781 AACCCAAAACCCAGGCTGAAAAACCTGACCGCGCTTGGGTCTTGGCCACTGATG 840
Oy 1070 caccagagtgctgagatcgatcttggtgggagaaagaaataacacagatlaagacca 1129
Db 841 AATACAGTGGTACAAATAGATTTGATAGAGAAAGAAATACAGCATTAATTAAGCA 900
Oy 1130 caggatctcagcagagctgaacttcaactttagtlaagagcttctgtgagacttcaaa 1189
Db 901 CTGATTCACCATGCTGAGC-ACAAATTACTATGTGTCTGCTACAGAAATCCTGTACAGTG 959
Oy 1190 acaataatctcaagtgaagagacctataaag-gaatltgaaataagaaagagtgctt 1248
Db 960 ATGATGGCGACAAATAGGACTGTGTACAGAGAGCTGTGCTGTGACAGAAATAGATNTT 1019
Oy 1249 caggatlaacttaacttacttggagc--ccagtgcaaaagcaatllcatccctccatcgtg 1305
Db 1020 CAAGGAACAAAGAAATTAACACAGATGCTGCTTAATTAATCTTTGACCAATTAAT 1079
Oy 1306 gccagataatgtagctgtgtccccaagacatgacacagagagataagcttgaagtgtag 1365
Db 1080 G-CAGGTTAATTACAGTAGAATCTTACCCCAATGSCACAGAAATTCATCAATAAATGAG 1138
Oy 1366 ctcaatgtgtccagatla 1384
Db 1139 CTGCTGGATGTCAGTTTA 1157

Search completed: July 9, 2002, 01:13:21
Job time: 6038 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd

OM nucleic - nucleic search, using sw model

Run on: July 8, 2002, 23:26:13 ; Search time 1913.71 seconds

12419.927 Million cell updates/sec

Title: US-09-691-344A-3
Page: 1261

Perfect score: 1761
Score: 1

scoring cable: IDENTITY_NUC Count 1 0
 Count 10 0

Searched: 13736207 seqs, 6748477542 residues

Total number of hits satisfying chosen parameters: 27472414

```

Maximum DB seq length: 20000000000
Minimum DB seq length: 0

```

Maximum DB seq length: 2000000000

post-processing:	Minimum Match	0%
Maximum Match	100%	

Listing first 45 summaries

Database : EST: *

```

1:  em_estba:*
2:  em_estlum:*
3:  em_estlin:*
4:  em_estlum:*
5:  em_estcov:*
6:  em_estpl:*
7:  em_estro:*
8:  em_hc:*
9:  gb_est1:*
10: gb_est2:*
11: gb_hc:*
12: gb_gss:*
13: em_gss_hum:*
14: em_gss_inv:*
15: em_gss_pln:*
16: em_gss_vrt:*

```

Pred. NO. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	540.8	30.7	1934	11	AA016485	AK014485 Mus muscu
2	539.8	30.7	1934	11	AA016485	AK013571 Mus muscu
3	470.6	26.7	882	10	BC025511	AK013571 Mus muscu
4	444.8	25.3	883	10	BC025511	AK013571 Mus muscu
5	431.2	24.7	466	9	AA090343	BC025511 Mus muscu
6	385.4	20.2	449	9	AA083656	AA090343 R6C-SP018
7	335.4	19.0	406	10	BF740455	AA083656 55566 MR
8	277.2	15.5	975	10	BF740455	BF740455 R6C2-BH000
9	273.2	15.5	975	10	BF740455	BF740455 601787144
10	243.2	14.3	257	9	BE036835	BE036835 MR0-BT037
11	243.2	14.2	260	10	BF031266	BF031266 MR0-BT037
12	228.4	13.0	444	9	BE005052	AA030044 m12810.t
13	212.2	12.0	451	10	BC008626	BE005052 R6C3-HW023
14	209.4	11.9	406	9	AA040037	AA040037 m104412.t
15	203.2	11.5	896	10	BF159411	BF159411 601785465
16	198	11.2	412	9	AJ135615	AJ135615 w08Rf03.x
17	189.8	10.8	318	10	H32466	H32466 EST107591.R

18	185.2	10.5	482	10	EP071655	BP071655 OV0-ET03
19	179	10.2	219	9	BE068836	BE068836 MR0-BT037
20	160.8	9.1	914	10	BI113107	BI113107 G62990444
21	155.6	8.8	295	9	BB555422	BB555422 BB58544
22	150.6	8.6	643	9	BE119946	BE119946 BB179946
23	148.9	8.4	694	10	BE527635	BE527635 G62377306
24	138.6	7.9	670	12	BS52126	BS52126 CTR-HS-200
25	136.4	7.7	667	9	AL556385	AL556385 AL586285
26	134	7.6	664	9	AM383859	AM383859 OV3-HT036
27	129.6	7.4	639	9	AL048059	AL048059 DKP2P86P
28	128.2	7.3	587	9	AM383890	AM383890 OV3-HT036
29	127.8	7.3	459	10	N46066	N46066 YV35905-HT1
30	127.2	7.2	466	9	AT750360	AT750360 CM06048
31	125.2	7.1	693	10	BF732384	BF732384 nseel1a12
32	121	6.9	986	10	BI080802	BI080802 602878574
33	120	6.8	463	10	BF770080	BF770080 268692 KM
34	112	6.5	902	10	BF758391	BF758391 nseel16013
35	111.8	6.4	902	10	BF758391	BF758391 nseel16013
36	113.2	6.4	299	10	BP350222	BP350222 OV3-HT036
37	113.2	6.2	270	9	BE177683	BE177683 BB177683
38	108.8	5.8	703	9	AM070902	AM070902 xa31b09.x
39	102.2	5.6	408	10	BP825585	BP825585 y570e05.r11
40	101	5.7	578	9	AA122907	AA122907 mq23a10.x
41	102	5.8	745	9	AL577036	AL577036 AL577036
42	97.8	5.6	506	9	AL048089	AL048089 DKP2P86H
43	96	5.4	527	9	AL552613	AL552613
44	95.8	5.4				
45	94.4	5.4				

ALIGNMENTS

RESULT 1	AF016485	1924 bp	mRNA	linear	HTC 19-JAN-2003
LOCUS	AF016485	1924 bp	mRNA	linear	HTC 19-JAN-2003
DEFINITION	Mus musculus adult male testis cDNA, RIKEN full-length enriched library, clone 4931229A04:putative CUB domain containing protein.				
ACCESSION	AF016485				
KEYWORDS	HTC: CAP trapper.				
SOURCE	Mus musculus (strain:57BL/6J) adult male testis cDNA to mRNA, clone_1lb:RIKEN full-length enriched mouse cDNA library				
ORGANISM	Mus musculus				
REFERENCE	Enkayayta; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus;				
AUTHORS	Carninci,P. and Hayashizaki,Y.				
TITLE	High-efficiency full-length cDNA cloning				
JOURNAL	Meth. Enzymol. 303, 19-44 (1999)				
MEDLINE	99279253				
PUBMED	10349636				
REFERENCE	2 (sites)				
AUTHORS	Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K., Itoh,M., Kono,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.				
TITLE	Normalization and subtraction of cap-trapper selected cDNAs to				
JOURNAL	Genome Res. 10 (10), 1617-1630 (2000)				
MEDLINE	20459374				
PUBMED	11042159				
REFERENCE	3 (sites)				
AUTHORS	Shibata,K., Itoh,M., Aizawa,K., Nagaoka,S., Sasaki,N., Carninci,P., Kono,H., Akiyama,J., Ishii,K., Kitajima,T., Teshiro,T., Itoh,M., Sumi,N., Ishii,Y., Nakamura,S., Hazama,M., Nishino,T., Hatada,A., Iemamoto,K., Matsumoto,H., Sakaguchi,S., Ikegami,T., Kasai,M., Yamamoto,S., Ishikawa,T., Oshino,K., Tanaka,Y., Saitaka,K., Yokoyama,C., Oshino,K., Kono,H., Inoue,Y., Kira,A. and Hayashizaki,Y.				
TITLE	RIKEN integrated sequence analysis (RISA) system--384-format				
JOURNAL	sequencing pipeline with 384 multiplexillary sequencer				
PUBMED	Genome Res. 10 (11), 1757-1771 (2000)				

	DB	422	AAMRACGAATTTCTGCCACCAGCGGTGTAAGCAATACAGAGNATVMTTCGGCAAA	481
	Dd	706	atcgagtagtgcataatagagaacaccctttattatgtcaaacgctgcacatccaaaggagaata	765
	Dd	482	ACCAAAGACTGTTCAGAGTACAGTACCTTTATTGTGCATAAAGCATCCACCCAGGATC	541
Oy	766	atcgttagtaacttcggagggaggaatcgtgatcgttcagagaggaagtcaaatcatat	825	
Dd	542	ATTCAGANTGACATGATGAGGCGCACATCACTTGCTTCAGAGAACAAAGGATATGACATAT	601	
Oy	826	gaagaggaattctgcgcacaagtgattcttccttcagaggaatgagttcccgtcacaaagcattt	885	
Dd	602	GAAAGACCTCTGCGCAAGAGGCTGCTCTCCGACAGATGGTCTTTGTGGAAAGCCGATTT	661	
Oy	886	cgttatcactccaatg	902	
Dd	662	CTTTTATACACCCACAG	678	
	RESULT 3			
	LOCUS	BG245910	872 bp	mRNA linear EST 13-FEB-2001
	DEFINITION	602358725F1 NC1.COAR_Mam1 Mus musculus cDNA clone IMAGE:4486950 5'		
	VERSION	BG245910.1		
	KEYWORDS	BG245910.1 GI:12755725		
	SOURCE	EST.		
	ORGANISM	Mus musculus		
	REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
	TITLE	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus,		
	JOURNAL	NCBI Genbank (http://www.ncbi.nih.gov/)		
	COMMENT	Unpublished (1999)		
		Contact: Robert Strunberg, Ph.D. Email: ccgabs-remail.nih.gov Tissue Procurement: Gilbert Smith, Ph.D. CDNA Library Preparation: Life Technologies, Inc. DNA Sequencing by: Incyte Genomics, Inc. Gene distribution: MGC clone distribution information can be found at: http://image.llnl.gov/ Plate: LTM10331 row: b column: 07 High quality sequence stop: 786.		
	FEATURES			
	source	location/Qualifiers		
		1..872		
		/organism="Mus musculus"		
		/strain="FVB/N"		
		/db_xref="taxon:10090"		
		/clone_image="4486950"		
		/clone_libname="LCAR_Mam1"		
		/clone_library="Library Diversity sample"		
		/dev_stage="10 months, virgin"		
		/lab_host="DH10B"		
		/note="Orig: mammary. Vector: pCMV-SPORT6. Site.1: SalI; Site.2: NotI. Cloned unidirectionally. Primer: Oligo dT, Library constructed by Life Technologies. Investigator providing samples: Gilbert Smith, NIH"		
	BASE COUNT	213 a 202 c 249 g 208 t		
	ORIGIN			
	Query Match	26.7%	Score 470.6;	DB 10;
	Best local similarity	79.4%	Pred No.2,-4e+90;	
	Matches 596;	Conservative 0;	Mismatches 149;	Indels 6;
			Gaps 3;	
Oy	219	cttcgccgcgtcgcgtctgcagagcgaggaatctcgatgacctgtagaacctctagtaa	278	

Db	109	GTGTGCTCCGCTCCGGTTCGACAGCGAGGAGACGTGGAGTATGAGCTGTGAGGGACACTATGATGAC	168
Qy	279	LTATCGGATGATGCGCAAAATGACATCTATAAGATATATCTCCGGAGGACCTACCCATCAACAC	338
Db	169	CTCTCGACACAGGAGCAATACATATCATATATGAAATATTCACAGGAGACCTTACCCATATACAC	228
Qy	339	TGTTCTCGAAAGAGCAATATCAAGATCAAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG	398
Db	229	TGTGTGTGAAATGATCATCATCATCATCATCATCATCATCATCATCATCATCATCATCATCATCAT	288
Qy	399	TTTGATATCGATCCCGAGAGCTGTGATCTGTGATCTGTGATCTGTGATCTGTGATCTGTGATCTG	458
Db	289	TTTATCATATATATCATCATCATCATCATCATCATCATCATCATCATCATCATCATCATCATCAT	348
Qy	459	TCATATGTGATCTCTGTGAGAGATATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG	518
Db	349	TGAGTATGAGTGCATATTTGTGGAGTTTGGGCTGTTCCTCCAAAGACATCCGGCTGAAATCATAA	408
Qy	519	TGAAGTAAACGCTCGCTGTGAAGATGTAGATCCCAATCTTCGACGAGGAGTCTTTTGCTGAGAC	578
Db	409	CGAAGATGATCTCTCTCTCATAGATGATCATCATCATCATCATCATCATCATCATCATCATCAT	468
Qy	579	CATGCGAG	638
Db	469	CTACGCCACAGAGACATCATCATCATCATCATCATCATCATCATCATCATCATCATCATCATCAT	528
Qy	639	GAAAGACAGATATACAGCAATCTCTCCAGATCGTGTGTAGAGAGAGAGAGAGAGAGAGAGAGAG	698
Db	529	CGAGGAAATATACAGCAATCTCTCCAGATCGTGTGTAGAGAGAGAGAGAGAGAGAGAGAGAGAG	588
Qy	699	TGAGATATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG	757
Db	589	TGGGATATACAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT	648
Qy	758	CAGGATATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG	818
Db	649	AGGATATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG	708
Qy	818	ATCGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG	878
Db	709	AAGGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG	768
Qy	878	AGACAGAGATCTCTGATCTCTGATCTCTGATCTCTGATCTCTGATCTCTGATCTCTGATCTCTG	903
Db	769	GGAAAGAGCATATCTTTTAAACACACCGAGAT	799
RESULT 4			
LOCUS	BC975603	883 bp	linear
DEFINITION	6028435306F1 NIH_GCAF_MamM Mus musculus CDNA clone IMAGE:4981009 5'	EST 12-JUN-2001	
ACCESSION	BC975603	BC975603.1	GI:14363240
VERSION	BC975603		
KEYWORDS	EST.		
REMARKS	Mouse musculus		
ORGANISM	musculus		
REFERENCE	NIH-MGC	http://www.ncbi.nlm.nih.gov/	
AUTHORS	NIH-MGC	http://www.ncbi.nlm.nih.gov/	
TITLE	National Institutes of Health, Mammalian Gene Collection (MGC)		
JOURNAL	Unpublished (1999)		
COMMENT	Contact: Robert Strusberg, Ph.D. Email: rstrus@ncbi.nlm.nih.gov Lab: Mouse Musculus Eukaryote: Metazoa: Chordata: Craniata: Vertebrata: Euteleostomi: Mammalia: Eutheria: Rodentia: Scleroglossa: Muridae: Murinae: Mus: 1 (bases 1 to 883) NIH-MGC		
	clone distribution: MGC clone distribution information can be found through the i.M.A.G.E. Consortium/MLNT at:		


```

Db 286 TTCACGTGCTCCGCGCAAGCCGACTTCAGACCAAGCCCAATCATGGGCTTCGGGCG 227
Oy 1049 acacagagacaacacacacacacacagagatgctcgagatcagatcagatcagagaaagaa 1108
Db 226 ACAGTACACACACACACACACACACACACACACACACACACACACACACACACACACACAC 167
Oy 1109 aaataacagagatcagacacacacacacacacacacacacacacacacacacacacacacac 1166
Db 156 AAGTACACACACACACACACACACACACACACACACACACACACACACACACACACACAC 107
Oy 1169 gcttcgtgacacacacacacacacacacacacacacacacacacacacacacacacacacacac 1228
Db 106 GTTTTGATGATCCTTCAAAAACATATTCCTAAGTCGACGACCTTAAAGAAATTTGCA 47
Oy 1229 ataatgagaagaagatgcttcgaggaacacacacacacacacacacacacacacacacacac 1275
Db 46 ATATGATGAGGAGGATTCAGAGT-ACCTCACTTCCTGGACCA 1

RESULT 6
LOCUS AM483656 434 bp mRNA linear EST 25-APR-2001
DEFINITION 55586 MARC 1BOV Bos taurus cDNA 5', mRNA sequence.
ACCESSION AM483656
VERSION AM483656.1 GI:7053762
XREF EST.
SOURCE Bos taurus
ORGANISM Bos taurus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Bovinae; Bos.

REFERENCE
1 (Bases 1 to 434)
Smith T.P.L., Grosse,W.M., Freking B.A., Roberts,A.J., Stone,R.T.,
Casas,T., May,J.E., White,J., Cho,J., Fahnenkrug,S.C., Bennett
,G.L., Heaton,M.P., Laegreid,M.W., Rohrer,G.A., Chlch-mcDon,C.G.,
Keele,J.F., Holt,L., Karamcheva,S., Liang,F., Quackenbush,J. and
Sequence evaluation of four pooled-tissue normalized bovine cDNA
libraries and construction of a gene index for cattle
Genome Res. 11 (4), 626-630 (2001)

JOURNAL 21180013
MEDLINE
COMMENT Contact: Smith TPL
USDA, ARS, US Meat Animal Research Center
PO Box 166, Clay Center, NE 68933-0166, USA
Tel: 402 762 4390
Fax: 402 762 4390
Email: smithemil@marc.usda.gov
Single pass sequencing. Bases called and trimmed with phred
v0.980904.e. Vector identified by cross-match with the -minscore 20
and -mismatch 12 options.
PCR Primers
FORWARD: AGCAACACCTATGACCAT
REVERSE: GTTTCACATGACGAG
BLAST: 100
Seq primer: ATTTAGTACACACTTAA.
Location/Qualifiers
source 1..434
/organism="Bos taurus"
/db_xref="taxon:9913"
/clone_lib="VANC 1BOV"
/tissue_type="pooled"
/adb_pos="DB100CMV SP096; Site.1; Xlat: Site.2; Xhol:
Library made from pooled tissue from lymph node, ovary,
fat, hypothalamus, and pituitary."
ORIGIN
102 a 93 c 128 g 111 t

```

```

Oy 613 tggttggaagagctcagcctatttggaaagacagaaatttcgccagctgct 672
Db 14 TGTGTGATGACGACTTAACCTATTATTGAAAGACGAAATTCAGCAAGTTCTGCGCAGCTGCT 73
Oy 673 tgcagagcagtcagcagagacacatcttcggaaataagtcagataagataagatactctc 732
Db 74 TGTGAGAGCTACCGAGAGATTTTCTGGAATGCGATGCGATCTTATGAGATACG 133
Oy 733 tttttggaagctgcgcacatcctgagataatttcgataagcagtcagtcgacacac 792
Db 134 TTAATTGCAAAACCCGACATCATGCAAGGATGATGCAAGATGAGTGGGTGATATC 193
Oy 793 agtcgtcttcagcgcgaagagacacacacacacacacacacacacacacacacacacacac 852
Db 194 ACCCTGTTCCTGCGCAAGGCGCTTAAATGATATGAAAGAAATTCGCGCAATGCTTCTC 253
Oy 853 tcgagagatgctccctgcgcagacacacacacacacacacacacacacacacacacacacac 912
Db 254 TCAGGAGATGTTCCCTCTGTACACACGCAATTCCTTTACCTGCACATGCGTCAAGCA 313
Oy 913 tcccttgatctgaacctcagcggagaaatcagagatctctctcctcagcagtcgataat 972
Db 314 TCTCTGATGTTGGAACCTGACGACGCAAGTAAATGAGCACTTCTCTCTCTGCGAGTGAATCAT 373
Oy 973 gtagctgagacacagctcactcgtctcttcgagcaagcgcgcacacacacacacacacacac 1032
Db 374 GAGCTGCAAGTACGCTGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 433
Oy 1033 t 1033
Db 434 T 434

RESULT 7
LOCUS BF740455 406 bp mRNA linear EST 10-JAN-2001
DEFINITION RC2-HB0006-051200-011-b07 HB0006 Homo sapiens cDNA, mRNA sequence.
ACCESSION BF740455
VERSION BF740455.1 GI:12067131
XREF EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
1 (Bases 1 to 406)
Diaz-Nieto E., Garcia-Correa R., Verjovsky-Almeida S., Brijones,M.R.,
Nagel,M.A., da Silva,W.J., Zago,M.A., Bordin,S., Costa,F.P.,
Goldman,G.H., Carvalho,A.F., Matsushima,A., Bala,G.S., Simpson,D.H.,
Brustein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
,M.J., Soares,F., Brentani,L.R.R., Reis,L.F., de Souza,S.J. and
Simpson,A.J.
Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags
Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
JOURNAL 20202663
MEDLINE
COMMENT Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Pudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This manuscript has been derived from the FAPESP/LICR Human Genome
Project. This entry can be seen in the following URL
http://www.ludwig.org.br/scripts/gethtml2.pl?li-RC242-RC2-HB0006-
051200-011-b07453-2000-12-0544-1)
Seq primer: puc 18 forward
High quality sequence start: 47
High quality sequence stop: 406.
Location/Qualifiers
source 1..406
/organism="Homo sapiens"

```

```

Query Match 20.2% Score 355.4; DB 9; Length 434;
Best Local Similarity 90.3%; Pred. NO. 8.9e-86;
Matches 380; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

```

```

/db, xref="taxon:9606"
/clone.lib="HB006"
/dev.stage="Adult"
/note="Organ: bocio; tumor; Vector: puc18; Site: 1; Smal;
Site: 2; Smal; A mini-library was made by cloning products
derived from OHSR85 PCR (0.5. Letters patent application
no. 956, 16. Ludwig Institute for Cancer Research)
No. 956, 16. Ludwig Institute for Cancer Research)
of the 1.6 kb. cDNA. Reverse transcription of
tissue mRNA and cDNA amplification were performed under
low stringency conditions."
BASE COUNT      135 a      80 c      101 g      90 t
ORIGIN

```

```

Query Match      19.08; Score 335.4; DB 10; Length 406;
Best Local Similarity 94.98; Pred. No. 1.7e-61;
Matches 369; Conservative 0; Mismatches 16; Indels 4; Gaps 2;

Oy 1372 ggttccagattacacaaagtgatattatggtgttgccagagcaagctaaagacc 1431
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1 GGGAGCTAGTATTATCAAGGTAATATATCATAGCTGTGG-CGAAACAGATCAACACACC 59

Oy 1432 agtgttcaactaagaagaagaatgagacaatcaccaagccacccctccgaaagaca 1491
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 60 AGGTGCTACACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 119

Oy 1492 tccacaggaataacagatcaagtgatccatccatggtgtgtgtgtgtgtgtgtgt 1551
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 120 TCCAGAGAAATTAACATFACACGCGCTATTCATTCCTCTCTCTCTCTCTCTCTCT 179

Oy 1552 ttgtctgaaatgagagatcttgcagcctttgaaagaagaagaagaagatcgatatt 1611
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 180 TTTCCTGGAATCGCATCTTTCGACCTTTTACA--AGAGAGAGAGAGAGAGAGAGAG 236

Oy 1612 ggaatcagagagagctcaagaagagctttgagaagagatcaatctcccttcgaca 1671
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 237 GGTATCAGACAGAGCTCAGAAANAGACTGTTGAGACAGATTAATATCCCTGCCACA 296

Oy 1672 catcagcagctgagcttaccacagatctgataaagagaagaagaagaagaagatca 1731
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 297 GATCAGTCAAGCTGAGTTTACATCGATTGATATGATACAGAGAGATGACACAAAAGTTA 356

Oy 1732 gatctcacaagaatgatatgagaagat 1760
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 357 GATCTATCCATCAAGTCATATGTCAGAGATTA 385

RESULT 8
BF144325 975 bp mRNA Linear EST 24-OCT-2000
LOCUS B0107144F1 NC1,CGAP,LU30 Mus musculus cDNA clone IMAGE:401478 5',
DEFINITION Mus musculus B0107144F1 sequence.
ACCESSION BF144325
VERSION BF144325.1 GI:10983365
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sclerogamathi; Muridae; Murinae; Mus.
NITWCBRL10/975/nc1.nh.gov/
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-femail.nih.gov
Tissue Procurement: Gilbert Smith, Ph.D.
cDNA Library Preparation: Life Technologies, Inc.
DNA Sequencing by: Incyte Genomics, Inc.
Source Distribution: NCICGAP, cDNA distribution information can be
found at: http://www.ncbi.nlm.nih.gov
ftp://image.nih.gov
Plate: LLM9259 row: h column: 11

```

```

FEATURES
source
location/Qualifiers
1..975
/organism="Mus musculus"
/strain="CE3H II"
/db, xref="taxon:10090"
/clone="IMAGE:4014778"
/clone.lib="NC1,CGAP,LU30"
/ISSUE="Unpublished, metastatic to mammary"
/labhost="Dn100mer, metastatic to mammary"
/note="Organ: lung; Vector: pCMV-Sp6R6; Site: 1; NotI;
Site: 2; SalI; transgenic model MMT-1, expression driven by
MMTV-LTR enhancer; Cloned unidirectionally. Primer: 01190
dT. Library constructed by Life Technologies.
Investigator providing samples: Gilbert Smith, NIH"
BASE COUNT      248 a      240 c      299 g      188 t
ORIGIN

```

```

Query Match      15.5%; Score 273.2; DB 10; Length 975;
Best Local Similarity 82.4%; Pred. No. 4.2e-48;
Matches 361; Conservative 0; Mismatches 73; Indels 4; Gaps 4;

Oy 466 gttccatattcttggaagatgactgtgttcccaagaacctcttgaacacagtaagta 525
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 200 GGTTCATATATAGTGGAGAGTGGGCTGTTCCTCCAAAGATCGGCTGAAATCTCAACAGAT 259

Oy 526 accgtcgcttgatgagatcccaattcttcgctgggggtttttgtctgaactatgag 585
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 260 ACTGTCCTCTCAAGAGGATCTCATCATTTCTGCGCGGCGCTTCTGCTACCTACGCC 319

Oy 586 agcagcgaccatccagatcttaataacatttltgaaagagctgacatattgaagaca 649
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 320 AGCATGACACATTCAGATTTATTAACCTGTTTGTGAAGAGAGAGAGAGAGAGAGAG 379

Oy 646 gaatcagcaattctgcccacatgtgttgaagagctgagagagagagagagagagat 705
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 380 AATATACGCAAAATTCTGCCACTGCTGCTGTAGAGACATACAGAGAGATTTCTGGAGAT 439

Oy 706 atgtgataatgatatagatctctcttattctgcaaaagctgacatcaatgcaagaata 765
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 440 ACAAAGATAGT-TACAGAGATACCTCTTATTTATGTGCAAGCTG-CATCCAGCAGAGATC 497

Oy 766 attctgataatgactgagtgagca-gatgagtggtcttcgcaagaagtgatcagtc 824
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 498 ATCCAGATGAGATAGAGTGCCACCATCAATCTTCCTGACAGCAGAGATATAGTCTCA 557

Oy 825 tgaagagatctgcaaatgagttcttcttcgagagatgctctctgacagacagatatt 884
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 558 TGAAGAGACCTGTGG-CAATGGCTGCTCTCCGCGCATGTGCTTTTGTGCGAAAGCGATT 616

Oy 885 tctgtcttacctcaatgag 902
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 617 TCTTTTTCATACCCCGAG 634

RESULT 9
BE068835 257 bp mRNA Linear EST 09-JUN-2000
LOCUS B06068835
DEFINITION M80-B070374-220300-001-F07 B07374 Homo sapiens cDNA, mRNA sequence.
ACCESSION BE068835
VERSION BE068835.1 GI:8413485
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE
1 (bases 1 to 257)
Dias Neto, E., Garcia Correa, R., Verjowski-Almeida, S., Britones, M.R.,
Nagai, M.A., da Silva, W., Jr., Zago, M.A., Bordin, S., Costa, F.F.,
Geldman, G.H., Carvalho, A.F., Matsushima, A., Bala, G.S., Simpson, D.B.,
Bumstedt, A., de Oliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare,
M.C., Soares, F., Breneman, R.R., Reis, L.F., de Souza, S.J., and

```

TITLE Shotgun sequencing of the human transcriptome with ORF expressed sequence tags
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE 20202663
COMMENT Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2707001
Fax: +55-11-2704922

FEATURES
source
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="BT0374"
/note="Organ: breast; Vector: puc18; Site:1; Sma1; Site:2; Sma1; A mini-library was made by cloning products derived from ORFESTES PCR (U.S. Letters Patent application No. 196 716 - 1998) into the puc18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."
Seq primer: puc 18 forward.
High quality sequence scdp: 257.
Location/Qualifiers
1. 257

BASE COUNT 87 a 48 c 60 g 62 t
ORIGIN
human

Query Match 14.3%; Score 252.2; DB 9; Length 257;
Best Local Similarity 98.8%; Pred. No. 9.5e-44;
Matches 254; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 1090 gatttggggggaagaaataacaggaattagacacacagatctacacagtcgagac 1149
Db 1 GATTGGGGGAGAAAATAACAGGAATTAGACACACAGATCTACACAGTGCAC 60
Matches 254; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 1150 ttcacatttcttgaagaattctgtaagtaactcaatcaatgaatgagag 1209
Db 61 TTCACATTTTATGTAAAGCTTTGATGACACCTCAAAACNATTTCAAGTGAG 120
Oy 1210 accctaaagaattctgaaatgaagaagaagtgcttcaagtgtaacctcaacttcg 1269
Db 121 ACCCTAAAGAAATGTGTAATGAAGAAAGAGTGTTCAGSGTAACCTTAAGTGG 180
Oy 1270 gaccagatgcacaaacattctacccctccatcgatggcagatctatgctggtccccc 1329
Db 181 GACCAGATGCACAAACATTCTCCATCTGATGACGAGATATGTGCGGATGTGCCCC 240
Oy 1330 cagacatgcacacacagag 1346
Db 241 CAGACATGCACACAGAG 257

RESULT 10
LOCUS BF31266 260 bp mRNA linear EST 22-MAY-2000
DEFINITION MR0-BT0374-220300-001-h01 BT0374 Human sapiens cDNA, mRNA sequence.
ACCESSION BF31266
VERSION BF31266.1 GI:11302014
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 260)

AUTHORS Diac Neto E., Garcia Corrêa R., Vojtisek-Almeida S., Brites M.R.,
Nogueira M., da Silva W. Jr., Zeng M.A., Bordino S., Costa F.P.,
Goldman G.H., Carvalho A.F., Matsukuma A., Bata G.S., Simpson D.H.,
Brunstein A., deoliveira P.S., Bucher P., Jongeneel C.V., O'Hare
M.J., Soares F., Brentani R.R., Reis L.F., de Souza S.J. and
Simpson A.J.G.
TITLE Shotgun sequencing of the human transcriptome with ORF expressed sequence tags
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE 20202663
COMMENT Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2707001
Fax: +55-11-2704922

FEATURES
source
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="BT0374"
/note="Organ: breast; Vector: puc18; Site:1; Sma1; Site:2; Sma1; A mini-library was made by cloning products derived from ORFESTES PCR (U.S. Letters Patent application No. 196 716 - 1998) into the puc18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."
Seq primer: puc 18 forward.
Location/Qualifiers
1. 260

BASE COUNT 90 a 49 c 61 g 60 t
ORIGIN
human

Query Match 14.2%; Score 249.2; DB 10; Length 260;
Best Local Similarity 98.8%; Pred. No. 4.2e-43;
Matches 251; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 1093 ttggggggaagaaataacaggaattagacacacagatctacacagtcgagac 1152
Db 7 TTGGGGGAGAAAATAACAGGAATTAGACACACAGATCTACACAGTGCAC 66
Oy 1153 aacctatgctgaagatcttgtaagaactcaaaacaaatctcaagtggaagacc 1212
Db 67 AACCTTATGTAAAGTGTGATGATGACACTCAAAACNATTTCAATGAGAGACC 126
Oy 1213 tataaagaattctgaaatgaagaagaagtgcttcaagtgtaacctcaacttcgagac 1272
Db 127 TATAAAGAAATGTGTAATGAAGAAAGAGTGTTCAGSGTAACCTTAAGTGG 186
Oy 1273 cgaatcaaaacattctacccctccatcgatggcagatctatgctggtcccccag 1332
Db 187 CGAATCAAAACATTCTCCATCTGATGACGAGATATGTGCGGATGTGCCCCAG 246
Oy 1333 acatgcacacagag 1346
Db 247 ACATGCAACAGAG 260

RESULT 11
LOCUS AA050442 474 bp mRNA linear EST 09-SEP-1996
DEFINITION m12e10.r1 Soares mouse embryo NM613.5 14.5 Mus musculus cDNA
ACCESSION AA050442
VERSION AA050442.1 GI:1530113
KEYWORDS EST.

1

JOURNAL Unpubl

COMMENT Contact: Marra M/Mouse EST Project

Gencore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 8, 2002, 23:34:13 : Search time 78.07 Seconds

5540.676 Million cell updates/sec

Title: US-09-691-344A-3

Perfect score: 1 atgagatcgcgtgcggggca.....caagtgatgcagtgtaa 1761

Sequence: IDENTITY_NOC

Gapop 10.0, Gapext 1.0

Searched: 38353 segs, 122816752 residues

Total number of hits satisfying chosen parameters: 767066

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 08

Maximum Match 1008

Listing first 45 summaries

Database : Issued Patents, NA: *
1: /cgn2.6/p/cdata2/1/na/5A.COMB.seq: *
2: /cgn2.6/p/cdata2/2/na/5B.COMB.seq: *
3: /cgn2.6/p/cdata2/3/na/6A.COMB.seq: *
4: /cgn2.6/p/cdata2/4/na/6B.COMB.seq: *
5: /cgn2.6/p/cdata2/5/na/6C.COMB.seq: *
6: /cgn2.6/p/cdata2/6/na/6D.COMB.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	92.8	5.3	6909	2	US-08-804-196-1
2	92.8	5.3	6909	2	US-08-658-340-1
3	92.8	5.3	6909	2	US-08-746-111-26
4	92.8	5.3	7032	4	US-09-324-867-1
5	80.6	4.6	6585	4	US-08-746-111-4
6	80.6	4.6	6585	4	US-08-484-891-7
7	78.4	4.5	4629	2	US-08-717-254-11
8	78.4	4.5	4629	2	US-08-717-254-11
9	78.4	4.5	4629	2	US-08-717-254-11
10	78.4	4.5	4629	2	US-08-717-254-11
11	78.4	4.5	5035	2	US-08-882-083-1
12	78.4	4.5	5035	2	US-08-558-107-1
13	78.4	4.5	5035	2	US-09-243-539-1
14	78.4	4.5	6999	1	US-08-276-594A-1
15	78.4	4.5	7056	1	US-08-121-202-1
16	78.4	4.5	8241	6	517844-1
17	78.4	4.5	8241	6	517844-1
18	78.4	4.5	8241	6	517844-1
19	78.4	4.5	8241	6	517844-1
20	78.4	4.5	9009	1	US-08-251-937A-3
21	78.4	4.5	9009	1	US-08-212-133A-1
22	78.4	4.5	9009	1	US-08-474-503-1
23	78.4	4.5	9009	1	US-09-037-601-1
24	78.4	4.5	9009	5	PCT-US93-03275-3
25	78.4	4.5	9009	5	PCT-US94-13200-3
26	78.4	4.5	9009	5	PCT-US94-13200-3
27	78.4	4.5	11933	4	US-08-683-839B-2
28	78.4	4.5	11933	4	US-09-304-862-13

28	58	3.3	2303	2	US-08-480-229C-9	Sequence 9, Appl1
29	58	3.3	2303	2	US-08-659-235C-9	Sequence 9, Appl1
30	57.6	3.3	1384	1	US-07-607-538C-1	Sequence 1, Appl1
31	57.6	3.3	1384	2	US-08-162-402B-1	Sequence 1, Appl1
32	57.6	3.3	1934	2	US-08-162-402B-7	Sequence 42, Appl1
33	54.4	3.1	4451	3	US-08-717-294-42	Sequence 19, Appl1
34	53.8	3.1	318	2	US-08-480-229C-19	Sequence 19, Appl1
35	53.8	3.1	318	2	US-08-659-235C-19	Sequence 5, Appl1
36	53.4	3.0	7493	1	US-08-474-533A-7	Sequence 5, Appl1
37	53.4	3.0	7493	1	US-08-474-533A-7	Sequence 5, Appl1
38	53.4	3.0	7493	1	US-08-670-707A-5	Sequence 5, Appl1
39	53.4	3.0	7493	5	US-09-037-601-5	Sequence 5, Appl1
40	53.4	3.0	7493	5	PCT-US94-13200-5	Sequence 38, Appl1
41	52.8	3.0	4334	2	US-08-670-707A-38	Sequence 38, Appl1
42	52.8	3.0	4334	4	US-09-037-601-38	Sequence 36, Appl1
43	52.8	3.0	6402	2	US-08-670-707A-36	Sequence 36, Appl1
44	52.8	3.0	6402	2	US-09-037-601-36	Sequence 11, Appl1
45	52.2	3.0	1780	2	US-08-480-229C-11	

ALIGNMENTS

RESULT 1
US-08-804-196-1 Application US/08804196
Patent No. 5874236
GRANTEE: INVENTION:
APPLICANT: Bertina, Roger
TITLE OF INVENTION: A method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same.
TITLE OF INVENTION: Thrombosis and kit for use with the same.
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESSES: 14
ADDRESS: 10672661 Patent Department
SPRINGER 10672661 Patent Department
CITY: Rockville
STATE: Maryland
COUNTRY: USA
ZIP: 20850
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
SERIALS SYSTEM: PC-DOS/MS-DOS
CURRENT APPLICATION DATA: Release #1.0, Version #1.25 (EP0)
APPLICATION NUMBER: US/08/804, 196
FILING DATE:
PRIOR APPLICATION DATA: US 08/454, 353
FILING DATE: 06-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Gormley, Mary E.
ADDRESS: 14409
TELEPHONE: (301) 948-9751
TELEFAX: (301) 948-7400
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 6909 base pairs
TYPE: nucleic acid
STANDARD: both
MOLWTUPE TYPE: CDM
US-08-804-196-1

Query Match 5.3%; Score 92.8; DB 2; Length 6909;
Best local Similarity 51.0%; Pred. No. 1.2e+13;
Matches 248; Conservative 0; Mismatches 232; Indels 6; Gaps 1;
957


```

: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/746,111
: FILING DATE: 06-NOV-1996
: CLASSIFICATION:
: ATTORNEY/AGENT INFORMATION:
: NAME: Ingolia, Diane E.
: REGISTRATION NUMBER: 40,027
: REFERENCE/DOCKET NUMBER: 08-02536
: TELEPHONE: (415) 705-8410
: TELEFAX: (415) 397-8338
: INFORMATION FOR SEQ ID NO: 4:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 6585 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: double
: TOPOLOGY: linear
: MOTIF: none
: DESCRIPTION: /desc = "DNK"
: FEATURE:
: NAME/KEY: CDS
: LOCATION: 6..6554
:
: US-08-746-111.4

```

```

Query Match
: Best Local Similarity 52.1%; Score 80.6; DB 3; Length 6585;
: Matches 207; Conservative 0; Mismatches 184; Indels 6; Gaps 1;

```

```

Oy 987 agtcaatgagctcctgcgcaagccgacatcagacagagccatcatggtctcgag 1046
Db 6161 AGACTACTGAGGACCTCTCTCCCTTACAGCCGACGACGACGACGCTTGCA 6220
Oy 1047 cgaagtagaacaacacacacagagagatgagtgagatgatttgggagagaaaa 1106
Db 6221 GAAAGACGACAAACACAAACAGC-----AGTGGTACAGTGTGCTGCTCAAAATCA 6274
Oy 1107 gaaataaagaagattaggacacagagatcagacagtcgaactcaactttatgttaa 1166
Db 6275 GAAGGTAGAGGCGCATGTGACGAGGGCTGTAGTGTCTCTGTGATGTACTGTAA 6334
Oy 1227 gaataaagaaagagtggttcagggttaacttcaacttcggagccagtgcaaaaaa 1286
Db 6335 GAGCTACAGATCCAGTACAGTACAGAGCTGTGCGATGAAACCTTACCGCAAAATC 6394
Oy 1167 gagtttgagtagactcaaaaaacataattctaaagtggagaaagccataaagaaatgt 1226
Db 6395 CTCGATGTGCGACAGATTTTGAAGCAACAGCATACAGAGGCGCATGAAGAATT 6454
Oy 1287 ttctatccctccatcgctggccagatattgaggtgtgtcccccagacatggcacaag 1346
Db 6455 GTTCACACCGCCCATATTTCAGATTTACGATTCAGCATTCAGAAACAGAACAGAG 6514
Oy 1347 agtccctgaagtgagtgagctatgttgcgcagatt 1383
Db 6515 CATGCCCTTCGCTGAGAGCTTCTGCGCTGTGACATT 6551

```

```

: RESULT 6
: US-08-484-891-7
: Sequence 7, 591535
: GENERAL INFORMATION:
: APPLICANT: Connolly, Sheila
: APPLICANT: Kalesko, Michael
: APPLICANT: Smith, Theodore
: TITLE OF INVENTION: Adenoviral Vectors for
: NUMBER OF SEQUENCES: 7
: TREATMENT OF Hemophilia
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Carrelle, Byrne, Beil, Gilfillan,
: ADDRESS: 6001 S.
: STREET: 6 Becker Farm Road

```

```

: CITY: Roseland
: STATE: New Jersey
: COUNTRY: USA
: ZIP: 07068
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5 inch diskette
: COMPUTER: IBM PS/2
: OPERATING SYSTEM: MS-DOS
: SOFTWARE: SYSDIG-Effect 5.1
: CURRENT APPLICATION DATA: 51
: APPLICATION NUMBER: US/08/484,891
: FILING DATE: 07-JUN-1995
: CLASSIFICATION: 514
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/218,335
: FILING DATE: 25-MAR-1994
: APPLICATION NUMBER: 08/197,920
: ATTORNEY/AGENT INFORMATION:
: NAME: Olstein, Elliot M.
: REGISTRATION NUMBER: 24,025
: REFERENCE/DOCKET NUMBER: 271010-273
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 201-994-1700
: TELEFAX: 201-994-1747
: INFORMATION FOR SEQ ID NO: 7:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 4629 bases
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: cDNA primer
: FEATURE:
: NAME/KEY: Factor VIII cDNA with
: NAME/KEY: B domain deleted
:
: US-08-484-891-7

```

```

Query Match
: Best Local Similarity 54.1%; Score 78.4; DB 2; Length 4629;
: Matches 210; Conservative 0; Mismatches 166; Indels 12; Gaps 2;

```

```

Oy 993 ctgtctctcgcgaagccgcgactgaagacagagcccatcaggtctcgagagag 1052
Db 4023 CTGCTCTCTTCCAAAGTCGACTTCCCTCCAGG-----GAGGATGATCCTGGAG 4076
Oy 1053 tagcaataacacacacacacagagagtgagctgcgtatcgtattggagaaagaaat 1112
Db 4077 ACCCTACAGTGAATATCCAAAGAGTGCTGCTCAATGAGATTCACAGAACATTAAGAA 4136
Oy 1113 aacaggaatttgagcacagagctacacagtcgaactcaacttattgttaagattt 1172
Db 4137 CACAGAGTACACTCTCAGAGGAGTAAATCTCTGCTTACACAGCATGTGTGAAGAGATT 4196
Oy 1173 tctatgaactcaaaaacacataatctcaagtgtgaaagaccttaagaaatttgataaa 1232
Db 4197 CCTCATCTCCACAGTACAGATGAGCATATCTGACTCTCTTTT-----TTCAAGATGC 4250
Oy 1233 tgagaaagagtglttaagggttaactcaacttcaggacccagtgcaaaatcaatc 1292
Db 4251 CAAAGTAAAGGTTTTCAGGAGAAATCACTCTTCCACACCTGTGTGAATCTCTTGA 4310
Oy 1293 cctccacagtgagtgagatagtgaggtgtgtcccccagacatgagcagagagatagc 1352
Db 4311 CCCAGCTACTACTCTCTCACTTGCATTCACACCCCAAGTGGGTCCACAGATGCG 4370
Oy 1353 cttagaagtggaagctatctgattgctcag 1380
Db 4371 CCTGAGATGAGAGTCTTGCGCTCGAG 4398

```

```

: RESULT 7
: US-08-717-294-41

```

```

Sequence 41, Application US/08717294
Patent No. 6114148
GENERAL INFORMATION:
APPLICANT: HAAS, JURGEN
TITLE OF INVENTION: HIGH LEVEL EXPRESSION OF
PROTEINS
NUMBER OF SEQUENCES: 110
CORRESPONDENCE ADDRESS:
ADDRESSEE: Clark & Elbing LLP
STREET: 176 Federal Street
CITY: Boston
STATE: MA
COUNTRY: USA
TELEPHONE: 617-428-7049
COMPUTER: IBM compatible PC/XT
MEDIUM TYPE: Diskette
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/717,294
FILING DATE: 20-Sep-1996
PRIORITY DATE: 20-Sep-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Elbing, Karen L.
REGISTRATION NUMBER: 35,238
REFERENCE/DOCKET NUMBER: 00786/345001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-428-7049
TELEFAX: 617-428-7049
TELEX:
INFORMATION FOR SEQ ID NO: 41:
SEQUENCE CHARACTERISTICS:
LENGTH: 4670 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOL WT TYPE: CDNA
US-08-717-294-41
Query Match 4.5% Score 78.4 DB 3 Length 4670
Best Local Similarity 54.1% Pctid No. 46-10:
Matches 210: Conservative 0; Mismatches 166; Indels 12; Gaps 2:
Oy 993 ctggtctctctgagccagccgacttcagagcccaaccatctggtcttcgagcag 1052
Db 4049 ctggtctctctgagccagccgacttcagagcccaaccatctggtcttcgagcag 1052
Oy 1053 tagcaaacacacacacagagatgctctggaagatcagatcgagagaaagaaat 1112
Db 4103 acctagcagatgagatgagacaaagatgctctggaagatcagatcgagagaa 1112
Oy 1113 aacaggaattagacacagagatcacaacagtcgaacttaacttaattgtaagagtt 1172
Db 4163 cagcagcagatgagacacagagatcacaacagtcgaacttaacttaattgtaagagtt 1172
Oy 1173 tgggtgaactctcaaaaacatattcttaagtgaaagactataaagaaatgtaataa 1232
Db 4223 cctcatctccacacgacgacgacgacgacgacgacgacgacgacgacgacgacg 1232
Oy 1233 tgaagaaagagtggtttccagagtaacttaacttaacttcagagaccagtgcaaacatttcat 1292
Db 4277 ccaactgaaagagtggtttccagagtaacttaacttaacttcagagaccagtgcaaacatttcat 1292
Oy 1293 cccctccacatctggcagagataatgagtggtgtgcccacagacatgagcagagagatgc 1352
Db 4337 cccacatctgagcagagataatgagtggtgtgcccacagacatgagcagagagatgc 1352
Oy 4337 cccacatctgagcagagataatgagtggtgtgcccacagacatgagcagagatgc 4396

```

```

Oy 1353 cttagagtgagactatggttgcag 1380
Db 4397 cttagagtgagactatggttgcag 4424
RESULT 8
US-09-470-618-14
Sequence 14, Application US/09470618
Patent No. 6200560
GENERAL INFORMATION:
APPLICANT: Colston, Linda B.
TITLE OF INVENTION: Adeno-Associated Vectors for Expression of Factor VIII
FILE REFERENCE: Avigen-04082
CURRENT APPLICATION NUMBER: US/09/470,618
CURRENT FILING DATE: 1999-12-22
EARLIER APPLICATION NUMBER: 09/364,862
EARLIER FILING DATE: 1999-03-24
EARLIER APPLICATION NUMBER: 60/712,974
EARLIER FILING DATE: 1999-03-24
NUMBER OF SEQ ID NOS: 15
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO: 1599
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-470-618-14
Query Match 4.5% Score 78.4 DB 4 Length 4999
Best Local Similarity 54.1% Pctid No. 41e-10:
Matches 210: Conservative 0; Mismatches 166; Indels 12; Gaps 2:
Oy 993 ctggtctctctgagccagccgacttcagagcccaaccatctggtcttcgagcag 1052
Db 4396 ctggtctctctgagccagccgacttcagagcccaaccatctggtcttcgagcag 4449
Oy 1053 tagcaaacacacacacagagatgctctggaagatcagatcgagagaaagaaat 1112
Db 4450 acctagcagatgagatgagacaaagatgctctggaagatcagatcgagagaaagaaat 1112
Oy 1113 aacaggaattagacacagagatcacaacagtcgaacttaacttaattgtaagagtt 1172
Db 4510 cccagagtgaaactactcagagagatgaaatctcgtctacagcatgtagtggaagagtt 4569
Oy 1173 tgggtgaactctcaaaaacatattcttaagtgaaagactataaagaaatgtaataa 1232
Db 4570 cctcatctccacacgacgacgacgacgacgacgacgacgacgacgacgacgacg 1232
Oy 1233 tgaagaaagagtggtttccagagtaacttaacttaacttcagagaccagtgcaaacatttcat 1292
Db 4624 caagtgaaagagtggtttccagagtaacttaacttaacttcagagaccagtgcaaacatttcat 1292
Oy 1293 cccctccacatctggcagagataatgagtggtgtgcccacagacatgagcagagagatgc 1352
Db 4684 cccacatctgagcagagataatgagtggtgtgcccacagacatgagcagagagatgc 4743
Oy 1353 cttagagtgagactatggttgcag 1380
Db 4744 cttagagtgagactatggttgcag 4771

```

```

RESULT 9
US-09-364-862-14
Sequence 14, Application US/09364862
Patent No. 6221349
GENERAL INFORMATION:
APPLICANT: Colston, Linda B.

```

```

1 APPLICANT: CLOSTY, Peter C.
2 TITLE OF INVENTION: ADEMO-ASSOCIATED VECTORS FOR EXPRESSION OF FACTOR VIII
3 TITLE OF INVENTION: CRYSTALIGHT
4 TITLE OF INVENTION: CRYSTALIGHT
5 FILE REFERENCE: AVIGEN-03743
6 CURRENT APPLICATION NUMBER: US/09/364,862
7 CURRENT FILING DATE: 1999-07-30
8 EARLIER APPLICATION NUMBER: 60/125,974
9 EARLIER FILING DATE: 1999-03-24
10 EARLIER APPLICATION NUMBER: 60/104,994
11 EARLIER FILING DATE: 1998-10-20
12 EARLIER APPLICATION NUMBER: 60/108,714
13 SOFTWARE: PotentiIn Ver. 2.0
14 SEQ ID NO 14
15 LENGTH: 4899
16 TYPE: DNA
17 ORGANISM: Artificial Sequence
18 FEATURE:
19 OTHER INFORMATION: Description of Artificial Sequence: Synthetic
20 OS-09-364-862-14

```

Query Match	4.58;	Score 78.4;	DB 4;	Length 4999;
Best Local Similarity	54.18;	Pred. NO. 4.1e-10;		
Matches 210; Conservative	0;	Mismatches 166;	Indels 12;	Gaps 2;

```

QY 993  cgggtctctctgcccgaagcccgacttcagagacaaagcccatcatgagcttcgggagcaag 1052
      |||||      ||| |||||      |||||      ||| ||| |||
Db 4396  ctggctctctcaaaagctcgacttcacctccaag-----gagggglaaalgctcgag 4449

```

Db 4450 acctcagtgtaataatccaaagagtcgcgcgaagtcgactccagagaagacatgaaagt 4509

4510 caccagagtaactactcaggagtaaatctctgcttaaccagcatgtatgtgaagaagt 4569

Db 4570 cctcatctccagcagtcagaatgagctactctctt-----ttcagaatg 4623

Db 4624 caaagtaaggttttcaggaaatcaagaactcctcacacctgtgtgaacctctaga 4683

Db 4684 cccacgttactgtactgcgtactcctcgatccacccccagattggtgcaccagatgc 4743

Db 4744 cctgagatgaggtctctggtgcgag 4771

RESULT 10
US-08-882-083-1
; Sequence 1, Application US/08882083
Patent No. 5060000

```

GENERAL INFORMATION:
APPLICANT: VOORBERG, Johannes J.
TITLE OF INVENTION: HYBRID PROTEINS WITH MODIFIED ACTIVITY
NUMBER OF SEQUENCES: 17

```

1 CORRESPONDENCE ADDRESS:
2 ADDRESSEE: Foley & Lardner
3 STREET: 3000 K Street, N.W., Suite 500
4 CITY: Washington

SINGLE: D.C.
COUNTRY: USA
ZIP: 20007-5109

COMPUTER READABLE FORM:

COMPUTER: IBM PC compatible

```

:
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/882,083
: FILING DATE:

```

CLASSIFICATION: C14
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/558,107
FILING DATE: 13-NOV-1995

NAME: ISACSON, John P.
REGISTRATION NUMBER: 33,715
REFERENCE/DOCKET NUMBER: 30472/212

TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399
TELEX: 904136

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 5035 base pairs
; TYPE: nucleic acid
;

```

```

; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: CDS
;

```

US-08-882-083-1

993 cctcctctctgacccaagcccgacttcaggaacccaagcccatctgagcttcgggcgacag 1052
Matches 210; Conservative 0; Mismatches 166; Indels 12; Gaps 2;

Db 4627 CTGCTCTCTTCAAAAGCTGACTTCACCTCCAGG-----GAGGAGTAATGCTTGAG 4680

QY 1053 taagcaaacaccacaaaccacagatgtgtgtgagatcgtattgtggggagaaababgaat 1112

Db 4681 ACCTCAGGTGATTAATCCAAAAGAGCTGGCTGCAGTGGACTTCCAGAGACATGGAAGT 4740

Oy 1113 aacggaattagagaccacagatctcacagctcgaacttcaacttctgttaagagctt 1172

Db 4741 CACAGGAGTACTACTCAGGAGTAAATCTCTGCTTACCACATGATGTGAAGGAGTT 4800

QY 1173 tgttgtagacttcacaaacataattctaaigtgagaccataaagaaattgtgaatna 1232

Db 4801 CCTCATCTCCAGCAGTCAGATGGCCATCAGTGGACCTCTTTT-----TTCCAGAAATGG 4854

Db 4855 CAAAGTAAAGGTTTTCAGGGAATCAAGACCTCTTCACACCAGTGGTGACCTCAGAA 4314
QY 1293 ccctcccatcgtgagcagatattgaggtctgtcccccagacattgcaaccagagatagc 1352

DB 4915 CCCACCGGTATGACATCCGACACCTCCGAAATCCACCCCAAGATATGGGATCCACCAATATCC 4916
QY 1353 ctctgaagctgagacatcattggtgtccag 1380

00 4373 CCICAO00A100000011C10000C100000 0002

```

US-08-558107-1
; Sequence 1, Application US/08558107
; Patent No. 5910481
; GENERAL INFORMATION:

```

TITLE OF INVENTION: HYBRID PROTEINS WITH MODIFIED ACTIVITY
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:

STREET: 3000 K Street, N.W., Suite 500

RESULT 13
 US-08-276594A-1
 / Sequence 1 Application US/08276594A
 / Patent No. 5693499
 / GENERAL INFORMATION:
 / APPLICANT: YONEMURA, Hiroshi
 / APPLICANT: TAJIMA, Yoshitaka
 / APPLICANT: SUGAMARA, Keishin
 / APPLICANT: MASUDA, Kenichi
 / TITLE OF INVENTION: PROCESS FOR PREPARING HUMAN CONJUGATION
 / NUMBER OF INVENTION: PROTON VIII PROTEIN COMPLEX
 / NUMBER OF SEQUENCES: 11
 / CORRESPONDENCE ADDRESS:
 / ADDRESSEE: Foley & Lardner
 / STREET: 3000 K Street, N.W., Suite 500
 / CITY: Washington
 / STATE: D.C.
 / COUNTRY: USA
 / COMPUTER READABLE FORM:
 / MEDIUM TYPE: Floppy disk
 / OPERATING SYSTEM: IBM PC compatible
 / SOFTWARE: Patentin Release #1.0, Version #1.30
 / CURRENT APPLICATION DATA:
 / APPLICATION NUMBER: US/08/276,594A
 / CLASSIFICATION: 15-117, 1594
 / PRIORITY APPLICATION DATA:
 / APPLICATION NUMBER: US 07/950,191
 / FILING DATE: 24-SEP-1992
 / PRIOR APPLICATION DATA:
 / APPLICATION NUMBER: JP 243262/1991
 / FILING DATE: 24-SEP-1991
 / ATTORNEY/AGENT INFORMATION:
 / REGISTRATION NUMBER: 25,258
 / REFERENCE/DOCKET NUMBER: 74129/195/AOPA
 / TELEPHONE: (202)672-5300
 / TELEFAX: (202)672-5399
 / TELEX: 904136
 / INFORMATION FOR SEQ ID NO: 1:
 / SEQUENCE CHARACTERISTICS:
 / LENGTH: 6699
 / TYPE: nucleic acid
 / STRANDEDNESS: single
 / TOPOLOGY: linear
 / FEATURE:
 / NAME/KEY: CDS
 / LOCATION: 1..6696
 / US-08-276-594A-1
 Query Match 4.5%; Score 78.4; DB 1; Length 6699;
 Best Local Similarity 54.1%; Pred. No. 4.7e-10;
 Matches 210; Conservative 0; Mismatches 166; Indels 12; Gaps 2;

Query Match 4.5%; Score 78.4; DB 1; Length 7056;
 Best Local Similarity 54.1%; Pred. No. 4.7e-10;
 Matches 210; Conservative 0; Mismatches 166; Indels 12; Gaps 2;
 US-08-121-202-1
 / Sequence 1 Application US/08121202
 / Patent No. 55045
 / GENERAL INFORMATION:
 / APPLICANT: Pittman, Debra
 / APPLICANT: Rehemtulla, Alinaaz
 / APPLICANT: Wozney, John M.
 / APPLICANT: Kaufman, Randel J.
 / TITLE OF INVENTION: CHIMERIC PROCONJULANT PROTEINS
 / NUMBER OF SEQUENCES: 27
 / CORRESPONDENCE ADDRESS:
 / ADDRESSEE: Local Affairs, Genetics Institute, Inc.
 / STREET: 87 Cambridgepark Drive
 / CITY: Cambridge
 / STATE: MA
 / COUNTRY: USA
 / ZIP: 02140
 / COMPUTER READABLE FORM:
 / MEDIUM TYPE: Floppy disk
 / OPERATING SYSTEM: IBM PC compatible
 / SOFTWARE: Patentin Release #1.0, Version #1.25
 / CURRENT APPLICATION DATA:
 / APPLICATION NUMBER: US/08/121,202
 / FILING DATE: 14-SEP-1993
 / CLASSIFICATION: 435
 / ATTORNEY/AGENT INFORMATION:
 / REGISTRATION NUMBER: 31,544
 / REFERENCE/DOCKET NUMBER: GI 5195A
 / TELECOMMUNICATION INFORMATION:
 / TELEPHONE: (617)876-1210 X8574
 / TELEFAX: (617) 876-5851
 / INFORMATION FOR SEQ ID NO: 1:
 / SEQUENCE CHARACTERISTICS:
 / LENGTH: 7056 base pairs
 / TYPE: nucleic acid
 / STRANDEDNESS: single
 / TOPOLOGY: linear
 / MOLECULE TYPE: CDNA
 / HYPOTHEICAL: NO
 / ANTI-SENSE: NO
 / FEATURE:
 / NAME/KEY: CDS
 / LOCATION: 1..7053
 / US-08-121-202-1
 Query Match 4.5%; Score 78.4; DB 1; Length 7056;
 Best Local Similarity 54.1%; Pred. No. 4.7e-10;
 Matches 210; Conservative 0; Mismatches 166; Indels 12; Gaps 2;
 US-08-121-202-1
 / Sequence 1 Application US/08121202
 / Patent No. 55045
 / GENERAL INFORMATION:
 / APPLICANT: Pittman, Debra
 / APPLICANT: Rehemtulla, Alinaaz
 / APPLICANT: Wozney, John M.
 / APPLICANT: Kaufman, Randel J.
 / TITLE OF INVENTION: CHIMERIC PROCONJULANT PROTEINS
 / NUMBER OF SEQUENCES: 27
 / CORRESPONDENCE ADDRESS:
 / ADDRESSEE: Local Affairs, Genetics Institute, Inc.
 / STREET: 87 Cambridgepark Drive
 / CITY: Cambridge
 / STATE: MA
 / COUNTRY: USA
 / ZIP: 02140
 / COMPUTER READABLE FORM:
 / MEDIUM TYPE: Floppy disk
 / OPERATING SYSTEM: IBM PC compatible
 / SOFTWARE: Patentin Release #1.0, Version #1.25
 / CURRENT APPLICATION DATA:
 / APPLICATION NUMBER: US/08/121,202
 / FILING DATE: 14-SEP-1993
 / CLASSIFICATION: 435
 / ATTORNEY/AGENT INFORMATION:
 / REGISTRATION NUMBER: 31,544
 / REFERENCE/DOCKET NUMBER: GI 5195A
 / TELECOMMUNICATION INFORMATION:
 / TELEPHONE: (617)876-1210 X8574
 / TELEFAX: (617) 876-5851
 / INFORMATION FOR SEQ ID NO: 1:
 / SEQUENCE CHARACTERISTICS:
 / LENGTH: 7056 base pairs
 / TYPE: nucleic acid
 / STRANDEDNESS: single
 / TOPOLOGY: linear
 / MOLECULE TYPE: CDNA
 / HYPOTHEICAL: NO
 / ANTI-SENSE: NO
 / FEATURE:
 / NAME/KEY: CDS
 / LOCATION: 1..7053
 / US-08-121-202-1

Search completed: July 9, 2002, 01:07:08
 Job time: 5575 sec

```

Db 6717 ACCGACGATATATCTCAAAAGAGTGGCTGGAGTGTGACCTTCGAGAAAGCATCAAGACT 6776
Oy 1113 AACAGGAATAGGACCAAGGATCTACAGCTCAAGCTCAACTCTTATATGTAAGATT 1172
Db 6777 CACAGAGACTACTACTGACAGAGTAAATCTCTCTTACCGACATGTATGTGAAGAGTT 6836
Oy 1173 TGATGTAACCTCAAAACAATATCTAAGTGTGAAGACCTATAAGGAATGTGAAATA 1232
Db 6837 CCTCATCTCCACGACGTCAAGATGCCATCATGGAATCTCTCTTT-----TTCAAAATGG 6890
Oy 1233 TGAAGAAAGGTGTTTCAGGTAACCTCAACTCTCGAGCCCGAGTGCAGAAACATTCAT 1292
Db 6891 CAAGTAAAGCTTTTTCAGGAAATCAAGACTCTTCAACCTCGTGGTGAATCTCTAGA 6950
Oy 1293 GCTCCATCTGTGCGACATATGCGGAGTGTCTCCCGAGACATGGCACAGAGATAGC 1352
Db 6951 CCCACCTTACTGACTCGCTACTTCGAAATTCACCCCAAGTGTGGTCCAGATTC 7010
Oy 1353 CTGGAAGTGGAGCTCATGTGTGCGAG 1380
Db 7011 CCTGAGATGAGAGTCTGTGGCTGCCAG 7038

RESULT 15
5171844-1
; Patent No.: 5171844
; APPLICANT: VAN OOVEN, ALBERT J.J.; PANNEKOEK, HANS; VERBERT,
; MARTINUS P.; VAN LEEN, ROBERT W.
; TITLE OF INVENTION: PROTEINS WITH FACTOR VIII ACTIVITY
; PROCESS FOR THEIR PREPARATION USING GENETICALLY-ENGINEERED CELLS
; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
; NUMBER OF SEQUENCES: 12
; NUMBER OF SEQUENCES: DATA:
; APPLICATION NUMBER: 185/07/205.226
; FILING DATE: 10-JUN-1988
; SEQ ID NO:1:
; LENGTH: 8241
5171844-1

```

```

Query Match 4.58; Score 78.4; DB 6; Length 8241;
Best Local Similarity 54.18; Pct Ident 1e-10;
Matches 210; Conservative 0; Mismatches 106; Indels 12; Gaps 2;

Oy 993 CTGTCTCCCTGGACAGCCGACTTCAGAGCCCAAGGCCATCTGGCTTCGGGAGAG 1052
Db 6669 CTGTCTCTCTCAAGATCGATTCACCTCAAG-----GAGGATAGTGCCTGGAG 6722
Oy 1053 TAGCAACAACAACAACCAAGAGTGTCTGAGATCGATTGTGGGAGGAAAGAAAT 1112
Db 6723 ACTCTAGTGTAGTAAACCAAGAGTGTCTGCAAGTGTGACTCCAGGAAGACATGAAGT 6782
Oy 1113 AACAGGAATAGGACCAAGGATCTACAGCTCAAGCTCAACTCTTATATGTAAGATT 1172
Db 6783 CAAAGGATGTAACCTACCGAGGATGAATCTCTTACAGCATGATGTGAAGAGT 6842
Oy 1173 TGATGTAACCTCAAAACAATATCTAAGTGTGAAGACCTATAAGGAATGTGAAATA 1232
Db 6843 CCTCATCTCCACGACGTCAAGATGGCATCGATGTGACTCTCTT-----TTCAAGATGG 6896
Oy 1233 TGAAGAAAGGTGTTTCAGGTAACCTCAACTCTCGAGCCCGAGTGCAGAAACATTCAT 1292
Db 6897 CAAGTAAAGCTTTTTCAGGTAACCTCAAGACTCTTCAACCTCGTGGTGAATCTCTAGA 6956
Oy 1293 GCTCCATCTGTGCGACATATGCGGAGTGTCTCCCGAGACATGGCACAGAGATAGC 1352
Db 6957 CCCACCTTACTGACTCGCTACTTCGAAATTCACCCCAAGTGTGGTCCAGATTC 7016
Oy 1353 CTGGAAGTGGAGCTCATGTGTGCGAG 1380
Db 7017 CCTGAGATGAGAGTCTGTGGCTGCCAG 7044

```

157

	RESULT	1
AA000629	ID	AA000629 standard; Protein; 586 AA.
XX		
AC	AA000629;	
XX		
XZ	29-MUG-2001	(first entry)
DE	Novel human protein (NHP) sequence #2.	
KW	Novel human protein; NHP; CUB domain; extracellular domain; gene therapy;	
KW	osteoporosis; high blood pressure; connective tissue disorder; infertility;	
KW	NHP-mediated pathway.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200129219-A1.	
XX		
PD	26-APR-2001.	
XX		
FE	08-OCT-2000; 2000MO-US28798.	
XX		
PR	19-OCT-1998; 98US-0160285.	
XX	18-FEB-2000; 2000US-0183583.	
PA	(LEXI-) LEXICON GENETICS INC.	
PI		
PI	Donoho G., Turner CA, Nehls M, Friedrich G, Zambrowicz B, Sands AT;	
DR	WPI: 2001-290917/30.	
DR	N-PSDB: AAS00614.	
PT	Novel nucleic acid encoding human CUB-domain containing protein, useful	
PT	for drug screening, diagnosis and treatment of physiological disorders	

PT or diseases -

XX Claim 2; page 27-28; 33pp: English.

XX The sequence represents a novel human protein (NHP) containing a CUB

CC domain. Such proteins have been associated with

CC regulating development, modulating cellular processes and preventing

CC infectious disease. NHP nucleotide sequences are useful for gene therapy

CC of physiological disorders or diseases. NHP oligonucleotides are useful

CC as hybridisation probes for screening libraries and assessing gene

CC patterns. NHP nucleotide sequences are useful for detecting mutant or

CC inappropriately expressed NHPs (for example, those proteins associated

CC with obesity, high blood pressure, connective tissue disorders and

CC infertility) for the diagnosis of a disease. The polynucleotides may also

CC be used in the treatment of symptomatic

CC or phenotypic manifestations of perturbing the normal function of NHP in

CC the body. Nucleotide constructs encoding NHP products are used to

CC genetically engineer host cells to express such products in vivo. These

CC host cells allow for the identification of compounds that bind to NHP

CC receptors or trigger NHP-mediated pathways.

XX Sequence 586 AA:

Query Match 100.0%: Score 3052; DB 22; Length 586;
Best Local Similarity 100.0%; Pred. No. 5.7e-265;
Matches 586; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

0Y 1 MEFAGAGRLRPVPAPSSAEAPAPGQLIRGKFAKLKAPGVWPGACGGALAR 60
D 1 mfgfagagrlrpvpapssaeearp9gl1grrgsealakiapsyvmvpgarv9galat 60
0Y 61 AAGRGALLLAVSAFLRLQAEELADGCGHLVYDDSGTWISKNYPRYPMHTVEKTT 120
D 61 aagrgalllavsapflrlqaeeladgcghlvdyddsgtwmksknyprypmhtvecktlc 120
0Y 121 VPKGKRLIRLGLDIESOTCASBYLLFTSSDOQGYGCSMTVPKRLMTSEVYRFP 180
D 121 vpkgrlrlrgldiesqcasdyllftssdqgygpcgsmtpkellltscevtvrf 180
0Y 181 SCSHISGRGFLTYASDHPDLITCLERASHYLTKEVSKFCPACGRVADISGNVDGY 240
D 181 scshisgrgfltyasdhpdlltclerashyltketykfcpcacgrvadisgnvdyg 240
0Y 241 RGTSALCKMAHNGITADRGISYVQAKISRENGILANQVYSRDSMDRPLFRFS 300
D 241 rgtsalckmahngitadrgisylvqakiskrengilangvysrdsmdrflfrfs 300
0Y 301 GCSNLSFPPDGOITRASSWQSVNESDDVMKSPQCAALDDGSPSAWSDSDSNHKKRPEK 360
D 301 gcsnlsfppdgoitraswqsvnesddvmkspqcaalddgspasawdsdssnhkkrpe 360
0Y 361 LKIDLGKKKLTGIRTTGOSNFYKSVWPKKNNKSKKTYKATVNNKEXVPOGNS 420
D 361 lkidlgkkkltgirttgosnfkykswpkknnskkytykatvnnkexvpoons 420
0Y 421 NRPPOVNNFPTPTVARYRVHPQTMHRIALVELICQITQONDSILVMKTSOSTSVS 480
D 421 nrp povnnfptptv ar yrvhpqtmhri alvelicqitqonsilvmktsostsvs 480
0Y 481 NTKEDPTTRTPRSESTSGCMTTVAFLVULVLPVAPKAGITPAFAKKGKSGPTGSA 540
D 481 ntkedpttrtp rsestsgcmttvaflvulvpvapkagitpa fakkgksgptgsa 540
0Y 541 ENOKTDCMKOIKTPFARHOGAERTISDNEKEKTKOGLDILTSDMAG 586
D 541 enoktdcmkoiktpfarhogae rtis d neke ktko gl dilt s dm ag 586

RESULT 2
AA000630
ID AN000630 standard: Protein: 539 AA.

AC AA000630:
XX 29-AUG-2001 (first entry)
D 29-AUG-2001 (first entry)
XX Novel human protein (NHP) sequence #3.
D Novel human protein (NHP) sequence #3.
XX Novel human protein (NHP) CUB domain; extracellular domain; gene therapy;
D Novel human protein (NHP) CUB domain; extracellular domain; gene therapy;
XX obesity; high blood pressure; connective tissue disorder; infertility;
D obesity; high blood pressure; connective tissue disorder; infertility;
XX NHP-mediated pathway.
D NHP-mediated pathway.
XX Homo sapiens.
D Homo sapiens.
XX W0200129219-A1.
D W0200129219-A1.
XX 26-APR-2001.
D 26-APR-2001.
XX 08-OCT-2000; 2000M0-US28798.
D 08-OCT-2000; 2000M0-US28798.
XX 19-OCT-1999; 9905-U160285.
D 19-OCT-1999; 9905-U160285.
XX 18-FEB-2000; 2000U5-U183583.
D 18-FEB-2000; 2000U5-U183583.
XX (LEXI-) LEXICON GENETICS INC.
D (LEXI-) LEXICON GENETICS INC.
XX Donoho G, Turner CA, Nehls M, Friedrich G, Zambrowicz B, Sands AT;
D Donoho G, Turner CA, Nehls M, Friedrich G, Zambrowicz B, Sands AT;
XX WPI: 2001-290917/20.
D WPI: 2001-290917/20.
XX N-FSDB; AAS00615.
D N-FSDB; AAS00615.

PT Novel nucleic acid encoding human CUB-domain containing protein, useful
D Novel nucleic acid encoding human CUB-domain containing protein, useful
PT for drug screening, diagnosis and treatment of physiological disorders
D for drug screening, diagnosis and treatment of physiological disorders
PT or diseases -
D or diseases -

XX Claim 5; page 29-30; 33pp: English.

XX The sequence represents a novel human protein (NHP) containing a CUB

CC domain (an extracellular domain). CUB proteins have been associated with

CC regulating development, modulating cellular processes and preventing

CC infectious disease. NHP nucleotide sequences are useful for gene therapy

CC of physiological disorders or diseases. NHP oligonucleotides are useful

CC as hybridisation probes for screening libraries and assessing gene

CC patterns. NHP nucleotide sequences are useful for detecting mutant or

CC inappropriately expressed NHPs (for example, those proteins associated

CC with obesity, high blood pressure, connective tissue disorders and

CC infertility) for the diagnosis of a disease. The polynucleotides may also

CC be used in the treatment of symptomatic

CC or phenotypic manifestations of perturbing the normal function of NHP in

CC the body. Nucleotide constructs encoding NHP products are used to

CC genetically engineer host cells to express such products in vivo. These

CC host cells allow for the identification of compounds that bind to NHP

CC receptors or trigger NHP-mediated pathways.

XX Sequence 539 AA:

Query Match 92.3%: Score 2818; DB 22; Length 539;
Best Local Similarity 100.0%; Pred. No. 5.2e-244;
Matches 539; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

0Y 48 WYFARGGALARAARGCLLALLAVSAPRLQAEELADGCGHLVYDDSGTWISKNYPRG 107
D 48 wyfarggalarargc llallavsaprlqaeeladgcghlvdyddsgtwmksknyprg 107
0Y 108 YPMHNVCEKTYRPAKGLRLRLGDIISORCASBYLLFTSSDOQGYGCSMTVPK 167
D 108 ypmhncektyrpakglrlrlgdiisorcasbyllftssdqgygpcgsmtpk 167
0Y 167 LYPHLVCEKLTLYPKKRL11RIGLDIESQCASDY11FTSSDQGYGPGSMTPK 120
D 167 lyphlvcekltypkkrl11r igldiesqcasdy11ftssdqgygpcgsmtpk 120
0Y 168 LLNLTSEYVWRFESGSHISGRFLTYASDHPDLITCLERASHYLTKEVSKFCPAC 227
D 168 llnl tseyvwrfesgshisgrfltyasdhpdlltclerashyltketykfcpcac 227
0Y 121 11ltsewlvtesghlsgrgllllyssadhpdl1clerashy1lkeysk1cpagctd 180
D 121 11ltsewlvtesghlsgrgllllyssadhpdl1clerashy1lkeysk1cpagctd 180
0Y 228 VACDSCNMDCYBPMSTLCKAH1HNGITADRGISYVQAKISRENGILANQVYSR 287
D 228 vacdscnm dcybpmstlckah1hngitadrgisylvqakiskrengilangvysr 287
0Y 181 VAGDSIGMMDGYRTDL1CKAHLHNGITADRGISYVQAKISRENGILANQVYSR 240
D 181 vagdsigmmdgyrt dl1cka hlhngitadrgisylvqakiskrengilangvysr 240

OY 288 GSLSDRKFLFTSNCKSRSLSPFDPOGIRASSSMQSVNSGDDVYHMSFGQARLADQGPSMA 347
 XX |||||||
 DB 241 galsdkrlfltsngcsrlsfepdqqlrasssqvnsesddvlpwspgarldqgspwa 300
 OY 348 SDDSNNHPRPEMLEIDGSKKKITGRTGSTOSNFYVSKFVNKFNKNSMKRTYK 407
 XX |||||||
 DB 301 sgdsnmhprpewleldlgexkkltgltltsqgnfrfyvskfvmfkmnskkklyk 360
 OY 408 IYNNKKYVPGNSNFRDPOVNNFIPPIVAVRVNVPOTMORILAKVELICQITGSDMS 467
 XX |||||||
 DB 361 lymeevrgnnefrdpygnflpplvayrvyvpqclwqglalkvelilgcqlbgnds 420
 OY 468 IYWKRTSGTSTVSTKKEDERTIRPISEPTSTGINTTVAIPLVLYLVFAGMGIFAPF 527
 XX |||||||
 DB 421 lwwktsgtstvtstkkedeltirpiseptstgintltvaplvlvlyvfaqmglfaaf 480
 OY 528 RKKKKKSPYGSAAQKTDCKMOKIKYFARNSGAFTTSDYDEKEMTKOITDITSDNA 586
 XX |||||||
 DB 481 fRKKKKSPYGSAAQKTDCKMOKIKYFARNSGAFTTSDYDEKEMTKOITDITSDNA 539
 RESULT 3
 ID AAU00670 standard; Protein: 715 AA.
 AC AAU00670:
 XX
 DT 07-SEP-2001 (first entry)
 DE Human TANGO 229 polypeptide.
 XX
 KM Human: TANGO 229; T cell; heart; liver; pancreas; placenta; brain; lung;
 KM skeletal muscle; kidney; spleen; lymph node; peripheral blood leukocyte;
 KM bone marrow; thymus; thymic; abnormal blood coagulation; asthma; cancer;
 KM melanoma; atopic dermatitis; myotrophic lateral sclerosis; meningitis;
 KM attention deficit disorder; Crohn's disease; gastroenteritis; goitre;
 KM hypovolaemia; diabetes mellitus; endometrialosis; pulmonary embolism;
 KM muscular dystrophy; immuno-competence; vertebrate; blood; serum.
 OS Homo sapiens.
 XX
 FT Key Location/Qualifiers
 FT Peptide 1-34
 FT Domain /note="Signal peptide"
 FT /note="Extracellular domain"
 FT Protein 35..715
 FT /note="Mature human TANGO 229"
 FT Domain 456..480
 FT /note="Transmembrane domain"
 FT Domain 481..715
 FT /note="Cytoplasmic domain"
 PN MO200129088-A1.
 XX
 PD 26-APR-2001.
 PF 23-JUN-2000; 2000MO-US17386.
 PR 19-OCT-1999; 99US-0420707.
 XX
 XX (MILL-) MILENNIUM PHARM INC.
 PI Mackay CR, Myers PS, Kilst SJ, Fraser CC, Leiby KR.
 DR WPI: 2001-30847/732.
 N-PSDB; AA00660.
 PF New isolated nucleic acid molecule for diagnosis, prevention, and
 therapy of human and other animal disorder, or as modulating agent for
 regulating cellular processes

XX
 PS Claim 8: Fig 1; 263pp; English.
 XX
 CC The sequence represents human TANGO 229 polypeptide. This protein and
 CC smaller others exhibit the ability to affect growth, proliferation,
 CC survival, differentiation, activity, morphology, or movement/migration
 CC of, e.g., T cells and cells of the heart, liver, pancreas, placenta,
 CC brain, lung, skeletal muscle, kidney, spleen, lymph node, peripheral
 CC blood vessel, or other organs or tissues.
 CC modulating agents for regulating cellular processes, thus, the proteins
 CC and their associated nucleic acids can be used to prognosticate, prevent,
 CC diagnose, or treat disorders associated with physiological processes.
 CC These disorders include abnormal blood coagulation, asthma, anaphylaxis,
 CC hepatitis, multiple sclerosis, cancer, coronary artery disease, malaria,
 CC atopic dermatitis, amyotrophic lateral sclerosis, meningitis, attention
 CC deficit disorder, Crohn's disease, gastroenteritis, goitre,
 CC hypovolaemia, diabetes mellitus, endometrialosis, pulmonary embolism and
 CC muscular dystrophy.
 CC providing a polypeptide of the invention to an immuno-competent
 CC vertebrate and harvesting blood or serum from the vertebrate.
 XX
 SQ Sequence 715 AA:
 XX
 Query Match 92.1%; Score 2812; DB 22; Length 715;
 Best Local Similarity 100.0%; Pred. No. 2; 8e-263;
 Matches 538; Conservative 0; Indels 0; Gaps 0.
 OY 48 WVPARGGGLARARAGRGRLALLLASAPLRLAERLGDGCGLYTVYDSCWTSTKYRG 107
 XX |||||||
 DB 1 wparqggglaraaagrgllalllvasapllrlgaellgdgcghlytvysdwtstkyrgp 60
 OY 108 TYPMHTYKTKTIVRGKRLILRLGDLDESQCAVDYLFTSSSDQYGVGCSMTYPR 167
 XX |||||||
 DB 61 typhntvckellvprgkrlilrrgldldeqccasdylltsssdqygvpgsmtprks 120
 OY 168 LLWTSTYPMHTYPRFSSSHISORHPLFLTYASNDHPLRLCTCLERASHYKREYKPCAGCR 227
 XX |||||||
 DB 121 llwtstevlvfessghisgrflllyasndhplrlctclershykreykpcagcrd 180
 OY 228 VAGDISQNVGVGRTSILCKKAITHGIIADLEGQISVLRKQISNVEGILANCVSRD 287
 XX |||||||
 DB 181 vagdisgmvdgrytssilckkaithglladlegqisvlyrkqisnvegilanvglsrd 240
 OY 288 GSLSDRKFLFTSNCKSRSLSPFDPOGIRASSSMQSVNSGDDVYHMSFGQARLADQGPSMA 347
 XX |||||||
 DB 241 galsdkrlfltsngcsrlsfepdqqlrasssqvnsesddvlpwspgarldqgspwa 300
 OY 348 SDDSNNHPRPEMLEIDGSKKKITGRTGSTOSNFYVSKFVNKFNKNSMKRTYK 407
 XX |||||||
 DB 301 sgdsnmhprpewleldlgexkkltgltltsqgnfrfyvskfvmfkmnskkklyk 360
 OY 408 IYNNKKYVPGNSNFRDPOVNNFIPPIVAVRVNVPOTMORILAKVELICQITGSDMS 467
 XX |||||||
 DB 361 lymeevrgnnefrdpygnflpplvayrvyvpqclwqglalkvelilgcqlbgnds 420
 OY 468 IYWKRTSGTSTVSTKKEDERTIRPISEPTSTGINTTVAIPLVLYLVFAGMGIFAPF 527
 XX |||||||
 DB 421 lwwktsgtstvtstkkedeltirpiseptstgintltvaplvlvlyvfaqmglfaaf 480
 OY 528 RKKKKKSPYGSAAQKTDCKMOKIKYFARNSGAFTTSDYDEKEMTKOITDITSDNA 585
 XX |||||||
 DB 481 fRKKKKSPYGSAAQKTDCKMOKIKYFARNSGAFTTSDYDEKEMTKOITDITSDNA 538
 RESULT 4
 ID AAU00628 standard; Protein: 487 AA.
 AC AAU00628:
 XX
 DT 29-APR-2001 (first entry)
 DE

BEA ID NO: 4
 Database: A_gensseq-032802
 AC NO: AAU00670

CC and in compositions for the treatment of skin, connective tissue and
 CC immune system diseases. The polynucleotide is useful as marker for
 CC tissue, as a chromosome marker or tags in the identification of a
 CC genetic disorder.

XX Sequence 503 AA:

Query Match 42.6%; Score 1301.5; DB 21; Length 503;

Best Local Similarity 50.9%; Pred. No. 6,9e-108;

Matches 267; Conservative 26; Mismatches 33; Indels 199; Gaps 1;

```

0Y 61 AAGRLALLAVSAPLRLQAEELADGCGHLVYDQSGVTGKNTPGTYPHNTCEKTTT 120
    | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 5 aagpsvalilavcaplllqaeelagdgchlvaydsqstlmtakkyprklypyrvckllt 64
0Y 121 YRKGRLLRLRLGDLRESOTASQSYLLFPSSQNGPYGCSMPYKELLMTSEVTARE 180
    | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 65 vpkgrcllrlrgdlmtektcasqyllfsaqldqgyqcsawpkellmnevevlfx 124
0Y 181 SCSHLSRCGFLTVASSDHDLITCLERSHSLKTEKSCFACGARDVAGDIGNVAGY 240
    | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 125 RSHSLRGYGLTVASDHPDILCTELERSHYLEKYSKCPAGCDIARDISGNKGY 184
0Y 241 RSHSLRGYGLTVASDHPDILCTELERSHYLEKYSKCPAGCDIARDISGNKGY 300
    | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 185 rdtalllokaalhhgllldelgghnllgskjshyegjlangystrhsjsekrfl-- 241
0Y 301 GCSHLSRFPDGOIRASSQSVNSQDVHMSFGQARLDQGPSASGSDSNHKKPRE 360
    | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 242 ----- 241
0Y 361 LEIDLGERKKLTGTLRTGTSQSNRPYKSVPMNRKNNKSKTKYKGLVNEERPEQGS 420
    | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 242 ----- 241
0Y 421 NRFDQVNNPPIPTVARYRVYPTOMHQRALVELLCOITQGNDSIWMKTSQSTSVS 480
    | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 242 ----- 241
0Y 481 TKKEDETIREISETSTGINTTVAIPLVLLVLPVAFAGMGIPTAFKRRKKKSGPYGSA 540
    | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 242 ----- 241
0Y 541 EKQGTQCHQOIKYPRAPGASPTTISDDEKMGTCQDITDTPMA 585
    | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 286 daqktgvcgkqkypfarhgatetfitydeemtcqldliltidma 330

```

RESULT 6
 AAG75450 standard; Protein: 583 AA.

ID AAG75450
 XX AAG75450:
 DT 03-SEP-2001 (first entry)
 DE Human colon cancer antigen protein SEQ ID NO:6214.
 KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
 KW colorectal carcinoma.
 KW Homo sapiens.
 PN MO200122920-A2.
 PD 05-APR-2001.
 XX 28-SEP-2000: 2000MO-US26524.
 XX 29-SEP-1999: 99US-0157137.
 XX 03-NOV-1999: 99US-0163280.

PA (HUMA-) HUMAN GENOME SCI INC.

PI Ruben SM, Barash SC, Blase CE, Rosen CA;

DR WPI: 2001-233357/24.

DR N-PSDB: AAH34855.

PT Nucleic acids encoding 4277 human colon cancer-associated polypeptides;

XX useful for preventing, diagnosing and/or treating colorectal cancers -

XX Claim 11: Page 7657-7660; 9803PP: English.

AAH32943 to AAH37195 and AAG73514 to AAG77788 represent human colon
 CC cancer-associated nucleic acid molecules (N) and proteins (P), where
 CC the proteins are collectively known as colon cancer antigens. The colon
 CC cancer-associated nucleic acids (N) and proteins (P) are useful for
 CC therapy and vaccine production. N and P may be used in the prevention,
 CC diagnosis and treatment of diseases associated with inappropriate P
 CC association. For example, N and P may be used to treat disorders
 CC associated with decreased expression by rectifying mutations or deletions
 CC in a patient's genome that affect the activity of P by expressing P.
 CC Inactive proteins or to supplement the patient's own production of P.
 CC Additionally, N may be used to produce the colon cancer-associated Pa,
 CC by inserting the nucleic acids into a host cell and culturing the cell
 CC to express the proteins and nucleic acids can be used in the prevention,
 CC and AAG77789 represent sequences used in the exemplification of the
 CC present invention.
 CC N.B. Pages 666 to 682 and page 7053 of the sequence listing were
 CC missing at time of publication. Meaning no sequences are present for
 CC SEQ ID NO:1027 to 1052, 7921 and 7922.

XX Sequence 583 AA:

Query Match 29.6%; Score 903.5; DB 22; Length 583;

Best Local Similarity 38.3%; Pred. No. 4,4e-72;

Matches 212; Conservative 92; Mismatches 183; Indels 67; Gaps 14;

```

0Y 43 ARSCVWVGARGGALARAAGRGCL--TALLLAVSAPLRLQAEELADGCGHLVYDQSGT 99
    | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 2 apavaa1p1srslpccsnssstfmp1f1ll1v1ll1lledagagqgdcgchlvlgpsqst 61
0Y 100 MTSNRTGTYPHNTCEKTYPKGRLLALGDLDF-SOTCASQSYLLFPSSQNGPYGCSMP 154
    | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 62 ltslnpqtphnbtvcemeltkngervrkfgdltleasdechfirlnglysvarte 121
0Y 155 YGPRCG-SMIVPKELLMTSEVYARESHSISGGGELLTVASSDHDLCTELERSHSL 213
    | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 122 lqkycg19lghmhbsleekgneitllfmgslvayrgf1aasyvdqgdl1cldlaenfl 181
0Y 214 KTESKRCFACGCDVAGDISGNWVDYRDSILAKMAIANGI1ADEL3GQSTVYLORGIS 273
    | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 182 epeislkypcagclpfaelsgclphnydrasdp1cmahyagv1l9qslvaylsqglp 329
0Y 274 RYEGIIANGVLSRSDGSLSDKRFLETNCSGSLSEF---PPGQ1AASSQSVNSQVNSGQ 321
    | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 242 yyeas1annv1svgh1st1eltfk1spgcygl1lmeagv1adpql1assv1vlethgqe 301
0Y 330 VMSFGQARLDQGPSASGSDSNHKKPREMLIEDLEKKKTTGTSQSNRPYK 389
    | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 302 nsvkpkra1lkp9pwaata1ade---yqv1d1l1k1ek1t1g1t1gl1meh1my1s 357
0Y 390 SFVWNRKNNKSKTKYKGLVNEERPEQGSNRPVONNPTPTVARYRVYPTOMHQR 449
    | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 358 ayr1lysdqgkvtvryregviegk1lgkghdyhqdrtmx1lpl1lat1fltrp1qgqk 417
0Y 450 IALVELLCOQ-----ITQ-----GNDSLWMKTSQSTSVSTKKEDETIRAPI-- 492
    | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 418 lam1mell1cg1fk1p1gr1pk1lcp1pp1rns1d---1knt1lapk1ak1g1rap1fcp1d1p 473
0Y 493 -----PSEET--STGINITF-----VALPVLVLPVAFAGMGIPTAFKRRKKKSGPYGSA 527
    | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

```

SEA ID NO: 4

Date base: A-Gene-seq-032802 Page 6
Accession NO: AAB24216

Db 474 rsnefpaqteqtaspdintntvprvkdvlaavpvlvmylltlllllycawhvr 533
 Oy 528 -RRKKRKS---PY 537
 Db 534 nrkkklegtydlyp 547

RESULT 7
 AAV70539
 ID AAV70539 standard; Protein: 669 AA.
 AC AAV70539;
 NC 04-JUL-2000 (first entry)
 DE Human Factor 8 Homologue.
 FM Human: Factor 8 Homologue. F8H: coagulation cofactor; haemostatic;
 FM cerebroprotective; therapeutic; coagulation related disorder;
 KM haemophilia: stroke; screening.
 OS Homo sapiens.
 PN W0200012532-A1.
 PD 09-MAR-2000.
 PE 20-AUG-1999; 59MC-US19047.
 PR 31-AUG-1998; 98US-0098521.
 NC (ELL) LITLY & CO ELL.
 PI Rosteck PRJ. Su W. LI XM:
 XX WPI: 2000-26580/22.
 DR N-PSDB: AAZ51872.
 XX
 PT Factor 8 homolog polypeptides and nucleic acids encoding them, for
 PT treating coagulation related disorders such as hemophilia and stroke -
 XX
 PS Claim 3; Page 64-66; 68pp; English.

CC The present sequence is a human Factor 8 homologue (F8H).
 CC a coagulation cofactor which is selectively expressed in
 CC haematopoietic, heart and reproductive tissues. It has haemostatic and
 CC cerebroprotective activities. The F8H contains a Factor 5/8 signature
 CC and is useful as a therapeutic for treating coagulation related diseases
 CC such as haemophilia and stroke. The nucleic acid is useful as
 CC a probe for the detection of F8H gene mutations and for
 CC the study of F8H gene expression. F8H gene mutations and for
 CC monitoring regulation of gene expression and can be used in
 CC screening methods such as those using DNA chips. The present sequence is
 CC also useful as a target to screen therapeutically useful modulators
 CC of the F8H.

XX
 XX
 XX Sequence 669 AA:
 SQ

Query Match 25.88; Score 786.5; DB 21; Length 669;
 Best Local Similarity 35.98; Pctd NO: 9a-61;
 Matches 190; Conservative 94; Mismatches 164; Indels 81; Gaps 16;

Oy 124 GRRLRLRLADLDIE-SQTCASDYLLFTS---SSDQGVPCQ-SMTVPRELLNTSEVTV 177
 Db 2 geyvrlkfyddedsdschfyrltyingvstefskycqlqmmhsleskxnetll 61
 Oy 178 RFBSGSHISGRGFLTFTASDPDLITCERASHTKTEYSKFCPACGADVADTSSNMV 237
 Db 62 lmsghvsgvgtlsgsvyvdkgdlitcdasnllepefsyypagcllfaeysgclp 121
 Oy 238 DGYRDTSLCKAAIHAGIINDELGQISVLRGRGSTRRIEANGVNLSDSLSOKREFE 297

Db 122 hgydsaplcmaegvnyhgvantlsgqsvstasvsglpyrpyesslannrtvghstslft 181
 Oy 298 TSNCSRSLSIFE---PRGQIRASSMSQVNEGQVHMSPOQARLQDQSPMASGDSNV 353
 Db 182 ktsqcyglgmesgyvadpqltasvlewldhngqsmvskpkarlkpppmaafatde 241
 Oy 354 NIKPRELEIDCEKKITGITTCGTOSTQSNFTFYKSGFVNFKNNSKMTKTYGIVNNEB 413
 Db 242 ----yqvldlklkckkigtlttgsumehnyysayllysddqgkctvryepvegd 297
 Oy 414 KYFGQSNFRDPVONNFPIPIVARYRVVPTVHQRIALAKVELJGCO-----TTO- 463
 Db 298 klfqgnkdyhdgrnmlfplrlafllrtpvpyvgqklamkml19cqlfpkgrpkltp 357
 Oy 464 -----GNDSIVMKRTSGSTSVSTKKEDETITRPI-----PSEET-SFGINTTP- 505
 Db 358 ppprnmd----lntclaprkakmgtrpfqplqdprrsnsefpagteqctvrlntctv 413
 Oy 506 -----VAIPDLVLVLYPAGMGIRIAF-----RRKKRKS---PGSARMAOKTMC 547
 Db 414 fvnvtdvalaavlpvvlvmylltlllllyvcahwtrnrkkklegtydlypvr----dtrgy 469
 Oy 548 WKQIKYRF-----RRHQSASFRTSYDNKEXTOKRLDLYTSDNA 585
 Db 470 wqgmkgflpikavdheetpvrssse--vnlspvrcvtvlgasdeya 516

RESULT 8
 AAB24216
 ID AAB24216 standard; Protein: 889 AA.
 AC AAB24216;
 NC 06-FEB-2001 (first entry)
 DE Soluble neupoptillin snp-2 protein sequence SPO ID NO.4.
 XX
 XX Mouse; soluble neupoptillin.
 XX
 XX Mus sp.
 XX Synthetic.
 XX JP2000236879-A.
 PD 05-SEP-2000.
 PE 17-FEB-1999; 99UP-0038920.
 PR 17-FEB-1999; 99UP-0038920.
 XX (KACH-) KACHAU GIUTSU SHINKO JIGYODAN.
 XX WPI: 2000-658506/64.
 DR N-PSDB: AAC60787.
 XX
 XX
 XX Soluble neupoptillin having a deleted cell membrane-penetrating region,
 PT used to diagnose human disease conditions -
 PT
 XX
 XX
 XX Claim 5; Page 13-17; 18pp; Japanese.

CC The present invention describes a recombinant soluble neupoptillin (1)
 CC region and/or the intracellular region is deleted from membrane-penetrating
 CC neupoptillin. The soluble neupoptillin can be used for the elucidation of
 CC human bioactions and disease conditions. The present sequence
 CC represents a specifically claimed soluble neupoptillin protein
 CC sequence from the present invention.

XX
 XX
 XX Sequence 889 AA:
 SQ

Query Match 11.64; Score 353.5; DB 21; Length 889;

Best Local Similarity 23.1%; Pred. No. 2,3e-22;
Matches 120; Conservative 73; Mismatches 189; Indels 137; Gaps 17;

```

OY 49 VPAGAGGALRAAGRGRLALLAAVAPRLQAEELD-CGHLWTYQDSGTMTSKNPG 107
    ||| : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 15 vpsvsgdaa-----qparvavrsldpdpqgrprskdaayltsppypq 57
OY 108 TYRNNVCEKRTIYPR-GKRLILRG-DIDESOTCASDYL- - - - -TSSDOYCGYCS 161
    ||| : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 58 dypshqncwlvapepnqkvlfnphlelekhckdydfideldgsesadllghhghn 117
OY 132 MYVPELLINTSEVTVREFSGSHISGCGFLTY- - - - -ASSD- - - - - 198
    : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 118 I.aprlissagvlykltedyaragsglsrllyelkgsedcsnftspngltsppfp 176
OY 199 -HPDLITC- - - - -LERASHYLTKEYSKF- - - - -CPACRDVAADIS--GNMV 217
DB 177 ekympldctftllakprmeillqglfdleldpdlvsgedcdywdldagldphnpdl 236
OY 238 DGYRHTSLCKMAIHAGIIDEELGOSIVLOKGISRY- - - - -EG 277
DB 237 gkyqcltpsklrstsgllaltfhdmaavakgfsaryllbqpenfqcmyplgmsqy 296
OY 278 IIANGVLSRDSLSIDKRELFPSNGCSNLSPEPPGOIRASSWSQSVNESGDVWMSPGQA 337
    : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 297 rlaneqdasastfdagr-----wcpqqs 319
OY 338 RLODQGRSASGDSNNKPRFMEIDLEKKKTGTTC--STOSNPNFYKSPWMP 395
    ||| : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 320 rllghdngvtpnlasn---keylqvdlftlmltalstgalsretqgyvyskqlsv 375
OY 396 KNNNSKRTYKGIYNNNEKRYQGSNFRDPVONNFPIPIYARVYVPOTHQRIALXVE 435
DB 376 stngedwmvyrhghnh--klfgandatevlnklmpdltrfltrpqlvthgialtle 433
OY 436 LIICOTIQSNDLSLWKRKTS--OSTSVSTRKEDETTRP 491
DB 434 lfgcvtdapcsnmlgmisgladqlssastreylwap 472

RESULT 9
AAM96308
ID AAM96308 standard; Protein: 925 AA.
XX
XX AAM96308;
XX
XX 28-JUN-1999 (first entry)
XX
XX Neuropllin-2.
XX
XX Neuropllin; neuropllin-2; semaphorin; transmembrane protein; axon;
XX neurone; development; cell growth; immune response;
XX viral pathogenesis; treatment; disease; graft rejection;
XX viral diseases; oncological disease; cancer; screening; probes.
XX Rattus rattus.
XX MO9904263-A1.
XX
XX 28-JAN-1999.
XX
XX 17-JUL-1998; 98MO-US14632.
XX
XX 17-JUL-1997; 97US-0052762.
XX
XX (UFGO ) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX
XX Ginty DD, Kolodkin AL;
XX
XX WPI; 1999-132446/11.
XX
XX N-PSDB; AAX08417.
XX
XX New Isolated semaphorin receptor, neuropllin-2 - used to develop

```

PT products for the diagnosis and treatment of neurological,
PR immunological, oncological and viral diseases

XX Claim 13: Page 77-79; 88pp; English.

XX The neuropllins are type I transmembrane proteins and act as
CC semaphorin III (Sema III) receptors. The semaphorins have been
CC shown to be involved in the development of the nervous system
CC secreted protein that in vitro causes neuronal growth cone
CC collapse and chemorepulsion on neurites and is required in vivo for
CC correct sensory afferent innervation and other aspects of
CC development. Agents which inhibit or enhance the interaction of a
CC semaphorin and a neuropllin can be potent modulators of nerve cell
CC growth, immune responsiveness, and viral pathogenesis, and can be
CC used in the treatment and diagnosis of neurological disease,
CC neuro-regeneration, immune modulation including hypersensitivity and
CC allergic diseases, and in the treatment and diagnosis of neurological
CC diseases. These neuropllin-binding proteins are useful in screening chemical
CC libraries for regulators of semaphorin-mediated cell activity, and in
CC genetic mapping as probes for related genes, as diagnostic reagents
CC for genetic, neurological, immunological and oncological disease.

XX Sequence 925 AA:

Query Match 11.5%; Score 351.5; DB 20; Length 925;
Best Local Similarity 24.4%; Pred. No. 3,7e-72;
Matches 114; Conservative 76; Mismatches 181; Indels 97; Gaps 17;

```

OY 88 CGHLVYQDSGTMTSKNYPQYRNHVCEKRTIYPR-GKRLILRG-DIDESOTCASDY 145
    || : : : : : || : : : : : : : : : : : : : : : : : : : :
DB 28 cgrltnskdaayltsppypdpqshqncwvlyapepnqkvlfnphlelekhckdydf 87
OY 146 LUF- - - - -TSSDOYCGYCSMTVRELLINTSEVTVREFSGSHISGCGFLTY- - - - -AS 196
    ||| : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 88 lctrdgsesadllghhghnlt apellissagvlykltedyaragsglsrllyelkfgs 146
OY 197 SD- - - - -HPDLITC- - - - -LERASHYLTKEYSKF- - - - - 220
    | : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 147 edcsknftspngltsppfpkryphmdctftllakprmeillqglfdleldpqlqvsg 205
OY 221 -CPACRDVAADIS--GNMVDYRDRSLCKMAIHAGIIDEELGQIISYLOKGISRY- - - - - 276
DB 207 dckdywdldagldphnpdllygrygcltfrskltsstgylslfhdmaavakgfsaryl 266
OY 276 ---ECIIANGVLSRP-GSLSDGKRELFPSNGCSNLSLPEPPGOIRASSWSQSVNESGD 328
DB 267 vlqpenfqcmyplgmsqyrlane-----qlssastf- - - - -s 300
OY 339 OYHNSPQARILQDQGRSASGDSNNKPRFMEIDLEKKKTGTTC--STOSNPNF 386
    ||| : : : : : || : : : : : : : : : : : : : : : : : : : :
DB 301 dgrvtpqsrthqdnghvchpnda---keylqvdlftlmltalstgalsretqgyv 356
OY 367 YKRSNPNKNNNSKRTYKGIYNNNEKRYQGSNFRDPVONNFPIPIYARVYVPOTHQRI 446
DB 357 ykkykltvstngedwmvyrhghnh--klfgandatevlnklmpdltrfltrpqlvth 414
OY 447 HORIALKVELIGCOTIQSNDLSLWKRKTS--OSTSVSTRKEDETTRP 491
DB 415 hlgialrltfgcvtdapcsnmlgmisgladqlssastreylwap 462

```

```

RESULT 10
AAB64627
ID AAB64627 standard; Protein: 439 AA.
XX
XX AAB64627;
XX
XX 22-MAR-2001 (first entry)
XX
XX Human secreted protein BLAST search protein SEQ ID NO. 137.
XX
XX

```

KM Cytostatic; immunosuppressive; neurotrophic; neuroprotective; antiviral;
 KM antileukemic; hepatotropic; antidiabetic; antitumor; antileukemic; antileukemic;
 KM valnerary; anticonvulsant; antibacterial; antileukemic; antiparasitic;
 KM candid; gene therapy; cancer; immune disorder; cardiovascular disorder;
 KM neurological disease; infection; human; secreted protein.
 OS Homo sapiens.
 XX W020007197-AL.
 PN 21-DEC-2000.
 XX 01-JUN-2000; 2000MO-US14934.
 PF 11-JUN-1999; 9905-0138599.
 XX (HUNA-) HUMAN GENOME SCI INC.
 PA (ROSE/) ROSEN C A.
 FI Rosen CA, Ruben SM, Komatsu S, et al.
 XX WPI: 2001-032312/04.
 DR Isolated nucleic acid molecule encoding a human secreted protein is
 PT used in preventing, treating or ameliorating a medical condition -
 PS Disclosure: Page 524-526; 558pp; English.
 XX The invention relates to the isolation of genes AAF32757-F32803 encoding
 CC the human secreted proteins AAF32757-F32803. The sequence is a search
 CC result from a BLASTX homology search. The genes and proteins are useful
 CC for preventing, ameliorating or treating medical conditions, e.g., by
 CC the use of the genes or the proteins or the proteins or the proteins or the
 CC tissues disclosed herein. The genes are isolated from a range of human
 CC antibodies and (antibodies) are useful in the diagnosis, treatment, and
 CC and prevention of: (a) cancer, e.g., breast and ovarian cancer, and
 CC other cancers of the adrenal gland, bone, bone marrow, breast,
 CC gastrointestinal tract, liver, lung, or urogenital; (b) immune
 CC disorders e.g., Addison's disease, allergies, autoimmune hemolytic
 CC anemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
 CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
 CC cardiovascular disorders, such as myocardial ischemia; (d) wound
 CC healing; (e) infectious diseases, e.g., bacterial, viral, fungal and
 CC parasitic infections.
 CC Sequence 439 AA:
 SQ
 Query Match 11.4% Score 349; DB 22; Length 439;
 Description Similarity 25.3%; Pred. NO. 1.9e-22;
 Matches 109; Conservative 72; Mismatches 166; Indels 84; Gaps 16;
 QY 88 CCHLYATQSGTSMKPNYVKNYKKTIVK-GKRLILRG-DLIDESQTCASD 145
 DB 28 CGGfLnKaglytspypdyphqgkewyVapqpnqkLhfnphlekhdkydf 87
 QY 146 LRF---TSSDQYGYGTCGSMVREKLANTSEVYREFSGSHISGKGLTY---AS 196
 DB 88 felfrgdsadllghhgnl apellissmnlakltedyarqagsgistylrflkgs 146
 QY 197 SP-----HPDLITC-----LRASHLAKTYSKRF----- 220
 DB 147 edcokfctapngtlespfkryphndcttllkxpmellfflfdlshp,qygs 206
 QY 221 -CPAGCRDVAADIS-GNMYDYRDTSLICAAIHNGIADLGGQSVLWRGSRNRG 277
 DB 207 dckydvdldwqgipvhpqpllgkygcgrlatsstglsllftlmavak----- 259
 QY 278 ILANGLVLSRDSLSKRFLETSNCSKSLSTF---PDGQIRASSWSQSNESGQVMS 333
 DB 260 faatylvlnhgeplenf-----cnvplmeagntleqjastay-----sdgvt 305

QY 334 PGQARLDQSPGSMAGSOSNNKREMLDIDKKKKTITGTTG--STOSNPNFYKSP 391
 DB 306 pggarhlghdngvgtvdns-----keylvadlftlmaltatgalsretqnygykay 361
 QY 392 VNNKRNNSKKWYKGYGVNNEKEVFGSNSFRPQVNNFIPPIARYVAVPQYMGRLA 451
 DB 362 klvestngedwmyrtnghn--kyvgamdatevlnklnapllftrlcpqlvhaqla 419
 QY 452 LVELIGCOIT 462
 DB 420 lrlfclgcrvt 430
 RESULT 11
 AAY06320 standard; Protein: 555 AA.
 XX AAY06320:
 AC AAY06320:
 DT 06-SEP-1999 (first entry)
 XX Human soluble neuropilin-2.
 DE Neuropilin-2; human; vascular endothelial growth factor receptor;
 KM VEGF receptor; endothelial; angiogenesis; inflammation;
 KM antiangiogenic; antidiabetic; ophthalmological; antithrombotic;
 KM soluble.
 XX Homo sapiens.
 OS Synthetic.
 XX W09929858-AL.
 PN 17-JUN-1999.
 PF 09-DEC-1998; 98MO-US26138.
 PR 09-SEP-1998; 9805-0096419.
 PR 09-DEC-1997; 9705-0069155.
 PR 12-DEC-1997; 9705-0069687.
 PA (CHIL-) CHILDRENS MEDICAL CENT.
 XX Gagnon ML, Klagsbrun M, Soker S.
 XX WPI: 1999-394975/33.
 DR N-PSDB: AAX59154.
 PT Soluble human neuropilins and related polynucleotides
 PS Claim 6: Page 90-91; 98pp; English.
 CC The present sequence represents a soluble, truncated form of human
 CC neuropilin-2, a novel receptor of vascular endothelial growth
 CC factor (VEGF). The soluble neuropilin-2 deviates from the
 CC full-length protein (see AAY06318) between the b2 and c domains
 CC after amino acid 547, at the position of an exon-exon boundary,
 CC and includes 8 extra C-terminal amino acids. Soluble neuropilins
 CC are capable of binding to VEGF165 or any form of VEGF that contains
 CC exon 7 and are useful for inhibiting VEGF interaction not only
 CC with neuropilins but also with KDR/Flk-1 and Tie2. They may also
 CC dimerizing with intact neuropilin receptors. The soluble
 CC neuropilins are useful for treatment of diseases or disorders
 CC associated with VEGF, e.g., metastasis, inappropriate angiogenesis,
 CC chronic inflammation, diabetic retinopathy and arthritis. Solid
 CC tumors can also be treated.
 SQ Sequence 555 AA:
 Query Match 11.4% Score 349; DB 20; Length 555;

Tue Jul 9 08:27:35 2002

us-09-691-344a-4.rag

Copy 9 A-5'
Page 12

8

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: July 9, 2002, 01:12:13 ; Search time 66.82 Seconds

(without alignments)
214,208 Million cell updates/sec

Title: US-09-691-344A-4

Perfected score: 3052

Sequence: 1 MGFACGRKRPVAPFRSSAE.....VDNEKMTQKLDLITSDMG 586

Scoring table:

BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 231628 seqs, 24425594 residues

Total number of hits satisfying chosen parameters: 231628

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 08

Maximum Match 1008

Listing first 45 summaries

Database :

- 1: Issued Patents, AA.*
- 2: /cgn2.6/p/odata/2/1aa/5A_COMB pep.*
- 3: /cgn2.6/p/odata/2/1aa/5B_COMB pep.*
- 4: /cgn2.6/p/odata/2/1aa/6A_COMB pep.*
- 5: /cgn2.6/p/odata/2/1aa/6B_COMB pep.*
- 6: /cgn2.6/p/odata/2/1aa/Backfilltest1 pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	349	11.4	909	3	US-08-936-135-18	Sequence 18, Appl
2	349	11.4	926	3	US-08-936-135-20	Sequence 20, Appl
3	343.5	11.3	901	3	US-08-936-135-22	Sequence 22, Appl
4	343.5	11.3	906	3	US-08-936-135-24	Sequence 24, Appl
5	343.5	11.3	909	3	US-08-936-135-8	Sequence 8, Appl
6	343.5	11.3	909	3	US-08-936-135-10	Sequence 10, Appl
7	343.5	11.3	914	3	US-08-936-135-12	Sequence 12, Appl
8	343.5	11.3	926	3	US-08-936-135-14	Sequence 14, Appl
9	343.5	11.3	931	3	US-08-936-135-16	Sequence 16, Appl
10	329	10.8	923	3	US-08-936-135-18	Sequence 18, Appl
11	321	10.5	911	3	US-07-607-538C-4	Sequence 4, Appl
12	321	10.5	911	3	US-08-163-402B-4	Sequence 4, Appl
13	318	10.2	910	3	US-08-163-402B-4	Sequence 4, Appl
14	311	10.2	910	3	US-08-163-402B-14	Sequence 14, Appl
15	305.5	10.0	2343	4	US-09-324-867-2	Sequence 2, Appl
16	299	9.8	217	1	US-07-607-538C-3	Sequence 3, Appl
17	299	9.8	217	1	US-08-163-402B-3	Sequence 3, Appl
18	299	9.8	218	1	US-08-163-402B-2	Sequence 2, Appl
19	299	9.8	218	1	US-08-163-402B-1	Sequence 1, Appl
20	299	9.8	387	2	US-08-162-402B-6	Sequence 6, Appl
21	299	9.8	387	2	US-08-162-402B-8	Sequence 8, Appl
22	293	9.6	159	2	US-08-162-402B-12	Sequence 12, Appl
23	289.5	9.5	2351	6	5422260-1	Patent No. 5422260
24	285.5	9.4	1438	4	US-09-309-916-1	Sequence 1, Appl
25	285.5	9.4	1471	1	US-08-683-839B-3	Sequence 3, Appl
26	285.5	9.4	1661	2	US-08-882-083-2	Sequence 2, Appl
27	285.5	9.4	1661	2	US-08-558-107-2	Sequence 2, Appl

28	285.5	9.4	1661	4	US-09-243-539-2	Sequence 2, Appl
29	285.5	9.4	2332	1	US-07-664-004B-4	Sequence 4, Appl
30	285.5	9.4	2332	1	US-08-251-937A-4	Sequence 4, Appl
31	285.5	9.4	2332	1	US-08-212-137A-2	Sequence 2, Appl
32	285.5	9.4	2332	1	US-08-276-594A-2	Sequence 2, Appl
33	285.5	9.4	2332	1	US-08-474-503-2	Sequence 2, Appl
34	285.5	9.4	2332	2	US-08-474-503-2	Sequence 2, Appl
35	285.5	9.4	2332	4	US-06-027-601A-2	Sequence 2, Appl
36	285.5	9.4	2332	4	US-09-324-867-3	Sequence 4, Appl
37	285.5	9.4	2332	5	PCT-US93-03275-4	Sequence 5, Appl
38	285.5	9.4	2332	5	PCT-US94-13200-2	Sequence 2, Appl
39	285.5	9.4	2351	1	US-08-121-202-2	Sequence 2, Appl
40	285.5	9.4	2351	1	US-08-366-851A-2	Sequence 2, Appl
41	285.5	9.4	2351	6	517844-2	Patent No. 517844
42	284.5	9.3	218	1	US-07-607-538C-5	Sequence 5, Appl
43	284.5	9.3	218	1	US-08-163-402B-15	Sequence 15, Appl
44	276.5	9.1	2304	4	US-09-324-867-4	Sequence 4, Appl

ALIGNMENTS

RESULT 1
US-08-936-135-18
Sequence 18, Appl
Sequence 18, Appl
GENERAL INFORMATION:
APPLICANT: Tessier-Lavigne, Marc
APPLICANT: Chen, Hang
TITLE OF INVENTION: Semaphorin Receptors
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
CITY: MILWAUKEE, WISCONSIN 53233
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94010
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/936,135
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: OSMAN, RICHARD A.
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: 0097-288-2
TELEPHONE: (650) 343-4341
TELEFAX: (650) 343-4342
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 909 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-936-135-18

Query Match 11.4%; Score 349; DB 3; Length 909;
Best Local Similarity 25.3%; Pred. No. 8.6e-24;
Matches 109; Conservative 72; Mismatches 166; Indels 84; Gaps 16;
88 CGHLYVQDSGTWNSKNIPGTYNNYTCERTITPK-CGRLLILRG-DLIESQTCADY 145.
DB 28 CGRLNSKNGKILTSPTGPDYDSNQCENLYVAPSPNKKYLVNPNRHEIKDKCKDF 87

```

01 146 LLE-----TSSDPOGPPCCSVWVPEELLMTSTVAFEGSSHISGRDFUTY-----AS 139
02 Db 88 IETROGDSBESADLLGKHCNGI-APPTIISGSMALYETFSYVAMQDCAFSLREIFPTGS 146
03 197 SD-----APDLITC-----LEBASVYAKTEYSK-----222
04 147 EDSNNFTSPNGTSTESPEKPPHMLCTPFLAKKKEMLIOLFTLDEHPDLYGCG 206
05 01 221 -CPACDPAVGDIS-CGMDGYRPTSLCKFLKALHAGIITDELGCGISVQKRGISYTES 277
06 Db 207 DCMYGMILMDIMDIPHVGPIKCYCGKTPSELRSSTGILSLTPHDMVAK-----Dc 259
07 278 ILANGVLSRNGSLSDLRFLFTSNKGSRLSFE-----PDGQIRASSMSWOSVNESGPOVHS 333
08 Db 260 FSARYLVHQLPELHNQ-----CNVLOMSSGRANQISASVY-----SDCRNT 305
09 01 334 PGQALDLDGQSPASGSDSNHNRPREMLTLDGKKKTIIRTTG-STGSNENFYKSF 391
10 Db 306 POGSLIGDGNCKNTPRLSN-----KELVDLFLMLFLALTAQALISRETONGYVNSY 361
11 01 392 VAMFNNKSNKMTKCIYVNEEYEGCSNFPDPQWNEIPRLVARYVYRQTHORIA 451
12 Db 362 KLEVTSTGEDEWVYRGRKNH-KVFOANDNATEVYVNLKHLAPLLRFVFLRQTHESGIA 419
13 01 452 LKVELICQTT 462
14 Db 420 LRIELFCQRYT 430
15 RESULT 2
16 US-08-936-135-20
17 : Sequence 20, Application US/08936135
18 : Patent No. 6054293
19 :
20 : GENERAL INFORMATION:
21 : APPLICANT: Tessier-Lavigne, Marc
22 : APPLICANT: Chen, Hang
23 : APPLICANT: He, Zhigang
24 : NUMBER OF INVENTORS: 26
25 : NUMBER OF SEQUENCES: 26
26 : CORRESPONDENCE ADDRESS:
27 : ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
28 : STREET: 75 DENISE DRIVE
29 : CITY: HILLSBOROUGH
30 : STATE: CALIFORNIA
31 : COUNTRY: USA
32 : ZIP: 94010
33 :
34 : COMPUTER READABLE FORM:
35 : MEDIUM TYPE: Floppy disk
36 : OPERATING SYSTEM: IBM PC compatible
37 : OPERATING SYSTEM: DOS/MS-DOS
38 : SOFTWARE: Patent Release #1.0, Version #1.30
39 : CURRENT APPLICATION DATA:
40 : APPLICATION NUMBER: US/08/936/135
41 : FILING DATE:
42 :
43 : CLASSIFICATION: 435
44 : ATTORNEY/AGENT INFORMATION:
45 : NAME: OSMAN, RICHARD A
46 : REGISTRATION NUMBER: 36,667-288-2
47 : REFERENCE/DOCKET NUMBER: 0097-288-2
48 : TELECOMMUNICATION INFORMATION:
49 : TELEPHONE: (650) 343-4341
50 : TELEFAX: (650) 343-4342
51 : INFORMATION FOR SEQ ID NO: 20:
52 : SEQUENCE CHARACTERISTICS:
53 : LENGTH: 926 amino acids
54 : TYPE: amino acid
55 : STANDARDS: single
56 : TOPOLOGY: linear
57 :
58 : MOLECULE TYPE: peptide
59 :
60 : IS-08-936-135-20

```

```

      109: 11.4%; Score 349; DB 3; Length 926;
      110: Best Local Similarity 25.3%; Pred. No. 8.9e-24;
      111: Matches 109; Conservative 72; Mismatches 166; Indels 84; Gaps
      112:
      113:
      114:
      115:
      116:
      117:
      118:
      119:
      120:
      121:
      122:
      123:
      124:
      125:
      126:
      127:
      128:
      129:
      130:
      131:
      132:
      133:
      134:
      135:
      136:
      137:
      138:
      139:
      140:
      141:
      142:
      143:
      144:
      145:
      146:
      147:
      148:
      149:
      150:
      151:
      152:
      153:
      154:
      155:
      156:
      157:
      158:
      159:
      160:
      161:
      162:
      163:
      164:
      165:
      166:
      167:
      168:
      169:
      170:
      171:
      172:
      173:
      174:
      175:
      176:
      177:
      178:
      179:
      180:
      181:
      182:
      183:
      184:
      185:
      186:
      187:
      188:
      189:
      190:
      191:
      192:
      193:
      194:
      195:
      196:
      197:
      198:
      199:
      200:
      201:
      202:
      203:
      204:
      205:
      206:
      207:
      208:
      209:
      210:
      211:
      212:
      213:
      214:
      215:
      216:
      217:
      218:
      219:
      220:
      221:
      222:
      223:
      224:
      225:
      226:
      227:
      228:
      229:
      230:
      231:
      232:
      233:
      234:
      235:
      236:
      237:
      238:
      239:
      240:
      241:
      242:
      243:
      244:
      245:
      246:
      247:
      248:
      249:
      250:
      251:
      252:
      253:
      254:
      255:
      256:
      257:
      258:
      259:
      260:
      261:
      262:
      263:
      264:
      265:
      266:
      267:
      268:
      269:
      270:
      271:
      272:
      273:
      274:
      275:
      276:
      277:
      278:
      279:
      280:
      281:
      282:
      283:
      284:
      285:
      286:
      287:
      288:
      289:
      290:
      291:
      292:
      293:
      294:
      295:
      296:
      297:
      298:
      299:
      300:
      301:
      302:
      303:
      304:
      305:
      306:
      307:
      308:
      309:
      310:
      311:
      312:
      313:
      314:
      315:
      316:
      317:
      318:
      319:
      320:
      321:
      322:
      323:
      324:
      325:
      326:
      327:
      328:
      329:
      330:
      331:
      332:
      333:
      334:
      335:
      336:
      337:
      338:
      339:
      340:
      341:
      342:
      343:
      344:
      345:
      346:
      347:
      348:
      349:
      350:
      351:
      352:
      353:
      354:
      355:
      356:
      357:
      358:
      359:
      360:
      361:
      362:
      363:
      364:
      365:
      366:
      367:
      368:
      369:
      370:
      371:
      372:
      373:
      374:
      375:
      376:
      377:
      378:
      379:
      380:
      381:
      382:
      383:
      384:
      385:
      386:
      387:
      388:
      389:
      390:
      391:
      392:
      393:
      394:
      395:
      396:
      397:
      398:
      399:
      400:
      401:
      402:
      403:
      404:
      405:
      406:
      407:
      408:
      409:
      410:
      411:
      412:
      413:
      414:
      415:
      416:
      417:
      418:
      419:
      420:
      421:
      422:
      423:
      424:
      425:
      426:
      427:
      428:
      429:
      430:
      431:
      432:
      433:
      434:
      435:
      436:
      437:
      438:
      439:
      440:
      441:
      442:
      443:
      444:
      445:
      446:
      447:
      448:
      449:
      450:
      451:
      452:
      453:
      454:
      455:
      456:
      457:
      458:
      459:
      460:
      461:
      462:
      463:
      464:
      465:
      466:
      467:
      468:
      469:
      470:
      471:
      472:
      473:
      474:
      475:
      476:
      477:
      478:
      479:
      480:
      481:
      482:
      483:
      484:
      485:
      486:
      487:
      488:
      489:
      490:
      491:
      492:
      493:
      494:
      495:
      496:
      497:
      498:
      499:
      500:

```

TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-936-135-22

Query Match 11.3%; Score 343.5; DB 3; Length 901;
Best Local Similarity 23.2%; Pred. No. 2,86-233;
Matches 111; Conservative 72; Mismatches 177; Indels 119; Gaps 15;

```

88 CGHLYVDSGTMSTKNTPGTPYHNTVEKTIIVK--GKLLILRLG--DLDISSQASDY 145
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
28 CGGRPNKSDAGYITISPGODYPSHONCMIVYAPPEPKQYILNFNPHETLEKDKDF 87
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
146 LIF-----TSSSDQYPCGSMYVPELLINTSEVYVRESGSHISGRGLITY-----AS 196
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
88 IETRGDSADLLKRGKQNI--APPITISSVYLKRTSDYARQAGSLRTEIPTQGS 146
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
197 SD-----HPDLTC-----LEASHTLKRTSKF-----220
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
147 EDCSKNTPSGNTIESPGPEKYPHNDQFTPLAKPRMELLLOPLFLDHPDLOVGG 206
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
221 -CPACGADVADIS--GNWYDGYRDTSLCKAAIHAGIADLGGQISVLRKGISRY-- 275
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
207 DCKYMDLDMGIPHYGPIIGKGYCTKPSKLSSTGLSLTFPHDMAVAKDGFARYL 266
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
276 -----EGLIANGVLSQDLSLDRKPLTTSNGCSLSLSEFPDQIATAS 317
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
267 HQEPPENCNPVPLMGESGRINAEQISASTFSQCR-----303
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
318 SSMQSVESGDYVHSPQARLDQDGGSMAGSDSSNNHPRMLETIDLEKKKITGINTT 377
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
304 -----WTPQOSRLHGDONGWTFPLDSN---KEYLDVLFPLMTLTAIATQ 345
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
378 G--STQSNENFYKSFVANKNNKSKRTGYGVNNEKYFGQNSRDPQNNFTPIYV 435
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
346 GALSRETQGYTKYSLKLEYSTNGEDMWTYRHQKH--KIFQANNDATVYLKLNHLL 403
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
436 ARYRVAVPQTHORIALKVELLIGQITQGNDSLWYKRTS---QSTSVSTKKEDEFTTRP 491
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|
404 TFRIRPQTHGIALRLLEPGCRVTDAPCSNMLQSLGLADVTOISASTREYIAMP 462
      |||:|:| |||:|:| |||:|:| |||:|:| |||:|:| |||:|:|

```

RESULT 4

US-08-936-135-24
Sequence 24, Application US/08936135
Patent No. 6054293

GENERAL INFORMATION:

APPLICANT: Tessier-Lavigne, Marc
APPLICANT: He, Zhigang
APPLICANT: Chen, Hang
TITLE OF INVENTION: Semaphorin Receptors
INVENTOR: Semaphorin Receptors
CORRESPONDENCE ADDRESS: 26
ADDRESS: SCIENCE & TECHNOLOGY LAW GROUP
STREET: 75 DENISE DRIVE
CITY: HILLSBOROUGH
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94010

COMPUTER READABLE FORM:

RECORD TYPE: floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/936,135

FILING DATE:

CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
ATTORNEY: JOSHUA, ALTHAND A
REGISTRATION NUMBER: 36,627

REFERENCE/DOCKET NUMBER: UC97-288-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 343-4341
TELEFAX: (650) 343-4342
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 306 amino acids
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-936-135-24

Query Match 11.3%; Score 343.5; DB 3; Length 906;
Best Local Similarity 23.2%; Pred. No. 2,86-233;
Matches 111; Conservative 72; Mismatches 177; Indels 119; Gaps 15;

```

88 CGHLYVDSGTMSTKNTPGTPYHNTVEKTIIVK--GKLLILRLG--DLDISSQASDY 145
      |||:|:| |||:|:| |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
28 CGGRPNKSDAGYITISPGODYPSHONCMIVYAPPEPKQYILNFNPHETLEKDKDF 87
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
146 LIF-----TSSSDQYPCGSMYVPELLINTSEVYVRESGSHISGRGLITY-----AS 196
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
88 IETRGDSADLLKRGKQNI--APPITISSVYLKRTSDYARQAGSLRTEIPTQGS 146
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
197 SD-----HPDLTC-----LEASHTLKRTSKF-----220
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
147 EDCSKNTPSGNTIESPGPEKYPHNDQFTPLAKPRMELLLOPLFLDHPDLOVGG 206
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
221 -CPACGADVADIS--GNWYDGYRDTSLCKAAIHAGIADLGGQISVLRKGISRY-- 275
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
207 DCKYMDLDMGIPHYGPIIGKGYCTKPSKLSSTGLSLTFPHDMAVAKDGFARYL 266
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
276 -----EGLIANGVLSQDLSLDRKPLTTSNGCSLSLSEFPDQIATAS 317
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
267 HQEPPENCNPVPLMGESGRINAEQISASTFSQCR-----303
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
318 SSMQSVESGDYVHSPQARLDQDGGSMAGSDSSNNHPRMLETIDLEKKKITGINTT 377
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
304 -----WTPQOSRLHGDONGWTFPLDSN---KEYLDVLFPLMTLTAIATQ 345
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
378 G--STQSNENFYKSFVANKNNKSKRTGYGVNNEKYFGQNSRDPQNNFTPIYV 435
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
346 GALSRETQGYTKYSLKLEYSTNGEDMWTYRHQKH--KIFQANNDATVYLKLNHLL 403
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
436 ARYRVAVPQTHORIALKVELLIGQITQGNDSLWYKRTS---QSTSVSTKKEDEFTTRP 491
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~
404 TFRIRPQTHGIALRLLEPGCRVTDAPCSNMLQSLGLADVTOISASTREYIAMP 462
      |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~ |||:~|:~

```

RESULT 5

US-08-936-135-8
Sequence 8, Application US/08936135
Patent No. 6054293

GENERAL INFORMATION:

APPLICANT: Tessier-Lavigne, Marc
APPLICANT: He, Zhigang
APPLICANT: Chen, Hang
TITLE OF INVENTION: Semaphorin Receptors
INVENTOR: Semaphorin Receptors
CORRESPONDENCE ADDRESS: 26
ADDRESS: SCIENCE & TECHNOLOGY LAW GROUP
STREET: 75 DENISE DRIVE
CITY: HILLSBOROUGH
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94010

COMPUTER READABLE FORM:

RECORD TYPE: floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30

```

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/936,135
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: OSMAN, RICHARD A.
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: UC97-288-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 343-4341
FAX: (650) 343-4342
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 909 amino acids
TYPE: amino acid
STANDARDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-936-135-8

```

```

Query Match      11.3%; Score 343.5; DB 3; Length 909;
Best Local Similarity 23.2%; Pred. No. 2,8e-23;
Matches 111; Conservative 72; Mismatches 177; Indels 119; Gaps 15;

```

```

OY 88 CGHLYTQDSGWTSKNPGTYPMHNYCEKTIIVPK-GKRLILRLG-DLIESQTCASDY 145
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
DB 28 CGGRNSKDAQYITSPGPDYPSHQNCMIYAPPEPKYILNPNHPELEKHDKYDF 87
OY 146 LIF-----TSSDQYGYCGSKMTYKRELLINTSEYVRESGSHISGRGFLTY+---AS 196
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
DB 88 IETRDQSDSMDLCKHCGNI-APPTLISOSVYIKFTSDYARQAGCSLAREIFYTG 146
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
OY 197 SD-----HPLDITC-----LEKASHYLTATYSKPF----- 220
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
DB 147 EDCSKNFTSPNGTIESPGFEPEYKPHNIDCTFTLLAKPMREIILQPLFLEHDPLOYGEG 206
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
OY 221 -CPAGCEYVADIS--GNMYDGYRDTSLCAFAIHAGIADDELGSGISYLRQGISRY-- 275
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
DB 207 DCKYDMLDMGILPHVGLPGIKGYCGTKPSKLSSTGLSLFPHDMAVAADGFSARYL 266
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
OY 276 -----EGLIANGYLSRDSLSQKREFTLSNCSNLSLSEPDQIARAS 317
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
DB 267 IHQEPENOCNPLGMSGRIANQISASTSGR----- 303
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
OY 318 SSMQSVNESGDQYHNSPGQARLDQDGPMSAGSSNNKPRMELIDGCKKKITGITRT 377
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
DB 304 -----WTPQOSRLHDDNGMTPNLDSN-----KEYLDVLEFLTMALATQ 345
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
OY 378 G--STQSNFNFYKSPFNKNNKSKRTTYKGIYVNEEKYFGQSNRPDYQNNFTPIPV 435
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
DB 346 GAISETQKGYKYSKLEYSTNEDPMYVRHCKNH--KIFQANNDATVEYLVNKLHAPLL 403
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
OY 436 ARYRVVPTQMORIALKVELIGCOITQGNDSLVRKTS--OSTSVSKREDETTIRP 491
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
DB 404 TRFIRIRPQTHLGIARLELPGCRVYDAPCSNMGLMGLSLADPJOISASTREYLMSP 462
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|

```

```

RESULT 6
US-08-936-135-10
Sequence 10. Application US/08936135
Patent No. 6054293
GENERAL INFORMATION:
APPLICANT: Tessier-Lavigne, Marc
APPLICANT: Chen, Hang
TITLE OF INVENTION: Semaphorin Receptors
NAMES OF INVENTORS: 26
CORRESPONDENCE ADDRESS:
ADDRESS: SCIENCE TECHNOLOGY LAW GROUP
STREET: 75 DENISE DRIVE
CITY: HILLSBOROUGH
STATE: CALIFORNIA

```

```

COUNTRY: USA
ZIP: 94010
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPILED BY: IBM PC compatible
SOFTWARE: SYSTEM: PC DOS/MS DOS
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/936,135
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: OSMAN, RICHARD A.
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: UC97-288-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 343-4341
FAX: (650) 343-4342
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 909 amino acids
TYPE: amino acid
STANDARDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-936-135-10

```

```

Query Match      11.3%; Score 343.5; DB 3; Length 909;
Best Local Similarity 23.2%; Pred. No. 2,8e-23;
Matches 111; Conservative 72; Mismatches 177; Indels 119; Gaps 15;

```

```

OY 88 CGHLYTQDSGWTSKNPGTYPMHNYCEKTIIVPK-GKRLILRLG-DLIESQTCASDY 145
    ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:| ||:|:|
DB 28 CGGRNSKDAQYITSPGPDYPSHQNCMIYAPPEPKYILNPNHPELEKHDKYDF 87
OY 146 LIF-----TSSDQYGYCGSKMTYKRELLINTSEYVRESGSHISGRGFLTY+---AS 196
    ||:|:| ||:|:| ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
DB 88 IETRDQSDSMDLCKHCGNI-APPTLISOSVYIKFTSDYARQAGCSLAREIFYTG 146
    ||:|:| ||:|:| ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
OY 197 SD-----HPLDITC-----LEKASHYLTATYSKPF----- 220
    ||:|:| ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
DB 147 EDCSKNFTSPNGTIESPGFEPEYKPHNIDCTFTLLAKPMREIILQPLFLEHDPLOYGEG 206
    ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
OY 221 -CPAGCEYVADIS--GNMYDGYRDTSLCAFAIHAGIADDELGSGISYLRQGISRY-- 275
    ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
DB 207 DCKYDMLDMGILPHVGLPGIKGYCGTKPSKLSSTGLSLFPHDMAVAADGFSARYL 266
    ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
OY 276 -----EGLIANGYLSRDSLSQKREFTLSNCSNLSLSEPDQIARAS 317
    ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
DB 267 IHQEPENOCNPLGMSGRIANQISASTSGR----- 303
    ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
OY 318 SSMQSVNESGDQYHNSPGQARLDQDGPMSAGSSNNKPRMELIDGCKKKITGITRT 377
    ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
DB 304 -----WTPQOSRLHDDNGMTPNLDSN-----KEYLDVLEFLTMALATQ 345
    ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
OY 378 G--STQSNFNFYKSPFNKNNKSKRTTYKGIYVNEEKYFGQSNRPDYQNNFTPIPV 435
    ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
DB 346 GAISETQKGYKYSKLEYSTNEDPMYVRHCKNH--KIFQANNDATVEYLVNKLHAPLL 403
    ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
OY 436 ARYRVVPTQMORIALKVELIGCOITQGNDSLVRKTS--OSTSVSKREDETTIRP 491
    ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||
DB 404 TRFIRIRPQTHLGIARLELPGCRVYDAPCSNMGLMGLSLADPJOISASTREYLMSP 462
    ||:|:| ||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||:~||

```

```

RESULT 7
US-08-936-135-12
Sequence 12. Application US/08936135
Patent No. 6054293
GENERAL INFORMATION:
APPLICANT: Tessier-Lavigne, Marc
APPLICANT: Chen, Hang

```

TITLE OF INVENTION: Semaphorin Receptors
 NUMBER OF SEQUENCES: 26
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
 STREET: 75 DENISE DRIVE
 CITY: HILLSBOROUGH
 STATE: CALIFORNIA
 COUNTRY: USA
 ZIP: 94010
 COMPUTER READABLE FORM:
 MEDIA TYPE: Floppy disk
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patentin Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/936,135
 FILING DATE:
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: OSMAN, RICHARD A.
 REGISTRATION NUMBER: 36,627
 REFERENCE/DOCKET NUMBER: UC97-288-2
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (650) 343-4341
 TELEFAX: (650) 343-4342
 INFORMATION FOR SEQ ID NO: 12:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 126 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-936-135-12

Query Match 11.38: Score 343.5; DB 3; Length 914;
 Best Local Similarity 23.28; P-adj No. 2.9e-32;
 Matches 111; Conservative 72; Mismatches 177; Indels 119; Gaps 15;

```

      88 CGHLYVTQSGMTSKNRYPGTYPNHTVCERTITVPK-GKRLILRLG-DLDIESQTCASDY 145
      28 CGGRNSKIDAGVITSPGYDPSHONCMIVYAPPNOKIVLNFPHFELEKHDKDYF 87
      146 LRF-----TSSSDYGYPGSNWYPELLNLTSEVYRESGSHISNGEFLTY-----AS 196
      88 IETRGDSADLGRHONT-APPTLISSGSVLYIKFTSDYARQAGSLREIFKIGS 146
      197 SD-----HPRLITC-----LEFASHLYKTEYSKF-----220
      221 -CPACRDVAGDIS--GNWDGYRPTSLCAKAAIHAGIADLGQGLSVLQKGISRY-- 275
      207 DCKYMDLMDIGLTHVHGPLKICGKTPSKLSSGTLSLTPRTDMAVAKDGSAKRYL 266
      276 -----EGILANGVLSRSGSLSDKRFLLTNSGCSNSLSFEPDQGIAS 317
      267 IHQEPENQCVNPLQMGESGRILANQISASSTFSDGR-----303
      318 SSWQSVNESGDVYHMSFGQARLDDGFSNASGDSNNHKKPREWLEIDLGKKKITGIRTT 377
      304 -----WTPQDSHLGDGNCWTPMLDSN-----KEYLDVLEFRLTMALATQ 345
      378 G--STQSNFNRYVASTWANKRNNKSKKTYGKLYNNEKRYPGQNSNFRDPYQNNFTPIY 435
      346 GALSRETKNGYVASKYLEVSTNGEDMWYRHKGNH--KIFQANNDATEVYLVKLNKLPIL 403
      436 ARVAVRQPTWRIALAKVELICQITQGNDSIVKRTS--QSTSVSTKCKDEDTTPR 491
      404 TRFTRIPQTMALIALRIELFCGRVYDAPCSNMLQMLGLIADQIISASTREYLMSP 462
  
```

US-08-936-135-14
 ; Sequence 14, Application US/08936135
 ; Patient No. 6054293
 ; GENERAL INFORMATION:
 ; APPLICANT: Tessier-Lavigne, Marc
 ; APPLICANT: He, Zhigang
 ; APPLICANT: Chen, Hang
 ; TITLE OF INVENTION: Semaphorin Receptors
 ; NUMBER OF SEQUENCES: 26
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
 ; STREET: 75 DENISE DRIVE
 ; CITY: HILLSBOROUGH
 ; STATE: CALIFORNIA
 ; COUNTRY: USA
 ; ZIP: 94010
 ; COMPUTER READABLE FORM:
 ; MEDIA TYPE: Floppy disk
 ; OPERATING SYSTEM: IBM PC compatible
 ; SOFTWARE: Patentin Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/936,135
 ; FILING DATE:
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: OSMAN, RICHARD A.
 ; REGISTRATION NUMBER: 36,627
 ; REFERENCE/DOCKET NUMBER: UC97-288-2
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (650) 343-4341
 ; TELEFAX: (650) 343-4342
 ; INFORMATION FOR SEQ ID NO: 14:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 126 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 ; US-08-936-135-14

Query Match 11.38: Score 343.5; DB 3; Length 926;
 Best Local Similarity 23.28; P-adj No. 2.9e-32;
 Matches 111; Conservative 72; Mismatches 177; Indels 119; Gaps 15;

```

      88 CGHLYVTQSGMTSKNRYPGTYPNHTVCERTITVPK-GKRLILRLG-DLDIESQTCASDY 145
      28 CGGRNSKIDAGVITSPGYDPSHONCMIVYAPPNOKIVLNFPHFELEKHDKDYF 87
      146 LRF-----TSSSDYGYPGSNWYPELLNLTSEVYRESGSHISNGEFLTY-----AS 196
      88 IETRGDSADLGRHONT-APPTLISSGSVLYIKFTSDYARQAGSLREIFKIGS 146
      197 SD-----HPRLITC-----LEFASHLYKTEYSKF-----220
      221 -CPACRDVAGDIS--GNWDGYRPTSLCAKAAIHAGIADLGQGLSVLQKGISRY-- 275
      207 DCKYMDLMDIGLTHVHGPLKICGKTPSKLSSGTLSLTPRTDMAVAKDGSAKRYL 266
      276 -----EGILANGVLSRSGSLSDKRFLLTNSGCSNSLSFEPDQGIAS 317
      267 IHQEPENQCVNPLQMGESGRILANQISASSTFSDGR-----303
      318 SSWQSVNESGDVYHMSFGQARLDDGFSNASGDSNNHKKPREWLEIDLGKKKITGIRTT 377
      304 -----WTPQDSHLGDGNCWTPMLDSN-----KEYLDVLEFRLTMALATQ 345
      378 G--STQSNFNRYVASTWANKRNNKSKKTYGKLYNNEKRYPGQNSNFRDPYQNNFTPIY 435
      346 GALSRETKNGYVASKYLEVSTNGEDMWYRHKGNH--KIFQANNDATEVYLVKLNKLPIL 403
  
```

OY 436 ARYVAVPQTHQRIALKEVLCGQITGQNDLSYWRKTS---OSTSVSTKDEETTRP 491
DB 404 TFFRRRQTHWHLGIALRLELPGCRVTDPAPCSNMGLMGLSLADTQISASTREYLMSP 462

RESULT 9
US-08-936-135-16
Sequence 16, Application US/08936135
Patent No. 6054293
GENERAL INFORMATION:
APPLICANT: Tessier-Lavigne, Marc
APPLICANT: He, Zhigang
TITLE OF INVENTION: Semaphorin Receptors
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESS: SCIENCE & TECHNOLOGY LAW GROUP
STREET: 75 DENISE DRIVE
CITY: HILLSBOROUGH
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94010
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/936.135
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: OSMAN, RICHARD A
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: UC97-288-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 343-4341
TELEFAX: (650) 343-4342
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 931 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-936-135-16

Query Match
Best Local Similarity 11.3%; Score 343.5; DB 3; Length 931;
Beat Local Similarity 23.2%; Pred. No. 3e-23; 177; Indels 119; Gaps 15;
Matches 111; Conservative 72; Mismatches 177; Indels 119; Gaps 15;

OY 88 CGHLYVDSGVTGTPYRNHYVCEKTIYVK-GKRLTLRG-DLDESQTSADY 145
DB 28 CGGRPMKADGYTSPGYPDYPSHONCEWYVAEPNOKIYLNPHREIEKHCAYDP 87

OY 146 LCF---TSSSDQVGYCSQMTYVKELLNTSEVYFESGSHISRGFLTY---AS 196
DB 86 IETIDSDSSDLNKRKNGHT-APPTITSSGVLTKFTSDYANQAGSILKTEIYFTGS 146

OY 197 SP-----HPLDITC-----LEBASHTKTEYK- 220
DB 147 EDCSKFTSPNCTIESCPPEKRYPHNLDCPTFLAKRREIILQFTTDLHDHPLOYGGB 206

OY 221 -CPAGCRVANDIS--GNWVDYEDHTSLCKAAIHAGIINADLGQISVLRGRGISRY-- 275
DB 207 DCKIDMLDMGSPHVPGLKGYGKTPKSLSSFTGISLTFPTMAVAADGFSARYVL 266

OY 276 -----EGILANGVLSDGSIKRRFLTFSNGCSLSLFEFDQIRAS 317
DB 267 IHQPPENQCNVPLGMEGRITANEDISASTISDGR----- 303

OY 318 SSKQSVNESGQVHNSKQALDOQCPSSMAGSDSSNNHRRPRLNLEIDGKXKTIQRT 377
DB 304 -----WTPQSRILHDDQNGWPNIDSN-----KEYLDQDLRFULTMALATAO 345

OY 378 G--TQSNFNFYKSFYNNKNNKNNKMKTYGIVNNEKYPFGNSFPDVPONRFPITV 435
DB 346 GAISETQGYVYKSYKLEVSNEEMWYHIGKNH--KTFQANNATEVYLYNKLHMLPL 403

OY 436 ARYVAVPQTHQRIALKEVLCGQITGQNDLSYWRKTS---OSTSVSTKDEETTRP 491
DB 404 TFFRRRQTHWHLGIALRLELPGCRVTDPAPCSNMGLMGLSLADTQISASTREYLMSP 462

RESULT 10
US-08-936-135-6
Sequence 6, Application US/08936135
Patent No. 6054293
GENERAL INFORMATION:
APPLICANT: Tessier-Lavigne, Marc
APPLICANT: He, Zhigang
TITLE OF INVENTION: Semaphorin Receptors
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESS: SCIENCE & TECHNOLOGY LAW GROUP
STREET: 75 DENISE DRIVE
CITY: HILLSBOROUGH
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94010
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/936.135
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: OSMAN, RICHARD A
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: UC97-288-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 343-4341
TELEFAX: (650) 343-4342
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 923 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-936-135-6

Query Match
Best Local Similarity 10.8%; Score 329; DB 3; Length 923;
Beat Local Similarity 24.0%; Pred. No. 6.8e-22;
Matches 113; Conservative 79; Mismatches 161; Indels 118; Gaps 21;

OY 64 RGL-----TALLAVSAPRLQAELEDDCGSHLYVQDSSTMTSKNTPYRNHYVCEK 117
DB 3 KEDPLLCATLALALAGAFR-----SDKCGSLTKTEPGLTSPGTHSHSEKCEW 56

OY 118 TPIYPPG-KRLTLRG-DLDESQTSADYLTSSSDQ---YPGVCSMTYVKRLLN 171
DB 57 LIAQPEPQRIIINPNHDELDKCKYDVYVYIDGBNCGRLMGKFCGRK-ASPYVS 115

OY 172 TSEVYFESGSHISRGFLTYA-----SSDHPDLITC-- 205
DB 116 GPELFTKVSDEYTHGAGFSIREIKRKGESQSYATPQVTKSGPPEKYPMCEYCY 175

OY 206 -----LEBASHTKTEYKFCAG--CNDVAGDISGNWVDGYRQTSILCKAAIH 252

DB 176 IIPARKSEITIEFSEFDKDSNP--FGQMFCTHRELT--WDSPTE-----YQPH 223
 OY 253 AG-11ABELGROI-----SVLOKKSIRREGLANCVLSRDSLSLDRFLF 297
 DB 224 IGHYCGKPKPGKIRSSQVLSWVFYTSALAEKGFANYSVLOSSI--SEDFE----- 274
 OY 298 TSNCCSRLSEFPF---PQGIIRASSWQSVNESGDVHMSPGQARLDQGPMSASGSSN 353
 DB 275 ---OMELGAMESOEIHSDDITASSQGT-----NMSVERSLKNTPEKMTGDSY 322
 OY 354 NNKPREMLEITDGEKKKITGIRTTG--STQSNFNFYASFPVNFKNNSKTKYGIYVNE 411
 DB 323 ---KEMIQYDGLIFRFTYAVGTGQALSKETKKKYVVKRYRNVISSNGEDMWSLK--RGN 376
 OY 412 EKVFGQSNFNDPQONNFIPIYAVRYVQTMHQRALAKVELIGCOIT 462
 DB 377 KALIFQONTNPTDVLGVKSPKLTIRREVIRKINSMENIGIRREVYCGCKIT 427

RESULT 11
 US-07-607-538C-4
 : Sequence 4, Application US/07607538C
 : Patent No. 5455031
 : GENERAL INFORMATION:
 : APPLICANT: Ceriant Dr., Roberto L.
 : APPLICANT: LAROCCA, PETERSON, JERRY A.
 : APPLICANT: INVENTION: DIFFERENTIATION ANTIGEN BINDING SPECIFICITY AND CLOTTING
 : TITLE OF INVENTION: FACTORS V AND VIII LIGHT-CHAIN HOMOLOGIES,
 : TITLE OF INVENTION: POLYPEPTIDE ANTIBODIES, KITS AND METHODS OF
 : TITLE OF INVENTION: POLYPEPTIDE ANTIBODIES, KITS AND METHODS OF
 : NUMBER OF SEQUENCES: 5
 : ADDRESS: 2055 No. 5455031th Broadway
 : CITY: Walnut Creek
 : STATE: California
 : COUNTRY: USA
 : ZIP: 94596
 : COMPUTER READABLE FORM:
 : MEDIUM TYPE: Floppy disk
 : OPERATING SYSTEM: IBM compatible
 : SOFTWARE: PASTISO for Windows Version 2.0
 : CURRENT APPLICATION DATA:
 : FILING DATE: 01-NOV-1990
 : APPLICATION NUMBER: US/07/607,538C
 : CLASSIFICATION: 435
 : ATTORNEY/AGENT INFORMATION:
 : NAME: Viviana Amzel
 : REGISTRATION NUMBER: 30,930
 : TELEPHONE: (510) 943-1189
 : TELEFAX: (510) 943-1189
 : INFORMATION FOR SEQ ID NO: 4:
 : SEQUENCE CHARACTERISTICS:
 : LENGTH: 218 amino acids
 : TYPE: amino acid
 : STRANDEDNESS: unknown
 : TOPOLOGY: linear
 : MOLECULE TYPE: protein
 : FRAGMENT TYPE:
 : US-07-607-538C-4

Query Match 10.5% Score 321, DB 1, Length 218;
 Best Local Similarity 42.6% Pred. No. 3, 5e-22;

Matches 72: Conservative 30; Mismatches 51; Indels 16; Gaps 5;
 OY 300 NCCSRLSEFPF---PQGIIRASSWQSVNESGDVHMSPGQARLDQGPMSASGSSN 352
 DB 58 NCCSTPLGEMNGKIRNKQITASSFEKSKMW---GD--YWEPRFARLANQGVNMAQAKA 110
 OY 353 NNKPREMLEITDGEKKKITGIRTTG--STQSNFNFYASFPVNFKNNSKTKYGIYVNE 412
 DB 111 NNK--OMELIDELKTKITALLITGQKSLSEMYVYTIHYSQGVYKMRFLKSSNV 168
 OY 413 EKVFGQSNFNDPQONNFIPIYAVRYVQTMHQRALAKVELIGCOI 461
 DB 169 DKIFGSNTNTGKHKNFNPISIRFIRVIRKTNOSIALRELFQCDI 217

RESULT 12
 US-08-162-402B-4
 : Sequence 4, Application US/08162402B
 : Patent No. 5972337
 : GENERAL INFORMATION:
 : APPLICANT: CERTANT, ROBERTO L.
 : APPLICANT: PETERSON, JERRY A.
 : APPLICANT: LAROCCA, DAVID J.
 : TITLE OF INVENTION: 46 KDALTON HUMAN MILK FAT
 : TITLE OF INVENTION: GLOBULE (HMF) ANTIGEN, FRAGMENTS & FUSION PROTEIN
 : NUMBER OF SEQUENCES: 29
 : ADDRESS: "Pretty" Schroeder & Poplawski
 : STREET: 444 South Flower St., 19th Floor
 : CITY: Los Angeles
 : STATE: CA
 : COUNTRY: USA
 : ZIP: 90071
 : COMPUTER READABLE FORM:
 : MEDIUM TYPE: 3.5" Diskette
 : OPERATING SYSTEM: IBM compatible
 : SOFTWARE: PASTISO for Windows Version 2.0
 : CURRENT APPLICATION DATA:
 : APPLICATION NUMBER: US/08/162,402B
 : FILING DATE: 03-DEC-1993
 : CLASSIFICATION: 435
 : ATTORNEY/AGENT INFORMATION:
 : NAME: Amzel, Viviana
 : REGISTRATION NUMBER: 30,930
 : TELEPHONE: 213-622-7700
 : TELEFAX: 213-689-4210
 : INFORMATION FOR SEQ ID NO: 4:
 : SEQUENCE CHARACTERISTICS:
 : LENGTH: 218 amino acids
 : TYPE: amino acid
 : STRANDEDNESS: unknown
 : TOPOLOGY: unknown
 : MOLECULE TYPE: peptide
 : US-08-162-402B-4

Query Match 10.5% Score 321, DB 2, Length 218;
 Best Local Similarity 42.6% Pred. No. 3, 5e-22;
 Matches 72: Conservative 30; Mismatches 51; Indels 16; Gaps 5;
 OY 300 NCCSRLSEFPF---PQGIIRASSWQSVNESGDVHMSPGQARLDQGPMSASGSSN 352
 DB 58 NCCSTPLGEMNGKIRNKQITASSFEKSKMW---GD--YWEPRFARLANQGVNMAQAKA 110
 OY 353 NNKPREMLEITDGEKKKITGIRTTG--STQSNFNFYASFPVNFKNNSKTKYGIYVNE 412

Db 111 NNK--OMLEIDLKIKITAIITOGCKSLSEMYKSTIHKSPGVEMKPYRLKSSMY 168
QY 413 EKVQGSNFPDQVONNFPPIYARVYVPOFMHRIALAKVELICOI 461
Db 169 DKIFGNSNTRKGHNKFNFPPIISRFIRIVIKTMOSIALRLFLFCOI 217

RESULT 13
US-08-746-111-5
Sequence 5, Application US/08746111
Patent No. 6066778
GENERAL INFORMATION:
APPLICANT: Ginsburg, David
APPLICANT: Cui, Jisong
TITLE OF INVENTION: Compositions And Methods For Screening
TITLE OF INVENTION: Compounds For Anticogulant Activity
NUMBER OF SEQUENCES: 54
CORRESPONDENCE ADDRESS:
ADDRESSEE: Medlen & Carroll, LLP
STREET: 220 Montgomery Street, Suite 2200
CITY: San Francisco
STATE: California
COUNTRY: United States of America
ZIP: 94102
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/746,111
FILING DATE: 06-NOV-1996
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Ingolia, Diane E.
REGISTRATION NUMBER: 40,027
REFERENCE/DOCKET NUMBER: UM-02536
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 357-8338
TELEFAX: (415) 357-8338
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 2183 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-746-111-5

Query Match 10.48; Score 318; DB 3; Length 2183;
Best Local Similarity 40.88; Pred No. 3, 1e-21;
Matches 69; Conservative 31; Mismatches 53; Indels 16; Gaps 5;

QY 300 NCGRSLSFE---PDGQIRASS---SMQSVNESGDVHMSFGQARLDGQPSMASGDS 352
Db 2023 NCGSRFTLEDRIDQKQITVSSKFSKSW-----GD--YMEPSLARLMAQGRVNAOMAKA 2075
QY 353 NHHPREMLEIDGERRKITGRTGTSQSNFNFYVSPVNNKNNNSKMTYKGIYNNE 412
Db 2076 NNK--OMLOVDLRIKIKYTAIVTGCKSLSEMYKSTIHKSPGVEMKPYRLKSSMY 2133

QY 413 EKVQGSNFPDQVONNFPPIYARVYVPOFMHRIALAKVELICOI 461
Db 2134 DKIFGNSNTRKGHNKFNFPPIISRFIRIVIKTMOSIALRLFLFCOI 2182

RESULT 14
US-08-162-402B-14
Sequence 14, Application US/08162402B
Patent No. 5972337
GENERAL INFORMATION:
APPLICANT: CERIANI, ROBERTO L.
APPLICANT: PETERSON, JERRY A.

APPLICANT: LARROCA, DAVID J.
TITLE OF INVENTION: 46 KIDULTON HUMAN MILK FAT
TITLE OF INVENTION: MOLECULE (HMF) ANTIGEN, FRAGMENTS & FUSION PROTEIN
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pretty, Schroeder & Poplawski
STREET: 444 South Flower St., 19th Floor
CITY: Los Angeles
STATE: CA
COUNTRY: USA
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTED for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/162,402B
FILING DATE: 03-DEC-1993
CLASSIFICATION: 415
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: P66 38215
TELECOMMUNICATION INFORMATION:
TELEPHONE: 213-632-7700
TELEFAX: 213-489-4210
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 160 amino acids
TYPE: amino acid
TOPOLOGY: unknown
MOLECULE TYPE: peptide
US-08-162-402B-14

Query Match 10.28; Score 311; DB 2; Length 160;
Best Local Similarity 41.78; Pred. No. 1, 8e-21;
Matches 70; Conservative 30; Mismatches 52; Indels 16; Gaps 5;

QY 301 NCGRSLSFE---PDGQIRASS---SMQSVNESGDVHMSFGQARLDGQPSMASGDS 353
Db 1 GCSPTLGHENKIKNKQITVSSKFSKSW-----GD--YMEPSLARLMAQGRVNAOMAKAN 53

QY 354 NHHPREMLEIDGERRKITGRTGTSQSNFNFYVSPVNNKNNNSKMTYKGIYNNE 413
Db 54 NNK--OMLEIDLKIKITAIITOGCKSLSEMYKSTIHKSPGVEMKPYRLKSSMYD 111

QY 414 KTVQGSNFPDQVONNFPPIYARVYVPOFMHRIALAKVELICOI 461
Db 113 KIFGNSNTRKGHNKFNFPPIISRFIRIVIKTMOSIALRLFLFCOI 159

RESULT 15
US-09-324-867-2
Sequence 2, Application US/09324867A
Patent No. 6251332
GENERAL INFORMATION:
APPLICANT: Lillietrap, David
APPLICANT: Cameron, Charlie
APPLICANT: Hough, Christine
APPLICANT: Horrocks, L. Suzanne Hoyle
TITLE OF INVENTION: Canine Factor VIII Gene, Protein and Methods of Use
TITLE REFERENCE: 1969 0010002/246/BD
CURRENT PILING DATE: 09/09/324,867A
EARLIER APPLICATION NUMBER: 09/035,141

.. Tue Jul 9 08:27:36 2002

```

1  EARLIER FILING DATE: 1998-03-059
2  EARLIER APPLICATION NUMBER: 60/039,955
3  EARLIER FILING DATE: 1997-03-06
4  NUMBER OF SEQ ID NOS: 63
5  SOFTWARE: PatentIn Ver. 2.0
6  SEQ ID NO: 2
7  LENGTH: 2343
8  TYPE: PRT
9  ORGANISM: Canis familiaris
10 OS-09-324-867-2

```

Query Match	Best Local Similarity	10.0%	Score 306.5	Seq 4	Length 2343
Beat Match	10.5%	Pred. No. 4.2e-19			
Matches	69	Conservative	26	Mismatches	61
				Indels	13
				Gaps	4
QY	300	NCOSRSLSTFE---	PDQQLBASSWSQSVNSESQGVYNSPQALQDQGFSSMASSDSSNNH	355	
Db	2183	NCOSMLCHSKAKSIADQMLSTSLSSLSMLA---	MSQSRALQDQGTANRPOAHN-	2236	
QY	356	KRPENLEIDLGGEKKTKITPTTSGQSQSNPNFYVQVKNKNSAKYTKGSGVINDXKY	415		
Db	2237	-KRPENLDVDFKTKMFLVGLITQGVKSLISUYKKEFLISSODDHNHPLF-	LQNGKAYK	2293	
QY	416	FGQSNFNDPQVNNHNEIPRIYARVYVVUTQNRGKATLAKVELLGGSLTQ	463		
Db	2294	FGQGRDSSSTPVNRRLEPRPLAAVYVLLDQSMANIALRLFVGLDSTQ	3241		

Search completed: July 9, 2002, 02:15:21
Job time: 3788 sec



GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 8, 2002, 23:36:58 : Search time 296.45 seconds

10198.976 million cell updates/sec

Title: US-09-691-344a-3

Sequence: 1 atggagctgctgctgctgctgca.....caagtgatagctgctgctgtaa 1761

Scoring table: IDENTITY.MTC

Gapop 10.0, Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 08

Listing first 45 summaries

Database :

N.GeneSeq_032802:*

1: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1980.DAT:*

2: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1981.DAT:*

3: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1982.DAT:*

4: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1983.DAT:*

5: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1984.DAT:*

6: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1985.DAT:*

7: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1986.DAT:*

8: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1987.DAT:*

9: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1988.DAT:*

10: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1989.DAT:*

11: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1990.DAT:*

12: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1991.DAT:*

13: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1992.DAT:*

14: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1993.DAT:*

15: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1994.DAT:*

16: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1995.DAT:*

17: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1996.DAT:*

18: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1997.DAT:*

19: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1998.DAT:*

20: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1999.DAT:*

21: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA2000.DAT:*

22: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA2001A.DAT:*

23: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA2001B.DAT:*

24: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1761	100.0	1761	22	AA500614 Novel human protei
2	1686.8	95.8	1686	22	AA500660 Human TANGO 229 cp
3	1630	92.0	1630	22	AA500615 Novel human protei
4	1532	86.4	1768	22	AA500613 Novel human protei
5	539.2	30.6	1871	21	AA506735 Polynucleotide iso
6	221.8	12.6	2428	22	AA524455 Human colon cancer
7	219.4	12.5	407	20	AA587469 EST Clone BP481
8	205.6	11.7	2046	21	AA531872 Human Factor 8 Hom
9	127.2	7.2	232	22	AA536736 Human colon cancer

10	94.4	5.4	6893	20	AA523182 Human coagulation
11	92.8	5.3	6909	16	AA503920 Human Factor V w11
12	92.8	5.3	6909	21	AA504448 Human Factor V cDN
13	92.8	5.3	6909	21	AA523631 Human Vth aggregat
14	92.8	5.3	6909	22	AA507368 Human DNA encoding
15	92.8	5.3	6925	17	AA531948 Human Factor V mut
16	91.6	5.3	6925	17	AA531948 Human Factor V mut
17	91.6	5.3	6925	17	AA531948 Human Factor V mut
18	81.6	4.6	7032	22	AA525579 Canine Factor VIII
19	81.6	4.6	7032	22	AA525579 Canine Factor VIII
20	80.6	4.6	6585	21	AA560446 Plasmid D27 encod
21	80.6	4.6	6585	21	AA560446 Plasmid D27 encod
22	80	4.5	10698	22	AA5218172 Human Factor VIII
23	78.4	4.5	480	19	AA540051 Human Factor VIII
24	78.4	4.5	4272	9	AA580447 Modified factor VI
25	78.4	4.5	4272	9	AA580447 Modified factor VI
26	78.4	4.5	4272	9	AA580447 Modified factor VI
27	78.4	4.5	4545	9	AA580447 Modified factor VI
28	78.4	4.5	4616	9	AA581545 Human Factor VIII
29	78.4	4.5	4629	20	AA582036 B-domain in deleted
30	78.4	4.5	4629	20	AA582036 Human Factor VIII
31	78.4	4.5	4670	19	AA523339 Human Factor VIII
32	78.4	4.5	4830	9	AA581544 Human Factor VIII
33	78.4	4.5	4832	19	AA515581 Human Factor VIII
34	78.4	4.5	4832	19	AA515581 Human Factor VIII
35	78.4	4.5	4899	21	AA508613 Human factor VIII
36	78.4	4.5	5035	18	AA509831 Human factor VIII
37	78.4	4.5	5094	21	AA549231 DNA construct H50/
38	78.4	4.5	5094	21	AA549231 Human mature wild-
39	78.4	4.5	6996	22	AA518121 Factor VIII C codi
40	78.4	4.5	7053	18	AA513577 Sequence of human
41	78.4	4.5	7056	15	AA506615 Human Factor VIII-
42	78.4	4.5	7059	9	AA581543 Sequence encoding
43	78.4	4.5	7440	7	AA505897 Factor VIII CDM 1
44	78.4	4.5	7440	7	AA505897 Factor VIII CDM 1
45	78.4	4.5	8241	9	AA581539

ALIGNMENTS

RESULT 1	AA500614	Standard; CDM: 1761 BP.
XX	AA500614	
AC	AA500614	
XX	29-AUG-2001	(first entry)
XX	Novel human protein (NRP) DNA sequence #2.	
XX	Novel human protein; NRP: CUB domain; extracellular domain; gene therapy;	
XX	Obesity; High blood pressure; connective tissue disorder; infertility;	
XX	NRP-mediated pathway; ss.	
XX	Homo sapiens.	
CS	Key	Location/Qualifiers
XX	Key	1..1761
XX	CD5	/product="Novel human protein #2"
XX	W0200129219-A1.	
XX	26-APR-2001.	
XX	08-OCT-2000; 2000MO-US28798.	
XX	19-OCT-1999; 99US-0160285.	
XX	18-FEB-2000; 2000US-0183583.	
XX	(LEXI-) LEXICON GENETICS INC.	

P1 Donoho G, Turner CA, Nehls M, Friedrich G, Zambrowicz B, Sands AT;
 XX WPI: 2001-280917/30.
 DR P-PSDB: AA000629.
 PM Novel nucleic acid encoding human CUB-domain containing protein, useful
 PF for drug screening, diagnosis and treatment of physiological disorders
 PF or diseases
 XX
 XX Claim 1: Page 27, 33pp: English.
 CC The sequence represents a polynucleotide which encodes a novel human
 CC protein (NHP) containing a CUB domain (an extracellular domain). CUB
 CC proteins have been associated with regulating development, modulating
 CC protein processes and preventing infectious disease. NHP nucleotide
 CC sequence encodes a novel protein (NHP) which is useful for the treatment
 CC of disease. NHP oligonucleotides (decoy) physiological disorders or
 CC screening libraries and assessing gene patterns. NHP nucleotide codes
 CC are useful for detecting mutant or inappropriately expressed NHPs (for
 CC example, those proteins associated with obesity, high blood pressure,
 CC connective tissue disorders and infertility) for the diagnosis of a
 CC disease. The polynucleotides may also be used in screening for drugs
 CC effective in the treatment of symptomatic or phenotypic manifestations of
 CC a disease. The polynucleotides may be used to genetically engineer host cells to
 CC produce such products. The NHP polynucleotides may also be used for the
 CC identification of compounds that bind to NHP receptors or trigger
 CC NHP-mediated pathways.
 CC
 CC Sequence 1761 BP: 471 A; 402 C; 483 G; 405 T; 0 other:
 S0
 Query Match 100.0%; Score 1761; DB 22; Length 1761;
 Best Local Similarity 100.0%; P-Value 0;
 Matches 1761; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 541 agtggatcccaattcttcggccggggttttttcgtgacctatgagcagagacatcca 600
 Oy |||||||
 Db 601 gatttaataacagtttggaaacagagctaacatctcttggaaacagaaataacagcaatc 660
 Oy |||||||
 Db 601 gatttaataacagtttggaaacagagctaacatctcttggaaacagaaataacagcaatc 660
 Oy |||||||
 Db 661 taccagacttggttgaagacgttgaagagacatctctggaaatattgtatagatggat 720
 Oy |||||||
 Db 661 taccagacttggttgaagacgttgaagagacatctctggaaatattgtatagatggat 720
 Oy |||||||
 Db 721 aagaaatctcttttttcttgaacagctgcacatctctgtgaagaaatattgtatagat 780
 Oy |||||||
 Db 721 aagaaatctcttttttcttgaacagctgcacatctctgtgaagaaatattgtatagat 780
 Oy |||||||
 Db 781 gttgtgcagatcagtgatgcttcaacgcaaaagggatcagctgatgtgaagggattctg 840
 Oy |||||||
 Db 781 gttgtgcagatcagtgatgcttcaacgcaaaagggatcagctgatgtgaagggattctg 840
 Oy |||||||
 Db 841 aatgtagtcttttcaggagatggtcttcctgcagcaagaagggattctgtttaccat 900
 Oy |||||||
 Db 841 aatgtagtcttttcaggagatggtcttcctgcagcaagaagggattctgtttaccat 900
 Oy |||||||
 Db 901 gttgtgcagatcagcttgatgttgaacgtgaagggcaaatcaagctctctccatg 960
 Oy |||||||
 Db 901 gttgtgcagatcagcttgatgttgaacgtgaagggcaaatcaagctctctccatg 960
 Oy |||||||
 Db 961 cagtcgcatatgagatgtggagcaaatcttactgtctcctgcagcaagcagattgag 1020
 Oy |||||||
 Db 961 cagtcgcatatgagatgtggagcaaatcttactgtctcctgcagcaagcagattgag 1020
 Oy |||||||
 Db 1021 gaccagagcccatcaltgagcttcggcgagacagtacgaaacaacaacacagagatg 1080
 Oy |||||||
 Db 1021 gaccagagcccatcaltgagcttcggcgagacagtacgaaacaacaacacagagatg 1080
 Oy |||||||
 Db 1081 ctgaaacatcagcttttgggggagaaagaaatataacagaaattagagccacagatcata 1140
 Oy |||||||
 Db 1081 ctgaaacatcagcttttgggggagaaagaaatataacagaaattagagccacagatcata 1140
 Oy |||||||
 Db 1141 cagtcgcaacttcaactttatgttaagagtttggatgtgaacttcaaaaataaattct 1200
 Oy |||||||
 Db 1141 cagtcgcaacttcaactttatgttaagagtttggatgtgaacttcaaaaataaattct 1200
 Oy |||||||
 Db 1201 aagtgagagacataaagaaatattgtgataaagaaagaggtttctcaggatcact 1260
 Oy |||||||
 Db 1201 aagtgagagacataaagaaatattgtgataaagaaagaggtttctcaggatcact 1260
 Oy |||||||
 Db 1261 aacttctcgagaccagtcgaaacaataattcaatccctccatcagtcgacataatg 1320
 Oy |||||||
 Db 1261 aacttctcgagaccagtcgaaacaataattcaatccctccatcagtcgacataatg 1320
 Oy |||||||
 Db 1321 gttctccccaagacatgagcaccagagatctgagcttgaaggttgagagctcattgtgtccag 1380
 Oy |||||||
 Db 1321 gttctccccaagacatgagcaccagagatctgagcttgaaggttgagagctcattgtgtccag 1380
 Oy |||||||
 Db 1381 atctcccaaggtatgatcatctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 1440
 Oy |||||||
 Db 1381 atctcccaaggtatgatcatctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 1440
 Oy |||||||
 Db 1441 actaaagaagagatgtgacataatcaaaagcccatcctctcgaaagaatacatccacagga 1500
 Oy |||||||
 Db 1441 actaaagaagagatgtgacataatcaaaagcccatcctctcgaaagaatacatccacagga 1500
 Oy |||||||
 Db 1501 ataaacattcaagagtggtctatccatttggtctgtgtgtgtgtgtgtgtgtgtgtgtgt 1560
 Oy |||||||
 Db 1501 ataaacattcaagagtggtctatccatttggtctgtgtgtgtgtgtgtgtgtgtgtgtgt 1560
 Oy |||||||
 Db 1561 atgggagacttttgcagcctttgaagaagaaagaaagaaagaaagaaagaaagaaagaa 1620
 Oy |||||||
 Db 1561 atgggagacttttgcagcctttgaagaagaaagaaagaaagaaagaaagaaagaaagaa 1620
 Oy |||||||
 Db 1621 aagtgagacataatctgtcttgaagcagataataatccctctgcacagataatcagata 1680
 Oy |||||||

Db	841	gattctcttgagcttcttgaaacccgagccggaatccaaatgactcttcttcacgtgagacgtgtca	900
Oy	971	atgagagctgagagatccagatctccacgctgctctctgagccagccgctcttaagagcaagcc	1030
Db	901	attgagatgtagagacacagctctacactctgctctctctgccaagcccgactcttagcgcaagcc	960
Oy	1031	catcatggtgctctcgccgcacagtagcagcaacacacacacacacacagaaatgctgagacatcg	1090
Db	961	catcatggtgctctcgccgcacagtagcagcaacacacacacacacacacagtagctgagacatcg	1020
Oy	1091	atttgagggggaaaaaagaataacagatagacagatcttaggcacacagatctcaacagtcgaact	1150
Db	1021	atttgagggggaaaaaagaataacagatagacagatcttaggcacacagatctcaacagtcgaact	1080
Oy	1151	tcaactcttagcttaagagcgtcttgtagtgactctcaaaacacatctcaagtgagaaaga	1210
Db	1081	tcaactcttagcttaagagcgtcttgtagtgactctcaaaacacatctcaagtgagagaaaga	1140
Oy	1211	acttatagagatctggaataatgagaagaagctgctcagatgtaactctaaactccagg	1270
Db	1141	acttatagagatctggaataatgagaagaagctgctcagatgtaactctaaactccagg	1200
Oy	1271	accacagtgcaaaacaaatctcaatccctccatcgtgagcagatctgctgagctgctcccc	1330
Db	1201	accacagtgcaaaacaaatctcaatccctccatcgtgagcagatctgctgagctgctcccc	1260
Oy	1331	agacatcgccacagagct	1390
Db	1261	agacatcgccacagagct	1320
Oy	1361	gtaatgactctcatctgtagtgagcgcgaagacagatcaaacagccacagctgtcttaataagaag	1450
Db	1321	gtaatgactctcatctgtagtgagcgcgaagacagatcaaacagccacagctgtcttaataagaag	1380
Oy	1451	agatattgagccatctcagagccatccctccgagagaaacatctccagatcttaacaaagta	1510
Db	1381	agatattgagccatctcagagccatccctccgagagaaacatctccagatcttaacaaagta	1440
Oy	1511	caacagtgactctcatctgtagtgact	1570
Db	1441	caacagtgactctcatctgtagtgact	1500
Oy	1571	cttagccctcttgaataaagaataagaggaagaatctcgtatgatacggcgagagcttga	1630
Db	1501	cttagccctcttgaataaagaataagaggaagaatctcgtatgatacgaagagagcttga	1560
Oy	1631	aaacagagcgtcttggaagcagctcttaaatatccctcttccagagcctcaagccagctagttta	1690
Db	1561	aaacagagcgtcttggaagcagctcttaaatatccctcttccagagcctcaagccagctagttta	1620
Oy	1691	cccttcacatctgataatctagaagagagctgacacaaagcttgatctctcaacaagtgata	1750
Db	1621	cccttcacatctgataatctagaagagagctgacacaaagcttgatctctcaacaagtgata	1680
Oy	1751	tggcagagttta 1760	
Db	1681	tggcagagttta 1690	

RESULT 3

AAAS00615

AAAS00615 standard; cDNA; 1620 BP.

29-AUG-2001 (first entry)

Novel human protein (NHP) DNA sequence #3.

Novel human protein: NHP; CUB domain; extracellular domain; gene therapy; obesity; high blood pressure; connective tissue disorder; infertility; NHP-mediated pathway; ss.

[illegible]

Db	241	atccgaggtctggagaaatttgatctctgaaccccaagccgtgtcttcctgacatcttc	300
Oy	442	ttcacacgcctcttcacataatgatctgctacatctcgtggaaatctgactgtcccaaga	501
Db	301	cttcacacgcctcttcacataatgatctgctacatctcgtggaaatctgactgtcccaaga	361
Oy	502	ctctcttgaaacaaatctgaagaaacgcttcgcctcttgagagtgatctccacattctgc	561
Db	361	ctctcttgaaacaaatctgaagaaacgcttcgcctcttgagagtgatctccacattctgc	420
Oy	562	cggaggtcttttgcgacactgaagcagcgacgacacagatttaacatgatttgga	621
Db	421	cggaggtcttttgcgacactgaagcagcgacgacacagatttaacatgatttgga	480
Oy	622	cgaactcagcatctcttgaaagcagaaataacagaaattctgcgccgctggtctgaaagc	681
Db	481	cgaactcagcatctcttgaaagcagaaataacagaaattctgcgccgctggtctgaaagc	340
Oy	682	gtgagcagaggaacattcttggaatctgtgataatgtgataatgaaactctttgtgc	741
Db	541	gtgagcagaggaacattcttggaatctgtgataatgtgataatgaaactctttgtgc	600
Oy	742	aaagctccacatctgcagagaaataatgctgcgtgaacactagctgtgcacatcagctgc	801
Db	601	aaagctccacatctgcagagaaataatgctgcgtgaacactagctgtgcacatcagctgc	660
Oy	802	cagcgcaagaggaatctcagctgaatgaagaggaattctcgcccaatgtgtctcttcagaggat	861
Db	661	cagcgcaagaggaatctcagctgaatgaagaggaattctcgcccaatgtgtctcttcagaggat	720
Oy	862	ggtctccctctcagacaaacagattctctgttctacccataatgtgtccacattcttgagct	921
Db	721	ggtctccctctcagacaaacagattctctgttctacccataatgtgtccacattcttgagct	780
Oy	922	cttgaacactgagagcaatcagaagactctctctccatctgacagctcgtgcatactgaagctga	981
Db	781	cttgaacactgagagcaatcagaagactctctctccatctgacagctcgtgcatactgaagctga	840
Oy	982	gacacaaattctcgtctctctcgtcccaagcagcaattccagaaacgaagcccatctaac	1041
Db	841	gacacaaattctcgtctctctcgtcccaagcagcaattccagaaacgaagcccatctaac	900
Oy	1042	tcggcgcaagactcagcaacaaacacaaacaaacgaagctgtcgtgaatctcaattctggggag	1101
Db	901	tcggcgcaagactcagcaacaaacacaaacaaacgaagctgtcgtgaatctcaattctggggag	960
Oy	1102	aaagaagaataaagagaattcttgagccacaaagatctacacagctcgaactcaattctaac	1161
Db	961	aaagaagaataaagagaattcttgagccacaaagatctacacagctcgaactcaattctaac	1020
Oy	1162	gttcaagagcttctgtgtgaactcaaaaacaaataaatttaagtgaagaccttaaaagag	1221
Db	1021	gttcaagagcttctgtgtgaactcaaaaacaaataaatttaagtgaagaccttaaaagag	1080
Oy	1222	attctgtgaataatgaagaagaagctgtcttcaggcttaactctgaactcttgcggagccagtgaa	1281
Db	1081	attctgtgaataatgaagaagaagctgtcttcaggcttaactctgaactcttgcggagccagtgaa	1140
Oy	1282	aacaaattcaacccctccacgtctgagcagatactgagtgagggtgtgtccccaagacatgagac	1341
Db	1141	aacaaattcaacccctccacgtctgagcagatactgagtgagggtgtgtccccaagacatgagac	1200
Oy	1342	cagagcagtagactcttcaagctggagactctatctgtctgcagagctacacaaagtaattgtcca	1401
Db	1201	cagagcagtagactcttcaagctggagactctatctgtctgcagagctacacaaagtaattgtcca	1260
Oy	1402	tctgt	1461
Db	1261	tctgt	1320
Oy	1462	atccacaaagcccatctccctctcggagagaaataacacacagaaataaactctacaagctgtgac	1521
Db	1321	atccacaaagcccatctccctctcggagagaaataacacacagaaataaactctacaagctgtgac	1380

Dy	1582	atcccttggcgtgccttcctttgctcccggtgttcttcgttgaaatcgggaacatttgcagocctt	1581
Oy	1583	alccaatcgtggcctcccttgatccgatccggtgttcttgagaacttgggaacctttgcagocctt	1440
Oy	1584	aaaaaagaagaagaagaagaagaagatccgtatccgatccgacgccaccaaaagcagcgcgc	1641
Dd	1441	agaagaaggagaagaagaagaagatccgtatccgatccgacgccaccaaaagcagcgcgc	1500
Oy	1642	tggagaagcatataatctccctttgcgcgcacatcaatgcagctgaatttaccatcacat	1701
Dd	1501	tggagaagcatataatctccctttgcgcgcacatcaatgcagctgaatttaccatcacat	1560
Oy	1702	gttatgagaagaaggatccgcacaaaagtctgattctcatccacagtgatttggcaggttaa	1761
Dd	1561	gatatgagaagaaggatccgcacaaaagtctgattctcatccacagtgatttggcaggttaa	1620
 RESULT 4 AAS00613 standard; DNA: 1768 BP.			
ID	AAS00613		
XX	AAS00613;		
XX			
XX	29-AUG-2001 (first entry)		
DE	Novel human protein (NHP) DNA sequence #1.		
KM	Novel human protein; NHP; CUB domain; extracellular domain; gene therapy		
RW	obesity; high blood pressure; connective tissue disorder; infertility;		
CS	NHP-mediated pathway; ds.		
OS	Homo sapiens.		
FH	Key	Location/Qualifiers	
FT	CDS	59..1522	/'tag= a
FT			/product= "Novel human protein #1"
XX	WO200129219-A1.		
PX	26-APR-2001.		
PE	08-OCT-2000; 2000MO-US28798.		
PX	19-OCT-1999; 99US-0160285.		
PX	18-FEB-2000; 2000US-0183593.		
PX	(LEXI-) LEXICON GENETICS INC.		
PA	Donoho G, Turner CA, Nehls W, Friedrich G, Zambrowicz B, Sands AT;		
DR	MP1: 2001-290917/30.		
DR	P-PADB; AAU00628.		
XX			
PT	Novel nucleic acid encoding human CUB-domain containing protein, useful		
PT	for drug screening, diagnosis and treatment of physiological disorders		
PT	or diseases -		
PS			
PS	Disclosure: Page 30-31; 33pp: English.		
CC			
CC	The sequence represents a polynucleotide which encodes a novel human		
CC	protein (NHP) containing a CUB domain (an extracellular domain). CUB		
CC	proteins have been associated with regulating development, modulating		
CC	cellular processes and preventing infectious disease. NHP nucleotide		
CC	sequences are useful for gene therapy of physiological disorders or		
CC	diseases. NHP oligonucleotides are useful as hybridisation probes for		
CC	diagnosis and assessing gene patterns. NHP nucleotide sequences		
CC	are useful for detecting and identifying abnormally expressed NHPs (for		
CC	example, those proteins associated with osteoporosis).		
CC	connective tissue disorders and infertility) for the diagnosis of a		
CC	disease. The polynucleotides may also be used in screening for drugs		
CC	effective in the treatment of symptomatic or phenotypic manifestations of		

CC perturbing the normal function of NRP in the body. Nucleotide constructs
CC encoding NRP products are provided and methods are described to allow for the
CC identification of compounds that bind to NRP receptors or trigger
CC NRP-mediated pathways.
CC

SQ Sequence 1768 BP; 539 A; 370 C; 421 G; 438 T; 0 other;

Query Match 86.4%; Score 1532; DB 22; Length 1768;
Best Local Similarity 100.0%; Prod NO 0;
Matches 1522; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 240 ggcggagagacgtggtgagtcgctgcgcgcacccacgaactatcaagtcagtcgacacat 299
DB 1 ggcggagagacgtggtgagtcgctgcgcgcacccacgaactatcaagtcagtcgacacat 60
QY 300 gacattagaattatccggagacccacgaactatcaagtcagtcgacacat 359
DB 61 gacattagaattatccggagacccacgaactatcaagtcagtcgacacat 120
QY 360 agtcccaagaaggagaaagacgtatctcaggtctggagagatcttggaatcagacacccagac 419
DB 121 agtcccaagaaggagaaagacgtatctcaggtctggagagatcttggaatcagacacccagac 180
QY 420 ctgtgtctcgcagatctctctctccacagctcttcagatcattatggtccaaatctgg 479
DB 181 ctgtgtctcgcagatctctctctccacagctcttcagatcattatggtccaaatctgg 240
QY 480 aagatcagacgtctccccaagaagacactctgtgaacacaaagagaaagaaacgtccgtctga 539
DB 241 aagatcagacgtctccccaagaagacactctgtgaacacaaagagaaagaaacgtccgtctga 300
QY 540 gaatgcagatcccaatcttcgcgcgggtcttctgtgaactatgacgaagagaaagaaacac 599
DB 301 gaatgcagatcccaatcttcgcgcgggtcttctgtgaactatgacgaagagaaagaaacac 360
QY 600 agatcttaataacatcttctggagacagacacagacatcttctgaagacagaaacacacacac 659
DB 361 agatcttaataacatcttctggagacagacacagacatcttctgaagacagaaacacacacac 420
QY 660 ctgcacacagctggtctgagagacgtgagacagagacatcttcggagatactgtcagatcgata 719
DB 421 ctgcacacagctggtctgagagacgtgagacagagacatcttcggagatactgtcagatcgata 480
QY 720 tagagataacctcttatgtgcaaacgtctgcacacacagagagataattgtctgaagac 779
DB 481 tagagataacctcttatgtgcaaacgtctgcacacacagagagataattgtctgaagac 540
QY 780 aagtgagcagagatcaatgtctctcagcgcaaaagagatcaatgagaaagagatctcagc 839
DB 541 aagtgagcagagatcaatgtctctcagcgcaaaagagatcaatgagaaagagatctcagc 600
QY 840 caatgagatgctcttgagagagatggtctccctctcaacacagagacgtctctctccacac 899
DB 601 caatgagatgctcttgagagagatggtctccctctcaacacagagacgtctctctccacac 660
QY 900 tggcttgagacagatcctctgagcttctgaacacgtgcagagagacacacagatctctccacac 959
DB 661 tggcttgagacagatcctctgagcttctgaacacgtgcagagagacacacagatctctccacac 720
QY 960 gcaatctgagacagagatgagacacagatctggtctggtctgagcagagccagacttca 1019
DB 721 gcaatctgagacagagatgagacacagatctggtctggtctgagcagagccagacttca 780
QY 1020 ggaacaaagcccatcagtggtctcgggagcaatgagcaacacacacacacacacagagatg 1079
DB 781 ggaacaaagcccatcagtggtctcgggagcaatgagcaacacacacacacacacagagatg 840
QY 1080 gctcgagatcagatctcgaggagaaagaaagaaataacacagatctgagccacagatctac 1139
DB 841 gctcgagatcagatctcgaggagaaagaaagaaataacacagatctgagccacagatctac 900

QY 1140 aacgtccgaactcaactctctatgaagattgttgatgagacttcaaaaacataatc 1199
DB 901 aacgtccgaactcaactctctatgaagattgttgatgagacttcaaaaacataatc 960
QY 1200 taagtgaagaaccttaaaaggaattgtgaataatgaaagaagaagtgattccaggttaactc 1259
DB 961 taagtgaagaaccttaaaaggaattgtgaataatgaaagaagaagtgattccaggttaactc 1020
QY 1260 taactctggagccacagctgcgaacacatctccctccctccctccctccctccctccctcc 1319
DB 1021 taactctggagccacagctgcgaacacatctccctccctccctccctccctccctccctcc 1080
QY 1320 ggtgtgtcccccagacatgagccacagagataagccttgaaagtgtgagactcattgtctgcca 1379
DB 1081 ggtgtgtcccccagacatgagccacagagataagccttgaaagtgtgagactcattgtctgcca 1140
QY 1380 gatctcccaagatcaatgattatggtgtgtgagagaaagagacagagacagatgttc 1439
DB 1141 gatctcccaagatcaatgattatggtgtgtgagagaaagagacagagacagatgttc 1200
QY 1440 aacaaagaagaagaatgagaacatctccacaaagcccatccctcccgaaagaacatccacaaag 1499
DB 1201 aacaaagaagaagaatgagaacatctccacaaagcccatccctcccgaaagaacatccacaaag 1260
QY 1500 aatcaaatcgaagaagatgagctctccatccatccatccatccatccatccatccatccatcc 1559
DB 1261 aatcaaatcgaagaagatgagctctccatccatccatccatccatccatccatccatccatcc 1320
QY 1560 aatggagatctcttgagcctcttgaaagaagaagaagaagaagatccgtatcgatcagac 1619
DB 1321 aatggagatctcttgagcctcttgaaagaagaagaagaagaagaagatccgtatcgatcagac 1380
QY 1620 ggaagctcaaaaagaagatcttgagagacagatctgaatctccctcttgagagacatcagac 1679
DB 1381 ggaagctcaaaaagaagatcttgagagacagatctgaatctccctcttgagagacatcagac 1440
QY 1680 agctcgagcttaccatcagccttgatataagagaagaagaagaacacaaagttcgatcattc 1739
DB 1441 agctcgagcttaccatcagccttgatataagagaagaagaagaacacaaagttcgatcattc 1500
QY 1740 caaagatgataatggagattaa 1761
DB 1501 caaagatgataatggagattaa 1522

RESULT 5
AAA96736 standard; DNA: 1871 BP.
AAA96736:
19-FEB-2001 (first entry)
DB
XX Polynucleotide isolated from lymph node stromal cells of fan -/- mice.
XX
XX Lymph node stromal cell; fan -/- mice; inflammatory disorder;
KW Immune system disorder; cancer; viral disorder; HIV infection;
KW blood vessel growth; cancer; necrosis; tumor; tumor; tumor;
KW inflammatory disease; fibroblast growth factor-mediated disorder;
KW cardiac failure; ss.
XX
XX Mus sp.
XX
XX
XX Key Location/Qualifiers
FH CDS 64..1575
FT /tag- a
XX WC200058463-A1.
XX 05-OCT-2000.
XX 18-FEB-2000; 2000MO-NZ00015.
XX

[illegible]

D0	474	ctatgcgcgcgcgtgacccatccagatttaatacctggttgcagcagcagcattatctt	533
OY	639	gaagaaagcaatataagccaatctctgcgcacgcgtgtgtctatagaaatgtagcaggaattc	698
D0	534	cagagaaataataacgaacaaattccgcacgcgtgtgtctatagaaatgtagcaggaattc	593
OY	659	tgggaatggtgtagatgtgatatcttgagaaacctcttatctgtcaaaagtgtccatccacgc	758
D0	594	tgggaatcaaaaagtgtgtctcgcagaaacctcttatctgtcaaaagtgtccatccacgc	653
OY	759	aggaataatctgtctgtatcagatcagcgtgcacagatcagttgtcttcacgcagaaagatcg	818
D0	654	agggatcatcacagatgaactacagtgtgcacataactgtcttcacgcagaaagatcg	713
OY	819	tgcatactgaaggaattctgtgcacatcagttgtcttcacgcagatgattccctgcagacaa	878
D0	714	tcaattctgaaggaacctccgtgcacaaatgagcgtgtcttcacgcagatgattccctgcagacaa	773
OY	879	ggaaattctcttcttaccctcaatg	902
D0	774	ggaaattctcttcttaccacccaag	797
RESULT	6		
AAH34855			
ID	AAH34855 standard; cDNA; 2428 bp.		
XX	AAH34855.		
XX	03-SEP-2001 (first entry)		
DE	Human colon cancer antigen encoding cDNA seq. ID NO:1937.		
XX	Human; colon cancer; colon cancer antigen; diagnosis; detection;		
KW	colorectal carcinoma; ss.		
XX	Homo sapiens.		
XX	NC00012920-A2.		
PN	05-APR-2001.		
PD	28-SEP-2000; 2000MO-US26524.		
PF	29-SEP-1999; 9908-0157137.		
PR	03-MAY-1999; 9905-0163280.		
XX	(HUMA-) HUMAN GENOME SCI. INC.		
XX	Ruben SM, Barash SC, Birse CE, Rosen CA;		
PI	WPI: 2001-233357/24.		
DR	p-PSDB; AAG75450.		
XX	Nucleic acids encoding 4277 human colon cancer-associated polypeptides,		
XX	useful for preventing, diagnosing and/or treating colorectal cancers -		
PS	Claim 1; Page 3444-3445; 9803pp; English.		
XX	AAH32913 to AAH37195 and AAG75514 to AAG77788 represent human colon		
CC	cancer-associated nucleic acid molecules (N) and proteins (P), where		
CC	the proteins are collectively known as colon cancer antigens. The colon		
CC	cancer antigens have cytostatic activity and can be used in gene		
CC	therapy and vaccine production. N and P may be used in the prevention,		
CC	diagnosis and treatment of diseases associated with inappropriate P		
CC	expression. For example, N and P may be used to treat disorders deleterious		
CC	associated with colorectal cancer, such as the production of P by expressing		
CC	in a patient's genome that affect the activity of P by expressing of P.		
CC	Inactive proteins or to supplement the patient's own production of P,		
CC	by inserting the nucleic acids into a host cell and culturing the cell		
CC	to express the proteins. N and P can be used in the prevention, diagnosis		
CC	and treatment of colorectal carcinomas and cancers. AAH37196 to AAH37204		

XX Sequence 407 BP; 117 A; 83 C; 95 G; 111 T; 1 other;

Query Match 12.5%; Score 219.4; DB 20; Length 407;
 Best Local Similarity 99.5%; Pred. No. 1.6e-46;
 Matches 220; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 901 ggttcgacacacttgatttgattgacacgagccaaatcgaagcttcttcctcgaag 960
 Db 183 ggttcgacacacttgatttgattgacacgagccaaatcgaagcttcttcctcgaag 242

Oy 961 cagtcgacacatgagatgagacacagttcactgctccttcgacacagccgactcga 1020
 Db 243 cagtcgacacatgagatgagacacagttcactgctccttcgacacagccgactcga 302

Oy 1021 gacacagccacatcagcttcgagcagcagatgacacacacacacacagagatg 1080
 Db 303 gacacagccacatcagcttcgagcagcagatgacacacacacacacagagatg 362

Oy 1081 ctgagatcgactttgggggagaaagaataacaggaat 1211
 Db 363 ctgagatcgactttgggggagaaagaataacaggaat 403

RESULT 8
 AA251872
 ID AA251872 standard: cDNA; 2046 BP.
 XX
 AC AA251872;
 XX
 DT 04-JUL-2000 (first entry)
 XX
 DE Human Factor 8 Homologue cDNA.
 XX
 KM Human Factor 8 Homologue; F8H; coagulation cofactor; haemostatic;
 KM cerebroprotective; therapeutic; coagulation related disorder;
 KM haemophilia; stroke; screening; ss.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FH CDS 19..2028
 FT /product= "Factor 8 Homologue"
 FT

FN MO20012532-AL.
 FN
 PD 09-MAR-2000.
 XX
 PF 20-AUG-1999; 99MO-US19047.
 XX
 XX 31-AUG-1998; 98US-0098521.
 XX
 PA (ELIL) LILLY & CO ELI.
 XX
 PI Rostock PDJ, Su W, LI XM;
 XX
 DR WPI: 2000-256580/22.
 DR P-PSDB: AA170539.
 XX
 PF Factor 8 homolog polypeptides and nucleic acids encoding them for
 PF treating coagulation related disorders such as hemophilia and stroke
 XX
 PS Claim 1: Page 61-64; 68pp; English.

The present sequence is a cDNA encoding human Factor 8 homologue (F8H) which is a coagulation cofactor. The protein is selectively expressed in haematopoietic, heart and reproductive tissues. It has haemostatic and cerebroprotective activities. The F8H contains a Factor 5/8 signature and is useful as a therapeutic for treating coagulation related diseases such as hemophilia and stroke. The nucleic acid is useful as a hybridisation probe and amplification primer for detecting deficiencies

CC in the level of F8H mRNA, for screening F8H gene mutations and for
 CC monitoring regulation of gene expression. Fragments of the nucleic acid
 CC are also useful as diagnostic probes and primers, and can be used in
 CC screening methods such as those using DNA chips. The present sequence is
 CC also useful as a target to screen therapeutically useful modulators
 CC of the F8H.
 CC
 XX
 XX Sequence 2046 BP; 615 A; 457 C; 467 G; 507 T; 0 other;

Query Match 11.7%; Score 205.6; DB 21; Length 2046;
 Best Local Similarity 54.2%; Pred. No. 1.2e-42;
 Matches 477; Conservative 0; Mismatches 379; Indels 24; Gaps 2;

Oy 517 agtgaagtaacgctccgcttgagagatgagatccacattctctggccggagttttctgtg 576
 Db 187 agtgaagtaacgctccgcttgagagatgagatccacattctctggccggagttttctgtg 246

Oy 577 accatgagcagcagcgacccacacagtttaataagatgatttgagacagcctgagcatc 636
 Db 247 tcaactctgtctatagataaagaagatcaattactgtttggacccctgacatccattt 306

Oy 637 ttgaagaagaaataacagcaattctccacagcttgatttgatagagccgtgacagagaatc 696
 Db 307 ttgaagaagaaataacagcaattctccacagcttgatttgatagagccgtgacagagaatc 366

Oy 697 tctggaataatgagatgagatagataaagatacctttatttgcaagcttctgtccatc 756
 Db 367 tctggaataatgagatgagatagataaagatacctttatttgcaagcttctgtccatc 426

Oy 757 gcaagaaataattgctgatactgataagctgagccagacagatgctgcttcaacgcaagagatc 816
 Db 427 gcaagaaataattgctgatactgataagctgagccagacagatgctgcttcaacgcaagagatc 486

Oy 817 agtcgataagagagatcttgagacacatgctgcttcttcgagagctggttcctgcgcagac 876
 Db 487 cccattatgagaagcttcttgctcaacacgctacatctctgtgtggagaaactatctaca 546

Oy 877 aagcgatttcgttactccacatgctgctgacagacatctctgaatttgaacatgacagg 936
 Db 547 agctctttacatttaagaacagcagatgagatggaacacgtggagatggaattctgtg 606

Oy 937 -----aaatcagagcttcttccatctgcatgcaatgctgacacagagatgagac 984
 Db 607 atcgggactcctaataatagatctatctgtctgtgagatgagacacacagagcaca 666

Oy 985 caagttacatgctcctcctggccacagccagatctcgagacacagccatctatggctctg 1044
 Db 667 gagaacagcttgagaaacccaaagaacgcaagctgataaagaacccgctctggctgctc 726

Oy 1045 ggcgacagatgacaaacacacacacacagagatgctgctgagatcgattttggggagaa 1104
 Db 727 tctgcacacgataaac-----agtggtttacaaacagatctgtaataagaa 774

Oy 1105 aggaataatacagaatttgaagacacagatgatacagatgcaacttcaactttatgtt 1164
 Db 775 aggaataatacagaatttgaagacacagatgatacagatgcaacttcaactttatgtt 834

Oy 1165 aagagtttggatgaactcaaaaataataatctcaatgaagagacataaagaatt 1224
 Db 835 tctgcctacagaatccctgacagatgagatgagcagaaatgacatgctgtaagaagcc 894

Oy 1225 ggtatgataagaaagaatggttcacagatccacttcaactctggagccagatgagaac 1284
 Db 895 ggttggagcagaataagatatttcaagaaagaagaattatccacagatgagcgaat 954

Oy 1285 aattcactccctcagctggccagaaatctgtcgggtgtctcccccagacagacagcag 1344
 Db 955 aacttttgcacacattatctgcgctttttatgagatgcaacttcaacaaatgacagcag 1014

Oy 1345 agatagaccttgagatgagacatctatgctgcgcagatc 1384
 Db 1015 aaaaatgcatagaataagcgcgcagatgcagttta 1054


```

Db 6386 atgcccagagactgtgtgaatgcctcgtcagagccaggaacacatacaataaagc-----ag 6439
Oy 1078 tggcttgagatcgatcttgggggagaaagaataaatacaaggaatttgaagaccagatct 1137
Db 6440 tggctagaatctgactactcaagatcaagaagataacgcaattataaacaagagctgc 6499
Oy 1138 aacagctgacctcaactcttatttgaagcttttgagatcttgatgaactccaanaacaat 1197
Db 6500 aagctctgcctctgaaatgtatgataagagctataccatccatcaatgaatgagcagga 6559
Oy 1198 tccaagtgagaagacctataaagaaattctgataaatagaagaatggttttcaggtatgc 1257
Db 6560 gtggaatggaacacatacagcgtgaatccctcatgtgtgacagaagattttgaaagaaat 6619
Oy 1258 tctaaatttcggagaccagtgcaaaaacattctccctccatcgtagccagataatg 1317
Db 6620 actaatcaacaagaatcgtgaagacttttcaacccacatcaatctccaggtatgc 6679
Oy 1318 cgggtctgccccagacatgacacagagataagcttgaaggttgagctcatgtgtgc 1377
Db 6680 cgtgtccttctcttaaacatcgtgaatcaagattctgcacttcgtcgtgaactcttgctgt 6739
Oy 1378 cagatt 1383
Db 6740 gatatt 6745

```

RESULT 11

AA03920 standard; cDNA: 6909 BP.

AA03920;

20-DEC-1995 (first entry)

Human Factor-V wild-type cDNA.

Factor-V; thrombosis; thrombophilia; diagnosis; anticoagulant; activated protein-C; APC; homozygosity; heterozygosity; ss.

Homo sapiens.

M05521938-A1.

17-AUG-1995.

14-FEB-1995: 95MO-EF00553.

14-FEB-1994: 94EP-0200377.

(UTLE-) RUMSUNIV LEIDEN.

Bertina RM, Reitsma PH;

WPI: 1995-293134/38.

Screening for genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein C - useful to determine homozygosity or heterozygosity for a mutation in Factor V, Val, VIII or VIIId.

Claim 16; Page 60-65; 98pp; English.

The probes/primers given in AA03921-31 are used to isolate and/or amplify and/or detect mutations in human Factor-V DNA (AA03920), esp. in DNA encoding the APC binding and/or cleavage site.

Sequence 6909 BP: 2096 A; 1700 C; 1430 G; 1683 T; 0 other:

Query Match 5.3%; Score 92.8; DB 16; Length 6909;
Best Local Similarity 51.0%; Pred. No. 2,3e-13;

```

Matches 248: Conservative 0; Mismatches 232; Indels 6; Gaps 1:
Oy 898 aatggtttgagagatcgttggattttgaacctgaaagcgaatcaagacttcttccaa 957
Db 6280 aatggaatgttccacacccctgggtatgtgaatgtgaagaatgtgaacaagaacatcacaa 6339
Oy 958 tggcagtcggtcaatgagatctggaagacaaagttcaactgtctctctggccaagccagact 1017
Db 6340 gctcttcgtttaagaatcttgggtggagatattggaaccttcctgcgtgccccttg 6399
Oy 6340 gctcttcgtttaagaatcttgggtggagatattggaaccttcctgcgtgccccttg 6399
Db 1018 cagagccagaagagccatcattggtcttcggcgacatgtagaacaacacacacagagag 1077
Oy 6400 aatgcccaagagcgtgtgtaatgtcctcggcgaacgaagcaaaabaabaataagc-----ag 6453
Db 1078 tggcttgagatcgatcttgggggagaaagaataaatacaagaaatttgaagaccagatct 1137
Oy 6454 tggctagaatctgactactcaagatcaagaagataacgcaattataaacaagagctgc 6513
Db 1138 aacagctgacctcaactcttatttgaagcttttgagatcttgatgaactccaanaacaat 1197
Oy 6514 aagctctgcctctgaaatgtatgataagagctataccatccatcaatgaatgagcagga 6573
Db 1198 tccaagtgagaagacctataaagaaattctgataaatagaagaatggttttcaggtatgc 1257
Oy 6574 gtggaatggaacacatacagcgtgaatccctcatgtgtgacagaagattttgaaagaaat 6633
Db 1258 tctaaatttcggagaccagtgcaaaaacattctccctccatcgtagccagataatg 1317
Oy 6634 actaatcaacaagaatcgtgaagacttttcaacccacatcaatctccaggtatgc 6693
Db 1318 cgggtctgccccagacatgacacagagataagcttgaaggttgagctcatgtgtgc 1377
Oy 6694 cgtgtccttctcttaaacatcgtgaatcaagattctgcacttcgtcgtgaactcttgctgt 6753
Oy 1378 cagatt 1383
Db 6754 gatatt 6759

```

RESULT 12

AA06048 standard; cDNA: 6909 BP.

AA06048;

09-OCT-2000 (first entry)

Human factor V cDNA sequence SEQ ID NO:26.

Factor V; FV; activated protein C; APC; anticoagulant; activated protein C resistant factor V; thrombosis; screening; thrombophilia; ds.

Homo sapiens.

US6066778-A.

23-MAY-2000.

06-NOV-1996: 96US-0746111.

06-NOV-1996: 96US-0746111.

(UNMT) UNIV MICHIGAN.

Ginsburg D, Cui J;

WPI: 2000-410682/35.

New transgenic mice expressing activated protein C resistant factor V and factor V null transgenic mice useful for screening anticoagulants, as models for human thrombophilia and as models for testing in utero gene therapy protocols -

SQ Sequence 6925 BP; 2106 A; 1703 C; 1432 G; 1684 T; 0 other;

=> fil reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE
ENTRY
0.38
TOTAL
SESSION
2.90

Uitra
691344

FILE 'REGISTRY' ENTERED AT 15:46:21 ON 09 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 8 JUL 2002 HIGHEST RN 437701-77-4
DICTIONARY FILE UPDATES: 8 JUL 2002 HIGHEST RN 437701-77-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e animal cub domain protein/cn 5

E1 1 ANIMAL BLACK/CN
E2 1 ANIMAL BLOOD, DENATURED/CN
E3 0 --> ANIMAL CUB DOMAIN PROTEIN/CN
E4 1 ANIMAL EXTRACTS, LIVER/CN
E5 1 ANIMAL FAT OLEINS/CN

=> e cub domain/cn 5

E1 1 CUAUII/CN
E2 1 CUAUTHEMONE/CN
E3 0 --> CUB DOMAIN/CN
E4 1 CUB DOMAIN-CONTAINING PROTEIN 1 (HUMAN A549/CALU 6 CELL GENE
CDCP1 PRECURSOR)/CN
E5 1 CUB-DOMAIN-CONTAINING PROTEIN RP43 (RIFTIA PACHYPTILA)/CN

=> e

E6 1 CUB2/CN
E7 1 CUBA BLACK/CN
E8 1 CUBA ORANGE/CN
E9 1 CUBA6/CN
E10 1 CUBANA BROWN/CN
E11 1 CUBANA BROWN R/CN
E12 1 CUBANE/CN
E13 1 CUBANE RADICAL CATION/CN
E14 1 CUBANE-1,2,4,7-TETRAAMMONIUM DINITRAMIDE/CN
E15 1 CUBANE-1,4-DIAMMONIUM DINITRAMIDE/CN
E16 1 CUBANE-1,4-DICARBOXYLIC ACID-1,4-PHENYLENEDIAMINE COPOLYMER/
CN
E17 1 CUBANE-1,4-DICARBOXYLIC ACID-1,4-PHENYLENEDIAMINE COPOLYMER,
SRU/CN

=> s e4-5

1 "CUB DOMAIN-CONTAINING PROTEIN 1 (HUMAN A549/CALU 6 CELL GENE
CDCP1 PRECURSOR)"/CN
1 "CUB-DOMAIN-CONTAINING PROTEIN RP43 (RIFTIA PACHYPTILA)"/CN
L1 2 ("CUB DOMAIN-CONTAINING PROTEIN 1 (HUMAN A549/CALU 6 CELL GENE
CDCP1 PRECURSOR)"/CN OR "CUB-DOMAIN-CONTAINING PROTEIN RP43

Searched by: Mary Hale 308-4258 CM-1 1E01

(RIFTIA PACHYPTILA)"/CN)

=> e coagulation factors v/cn 5

E1	1	COAGULATION FACTOR XIA/CN
E2	1	COAGULATION FACTORS (BLOOD)/CN
E3	0 -->	COAGULATION FACTORS V/CN
E4	1	COAGULEN/CN
E5	3	COAGULIN/CN

=> e coagulation factors xiii/cn 5

E1	1	COAGULATION FACTOR XIA/CN
E2	1	COAGULATION FACTORS (BLOOD)/CN
E3	0 -->	COAGULATION FACTORS XIII/CN
E4	1	COAGULEN/CN
E5	3	COAGULIN/CN

> => e milk fat globule egf factor 8/cn 5

E1	1	MILK BUNDLE-1 PROTEIN (SYNTHETIC)/CN
E2	1	MILK FAT GLOBULE ANTIGEN NP5 (HUMAN FRAGMENT)/CN
E3	0 -->	MILK FAT GLOBULE EGF FACTOR 8/CN
E4	1	MILK GLASS/CN
E5	1	MILK GROWTH FACTOR/CN

=> e transcriptional repressor/cn 5

E1	1	TRANSCRIPTIONAL REGULATORY PROTEIN (YERSINIA PESTIS STRAIN CO 92 GENE YPO1938)/CN
E2	1	TRANSCRIPTIONAL REPRESSION OF HYC AND HYP OPERONS (ESCHERICHIA COLI O157:H7 STRAIN EDL933 GENE HYCA)/CN
E3	0 -->	TRANSCRIPTIONAL REPRESSOR/CN
E4	1	TRANSCRIPTIONAL REPRESSOR (AEDES AEGYPTI STRAIN UGAL REDUCED)/CN
E5	1	TRANSCRIPTIONAL REPRESSOR (AGROBACTERIUM TUMEFACIENS STRAIN C58 GENE ACCR)/CN

=> e

E6	1	TRANSCRIPTIONAL REPRESSOR (AGROBACTERIUM TUMEFACIENS STRAIN C58 GENE TRAM)/CN
E7	1	TRANSCRIPTIONAL REPRESSOR (ARABIDOPSIS THALIANA CLONE G11C3 GENE RPD3A)/CN
E8	1	TRANSCRIPTIONAL REPRESSOR (ASPERGILLUS ORYZAE STRAIN TK3 GEN E CREA)/CN
E9	1	TRANSCRIPTIONAL REPRESSOR (BACILLUS HALODURANS STRAIN C-125 GENE BH0826)/CN
E10	1	TRANSCRIPTIONAL REPRESSOR (BACILLUS HALODURANS STRAIN C-125 GENE BH0847)/CN
E11	1	TRANSCRIPTIONAL REPRESSOR (BACTERIOPHAGE .PHI.CH1)/CN
E12	1	TRANSCRIPTIONAL REPRESSOR (BETA-GALACTOSIDASE GENE) (BACILLUS HALODURANS STRAIN C-125 GENE LACR)/CN
E13	1	TRANSCRIPTIONAL REPRESSOR (BRUCELLA MELITENSIS STRAIN 16M GENE BMEI1046)/CN
E14	1	TRANSCRIPTIONAL REPRESSOR (BRUCELLA MELITENSIS STRAIN 2308 GENE ERID)/CN
E15	1	TRANSCRIPTIONAL REPRESSOR (BUTTERFLY GENE EXTRA SEX COMBS)/CN
E16	1	TRANSCRIPTIONAL REPRESSOR (CANDIDA ALBICANS CLONE P371 GENE TUP1 REDUCED)/CN
E17	1	TRANSCRIPTIONAL REPRESSOR (CANDIDA UTILIS STRAIN NRRL Y1084 GENE MIG1)/CN

=> s transcriptional repressor ?/cn

L2 171 TRANSCRIPTIONAL REPRESSOR ?/CN


```

=> e "ae-binding protein-1"/cn 5
E1      1      AE-100/CN
E2      1      AE-3/CN
E3      0 --> AE-BINDING PROTEIN-1/CN
E4      1      AE-CELLULOSE/CN
E5      1      AE-F 117233/CN

=> e neurophilins 1/cn 5
E1      1      NEUROPEPTIDE, SUBOESOPHAGEAL GANGLION (BOMBYX MORI BOMPBAN G
AMMA-)/CN
E2      1      NEUROPEPTIDE-GLUTAMIC ACID-ISOLEUCINE/CN
E3      0 --> NEUROPHILINS 1/CN
E4      1      NEUROPHYSIN (BUFO JAPONICUS CLONE PVT-1 REDUCED)/CN
E5      1      NEUROPHYSIN (BUFO JAPONICUS CLONE PVT-4 REDUCED)/CN

=> e neurophilins 2/cn 5
E1      1      NEUROPEPTIDE, SUBOESOPHAGEAL GANGLION (BOMBYX MORI BOMPBAN G
AMMA-)/CN
E2      1      NEUROPEPTIDE-GLUTAMIC ACID-ISOLEUCINE/CN
E3      0 --> NEUROPHILINS 2/CN
E4      1      NEUROPHYSIN (BUFO JAPONICUS CLONE PVT-1 REDUCED)/CN
E5      1      NEUROPHYSIN (BUFO JAPONICUS CLONE PVT-4 REDUCED)/CN

=> e discoidin domain/cn 5
E1      1      DISCOGUATTINE/CN
E2      1      DISCOIDIC ACID/CN
E3      0 --> DISCOIDIN DOMAIN/CN
E4      1      DISCOIDIN DOMAIN RECEPTOR 1 KINASE/CN
E5      1      DISCOIDIN DOMAIN RECEPTOR 1 KINASE (HUMAN GENE DDR1 ISOENZYM
E DDR1D C-TERMINAL FRAGMENT)/CN

=> e
E6      1      DISCOIDIN DOMAIN RECEPTOR 1 KINASE (HUMAN GENE DDR1 ISOENZYM
E DDR1E FRAGMENT)/CN
E7      1      DISCOIDIN DOMAIN RECEPTOR 2 KINASE/CN
E8      1      DISCOIDIN DOMAIN RECEPTOR KINASE (HUMAN GENE CAK ISOENZYME C
AK II)/CN
E9      1      DISCOIDIN DOMAIN RECEPTOR KINASE (MUS MUSCULUS STRAIN C57BL
GENE CAK ISOENZYME CAK I)/CN
E10     1      DISCOIDIN DOMAIN RECEPTOR KINASE (MUS MUSCULUS STRAIN C57BL
GENE CAK ISOENZYME CAK II)/CN
E11     1      DISCOIDIN DOMAIN RECEPTOR TYROSINE KINASE/CN
E12     1      DISCOIDIN DP1 (DICTYOSTELIUM DISCOIDEUM STRAIN AX2)/CN
E13     1      DISCOIDIN I-A (DICTYOSTELIUM DISCOIDEUM REDUCED)/CN
E14     1      DISCOIDIN I-C (DICTYOSTELIUM DISCOIDEUM REDUCED)/CN
E15     1      DISCOIDIN II (DICTYOSTELIUM DISCOIDEUM CLONE D2)/CN
E16     1      DISCOKIOLIDE A/CN
E17     1      DISCOKIOLIDE B/CN

=> s e4-11
1 "DISCOIDIN DOMAIN RECEPTOR 1 KINASE"/CN
1 "DISCOIDIN DOMAIN RECEPTOR 1 KINASE (HUMAN GENE DDR1 ISOENZYME
DDR1D C-TERMINAL FRAGMENT)"/CN
1 "DISCOIDIN DOMAIN RECEPTOR 1 KINASE (HUMAN GENE DDR1 ISOENZYME
DDR1E FRAGMENT)"/CN
1 "DISCOIDIN DOMAIN RECEPTOR 2 KINASE"/CN
1 "DISCOIDIN DOMAIN RECEPTOR KINASE (HUMAN GENE CAK ISOENZYME CAK
II)"/CN
1 "DISCOIDIN DOMAIN RECEPTOR KINASE (MUS MUSCULUS STRAIN C57BL
GENE CAK ISOENZYME CAK I)"/CN
1 "DISCOIDIN DOMAIN RECEPTOR KINASE (MUS MUSCULUS STRAIN C57BL
GENE CAK ISOENZYME CAK II)"/CN

```


L3 1 "DISCOIDIN DOMAIN RECEPTOR TYROSINE KINASE"/CN
 8 ("DISCOIDIN DOMAIN RECEPTOR 1 KINASE"/CN OR "DISCOIDIN DOMAIN
 RECEPTOR 1 KINASE (HUMAN GENE DDR1 ISOENZYME DDR1D C-TERMINAL
 FRAGMENT)"/CN OR "DISCOIDIN DOMAIN RECEPTOR 1 KINASE (HUMAN
 GENE DDR1 ISOENZYME DDR1E FRAGMENT)"/CN OR "DISCOIDIN DOMAIN
 RECEPTOR 2 KINASE"/CN OR "DISCOIDIN DOMAIN RECEPTOR KINASE (HUMA
 N GENE CAK ISOENZYME CAK II)"/CN OR "DISCOIDIN DOMAIN RECEPTOR
 KINASE (MUS MUSCULUS STRAIN C57BL GENE CAK ISOENZYME CAK I)"/CN
 OR "DISCOIDIN DOMAIN RECEPTOR KINASE (MUS MUSCULUS STRAIN C57BL
 GENE CAK ISOENZYME CAK II)"/CN OR "DISCOIDIN DOMAIN RECEPTOR
 TYROSINE KINASE"/CN)

=> e nhp/cn 5

E1 1 NHJ 44/CN
 E2 1 NHMO/CN
 E3 0 --> NHP/CN
 E4 1 NHP2/RS6-LIKE PROTEIN (TRYPANOSOMA BRUCEI STRAIN 427 GENE NH
 P2)/CN
 E5 1 NHPTT/CN

=> fil medl,hcap,biosis,embase,jicst,wpids

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	46.28	49.18

FILE 'MEDLINE' ENTERED AT 15:49:39 ON 09 JUL 2002

FILE 'HCAPLUS' ENTERED AT 15:49:39 ON 09 JUL 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:49:39 ON 09 JUL 2002
 COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 15:49:39 ON 09 JUL 2002
 COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'JICST-EPLUS' ENTERED AT 15:49:39 ON 09 JUL 2002
 COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'WPIDS' ENTERED AT 15:49:39 ON 09 JUL 2002
 COPYRIGHT (C) 2002 THOMSON DERWENT

=> s (l1 or cub domain protein) and (coagulat? factor? or blood coagulation or milk
 fat globule egf factor 8 or mfg human milk or transcriptional repressor or crtr-1
 protein or ae-binding protein 1 or neurophilin?)

L4 0 FILE MEDLINE
 L5 1 FILE HCAPLUS
 L6 0 FILE BIOSIS
 L7 0 FILE EMBASE
 L8 0 FILE JICST-EPLUS

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'CUB-DOMAIN-CONTAINING PROTEIN
 RP43 (RIFTIA PACHYPTILA/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'CUB-DOMAIN-CONTAINING PROTEIN
 RP43 (RIFTIA PACHYPTILA/CN'

L9 1 FILE WPIDS

TOTAL FOR ALL FILES

L10 2 (L1 OR CUB DOMAIN PROTEIN) AND (COAGULAT? FACTOR? OR BLOOD COAGU

Searched by: Mary Hale 308-4258 CM-1 1E01

LATION OR MILK FAT GLOBULE EGF FACTOR 8 OR MFG HUMAN MILK OR
TRANSCRIPTIONAL REPRESSOR OR CRTR-1 PROTEIN OR AE-BINDING PROTEI
N 1 OR NEUROPHILIN?)

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11 1 DUP REM L10 (1 DUPLICATE REMOVED)

=> d cbib abs

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
2001:300872 Document No. 134:321614 Protein and cDNA sequences of a novel
human CUB-domain containing protein and uses thereof in diagnosis, therapy
and drug screening. Donoho, Gregory; Turner, C. Alexander, Jr.; Nehls,
Michael; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T. (Lexicon
Genetics Incorporated, USA). PCT Int. Appl. WO 2001029219 A1 20010426, 33
pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM,
CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT,
SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US28798
200001008. PRIORITY: US 1999-PV160285 19991019; US 2000-PV183583 20000218.
AB This invention provides protein and cDNA sequences for newly identified
human proteins, designated NHPs, which shares structural similarity with
animal **CUB domain proteins,**
coagulation factors V and XIII, milk
fat globule-EGF factor 8,
5 transcriptional repressor AE-
binding protein-1, and neuropilins 1 and 2
(which, like the presently described protein, contain both CUB and
discoidin domains). While NHP shares sequence homol. with other
CUB-domain contg. proteins, its primary sequence is unique. Its
expression is detected in human cell lines, and human prostate, pituitary,
fetal brain, brain, thymus, spleen, lymph node, trachea, kidney, fetal
liver, thyroid, adrenal gland, salivary gland, stomach, small intestine,
colon, muscle, heart, mammary gland, adipose, skin, esophagus, bladder,
cervix, rectum, and testis cells. In one embodiment, the invention
relates to diagnostic assays for detecting diseases assocd. with
inappropriate NHP activity or levels. Also disclosed are methods for
utilizing NHP in drug screening assays and in therapy directed against
diseases assocd. with inappropriate NHP activity or levels.

=> s (l1 or cub domain protein) and (discoidin domain or l3 or discoidin receptor
or ddr2 gene product?)
L12 0 FILE MEDLINE
L13 1 FILE HCAPLUS
L14 0 FILE BIOSIS
L15 0 FILE EMBASE
L16 0 FILE JICST-EPLUS

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE
(MUS MUSCULUS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE
(MUS MUSCULUS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE
(MUS MUSCULUS STRAIN/CN'

Searched by: Mary Hale 308-4258 CM-1 1E01

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE
(MUS MUSCULUS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE
(MUS MUSCULUS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE
(MUS MUSCULUS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE
(MUS MUSCULUS STRAIN/CN'
L17 0 FILE WPIDS

TOTAL FOR ALL FILES

L18 1 (L1 OR CUB DOMAIN PROTEIN) AND (DISCOIDIN DOMAIN OR L3 OR DISCOI
DIN RECEPTOR OR DDR2 GENE PRODUCT?)

=> s l18 not l10

L19 0 FILE MEDLINE
L20 0 FILE HCAPLUS
L21 0 FILE BIOSIS
L22 0 FILE EMBASE
L23 0 FILE JICST-EPLUS
L24 0 FILE WPIDS

TOTAL FOR ALL FILES

L25 0 L18 NOT L10

=> (l1 or cub domain or extracellular domain or ecd) and (novel human protein? or
nhps)

(L1 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s (l1 or cub domain or extracellular domain or ecd) and (novel human protein? or
nhps)

L26 1 FILE MEDLINE
L27 7 FILE HCAPLUS
L28 1 FILE BIOSIS
L29 1 FILE EMBASE
L30 0 FILE JICST-EPLUS

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'CUB-DOMAIN-CONTAINING PROTEIN
RP43 (RIFTIA PACHYPTILA/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'CUB-DOMAIN-CONTAINING PROTEIN
RP43 (RIFTIA PACHYPTILA/CN'
L31 1 FILE WPIDS

TOTAL FOR ALL FILES

L32 11 (L1 OR CUB DOMAIN OR EXTRACELLULAR DOMAIN OR ECD) AND (NOVEL
HUMAN PROTEIN? OR NHPS)

=> s l32 not (l10 or l18)

L33 1 FILE MEDLINE
L34 6 FILE HCAPLUS
L35 1 FILE BIOSIS
L36 1 FILE EMBASE
L37 0 FILE JICST-EPLUS
L38 0 FILE WPIDS

Searched by: Mary Hale 308-4258 CM-1 1E01

TOTAL FOR ALL FILES

L39 9 L32 NOT (L10 OR L18)

=> dup rem l39

PROCESSING COMPLETED FOR L39

L40 6 DUP REM L39 (3 DUPLICATES REMOVED)

=> d cbib abs 1-6

L40 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2002 ACS

2002:107557 Document No. 136:162371 Cloning and characterization of
novel human protein kinase family members

32374 and 18431 and their therapeutic uses. Meyers, Rachel;
Kapeller-Libermann, Rosana; Silos-Santiago, Immaculada (Millennium
Pharmaceuticals, Inc., USA). PCT Int. Appl. WO 2002010401 A2 20020207,
141 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG,
BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF,
CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML,
MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIIXD2.
APPLICATION: WO 2001-US23653 20010727. PRIORITY: US 2000-PV221543
20000728.

AB The invention provides isolated nucleic acid mols., designated 32374 or
18431 nucleic acid mols., which encode novel protein kinase family
members. The invention also provides antisense nucleic acid mols.,
recombinant expression vectors contg. 32374 or 18431 nucleic acid mols.,
host cells into which the expression vectors have been introduced, and
nonhuman transgenic animals in which a 32374 or 18431 gene has been
introduced or disrupted. Their putative function domains are analyzed and
their gene expression profiles are provided. The invention still further
provides isolated 32374 or 18431 proteins, fusion proteins, antigenic
peptides and anti-32374 or -18431 antibodies. Diagnostic methods
utilizing compns. of the invention are also provided.

L40 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2002 ACS

2002:10647 Document No. 136:80918 Protein and cDNA sequences of a novel
human **CUB domain**-containing protein sequence homolog
and uses thereof. Kapeller-Libermann, Rosana (Millennium Pharmaceuticals,
Inc., USA). PCT Int. Appl. WO 2002000843 A2 20020103, 107 pp. DESIGNATED
STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY,
DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE,
SN, TD, TG, TR. (English). CODEN: PIIXD2. APPLICATION: WO 2001-US20055
20010621. PRIORITY: US 2000-PV213963 20000623.

AB The invention provides protein and cDNA sequences of a **novel**
human protein, designated 56739, which has sequence
homol. with CUB family members. The invention also provides antisense
nucleic acid mols., recombinant expression vectors contg. 56739 nucleic
acid mols., host cells into which the expression vectors have been
introduced, and nonhuman transgenic animals in which a 56739 gene has been
introduced or disrupted. The invention still further provides isolated
56739 proteins, fusion proteins, antigenic peptides and anti-56739
antibodies. Diagnostic methods utilizing compns. of the invention are
also provided.

L40 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2002 ACS
2001:526099 Document No. 135:117953 cDNA and protein sequence of
novel human protein TANGO416 and TANGO457 and
their uses in drug screening, therapeutics and diagnosis. Fraser,
Christopher C.; Kirst, Susan J. (Millennium Pharmaceuticals, Inc., USA).
PCT Int. Appl. WO 2001051514 A1 20010719, 217 pp. DESIGNATED STATES: W:
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN,
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA,
GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.
(English). CODEN: PIXXD2. APPLICATION: WO 2001-US485 20010105.
PRIORITY: US 2000-479249 20000107; US 2000-559497 20000427.

AB The invention provides cDNA and protein sequence of two **novel**
human protein TANGO416 and TANGO457. The protein
TANGO416 was cloned from human fetal spleen and has high homol. with
murine protocadherin. Both proteins are transmembrane proteins and contg.
extracellular, transmembrane and intracellular domain. These nucleic and
proteins are useful for diagnosis, prevention, and therapy of a no. of
human and other animal disorders. The invention also provides antisense
nucleic acid mols., expression vectors contg. the nucleic acid mols. of
the invention, host cells into which the expression vectors have been
introduced, and non-human transgenic animals in which a nucleic acid mol.
of the invention has been introduced or disrupted. The invention still
further provides isolated polypeptides, fusion polypeptides, antigenic
peptides and antibodies. Diagnostic, screening, and therapeutic methods
using compns. of the invention are also provided. The nucleic acids and
polypeptides of the present invention are useful as modulating agents in
regulating a variety of cellular processes.

L40 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2002 ACS
2001:300759 Document No. 134:321609 Protein and cDNA sequences of human
secretory proteins and uses thereof in diagnosis, therapy and drug
screening. Turner, C. Alexander, Jr.; Donoho, Gregory; Nehls, Michael;
Hilbun, Erin; Zambrowicz, Brian; Sands, Arthur T. (Lexicon Genetics
Incorporated, USA). PCT Int. Appl. WO 2001029084 A2 20010426, 63 pp.
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ,
CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, ZA, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US28803
20001018. PRIORITY: US 1999-PV160106 19991018; US 1999-PV162547 19991029.

AB This invention provides protein and cDNA sequences for newly identified
human proteins, designated **NHPs**, which shares structure motifs
typical of human secreted proteins that share structural similarity with
animal chordins, NEL protein, and thrombospondin. Also disclosed is
another **novel human protein** that shares
structural similarity with animal protein that contains **CUB**
domain. In one embodiment, the invention relates to diagnostic
assays for detecting diseases assocd. with inappropriate NHP activity or
levels. Also disclosed are methods for utilizing NHP in drug screening
assays and in therapy directed against diseases assocd. with inappropriate
NHP activity or levels.

L40 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2002 ACS
1998:608707 Document No. 129:215729 Cloning of cDNA for **novel**

human proteins belong to tumor necrosis factor receptor superfamily. Tada, Hideaki; Konishi, Mikio; Fukushima, Daikichi (Ono Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 9838304 A1 19980903, 54 pp. DESIGNATED STATES: W: JP, KR, US; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1998-JP799 19980226. PRIORITY: JP 1997-43143 19970227.

AB The cDNA for proteins OAF065.alpha. and OAF065.beta. are isolated from human stroma cell line HAS303. OAF065.alpha. consists of 416 and OAF065.beta. of 423 amino acids, with identical N-terminal 1-415 residues. The C-terminal Glu-Ala of OAF065.alpha. is substituted with 8 amino acid residues in OAF065.beta.. Both protein contains a Cys-rich domain, commonly seen in the **extracellular domain** of the TNF receptor superfamily. Claimed are methods of recombinant prepn. of the proteins, (monoclonal) antibody to the proteins, oligonucleotide hybridizing to the cDNA, and therapeutics contg. the protein and/or the antibodies.

L40 ANSWER 6 OF 6 MEDLINE DUPLICATE 1
 96394649 Document Number: 96394649. PubMed ID: 8798755. Cloning and characterization of islet cell antigen-related protein-tyrosine phosphatase (PTP), a novel receptor-like PTP and autoantigen in insulin-dependent diabetes. Cui L; Yu W P; DeAizpurua H J; Schmidli R S; Pallen C J. (Cell Regulation Laboratory, Institute of Molecular and Cell Biology, National University of Singapore, 10 Kent Ridge Crescent, Singapore 0511, Republic of Singapore.) JOURNAL OF BIOLOGICAL CHEMISTRY, (1996 Oct 4) 271 (40) 24817-23. Journal code: 2985121R. ISSN: 0021-9258. Pub. country: United States. Language: English.

AB Cloning of the cDNA encoding a **novel human protein-** tyrosine phosphatase (PTP) called islet cell antigen-related PTP (IAR) predicts a receptor-like molecule with an **extracellular domain** of 614 amino acids containing a hydrophobic signal peptide, one potential N-glycosylation site, and an RGDS peptide which is a possible adhesive recognition sequence. The 376-amino acid intracellular region contains a single catalytic domain. Recombinant IAR polypeptide has phosphatase activity. Northern blot analysis shows tissue-specific expression of two IAR transcripts of 5.5 and 3.7 kilobases, which are most abundant in brain and pancreas. The IAR PTP is homologous in its intracellular region to IA-2, a putative PTP that is an insulin-dependent diabetes mellitus (IDDM) autoantigen. IAR is also reactive with IDDM patient sera. IAR and IA-2 may distinguish different populations of IDDM autoantibodies since they identify overlapping but nonidentical sets of IDDM patients. Thus IAR is likely to be an islet cell antigen useful in the preclinical screening of individuals for risk of IDDM.

=> s (l1 or cub domain or extracellular domain or ecd) and (agonist or antagonist)

L41 611 FILE MEDLINE
 L42 485 FILE HCAPLUS
 L43 408 FILE BIOSIS
 L44 359 FILE EMBASE
 L45 36 FILE JICST-EPLUS

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'CUB-DOMAIN-CONTAINING PROTEIN RP43 (RIFTIA PACHYPTILA/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'CUB-DOMAIN-CONTAINING PROTEIN RP43 (RIFTIA PACHYPTILA/CN'
 L46 203 FILE WPIDS

TOTAL FOR ALL FILES
 L47 2102 (L1 OR CUB DOMAIN OR EXTRACELLULAR DOMAIN OR ECD) AND (AGONIST

Searched by: Mary Hale 308-4258 CM-1 1E01

OR ANTAGONIST)

```
=> s l47 and (l3 or discoidin(w)(receptor! or domain))
L48      0 FILE MEDLINE
L49      1 FILE HCAPLUS
L50      0 FILE BIOSIS
L51      0 FILE EMBASE
L52      0 FILE JICST-EPLUS
```

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE (MUS MUSCULUS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE (MUS MUSCULUS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE (MUS MUSCULUS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE (MUS MUSCULUS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'DISCOIDIN DOMAIN RECEPTOR KINASE (MUS MUSCULUS STRAIN/CN'

L53 0 FILE WPIDS

TOTAL FOR ALL FILES

L54 1 L47 AND (L3 OR DISCOIDIN(W)(RECEPTOR! OR DOMAIN))

=> d cbib abs

L54 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS

1998:71221 Document No. 128:136859 Soluble ErbB receptor

extracellular domain fusion proteins their uses in antagonization of growth factors. Fizpatrick, Vincent Danial; Sliwkowski, Mark; Vandlen, Richard L. (Genentech, Inc., USA). PCT Int. Appl. WO 9802540 A1 19980122, 58 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1997-US11825 19970708. PRIORITY: US 1996-21640 19960712; US 1997-798326 19970210.

AB Sol. heteromultimeric immunoadhesin fusion proteins that contain the extracellular ligand-binding domains of ErbB receptors oligomerized via the multimerization domains of Igs are described for use as **antagonists** of neuregulins in the control of cell proliferation, e.g. in cancers. Specifically, the **extracellular domains** of ErbB2 and ErbB3 or ErbB2 and ErbB4 are used in combination. The prepn. ErbB/IgG fusion proteins and the characterization of their heregulin binding properties is reported.

```
=> s donoho, g?/au,in;s turner, c?/au;s nehls, m?/au,in;s friedrich, g?/au,in
'IN' IS NOT A VALID FIELD CODE
L55      6 FILE MEDLINE
L56      44 FILE HCAPLUS
L57      9 FILE BIOSIS
'IN' IS NOT A VALID FIELD CODE
L58      5 FILE EMBASE
L59      0 FILE JICST-EPLUS
```

Searched by: Mary Hale 308-4258 CM-1 1E01

L60 36 FILE WPIDS

TOTAL FOR ALL FILES

L61 100 DONOHO, G?/AU,IN

L62 1091 FILE MEDLINE

L63 1428 FILE HCAPLUS

L64 1198 FILE BIOSIS

L65 772 FILE EMBASE

L66 7 FILE JICST-EPLUS

L67 212 FILE WPIDS

TOTAL FOR ALL FILES

L68 4708 TURNER, C?/AU

'IN' IS NOT A VALID FIELD CODE

L69 38 FILE MEDLINE

L70 77 FILE HCAPLUS

L71 42 FILE BIOSIS

'IN' IS NOT A VALID FIELD CODE

L72 30 FILE EMBASE

L73 0 FILE JICST-EPLUS

L74 39 FILE WPIDS

TOTAL FOR ALL FILES

L75 226 NEHLS, M?/AU,IN

'IN' IS NOT A VALID FIELD CODE

L76 158 FILE MEDLINE

L77 337 FILE HCAPLUS

L78 163 FILE BIOSIS

'IN' IS NOT A VALID FIELD CODE

L79 167 FILE EMBASE

L80 1 FILE JICST-EPLUS

L81 105 FILE WPIDS

TOTAL FOR ALL FILES

L82 931 FRIEDRICH, G?/AU,IN

=> s l61 and l68 and l75 and l82

L83 0 FILE MEDLINE

L84 10 FILE HCAPLUS

L85 0 FILE BIOSIS

L86 0 FILE EMBASE

L87 0 FILE JICST-EPLUS

L88 10 FILE WPIDS

TOTAL FOR ALL FILES

L89 20 L61 AND L68 AND L75 AND L82

=> dup rem l89

PROCESSING COMPLETED FOR L89

L90 10 DUP REM L89 (10 DUPLICATES REMOVED)

=> d 1-10 cbib abs

L90 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
2001:360153 Document No. 134:363350 Characterization and applications of
novel human proteases. Donoho, Gregory; Hilbun, Erin; Turner,

Searched by: Mary Hale 308-4258 CM-1 1E01

C. Alexander, Jr.; Nehls, Michael; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T. (Lexicon Genetics Incorporated, USA). PCT Int. Appl. WO 2001034779 A2 20010517, 34 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US31179 20001109. PRIORITY: US 1999-PV165260 19991112.

AB The cDNA sequences and corresponding deduced amino acid sequences of novel human proteases (NHPs) are disclosed. The NHP genes were obtained from a human testis cDNA library using probes and/or primers generated from human gene trapped sequence tags. The described NHPs share significant similarity to a variety of mammalian proteases, and esp. carboxypeptidase A. The NHPs can be used in therapeutic, diagnostic, and pharmacogenomic applications.

L90 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 2
2001:360152 Document No. 134:363349 Characterization of novel human ATPase homologs. **Donoho, Gregory;** Turner, C. Alexander, Jr.; Hilbun, Erin; Nehls, Michael; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T. (Lexicon Genetics Incorporated, USA). PCT Int. Appl. WO 2001034778 A2 20010517, 45 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US31110 20001109. PRIORITY: US 1999-PV164624 19991110.

AB The present invention relates to the discovery, identification, and characterization of novel human proteins which share structural similarity with calcium transporting ATPases and aminophospholipid transporters. The cDNA sequences and the corresponding deduced amino acid sequences of the human ATPase homologs are disclosed. The human ATPase homologs can be used in therapeutic, diagnostic, and pharmacogenomic applications.

L90 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 3
2001:338573 Document No. 134:348997 Protein and cDNA sequences of human transport proteins and uses thereof in diagnosis, therapy and drug screening. Harras, Marie; **Donoho, Gregory;** Turner, C. Alexander, Jr.; Nehls, Michael; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T. (Lexicon Genetics Incorporated, USA). PCT Int. Appl. WO 2001032706 A2 20010510, 59 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US29852 20001031. PRIORITY: US 1999-PV163018 19991102.

AB This invention provides protein and cDNA sequences for newly identified human proteins, designated NHPs, which share structural similarity with mammalian multi-drug resistance (MDR) proteins and cellular transporters. In one embodiment, the invention relates to diagnostic assays for detecting diseases assocd. with inappropriate NHP activity or levels.

Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases assocd. with inappropriate NHP activity or levels. Seq ID No. 47 and 48 were claimed, but information was not provided.

L90 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 4
2001:300872 Document No. 134:321614 Protein and cDNA sequences of a novel human CUB-domain containing protein and uses thereof in diagnosis, therapy and drug screening. **Donoho, Gregory**; Turner, C. Alexander, Jr.; Nehls, Michael; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T. (Lexicon Genetics Incorporated, USA). PCT Int. Appl. WO 2001029219 A1 20010426, 33 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US28798 20001008. PRIORITY: US 1999-PV160285 19991019; US 2000-PV183583 20000218.

AB This invention provides protein and cDNA sequences for newly identified human proteins, designated NHPs, which shares structural similarity with animal CUB domain proteins, coagulation factors V and XIII, milk fat globule-EGF factor 8, 5 transcriptional repressor AE-binding protein-1, and neuropilins 1 and 2 (which, like the presently described protein, contain both CUB and discoidin domains). While NHP shares sequence homol. with other CUB-domain contg. proteins, its primary sequence is unique. Its expression is detected in human cell lines, and human prostate, pituitary, fetal brain, brain, thymus, spleen, lymph node, trachea, kidney, fetal liver, thyroid, adrenal gland, salivary gland, stomach, small intestine, colon, muscle, heart, mammary gland, adipose, skin, esophagus, bladder, cervix, rectum, and testis cells. In one embodiment, the invention relates to diagnostic assays for detecting diseases assocd. with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases assocd. with inappropriate NHP activity or levels.

L90 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 5
2001:247518 Document No. 134:276537 Protein and cDNA sequences of human carboxypeptidases and uses thereof in diagnosis, therapy and drug screening. **Donoho, Gregory**; Turner, C. Alexander, Jr.; Nehls, Michael; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T. (Lexicon Genetics Incorporated, USA). PCT Int. Appl. WO 2001023588 A1 20010405, 36 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US26876 20000929. PRIORITY: US 1999-PV156685 19990929.

AB This invention provides protein and cDNA sequences for newly identified human proteins, designated NHPs, which shares substantial sequence homol. with animal proteases, esp. carboxypeptidases. While NHP shares sequence homol. with other carboxypeptidases, its primary sequence is unique. Its expression is detected in various human tissues including brain, pituitary, spinal cord, thymus, spleen, lymph node, bone marrow, trachea, lung, kidney, prostate, testis, thyroid, adrenal gland, stomach, small intestine colon, skeletal muscle, uterus, mammary gland, bladder, cervix cells, and gene trapped human cells. In one embodiment, the invention

relates to diagnostic assays for detecting diseases assocd. with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases assocd. with inappropriate NHP activity or levels.

L90 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 6
2001:247510 Document No. 134:261891 Protein and cDNA sequences of human serine/threonine protein kinase and uses thereof in diagnosis, therapy and drug screening. **Donoho, Gregory**; Turner, C. Alexander, Jr.; Nehls, Michael; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T. (Lexicon Genetics Incorporated, USA). PCT Int. Appl. WO 2001023579 A1 20010405, 38 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US26621 20000927. PRIORITY: US 1999-PV156511 19990928.

AB This invention provides protein and cDNA sequences for newly identified human proteins, designated NHPs, which shares substantial sequence homol. with animal kinases, and more particular serine/threonine protein kinases. While NHP shares sequence homol. with other serine/threonine protein kinases, its primary sequence is unique. Its expression is detected in various human tissues including brain, pituitary, spinal cord, spleen, trachea, kidney, prostate, testis, adrenal gland cells, and gene trapped human cells. In one embodiment, the invention relates to diagnostic assays for detecting diseases assocd. with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases assocd. with inappropriate NHP activity or levels.

L90 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 7
2001:247499 Document No. 134:261870 Protein and cDNA sequences of a novel human organic anion transport protein. **Turner, C. Alexander, Jr.**; **Donoho, Gregory**; Wattler, Frank; **Nehls, Michael**; **Friedrich, Glenn**; Zambrowicz, Brian; Sands, Arthur T. (Lexicon Genetics Incorporated, USA). PCT Int. Appl. WO 2001023566 A1 20010405, 31 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US26630 20000927. PRIORITY: US 1999-PV156161 19990927.

AB This invention provides protein and cDNA sequences for newly identified human proteins, designated NHPs, which shares substantial sequence homol. with animal org. anion, and more particularly prostaglandin, transporter proteins. While NHP shares sequence homol. with other org. anion transport proteins, its primary sequence is unique. Its expression is detected in various human tissues including brain, pituitary, spinal cord, lymph node, trachea, heart, adipose, skin, pericardium, hypothalamus cells, and gene trapped human cells. In one embodiment, the invention relates to diagnostic assays for detecting diseases assocd. with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases assocd. with inappropriate NHP activity or levels.

L90 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 8

Searched by: Mary Hale 308-4258 CM-1 1E01

2001:229020 Document No. 134:262848 Cloning and characterization of human endothelin converting enzyme-like proteins. **Donoho, Gregory;** Turner, C. Alexander, Jr.; Nehls, Michael; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T. (Lexicon Genetics Incorporated, USA). PCT Int. Appl. WO 2001021773 A2 20010329, 31 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US26047 20000922. PRIORITY: US 1999-PV156102 19990924; US 2000-PV176689 20000118.

AB Novel human endothelin converting enzyme-like proteins of 255 and 883 amino acids in length and cDNAs encoding these proteins are disclosed. The endothelin converting enzyme-like proteins and encoding nucleic acids can be used in therapeutic, diagnostic, and pharmacogenomic applications.

L90 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 9
2001:228919 Document No. 134:247996 Protein and cDNA sequences for a novel human protease inhibitor-like protein NHP and use thereof. **Donoho, Gregory;** Turner, C. Alexander, Jr.; Wattler, Frank; Nehls, Michael; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T. (Lexicon Genetics Incorporated, USA). PCT Int. Appl. WO 2001021651 A2 20010329, 29 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US26048 20000922. PRIORITY: US 1999-PV156101 19990924.

AB The invention provides protein and cDNA sequences for a novel human protease inhibitor-like protein NHP that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

L90 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 10
2001:168158 Document No. 134:189017 Protein and cDNA sequences of human calcium dependent protease homologs, and uses thereof in therapy, diagnosis and drug screening. **Donoho, Gregory;** Turner, C. Alexander, Jr.; Nehls, Michael; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T. (Lexicon Genetics Incorporated, USA). PCT Int. Appl. WO 2001016336 A1 20010308, 39 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US24062 20000901. PRIORITY: US 1999-PV152057 19990902.

AB The invention provides protein and cDNA sequences of a novel class of human calcium dependent protease homologs which share structural similarity with animal calcium dependent proteases, or calpains. The novel calcium dependent protease homolog encoding cDNAs were obtained from human gene trap clones and human cDNA libraries. The invention further relates to the uses of calcium dependent protease homolog in therapy, diagnosis and drug screening.

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	71.52	120.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-10.53	-10.53

STN INTERNATIONAL LOGOFF AT 16:04:39 ON 09 JUL 2002

